BRSK2
Normalized values from positional scanning peptide array
Phospho-serine (pS) is a duplicate of phospho-tyrosine (pT) in PSPA
Position-wise Probabilities
Log-Odds: Probabilities / STY Background
Sites with acceptor types representing >8% and count ≥10 are included
S Sites Probabilities
T Sites Probabilities
Log-Odds: S Sites / S Background
Log-Odds: T Sites / T Background
Sites with acceptor types representing >8% and count ≥10 are included
Motif clusters with count ≥ 10 are shown
Download
| substrate_uniprot | site | source | substrate_genes | site_seq |
|---|---|---|---|---|
| A6NKT7 | S978 | Sugiyama | RGPD3 RGP3 | GRGVIFGQTSSTFTFADVAKstsGEGFQFGKKDLNFKGFSG |
| A6NKT7 | S980 | Sugiyama | RGPD3 RGP3 | GVIFGQTSSTFTFADVAKstsGEGFQFGKKDLNFKGFSGAG |
| O00273 | S37 | Sugiyama | DFFA DFF1 DFF45 H13 | TLKPCLLRRNysREQHGVAAsCLEDLRSKACDILAIDKSLT |
| O14639 | S452 | Sugiyama | ABLIM1 ABLIM KIAA0059 LIMAB1 | PtPsAEGyQDVRDRMIHRstsQGsINsPVySRHsYtPTTSR |
| O14715 | S977 | Sugiyama | RGPD8 RANBP2ALPHA RANBP2L1 RANBP2L3 | GRGVIFGQTSSTFTFADVAKstsGEGFQFGKKDLNFKGFSG |
| O14715 | S979 | Sugiyama | RGPD8 RANBP2ALPHA RANBP2L1 RANBP2L3 | GVIFGQTSSTFTFADVAKstsGEGFQFGKKDLNFKGFSGAG |
| O14974 | S445 | Sugiyama | PPP1R12A MBS MYPT1 | EEERKDEsPATWRLGLRKtGsyGALAEItASKEGQKEKDTA |
| O43815 | S229 | Sugiyama | STRN | TEAEVKETAMIAKSELtDsAsVLDNFKFLEsAAADFsDEDE |
| O43852 | S69 | Sugiyama | CALU | HDAFLGAEEAKtFDQLtPEEsKERLGKIVSKIDGDKDGFVt |
| O94885 | T460 | Sugiyama | SASH1 KIAA0790 PEPE1 | IKsPtASRISLGKKVKSVKEtMRKRMSKKYSSSVSEQDsGL |
| O95155 | S105 | Sugiyama | UBE4B HDNB1 KIAA0684 UFD2 | LsssPsNsLEtQsQsLsRsQsMDIDGVSCEKsMsQVDVDsG |
| O95218 | S181 | Sugiyama | ZRANB2 ZIS ZNF265 | DEDLsKyKLDEDEDEDDADLsKyNLDAsEEEDsNKKKSNRR |
| O95678 | S162 | Sugiyama | KRT75 K6HF KB18 | IQRVRAEEREQIKTLNNKFAsFIDKVRFLEQQNKVLETKWA |
| O95714 | S2928 | Sugiyama | HERC2 | ILLGRIRAEEEDLAAVPFLAsDNEEEEDEKGNSGsLIRKKA |
| P02538 | S176 | Sugiyama | KRT6A K6A KRT6D | IQRVRAEEREQIKTLNNKFAsFIDKVRFLEQQNKVLETKWT |
| P04075 | S36 | Sugiyama | ALDOA ALDA | LsDIAHRIVAPGKGILAADEstGsIAKRLQsIGtENtEENR |
| P04075 | S39 | Sugiyama | ALDOA ALDA | IAHRIVAPGKGILAADEstGsIAKRLQsIGtENtEENRRFy |
| P04259 | S176 | Sugiyama | KRT6B K6B KRTL1 | IQRVRAEEREQIKTLNNKFAsFIDKVRFLEQQNKVLDTKWT |
| P04406 | S241 | Sugiyama | GAPDH GAPD CDABP0047 OK/SW-cl.12 | IPELNGKLtGMAFRVPtANVsVVDLtCRLEKPAKyDDIKKV |
| P04406 | T237 | Sugiyama | GAPDH GAPD CDABP0047 OK/SW-cl.12 | VGKVIPELNGKLtGMAFRVPtANVsVVDLtCRLEKPAKyDD |
| P04792 | S82 | Sugiyama | HSPB1 HSP27 HSP28 | AIEsPAVAAPAYsRALsRQLssGVsEIRHtADRWRVsLDVN |
| P05423 | S250 | Sugiyama | POLR3D BN51 BN51T | AKMKAPPKAARKTPGLPKDVsVAELLRELSLTKEEELLFLQ |
| P05787 | S104 | Sugiyama | KRT8 CYK8 | IQAVRTQEKEQIKTLNNKFAsFIDKVRFLEQQNKMLETKWS |
| P06733 | T205 | Sugiyama | ENO1 ENO1L1 MBPB1 MPB1 | GAEVyHNLKNVIKEKyGKDAtNVGDEGGFAPNILENKEGLE |
| P07195 | S303 | Sugiyama | LDHB | GIENEVFLSLPCILNARGLtsVINQKLKDDEVAQLKKsADt |
| P07195 | T323 | Sugiyama | LDHB | sVINQKLKDDEVAQLKKsADtLWDIQKDLKDL_________ |
| P07737 | S30 | Sugiyama | PFN1 | NLMADGTCQDAAIVGYKDsPsVWAAVPGKtFVNITPAEVGV |
| P07900 | S399 | Sugiyama | HSP90AA1 HSP90A HSPC1 HSPCA | PEYLNFIRGVVDsEDLPLNIsREMLQQsKILKVIRKNLVKK |
| P07900 | S52 | Sugiyama | HSP90AA1 HSP90A HSPC1 HSPCA | LIINtFySNKEIFLRELIsNssDALDKIRyEsLtDPsKLDs |
| P08238 | S391 | Sugiyama | HSP90AB1 HSP90B HSPC2 HSPC3 HSPCB | PEYLNFIRGVVDsEDLPLNIsREMLQQsKILKVIRKNIVKK |
| P08729 | S104 | Sugiyama | KRT7 SCL | LQRVRQEESEQIKTLNNKFAsFIDKVRFLEQQNKLLETKWT |
| P0CG47 | S57 | Sugiyama | UBB | PPDQQRLIFAGKQLEDGRtLsDyNIQKEstLHLVLRLRGGM |
| P0CG48 | S57 | Sugiyama | UBC | PPDQQRLIFAGKQLEDGRtLsDyNIQKEstLHLVLRLRGGM |
| P0DJD0 | S962 | Sugiyama | RGPD1 RANBP2L6 RGP1 | GRGVIFGQTSSTFTFADVAKstsGEGFQFGKKDPNFKGFSG |
| P0DJD0 | S964 | Sugiyama | RGPD1 RANBP2L6 RGP1 | GVIFGQTSSTFTFADVAKstsGEGFQFGKKDPNFKGFSGAG |
| P10636 | S579 | GPS6|EPSD | MAPT MAPTL MTBT1 TAU | RLQTAPVPMPDLKNVKsKIGstENLKHQPGGGKVQIINKKL |
| P11279 | S141 | Sugiyama | LAMP1 | NLSDTHLFPNASSKEIKtVEsITDIRADIDKKYRCVSGTQV |
| P12004 | S172 | Sugiyama | PCNA | sHIGDAVVIsCAKDGVKFSAsGELGNGNIKLSQTSNVDKEE |
| P12035 | S211 | Sugiyama | KRT3 | IGQVKAQEREQIKTLNNKFAsFIDKVRFLEQQNKVLETKWN |
| P13647 | S181 | Sugiyama | KRT5 | IQRVRTEEREQIKTLNNKFAsFIDKVRFLEQQNKVLDTKWT |
| P14625 | T171 | Sugiyama | HSP90B1 GRP94 HSPC4 TRA1 | GVGMtREELVKNLGTIAKsGtsEFLNKMTEAQEDGQSTSEL |
| P15531 | S120 | Sugiyama | NME1 NDPKA NM23 | KPGtIRGDFCIQVGRNIIHGsDsVEsAEKEIGLWFHPEELV |
| P15531 | S122 | Sugiyama | NME1 NDPKA NM23 | GtIRGDFCIQVGRNIIHGsDsVEsAEKEIGLWFHPEELVDy |
| P16949 | S46 | Sugiyama | STMN1 C1orf215 LAP18 OP18 | PRsKEsVPEFPLsPPKKKDLsLEEIQKKLEAAEERRKsHEA |
| P18615 | S115 | Sugiyama | NELFE RD RDBP | KLKDPEKGPVPTFQPFQRsIsADDDLQEsSRRPQRKsLyEs |
| P18615 | S51 | Sugiyama | NELFE RD RDBP | ALKKQSSSSTTSQGGVKRsLsEQPVMDTATATEQAKQLVKS |
| P19338 | S460 | Sugiyama | NCL | ADAEKTFEEKQGtEIDGRsIsLyytGEKGQNQDYRGGKNST |
| P22059 | S240 | Sugiyama | OSBP OSBP1 | DLSTCNDLIAKHGTALQRsLsELEsLKLPAESNEKIKQVNE |
| P22626 | S189 | Sugiyama | HNRNPA2B1 HNRPA2B1 | IVLQKyHtINGHNAEVRKALsRQEMQEVQssRsGRGGNFGF |
| P26373 | S77 | Sugiyama | RPL13 BBC1 OK/SW-cl.46 | PIVRCPTVRYHTKVRAGRGFsLEELRVAGIHKKVARTIGIs |
| P27797 | S53 | Sugiyama | CALR CRTC | WtsRWIEsKHKSDFGKFVLssGKFyGDEEKDKGLQTSQDAR |
| P30291 | S642 | GPS6|iPTMNet|EPSD | WEE1 | STTQSNRTSRLIGKKMNRSVsLTIY________________ |
| P30307 | S216 | iPTMNet | CDC25C | EFsLKDQEAKVSRsGLYRsPsMPENLNRPRLKQVEKFKDNt |
| P30622 | S195 | Sugiyama | CLIP1 CYLN1 RSN | AAKEPsAtPPISNLTKtAsEsIsNLsEAGsIKKGERELKIG |
| P31943 | S23 | Sugiyama | HNRNPH1 HNRPH HNRPH1 | LGTEGGEGFVVKVRGLPWsCsADEVQRFFSDCKIQNGAQGI |
| P35221 | S641 | Sugiyama | CTNNA1 | GIRDIRKAVLMIRtPEELDDsDFEtEDFDVRsRtsVQtEDD |
| P35908 | S191 | Sugiyama | KRT2 KRT2A KRT2E | IQNVKAQEREQIKTLNNKFAsFIDKVRFLEQQNQVLQTKWE |
| P37802 | S163 | Sugiyama | TAGLN2 KIAA0120 CDABP0035 | LFsGDPNWFPKKSKENPRNFsDNQLQEGKNVIGLQMGtNRG |
| P39023 | S13 | Sugiyama | RPL3 OK/SW-cl.32 | ________MSHRKFSAPRHGsLGFLPRKRSSRHRGKVKSFP |
| P40818 | S719 | Sugiyama | USP8 KIAA0055 UBPY | KPQIPAERDREPSKLKRsyssPDItQAIQEEEKRKPTVtPT |
| P43490 | S472 | Sugiyama | NAMPT PBEF PBEF1 | EYGQDLLHTVFKNGKVTKsysFDEIRKNAQLNIELEAAHH_ |
| P48668 | S176 | Sugiyama | KRT6C KRT6E | IQRVRAEEREQIKTLNNKFAsFIDKVRFLEQQNKVLDTKWT |
| P49327 | T2215 | Sugiyama | FASN FAS | DEAsELACPtPKEDGLAQQQtQLNLRSLLVNPEGPtLMRLN |
| P49792 | S1953 | Sugiyama | RANBP2 NUP358 | GRGVIFGQTSSTFTFADLAKstsGEGFQFGKKDPNFKGFSG |
| P49792 | S1955 | Sugiyama | RANBP2 NUP358 | GVIFGQTSSTFTFADLAKstsGEGFQFGKKDPNFKGFSGAG |
| P49815 | S1387 | EPSD|PSP | TSC2 TSC4 | GGRPsVDLsFQPsQPLsKssssPELQtLQDILGDPGDKADV |
| P52565 | S174 | PSP | ARHGDIA GDIA1 | EEyEFLtPVEEAPKGMLARGsYsIKSRFTDDDKTDHLSWEW |
| P52594 | S293 | Sugiyama | AGFG1 HRB RAB RIP | GSAASVNANFAHFDNFPKsssADFGtFNTsQSHQTASAVSK |
| P55010 | S10 | Sugiyama | EIF5 | ___________MSVNVNRsVsDQFyRyKMPRLIAKVEGKGN |
| P62249 | S9 | Sugiyama | RPS16 | ____________MPsKGPLQsVQVFGRKKTATAVAHCKRGN |
| P62273 | Y7 | Sugiyama | RPS29 | ______________MGHQQLyWsHPRKFGQGSRSCRVCSNR |
| P62979 | S57 | Sugiyama | RPS27A UBA80 UBCEP1 | PPDQQRLIFAGKQLEDGRtLsDyNIQKEstLHLVLRLRGGA |
| P62987 | S57 | Sugiyama | UBA52 UBCEP2 | PPDQQRLIFAGKQLEDGRtLsDyNIQKEstLHLVLRLRGGI |
| P63220 | S65 | Sugiyama | RPS21 | RFNGQFKtyAICGAIRRMGEsDDsILRLAKADGIVSKNF__ |
| P83731 | S38 | Sugiyama | RPL24 | GRRYARTDGKVFQFLNAKCEsAFLSKRNPRQINWtVLyRRK |
| P83731 | S86 | Sugiyama | RPL24 | EIQKKRTRRAVKFQRAItGAsLADIMAKRNQKPEVRKAQRE |
| P83731 | T83 | Sugiyama | RPL24 | QsEEIQKKRTRRAVKFQRAItGAsLADIMAKRNQKPEVRKA |
| Q00536 | S12 | EPSD|PSP | CDK16 PCTAIRE1 PCTK1 | _________MDRMKKIKRQLsMTLRGGRGIDKTNGAPEQIG |
| Q00587 | S192 | Sugiyama | CDC42EP1 BORG5 CEP1 MSE55 | PHDRDRDGsFPsEPGLRRsDsLLsFRLDLDLGPSLLSELLG |
| Q01546 | S196 | Sugiyama | KRT76 KRT2B KRT2P | IGQVKAQEREQIKTLNNKFAsFIDKVRFLEQQNKVLETKWE |
| Q08AD1 | S1313 | Sugiyama | CAMSAP2 CAMSAP1L1 KIAA1078 | sLNtGDNEsVHsGKRtPRsEsVEGFLsPsRCGsRNGEKDWE |
| Q08AD1 | S464 | Sugiyama | CAMSAP2 CAMSAP1L1 KIAA1078 | FDKEDSVQRstPNRGITRsIsNEGLtLNNsHVsKHIRKNLS |
| Q13131 | T183 | SIGNOR|EPSD|PSP | PRKAA1 AMPK1 | NAKIADFGLsNMMsDGEFLRtsCGsPNyAAPEVISGRLYAG |
| Q13464 | S576 | Sugiyama | ROCK1 | TESDTAVRLRKSHTEMSKSIsQLESLNRELQERNRILENSK |
| Q13615 | S613 | Sugiyama | MTMR3 KIAA0371 ZFYVE10 | YPAPGTSPDDPPLSRLPKtRsyDNLttACDNTVPLASRRCs |
| Q14568 | S52 | Sugiyama | HSP90AA2P HSP90AA2 HSPC2 HSPCAL3 | LIINTFYSNKEIFLRELIsNssDALDKIWYESLTDPSKLDS |
| Q14CN4 | S138 | Sugiyama | KRT72 K6IRS2 KB35 KRT6 KRT6IRS2 | IQRVRAQEREQIKALNNKFAsFIDKVRFLEQQNQVLETKWN |
| Q15293 | S80 | Sugiyama | RCN1 RCN | HEAFLGKEDsKtFDQLtPDEsKERLGKIVDRIDNDGDGFVt |
| Q15751 | S1512 | Sugiyama | HERC1 | LtAESRLVHtsPNYRLIKsRsEsDLsQPEsDEEGYALsGRR |
| Q16531 | T1125 | Sugiyama | DDB1 XAP1 | MQEVVANLQYDDGSGMKREAtADDLIKVVEELtRIH_____ |
| Q3SY84 | S143 | Sugiyama | KRT71 K6IRS1 KB34 KRT6IRS1 | IQKVRAQEREQIKALNNKFAsFIDKVRFLEQQNQVLETKWE |
| Q5XKE5 | S155 | Sugiyama | KRT79 K6L KB38 KRT6L | IQRVRTQEREQIKTLNNKFAsFIDKVRFLEQQNKVLETKWA |
| Q6GYQ0 | T798 | Sugiyama | RALGAPA1 GARNL1 KIAA0884 TULIP1 | tGNEVFGALNEEQPLPRssstsDILEPFTVERAKVNKEDMS |
| Q7RTS7 | S153 | Sugiyama | KRT74 K6IRS4 KB37 KRT5C KRT6IRS4 | IQKVRAQEREQIKVLNDKFAsFIDKVRFLEQQNQVLETKWE |
| Q7Z3J3 | S978 | Sugiyama | RGPD4 RGP4 | GRGVIFGQTSSTFTFADVAKstsGEGFQFGKKDPNFKGFSG |
| Q7Z3J3 | S980 | Sugiyama | RGPD4 RGP4 | GVIFGQTSSTFTFADVAKstsGEGFQFGKKDPNFKGFSGAG |
| Q7Z417 | S652 | Sugiyama | NUFIP2 KIAA1321 PIG1 | NtLLGsAKEQRYQRGLERNDsWGsFDLRAAIVYHTKEMEsI |
| Q7Z794 | S177 | Sugiyama | KRT77 KRT1B | IQRIKTQEREQIMVLNNKFAsFIDKVRFLEQQNQVLQTKWE |
| Q86VQ1 | S223 | Sugiyama | GLCCI1 | QTPsCWAEEGAEKRSHQRsAsWGsADQLKEQIAKLRQQLQR |
| Q86Y46 | S145 | Sugiyama | KRT73 K6IRS3 KB36 KRT6IRS3 | IQKVRAQEREQIKVLNNKFAsFIDKVRFLEQQNQVLETKWE |
| Q8IWQ3 | S367 | Sugiyama | BRSK2 C11orf7 PEN11B SADA STK29 HUSSY-12 | QEDEDLPPRNEIDPPRKRVDsPMLNRHGKRRPERKsMEVLS |
| Q8IWQ3 | S382 | Sugiyama | BRSK2 C11orf7 PEN11B SADA STK29 HUSSY-12 | RKRVDsPMLNRHGKRRPERKsMEVLSVtDGGsPVPARRAIE |
| Q8IWQ3 | S393 | Sugiyama | BRSK2 C11orf7 PEN11B SADA STK29 HUSSY-12 | HGKRRPERKsMEVLSVtDGGsPVPARRAIEMAQHGQRsRsI |
| Q8IWQ3 | S410 | Sugiyama | BRSK2 C11orf7 PEN11B SADA STK29 HUSSY-12 | DGGsPVPARRAIEMAQHGQRsRsIsGASSGLStsPLssPRV |
| Q8IWQ3 | S423 | Sugiyama | BRSK2 C11orf7 PEN11B SADA STK29 HUSSY-12 | MAQHGQRsRsIsGASSGLStsPLssPRVtPHPsPRGsPLPt |
| Q8IWQ3 | S426 | Sugiyama | BRSK2 C11orf7 PEN11B SADA STK29 HUSSY-12 | HGQRsRsIsGASSGLStsPLssPRVtPHPsPRGsPLPtPKG |
| Q8IWQ3 | S427 | Sugiyama | BRSK2 C11orf7 PEN11B SADA STK29 HUSSY-12 | GQRsRsIsGASSGLStsPLssPRVtPHPsPRGsPLPtPKGT |
| Q8IWQ3 | S513 | Sugiyama | BRSK2 C11orf7 PEN11B SADA STK29 HUSSY-12 | HRRKLQVPtPEEMSNLtPEssPELAKKSWFGNFISLEKEEQ |
| Q8IWQ3 | T389 | Sugiyama | BRSK2 C11orf7 PEN11B SADA STK29 HUSSY-12 | MLNRHGKRRPERKsMEVLSVtDGGsPVPARRAIEMAQHGQR |
| Q8IWQ3 | T501 | Sugiyama | BRSK2 C11orf7 PEN11B SADA STK29 HUSSY-12 | SIKNSFLGsPRFHRRKLQVPtPEEMSNLtPEssPELAKKSW |
| Q8IWQ3 | T509 | Sugiyama | BRSK2 C11orf7 PEN11B SADA STK29 HUSSY-12 | sPRFHRRKLQVPtPEEMSNLtPEssPELAKKSWFGNFISLE |
| Q8WUF5 | S102 | Sugiyama | PPP1R13L IASPP NKIP1 PPP1R13BL RAI | RGsPRKAATDGADtPFGRsEsAPtLHPysPLsPKGRPssPR |
| Q8WWI1 | S706 | Sugiyama | LMO7 FBX20 FBXO20 KIAA0858 | RLMVERLFQKIYGENGsKsMsDVsAEDVQNLRQLRYEEMQK |
| Q8WWI1 | T932 | Sugiyama | LMO7 FBX20 FBXO20 KIAA0858 | VtPRPFGsQtRGISsLPRsYtMDDAWKYNGDVEDIKRtPNN |
| Q93045 | S80 | Sugiyama | STMN2 SCG10 SCGN10 | PPsPISEAPRTLAsPKKKDLsLEEIQKKLEAAEERRKsQEA |
| Q96JJ7 | S268 | Sugiyama | TMX3 KIAA1830 TXNDC10 | LVALAVIDEKNTSVEHTRLKsIIQEVARDYRDLFHRDFQFG |
| Q96L92 | S51 | Sugiyama | SNX27 KIAA0488 My014 | AGNGGGGGGGPRVVRIVKsEsGYGFNVRGQVsEGGQLRSIN |
| Q99666 | S977 | Sugiyama | RGPD5 RANBP2L1 RGP5 RGP7 RGPD7; RGPD6 RANBP2L2 RGP6 | GRGVIFGQTSSTFTFADVAKstsGEGFQFGKKDLNFKGFSG |
| Q99666 | S979 | Sugiyama | RGPD5 RANBP2L1 RGP5 RGP7 RGPD7; RGPD6 RANBP2L2 RGP6 | GVIFGQTSSTFTFADVAKstsGEGFQFGKKDLNFKGFSGAG |
| Q9BX95 | S112 | Sugiyama | SGPP1 SPP1 | GLAAELGPAsPRRAGALRRNsLtGEEGQLARVSNWPLYCLF |
| Q9H6H4 | S152 | Sugiyama | REEP4 C8orf20 PP432 | AAVQAATKSQGALAGRLRsFsMQDLRSISDAPAPAyHDPLy |
| Q9HAU0 | S410 | Sugiyama | PLEKHA5 KIAA1686 PEPP2 | NRPNTGPLytEADRVIQRtNsMQQLEQWIKIQKGRGHEEET |
| Q9NQP4 | S125 | Sugiyama | PFDN4 PFD4 | VEsIQRVLADLKVQLYAKFGsNINLEADEs___________ |
| Q9NSB2 | S178 | Sugiyama | KRT84 KRTHB4 | AQRVKKDEKEQIKTLNNKFAsFIDKVRFLEQQNKLLETKWS |
| Q9NWS0 | S175 | Sugiyama | PIH1D1 NOP17 | NLQLNPEWRMMKNRPFMGsIsQQNIRSEQRPRIQELGDLyt |
| Q9UGV2 | T332 | Sugiyama | NDRG3 | GMGYIPSASMTRLARsRtHstsssLGsGEsPFsRsVtsNQs |
| Q9UII2 | S63 | Sugiyama | ATP5IF1 ATPI ATPIF1 | AGGAFGKREQAEEERyFRAQsREQLAALKKHHEEEIVHHKK |
| Q9UPU5 | S2047 | Sugiyama | USP24 KIAA1057 | VRRRYWNAYMLFYQRVSDQNsPVLPKKSRVSVVRQEAEDLs |
| Q9UQ35 | S1103 | Sugiyama | SRRM2 KIAA0324 SRL300 SRM300 HSPC075 | sPsLQSKSQTsPKGGRsRsssPVtELAsRsPIRQDRGEFsA |
| Q9Y3U8 | S91 | Sugiyama | RPL36 | KFIKKRVGTHIRAKRKREELsNVLAAMRKAAAKKD______ |
| Q9Y450 | S69 | Sugiyama | HBS1L HBS1 KIAA1038 | sVEPVEEyDyEDLKEssNsVsNHQLSGFDQARLYsCLDHMR |
Site Promiscuity
Motif of predicted substrate sequence
Reactome pathways of predicted substrates
Download
| name | reactome_id | p | -log10p | ref_path | ref_path_lowest |
|---|---|---|---|---|---|
| Signal Transduction | R-HSA-162582 | 5.652970e-08 | 7.248 | 0 | 0 |
| Cell Cycle | R-HSA-1640170 | 2.913894e-07 | 6.536 | 0 | 0 |
| Constitutive Signaling by AKT1 E17K in Cancer | R-HSA-5674400 | 1.283135e-06 | 5.892 | 0 | 0 |
| Diseases of signal transduction by growth factor receptors and second messengers | R-HSA-5663202 | 1.247493e-06 | 5.904 | 0 | 0 |
| Cell Cycle, Mitotic | R-HSA-69278 | 3.378763e-06 | 5.471 | 0 | 0 |
| Mitotic Prometaphase | R-HSA-68877 | 5.579935e-06 | 5.253 | 0 | 0 |
| Axon guidance | R-HSA-422475 | 7.865633e-06 | 5.104 | 0 | 0 |
| Mitotic Spindle Checkpoint | R-HSA-69618 | 1.787698e-05 | 4.748 | 0 | 0 |
| Cell Cycle Checkpoints | R-HSA-69620 | 2.508680e-05 | 4.601 | 0 | 0 |
| Amplification of signal from the kinetochores | R-HSA-141424 | 3.323975e-05 | 4.478 | 0 | 0 |
| Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | R-HSA-141444 | 3.323975e-05 | 4.478 | 0 | 0 |
| Nervous system development | R-HSA-9675108 | 9.605478e-05 | 4.017 | 0 | 0 |
| EML4 and NUDC in mitotic spindle formation | R-HSA-9648025 | 1.927576e-04 | 3.715 | 0 | 0 |
| NRAGE signals death through JNK | R-HSA-193648 | 2.267011e-04 | 3.645 | 0 | 0 |
| Resolution of Sister Chromatid Cohesion | R-HSA-2500257 | 2.796771e-04 | 3.553 | 0 | 0 |
| Recruitment of mitotic centrosome proteins and complexes | R-HSA-380270 | 3.102236e-04 | 3.508 | 0 | 0 |
| G alpha (12/13) signalling events | R-HSA-416482 | 2.975385e-04 | 3.526 | 0 | 0 |
| Defective Intrinsic Pathway for Apoptosis | R-HSA-9734009 | 3.388701e-04 | 3.470 | 0 | 0 |
| Regulation of TP53 Activity | R-HSA-5633007 | 3.648889e-04 | 3.438 | 0 | 0 |
| Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | R-HSA-8864260 | 3.925091e-04 | 3.406 | 0 | 0 |
| Centrosome maturation | R-HSA-380287 | 4.317273e-04 | 3.365 | 0 | 0 |
| Intracellular signaling by second messengers | R-HSA-9006925 | 4.525849e-04 | 3.344 | 0 | 0 |
| Neurodegenerative Diseases | R-HSA-8863678 | 4.939312e-04 | 3.306 | 0 | 0 |
| Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models | R-HSA-8862803 | 4.939312e-04 | 3.306 | 0 | 0 |
| CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | R-HSA-442742 | 5.082261e-04 | 3.294 | 0 | 0 |
| Long-term potentiation | R-HSA-9620244 | 6.550012e-04 | 3.184 | 0 | 0 |
| Unblocking of NMDA receptors, glutamate binding and activation | R-HSA-438066 | 7.188910e-04 | 3.143 | 0 | 0 |
| Negative regulation of NMDA receptor-mediated neuronal transmission | R-HSA-9617324 | 7.188910e-04 | 3.143 | 0 | 0 |
| PI3K/AKT Signaling in Cancer | R-HSA-2219528 | 7.949836e-04 | 3.100 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of cell cycle factors | R-HSA-8866911 | 1.033686e-03 | 2.986 | 0 | 0 |
| NFE2L2 regulating ER-stress associated genes | R-HSA-9818035 | 1.033686e-03 | 2.986 | 0 | 0 |
| AKT phosphorylates targets in the cytosol | R-HSA-198323 | 1.048468e-03 | 2.979 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest | R-HSA-6804116 | 1.084902e-03 | 2.965 | 0 | 0 |
| Mitotic G2-G2/M phases | R-HSA-453274 | 1.055696e-03 | 2.976 | 0 | 0 |
| Apoptotic cleavage of cellular proteins | R-HSA-111465 | 1.212946e-03 | 2.916 | 0 | 0 |
| Post NMDA receptor activation events | R-HSA-438064 | 1.316791e-03 | 2.880 | 0 | 0 |
| CaMK IV-mediated phosphorylation of CREB | R-HSA-111932 | 1.401154e-03 | 2.854 | 0 | 0 |
| Integrin signaling | R-HSA-354192 | 1.520881e-03 | 2.818 | 0 | 0 |
| Deactivation of the beta-catenin transactivating complex | R-HSA-3769402 | 1.570241e-03 | 2.804 | 0 | 0 |
| Cell death signalling via NRAGE, NRIF and NADE | R-HSA-204998 | 1.664746e-03 | 2.779 | 0 | 0 |
| Transcriptional Regulation by E2F6 | R-HSA-8953750 | 2.339564e-03 | 2.631 | 0 | 0 |
| Ras activation upon Ca2+ influx through NMDA receptor | R-HSA-442982 | 2.442599e-03 | 2.612 | 0 | 0 |
| G2/M Transition | R-HSA-69275 | 2.636250e-03 | 2.579 | 0 | 0 |
| PIP3 activates AKT signaling | R-HSA-1257604 | 2.586770e-03 | 2.587 | 0 | 0 |
| TRP channels | R-HSA-3295583 | 2.686578e-03 | 2.571 | 0 | 0 |
| M Phase | R-HSA-68886 | 2.738282e-03 | 2.563 | 0 | 0 |
| Signaling by cytosolic FGFR1 fusion mutants | R-HSA-1839117 | 2.758544e-03 | 2.559 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescence | R-HSA-9825895 | 2.837935e-03 | 2.547 | 0 | 0 |
| AURKA Activation by TPX2 | R-HSA-8854518 | 2.979467e-03 | 2.526 | 0 | 0 |
| Muscle contraction | R-HSA-397014 | 2.963315e-03 | 2.528 | 0 | 0 |
| Activation of RAC1 | R-HSA-428540 | 3.089814e-03 | 2.510 | 0 | 0 |
| Recruitment of NuMA to mitotic centrosomes | R-HSA-380320 | 3.118545e-03 | 2.506 | 0 | 0 |
| Separation of Sister Chromatids | R-HSA-2467813 | 3.183335e-03 | 2.497 | 0 | 0 |
| TP53 Regulates Transcription of DNA Repair Genes | R-HSA-6796648 | 3.309963e-03 | 2.480 | 0 | 0 |
| RET signaling | R-HSA-8853659 | 3.469277e-03 | 2.460 | 0 | 0 |
| Apoptotic execution phase | R-HSA-75153 | 3.875161e-03 | 2.412 | 0 | 0 |
| Loss of proteins required for interphase microtubule organization from the centrosome | R-HSA-380284 | 4.282738e-03 | 2.368 | 0 | 0 |
| Loss of Nlp from mitotic centrosomes | R-HSA-380259 | 4.282738e-03 | 2.368 | 0 | 0 |
| Activation of ATR in response to replication stress | R-HSA-176187 | 4.247088e-03 | 2.372 | 0 | 0 |
| Neurexins and neuroligins | R-HSA-6794361 | 4.288014e-03 | 2.368 | 0 | 0 |
| Signaling by LTK | R-HSA-9842663 | 4.370140e-03 | 2.360 | 0 | 0 |
| Signaling by Receptor Tyrosine Kinases | R-HSA-9006934 | 4.316676e-03 | 2.365 | 0 | 0 |
| Transcription of E2F targets under negative control by DREAM complex | R-HSA-1362277 | 4.709587e-03 | 2.327 | 0 | 0 |
| Regulation of TP53 Activity through Phosphorylation | R-HSA-6804756 | 4.933550e-03 | 2.307 | 0 | 0 |
| Activation of NMDA receptors and postsynaptic events | R-HSA-442755 | 5.048053e-03 | 2.297 | 0 | 0 |
| Developmental Lineage of Mammary Gland Myoepithelial Cells | R-HSA-9927432 | 5.182767e-03 | 2.285 | 0 | 0 |
| Impaired BRCA2 binding to RAD51 | R-HSA-9709570 | 5.182767e-03 | 2.285 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of growth factors and their receptors | R-HSA-8866910 | 5.412884e-03 | 2.267 | 0 | 0 |
| Regulation of NFE2L2 gene expression | R-HSA-9818749 | 5.800138e-03 | 2.237 | 0 | 0 |
| Signaling by ERBB2 | R-HSA-1227986 | 6.148831e-03 | 2.211 | 0 | 0 |
| Netrin-1 signaling | R-HSA-373752 | 6.673943e-03 | 2.176 | 0 | 0 |
| Regulation of PLK1 Activity at G2/M Transition | R-HSA-2565942 | 6.894344e-03 | 2.162 | 0 | 0 |
| Signaling by NTRKs | R-HSA-166520 | 6.996102e-03 | 2.155 | 0 | 0 |
| Transcriptional activation of cell cycle inhibitor p21 | R-HSA-69895 | 7.132420e-03 | 2.147 | 0 | 0 |
| Transcriptional activation of p53 responsive genes | R-HSA-69560 | 7.132420e-03 | 2.147 | 0 | 0 |
| FOXO-mediated transcription of cell cycle genes | R-HSA-9617828 | 7.594750e-03 | 2.119 | 0 | 0 |
| Presynaptic phase of homologous DNA pairing and strand exchange | R-HSA-5693616 | 7.430423e-03 | 2.129 | 0 | 0 |
| Platelet Aggregation (Plug Formation) | R-HSA-76009 | 7.798379e-03 | 2.108 | 0 | 0 |
| Autophagy | R-HSA-9612973 | 7.980918e-03 | 2.098 | 0 | 0 |
| Synthesis of PIPs at the plasma membrane | R-HSA-1660499 | 8.040285e-03 | 2.095 | 0 | 0 |
| Polo-like kinase mediated events | R-HSA-156711 | 9.065038e-03 | 2.043 | 0 | 0 |
| Signaling by ERBB2 ECD mutants | R-HSA-9665348 | 9.065038e-03 | 2.043 | 0 | 0 |
| Notch-HLH transcription pathway | R-HSA-350054 | 9.465536e-03 | 2.024 | 0 | 0 |
| Assembly and cell surface presentation of NMDA receptors | R-HSA-9609736 | 9.763473e-03 | 2.010 | 0 | 0 |
| Signaling by FGFR1 in disease | R-HSA-5655302 | 9.763473e-03 | 2.010 | 0 | 0 |
| Potassium Channels | R-HSA-1296071 | 9.513740e-03 | 2.022 | 0 | 0 |
| Signaling by NTRK2 (TRKB) | R-HSA-9006115 | 9.475172e-03 | 2.023 | 0 | 0 |
| PI Metabolism | R-HSA-1483255 | 9.402056e-03 | 2.027 | 0 | 0 |
| DNA Double-Strand Break Repair | R-HSA-5693532 | 1.045521e-02 | 1.981 | 0 | 0 |
| Phase 0 - rapid depolarisation | R-HSA-5576892 | 1.146482e-02 | 1.941 | 0 | 0 |
| RUNX2 regulates chondrocyte maturation | R-HSA-8941284 | 1.199952e-02 | 1.921 | 0 | 0 |
| Signaling by GSK3beta mutants | R-HSA-5339716 | 1.209622e-02 | 1.917 | 0 | 0 |
| Homologous DNA Pairing and Strand Exchange | R-HSA-5693579 | 1.224117e-02 | 1.912 | 0 | 0 |
| Cardiac conduction | R-HSA-5576891 | 1.195556e-02 | 1.922 | 0 | 0 |
| Drug resistance in ERBB2 KD mutants | R-HSA-9665230 | 1.415100e-02 | 1.849 | 0 | 0 |
| Drug-mediated inhibition of ERBB2 signaling | R-HSA-9652282 | 1.415100e-02 | 1.849 | 0 | 0 |
| Resistance of ERBB2 KD mutants to tesevatinib | R-HSA-9665245 | 1.415100e-02 | 1.849 | 0 | 0 |
| Resistance of ERBB2 KD mutants to osimertinib | R-HSA-9665247 | 1.415100e-02 | 1.849 | 0 | 0 |
| Resistance of ERBB2 KD mutants to sapitinib | R-HSA-9665244 | 1.415100e-02 | 1.849 | 0 | 0 |
| Resistance of ERBB2 KD mutants to AEE788 | R-HSA-9665250 | 1.415100e-02 | 1.849 | 0 | 0 |
| Resistance of ERBB2 KD mutants to trastuzumab | R-HSA-9665233 | 1.415100e-02 | 1.849 | 0 | 0 |
| Resistance of ERBB2 KD mutants to afatinib | R-HSA-9665249 | 1.415100e-02 | 1.849 | 0 | 0 |
| Resistance of ERBB2 KD mutants to neratinib | R-HSA-9665246 | 1.415100e-02 | 1.849 | 0 | 0 |
| Resistance of ERBB2 KD mutants to lapatinib | R-HSA-9665251 | 1.415100e-02 | 1.849 | 0 | 0 |
| Drug resistance in ERBB2 TMD/JMD mutants | R-HSA-9665737 | 1.415100e-02 | 1.849 | 0 | 0 |
| Sema4D induced cell migration and growth-cone collapse | R-HSA-416572 | 1.429969e-02 | 1.845 | 0 | 0 |
| CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde | R-HSA-442729 | 1.295281e-02 | 1.888 | 0 | 0 |
| Nephrin family interactions | R-HSA-373753 | 1.429969e-02 | 1.845 | 0 | 0 |
| Anchoring of the basal body to the plasma membrane | R-HSA-5620912 | 1.455186e-02 | 1.837 | 0 | 0 |
| Regulation of FOXO transcriptional activity by acetylation | R-HSA-9617629 | 1.608851e-02 | 1.793 | 0 | 0 |
| Signaling by CTNNB1 phospho-site mutants | R-HSA-4839743 | 1.608851e-02 | 1.793 | 0 | 0 |
| CTNNB1 T41 mutants aren't phosphorylated | R-HSA-5358752 | 1.608851e-02 | 1.793 | 0 | 0 |
| CTNNB1 S45 mutants aren't phosphorylated | R-HSA-5358751 | 1.608851e-02 | 1.793 | 0 | 0 |
| CTNNB1 S33 mutants aren't phosphorylated | R-HSA-5358747 | 1.608851e-02 | 1.793 | 0 | 0 |
| CTNNB1 S37 mutants aren't phosphorylated | R-HSA-5358749 | 1.608851e-02 | 1.793 | 0 | 0 |
| Diseases of DNA Double-Strand Break Repair | R-HSA-9675136 | 1.537240e-02 | 1.813 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA2 loss of function | R-HSA-9701190 | 1.537240e-02 | 1.813 | 0 | 0 |
| HDR through Homologous Recombination (HRR) | R-HSA-5685942 | 1.484340e-02 | 1.828 | 0 | 0 |
| Homology Directed Repair | R-HSA-5693538 | 1.686099e-02 | 1.773 | 0 | 0 |
| G2/M DNA damage checkpoint | R-HSA-69473 | 1.661030e-02 | 1.780 | 0 | 0 |
| Mitotic Metaphase and Anaphase | R-HSA-2555396 | 1.633789e-02 | 1.787 | 0 | 0 |
| Mitotic Anaphase | R-HSA-68882 | 1.536305e-02 | 1.814 | 0 | 0 |
| RAB GEFs exchange GTP for GDP on RABs | R-HSA-8876198 | 1.630494e-02 | 1.788 | 0 | 0 |
| Rab regulation of trafficking | R-HSA-9007101 | 1.550763e-02 | 1.809 | 0 | 0 |
| Macroautophagy | R-HSA-1632852 | 1.711231e-02 | 1.767 | 0 | 0 |
| Sema4D in semaphorin signaling | R-HSA-400685 | 1.717695e-02 | 1.765 | 0 | 0 |
| HDMs demethylate histones | R-HSA-3214842 | 1.717695e-02 | 1.765 | 0 | 0 |
| Inactivation of CDC42 and RAC1 | R-HSA-428543 | 1.811915e-02 | 1.742 | 0 | 0 |
| AKT phosphorylates targets in the nucleus | R-HSA-198693 | 1.811915e-02 | 1.742 | 0 | 0 |
| RUNX3 regulates CDKN1A transcription | R-HSA-8941855 | 1.859838e-02 | 1.731 | 0 | 0 |
| Formation of WDR5-containing histone-modifying complexes | R-HSA-9772755 | 1.798139e-02 | 1.745 | 0 | 0 |
| Semaphorin interactions | R-HSA-373755 | 1.855432e-02 | 1.732 | 0 | 0 |
| FLT3 Signaling | R-HSA-9607240 | 1.914216e-02 | 1.718 | 0 | 0 |
| Programmed Cell Death | R-HSA-5357801 | 1.790475e-02 | 1.747 | 0 | 0 |
| Caspase-mediated cleavage of cytoskeletal proteins | R-HSA-264870 | 1.811915e-02 | 1.742 | 0 | 0 |
| Paradoxical activation of RAF signaling by kinase inactive BRAF | R-HSA-6802955 | 1.993658e-02 | 1.700 | 0 | 0 |
| Signaling by moderate kinase activity BRAF mutants | R-HSA-6802946 | 1.993658e-02 | 1.700 | 0 | 0 |
| Signaling downstream of RAS mutants | R-HSA-9649948 | 1.993658e-02 | 1.700 | 0 | 0 |
| Signaling by RAS mutants | R-HSA-6802949 | 1.993658e-02 | 1.700 | 0 | 0 |
| Transcriptional Regulation by TP53 | R-HSA-3700989 | 2.054273e-02 | 1.687 | 0 | 0 |
| Signaling by FLT3 fusion proteins | R-HSA-9703465 | 2.055297e-02 | 1.687 | 0 | 0 |
| MECP2 regulates neuronal receptors and channels | R-HSA-9022699 | 2.055297e-02 | 1.687 | 0 | 0 |
| Signaling by EGFRvIII in Cancer | R-HSA-5637812 | 2.173220e-02 | 1.663 | 0 | 0 |
| Constitutive Signaling by EGFRvIII | R-HSA-5637810 | 2.173220e-02 | 1.663 | 0 | 0 |
| Cellular response to heat stress | R-HSA-3371556 | 2.148888e-02 | 1.668 | 0 | 0 |
| Diseases of programmed cell death | R-HSA-9645723 | 2.180822e-02 | 1.661 | 0 | 0 |
| p75 NTR receptor-mediated signalling | R-HSA-193704 | 2.263571e-02 | 1.645 | 0 | 0 |
| Signaling by RAF1 mutants | R-HSA-9656223 | 2.198816e-02 | 1.658 | 0 | 0 |
| Signaling by WNT in cancer | R-HSA-4791275 | 2.268412e-02 | 1.644 | 0 | 0 |
| Signaling by BRAF and RAF1 fusions | R-HSA-6802952 | 2.317805e-02 | 1.635 | 0 | 0 |
| Defective DNA double strand break response due to BARD1 loss of function | R-HSA-9699150 | 2.620345e-02 | 1.582 | 0 | 0 |
| Defective DNA double strand break response due to BRCA1 loss of function | R-HSA-9663199 | 2.620345e-02 | 1.582 | 0 | 0 |
| CREB phosphorylation | R-HSA-199920 | 2.707925e-02 | 1.567 | 0 | 0 |
| FOXO-mediated transcription of cell death genes | R-HSA-9614657 | 2.675436e-02 | 1.573 | 0 | 0 |
| Developmental Lineage of Mammary Stem Cells | R-HSA-9938206 | 2.583556e-02 | 1.588 | 0 | 0 |
| Interaction between L1 and Ankyrins | R-HSA-445095 | 2.438236e-02 | 1.613 | 0 | 0 |
| Voltage gated Potassium channels | R-HSA-1296072 | 2.416592e-02 | 1.617 | 0 | 0 |
| Developmental Lineages of the Mammary Gland | R-HSA-9924644 | 2.546898e-02 | 1.594 | 0 | 0 |
| Death Receptor Signaling | R-HSA-73887 | 2.879898e-02 | 1.541 | 0 | 0 |
| HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | R-HSA-5693567 | 2.930353e-02 | 1.533 | 0 | 0 |
| Chromatin modifying enzymes | R-HSA-3247509 | 2.924768e-02 | 1.534 | 0 | 0 |
| Oncogenic MAPK signaling | R-HSA-6802957 | 2.691594e-02 | 1.570 | 0 | 0 |
| Protein-protein interactions at synapses | R-HSA-6794362 | 2.691594e-02 | 1.570 | 0 | 0 |
| Signaling by NTRK1 (TRKA) | R-HSA-187037 | 2.411135e-02 | 1.618 | 0 | 0 |
| HDR through Single Strand Annealing (SSA) | R-HSA-5685938 | 2.642789e-02 | 1.578 | 0 | 0 |
| Regulation of TP53 Activity through Acetylation | R-HSA-6804758 | 2.642789e-02 | 1.578 | 0 | 0 |
| FGFR1 mutant receptor activation | R-HSA-1839124 | 2.642789e-02 | 1.578 | 0 | 0 |
| Signaling by ALK fusions and activated point mutants | R-HSA-9725370 | 2.813311e-02 | 1.551 | 0 | 0 |
| Signaling by ALK in cancer | R-HSA-9700206 | 2.813311e-02 | 1.551 | 0 | 0 |
| Transcriptional Regulation by MECP2 | R-HSA-8986944 | 2.863901e-02 | 1.543 | 0 | 0 |
| NFE2L2 regulating anti-oxidant/detoxification enzymes | R-HSA-9818027 | 3.059362e-02 | 1.514 | 0 | 0 |
| Expression of BMAL (ARNTL), CLOCK, and NPAS2 | R-HSA-9931509 | 3.176906e-02 | 1.498 | 0 | 0 |
| Signaling by APC mutants | R-HSA-4839744 | 3.213931e-02 | 1.493 | 0 | 0 |
| AXIN missense mutants destabilize the destruction complex | R-HSA-5467340 | 3.213931e-02 | 1.493 | 0 | 0 |
| APC truncation mutants have impaired AXIN binding | R-HSA-5467337 | 3.213931e-02 | 1.493 | 0 | 0 |
| Truncations of AMER1 destabilize the destruction complex | R-HSA-5467348 | 3.213931e-02 | 1.493 | 0 | 0 |
| Signaling by EGFR | R-HSA-177929 | 3.251502e-02 | 1.488 | 0 | 0 |
| Ion homeostasis | R-HSA-5578775 | 3.251502e-02 | 1.488 | 0 | 0 |
| DCC mediated attractive signaling | R-HSA-418885 | 3.328381e-02 | 1.478 | 0 | 0 |
| Beta-catenin phosphorylation cascade | R-HSA-196299 | 3.328381e-02 | 1.478 | 0 | 0 |
| Signaling by ROBO receptors | R-HSA-376176 | 3.347349e-02 | 1.475 | 0 | 0 |
| Signaling by CSF1 (M-CSF) in myeloid cells | R-HSA-9680350 | 3.520219e-02 | 1.453 | 0 | 0 |
| Interleukin-2 family signaling | R-HSA-451927 | 3.614790e-02 | 1.442 | 0 | 0 |
| Role of ABL in ROBO-SLIT signaling | R-HSA-428890 | 3.753446e-02 | 1.426 | 0 | 0 |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | R-HSA-354194 | 4.094024e-02 | 1.388 | 0 | 0 |
| HSF1-dependent transactivation | R-HSA-3371571 | 3.652775e-02 | 1.437 | 0 | 0 |
| IGF1R signaling cascade | R-HSA-2428924 | 3.941677e-02 | 1.404 | 0 | 0 |
| Activation of PUMA and translocation to mitochondria | R-HSA-139915 | 3.753446e-02 | 1.426 | 0 | 0 |
| DAG and IP3 signaling | R-HSA-1489509 | 3.654229e-02 | 1.437 | 0 | 0 |
| Diseases of DNA repair | R-HSA-9675135 | 4.104884e-02 | 1.387 | 0 | 0 |
| Sodium/Calcium exchangers | R-HSA-425561 | 4.113328e-02 | 1.386 | 0 | 0 |
| Signaling by AXIN mutants | R-HSA-4839735 | 4.113328e-02 | 1.386 | 0 | 0 |
| Signaling by AMER1 mutants | R-HSA-4839748 | 4.113328e-02 | 1.386 | 0 | 0 |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | R-HSA-2404192 | 4.344032e-02 | 1.362 | 0 | 0 |
| Negative regulation of the PI3K/AKT network | R-HSA-199418 | 4.428758e-02 | 1.354 | 0 | 0 |
| Downstream signal transduction | R-HSA-186763 | 4.476270e-02 | 1.349 | 0 | 0 |
| FLT3 signaling in disease | R-HSA-9682385 | 4.582252e-02 | 1.339 | 0 | 0 |
| Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | R-HSA-1236382 | 4.637869e-02 | 1.334 | 0 | 0 |
| Signaling by Ligand-Responsive EGFR Variants in Cancer | R-HSA-5637815 | 4.637869e-02 | 1.334 | 0 | 0 |
| Apoptosis | R-HSA-109581 | 4.728634e-02 | 1.325 | 0 | 0 |
| TGFBR3 regulates FGF2 signaling | R-HSA-9839397 | 5.439310e-02 | 1.264 | 0 | 0 |
| Signaling by TCF7L2 mutants | R-HSA-5339700 | 5.439310e-02 | 1.264 | 0 | 0 |
| TWIK-releated acid-sensitive K+ channel (TASK) | R-HSA-1299316 | 5.439310e-02 | 1.264 | 0 | 0 |
| Type I hemidesmosome assembly | R-HSA-446107 | 5.000125e-02 | 1.301 | 0 | 0 |
| Constitutive Signaling by Overexpressed ERBB2 | R-HSA-9634285 | 5.150559e-02 | 1.288 | 0 | 0 |
| Transport of Mature mRNA derived from an Intron-Containing Transcript | R-HSA-159236 | 5.059792e-02 | 1.296 | 0 | 0 |
| Ovarian tumor domain proteases | R-HSA-5689896 | 5.186654e-02 | 1.285 | 0 | 0 |
| NGF-stimulated transcription | R-HSA-9031628 | 5.119591e-02 | 1.291 | 0 | 0 |
| Diseases of mitotic cell cycle | R-HSA-9675126 | 5.123437e-02 | 1.290 | 0 | 0 |
| Adrenoceptors | R-HSA-390696 | 5.000125e-02 | 1.301 | 0 | 0 |
| Regulation of PTEN gene transcription | R-HSA-8943724 | 4.908638e-02 | 1.309 | 0 | 0 |
| MTOR signalling | R-HSA-165159 | 5.178121e-02 | 1.286 | 0 | 0 |
| Interleukin-15 signaling | R-HSA-8983432 | 5.150559e-02 | 1.288 | 0 | 0 |
| G0 and Early G1 | R-HSA-1538133 | 5.123437e-02 | 1.290 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in cell cycle and proliferation | R-HSA-9825892 | 5.453911e-02 | 1.263 | 0 | 0 |
| MITF-M-dependent gene expression | R-HSA-9856651 | 5.225957e-02 | 1.282 | 0 | 0 |
| MAPK family signaling cascades | R-HSA-5683057 | 5.510461e-02 | 1.259 | 0 | 0 |
| Signaling by ERBB4 | R-HSA-1236394 | 5.516921e-02 | 1.258 | 0 | 0 |
| Interleukin-4 and Interleukin-13 signaling | R-HSA-6785807 | 5.667448e-02 | 1.247 | 0 | 0 |
| Disassembly of the destruction complex and recruitment of AXIN to the membrane | R-HSA-4641262 | 5.716415e-02 | 1.243 | 0 | 0 |
| CD28 dependent PI3K/Akt signaling | R-HSA-389357 | 5.716415e-02 | 1.243 | 0 | 0 |
| Regulated Necrosis | R-HSA-5218859 | 5.723742e-02 | 1.242 | 0 | 0 |
| Processing of DNA double-strand break ends | R-HSA-5693607 | 5.761623e-02 | 1.239 | 0 | 0 |
| Signaling by SCF-KIT | R-HSA-1433557 | 5.786784e-02 | 1.238 | 0 | 0 |
| NFE2L2 regulating inflammation associated genes | R-HSA-9818026 | 5.794374e-02 | 1.237 | 0 | 0 |
| LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production | R-HSA-3134973 | 5.794374e-02 | 1.237 | 0 | 0 |
| NrCAM interactions | R-HSA-447038 | 5.794374e-02 | 1.237 | 0 | 0 |
| Heme signaling | R-HSA-9707616 | 5.925533e-02 | 1.227 | 0 | 0 |
| p130Cas linkage to MAPK signaling for integrins | R-HSA-372708 | 5.935694e-02 | 1.227 | 0 | 0 |
| Chromatin organization | R-HSA-4839726 | 6.102702e-02 | 1.214 | 0 | 0 |
| HuR (ELAVL1) binds and stabilizes mRNA | R-HSA-450520 | 6.446672e-02 | 1.191 | 0 | 0 |
| Regulation of TP53 Activity through Association with Co-factors | R-HSA-6804759 | 6.326981e-02 | 1.199 | 0 | 0 |
| Chaperone Mediated Autophagy | R-HSA-9613829 | 7.014783e-02 | 1.154 | 0 | 0 |
| Transport of Mature Transcript to Cytoplasm | R-HSA-72202 | 6.240721e-02 | 1.205 | 0 | 0 |
| Resolution of D-Loop Structures | R-HSA-5693537 | 6.594358e-02 | 1.181 | 0 | 0 |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | R-HSA-6811558 | 6.324395e-02 | 1.199 | 0 | 0 |
| TP53 Regulates Transcription of Cell Cycle Genes | R-HSA-6791312 | 6.718144e-02 | 1.173 | 0 | 0 |
| GP1b-IX-V activation signalling | R-HSA-430116 | 6.446672e-02 | 1.191 | 0 | 0 |
| Effects of PIP2 hydrolysis | R-HSA-114508 | 6.594358e-02 | 1.181 | 0 | 0 |
| Synaptic adhesion-like molecules | R-HSA-8849932 | 7.014783e-02 | 1.154 | 0 | 0 |
| EPHB-mediated forward signaling | R-HSA-3928662 | 6.440949e-02 | 1.191 | 0 | 0 |
| Selective autophagy | R-HSA-9663891 | 6.445346e-02 | 1.191 | 0 | 0 |
| Membrane Trafficking | R-HSA-199991 | 6.966278e-02 | 1.157 | 0 | 0 |
| Neuronal System | R-HSA-112316 | 6.622657e-02 | 1.179 | 0 | 0 |
| L1CAM interactions | R-HSA-373760 | 6.238017e-02 | 1.205 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in pigmentation | R-HSA-9824585 | 7.141367e-02 | 1.146 | 0 | 0 |
| RAF/MAP kinase cascade | R-HSA-5673001 | 7.268043e-02 | 1.139 | 0 | 0 |
| Caspase activation via Dependence Receptors in the absence of ligand | R-HSA-418889 | 6.446672e-02 | 1.191 | 0 | 0 |
| Signaling by ALK | R-HSA-201556 | 6.548586e-02 | 1.184 | 0 | 0 |
| Aggrephagy | R-HSA-9646399 | 7.307917e-02 | 1.136 | 0 | 0 |
| NPAS4 regulates expression of target genes | R-HSA-9768919 | 7.420039e-02 | 1.130 | 0 | 0 |
| RAF activation | R-HSA-5673000 | 7.420039e-02 | 1.130 | 0 | 0 |
| Signaling by ERBB2 KD Mutants | R-HSA-9664565 | 7.446936e-02 | 1.128 | 0 | 0 |
| MAPK targets/ Nuclear events mediated by MAP kinases | R-HSA-450282 | 7.446936e-02 | 1.128 | 0 | 0 |
| Formation of RNA Pol II elongation complex | R-HSA-112382 | 7.629963e-02 | 1.117 | 0 | 0 |
| TP53 Regulates Transcription of Death Receptors and Ligands | R-HSA-6803211 | 7.641796e-02 | 1.117 | 0 | 0 |
| CLEC7A (Dectin-1) induces NFAT activation | R-HSA-5607763 | 7.641796e-02 | 1.117 | 0 | 0 |
| Regulation of TP53 Expression | R-HSA-6804754 | 8.929188e-02 | 1.049 | 0 | 0 |
| Regulation of cortical dendrite branching | R-HSA-8985801 | 8.929188e-02 | 1.049 | 0 | 0 |
| Potassium transport channels | R-HSA-1296067 | 8.929188e-02 | 1.049 | 0 | 0 |
| GLI proteins bind promoters of Hh responsive genes to promote transcription | R-HSA-5635851 | 7.917374e-02 | 1.101 | 0 | 0 |
| MET activates RAP1 and RAC1 | R-HSA-8875555 | 8.087405e-02 | 1.092 | 0 | 0 |
| Folding of actin by CCT/TriC | R-HSA-390450 | 8.087405e-02 | 1.092 | 0 | 0 |
| Activation of PPARGC1A (PGC-1alpha) by phosphorylation | R-HSA-2151209 | 8.087405e-02 | 1.092 | 0 | 0 |
| Sema3A PAK dependent Axon repulsion | R-HSA-399954 | 9.092197e-02 | 1.041 | 0 | 0 |
| Signaling by ERBB2 in Cancer | R-HSA-1227990 | 8.418659e-02 | 1.075 | 0 | 0 |
| SHC1 events in ERBB2 signaling | R-HSA-1250196 | 8.418659e-02 | 1.075 | 0 | 0 |
| G1/S-Specific Transcription | R-HSA-69205 | 9.253977e-02 | 1.034 | 0 | 0 |
| RNA Polymerase II Transcription Elongation | R-HSA-75955 | 8.361748e-02 | 1.078 | 0 | 0 |
| Processing of Capped Intron-Containing Pre-mRNA | R-HSA-72203 | 8.672276e-02 | 1.062 | 0 | 0 |
| RNA Polymerase II Pre-transcription Events | R-HSA-674695 | 9.315872e-02 | 1.031 | 0 | 0 |
| Rap1 signalling | R-HSA-392517 | 8.199420e-02 | 1.086 | 0 | 0 |
| Developmental Cell Lineages of the Integumentary System | R-HSA-9734779 | 7.855382e-02 | 1.105 | 0 | 0 |
| Nuclear Events (kinase and transcription factor activation) | R-HSA-198725 | 7.990859e-02 | 1.097 | 0 | 0 |
| PKMTs methylate histone lysines | R-HSA-3214841 | 8.120254e-02 | 1.090 | 0 | 0 |
| Neurotransmitter receptors and postsynaptic signal transmission | R-HSA-112314 | 7.904200e-02 | 1.102 | 0 | 0 |
| Aberrant regulation of mitotic cell cycle due to RB1 defects | R-HSA-9687139 | 8.418659e-02 | 1.075 | 0 | 0 |
| Cellular Senescence | R-HSA-2559583 | 8.910507e-02 | 1.050 | 0 | 0 |
| Calmodulin induced events | R-HSA-111933 | 9.253977e-02 | 1.034 | 0 | 0 |
| CaM pathway | R-HSA-111997 | 9.253977e-02 | 1.034 | 0 | 0 |
| Tandem pore domain potassium channels | R-HSA-1296346 | 8.087405e-02 | 1.092 | 0 | 0 |
| Cell-extracellular matrix interactions | R-HSA-446353 | 9.092197e-02 | 1.041 | 0 | 0 |
| Kinesins | R-HSA-983189 | 8.747404e-02 | 1.058 | 0 | 0 |
| Trafficking of AMPA receptors | R-HSA-399719 | 9.461251e-02 | 1.024 | 0 | 0 |
| MAPK1/MAPK3 signaling | R-HSA-5684996 | 9.508442e-02 | 1.022 | 0 | 0 |
| Nonhomologous End-Joining (NHEJ) | R-HSA-5693571 | 9.524597e-02 | 1.021 | 0 | 0 |
| Co-stimulation by CD28 | R-HSA-389356 | 9.524597e-02 | 1.021 | 0 | 0 |
| Developmental Lineage of Mammary Gland Luminal Epithelial Cells | R-HSA-9927418 | 9.904609e-02 | 1.004 | 0 | 0 |
| Regulation of localization of FOXO transcription factors | R-HSA-9614399 | 9.912929e-02 | 1.004 | 0 | 0 |
| ChREBP activates metabolic gene expression | R-HSA-163765 | 9.912929e-02 | 1.004 | 0 | 0 |
| TCF dependent signaling in response to WNT | R-HSA-201681 | 1.024172e-01 | 0.990 | 0 | 0 |
| TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation | R-HSA-8869496 | 1.032590e-01 | 0.986 | 0 | 0 |
| NOTCH1 Intracellular Domain Regulates Transcription | R-HSA-2122947 | 1.041343e-01 | 0.982 | 0 | 0 |
| Late Phase of HIV Life Cycle | R-HSA-162599 | 1.058961e-01 | 0.975 | 0 | 0 |
| APC truncation mutants are not K63 polyubiquitinated | R-HSA-5467333 | 1.168555e-01 | 0.932 | 0 | 0 |
| Loss of Function of TP53 in Cancer | R-HSA-9723907 | 1.168555e-01 | 0.932 | 0 | 0 |
| Loss of function of TP53 in cancer due to loss of tetramerization ability | R-HSA-9723905 | 1.168555e-01 | 0.932 | 0 | 0 |
| Diseases of Telomere Maintenance | R-HSA-9673013 | 2.200618e-01 | 0.657 | 0 | 0 |
| Alternative Lengthening of Telomeres (ALT) | R-HSA-9006821 | 2.200618e-01 | 0.657 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere | R-HSA-9670621 | 2.200618e-01 | 0.657 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to ATRX Mutations | R-HSA-9670615 | 2.200618e-01 | 0.657 | 0 | 0 |
| TWIK-related spinal cord K+ channel (TRESK) | R-HSA-1299344 | 2.200618e-01 | 0.657 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to DAXX Mutations | R-HSA-9670613 | 2.200618e-01 | 0.657 | 0 | 0 |
| Defective Mismatch Repair Associated With MSH6 | R-HSA-5632968 | 2.200618e-01 | 0.657 | 0 | 0 |
| Defective MOGS causes CDG-2b | R-HSA-4793954 | 2.200618e-01 | 0.657 | 0 | 0 |
| Impaired BRCA2 binding to SEM1 (DSS1) | R-HSA-9763198 | 2.200618e-01 | 0.657 | 0 | 0 |
| Impaired BRCA2 translocation to the nucleus | R-HSA-9709275 | 2.200618e-01 | 0.657 | 0 | 0 |
| TLR3-mediated TICAM1-dependent programmed cell death | R-HSA-9013957 | 1.717754e-01 | 0.765 | 0 | 0 |
| AKT-mediated inactivation of FOXO1A | R-HSA-211163 | 1.717754e-01 | 0.765 | 0 | 0 |
| RUNX2 regulates genes involved in differentiation of myeloid cells | R-HSA-8941333 | 1.717754e-01 | 0.765 | 0 | 0 |
| PLCG1 events in ERBB2 signaling | R-HSA-1251932 | 1.717754e-01 | 0.765 | 0 | 0 |
| GRB7 events in ERBB2 signaling | R-HSA-1306955 | 1.717754e-01 | 0.765 | 0 | 0 |
| ARL13B-mediated ciliary trafficking of INPP5E | R-HSA-5624958 | 3.112125e-01 | 0.507 | 0 | 0 |
| Mitochondrial transcription initiation | R-HSA-163282 | 3.112125e-01 | 0.507 | 0 | 0 |
| Interactions of Tat with host cellular proteins | R-HSA-176034 | 3.112125e-01 | 0.507 | 0 | 0 |
| NFG and proNGF binds to p75NTR | R-HSA-205017 | 3.112125e-01 | 0.507 | 0 | 0 |
| Abasic sugar-phosphate removal via the single-nucleotide replacement pathway | R-HSA-73930 | 3.112125e-01 | 0.507 | 0 | 0 |
| TALDO1 deficiency: failed conversion of Fru(6)P, E4P to SH7P, GA3P | R-HSA-6791462 | 3.112125e-01 | 0.507 | 0 | 0 |
| XAV939 stabilizes AXIN | R-HSA-5545619 | 3.112125e-01 | 0.507 | 0 | 0 |
| Defective PGM1 causes PGM1-CDG | R-HSA-5609974 | 3.112125e-01 | 0.507 | 0 | 0 |
| Defective SLC12A6 causes agenesis of the corpus callosum, with peripheral neuropathy (ACCPN) | R-HSA-5619039 | 3.112125e-01 | 0.507 | 0 | 0 |
| Defective GFPT1 causes CMSTA1 | R-HSA-4085023 | 3.112125e-01 | 0.507 | 0 | 0 |
| Defective SLC6A2 causes orthostatic intolerance (OI) | R-HSA-5619109 | 3.112125e-01 | 0.507 | 0 | 0 |
| Defective SLC4A1 causes hereditary spherocytosis type 4 (HSP4), distal renal tubular acidosis (dRTA) and dRTA with hemolytic anemia (dRTA-HA) | R-HSA-5619050 | 3.112125e-01 | 0.507 | 0 | 0 |
| Defective SLC20A2 causes idiopathic basal ganglia calcification 1 (IBGC1) | R-HSA-5619111 | 3.112125e-01 | 0.507 | 0 | 0 |
| TALDO1 deficiency: failed conversion of SH7P, GA3P to Fru(6)P, E4P | R-HSA-6791055 | 3.112125e-01 | 0.507 | 0 | 0 |
| MyD88 deficiency (TLR5) | R-HSA-5602680 | 3.112125e-01 | 0.507 | 0 | 0 |
| Intestinal infectious diseases | R-HSA-8942233 | 3.112125e-01 | 0.507 | 0 | 0 |
| Defective ABCC9 causes CMD10, ATFB12 and Cantu syndrome | R-HSA-5678420 | 3.112125e-01 | 0.507 | 0 | 0 |
| POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation | R-HSA-2892245 | 1.298329e-01 | 0.887 | 0 | 0 |
| RUNX3 regulates WNT signaling | R-HSA-8951430 | 1.298329e-01 | 0.887 | 0 | 0 |
| Activated NTRK3 signals through PI3K | R-HSA-9603381 | 1.298329e-01 | 0.887 | 0 | 0 |
| Binding of TCF/LEF:CTNNB1 to target gene promoters | R-HSA-4411364 | 1.298329e-01 | 0.887 | 0 | 0 |
| Resolution of AP sites via the single-nucleotide replacement pathway | R-HSA-110381 | 2.164912e-01 | 0.665 | 0 | 0 |
| G2 Phase | R-HSA-68911 | 2.164912e-01 | 0.665 | 0 | 0 |
| Signaling by membrane-tethered fusions of PDGFRA or PDGFRB | R-HSA-9673768 | 2.164912e-01 | 0.665 | 0 | 0 |
| Regulation by c-FLIP | R-HSA-3371378 | 1.585068e-01 | 0.800 | 0 | 0 |
| RSK activation | R-HSA-444257 | 1.585068e-01 | 0.800 | 0 | 0 |
| Dimerization of procaspase-8 | R-HSA-69416 | 1.585068e-01 | 0.800 | 0 | 0 |
| NFE2L2 regulates pentose phosphate pathway genes | R-HSA-9818028 | 1.191083e-01 | 0.924 | 0 | 0 |
| Mitotic Telophase/Cytokinesis | R-HSA-68884 | 1.191083e-01 | 0.924 | 0 | 0 |
| Phosphorylation of the APC/C | R-HSA-176412 | 1.067356e-01 | 0.972 | 0 | 0 |
| SHC-related events triggered by IGF1R | R-HSA-2428933 | 1.406635e-01 | 0.852 | 0 | 0 |
| NFE2L2 regulating MDR associated enzymes | R-HSA-9818032 | 1.888876e-01 | 0.724 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex | R-HSA-937042 | 1.888876e-01 | 0.724 | 0 | 0 |
| Interleukin-21 signaling | R-HSA-9020958 | 1.888876e-01 | 0.724 | 0 | 0 |
| CASP8 activity is inhibited | R-HSA-5218900 | 1.888876e-01 | 0.724 | 0 | 0 |
| ALK mutants bind TKIs | R-HSA-9700645 | 1.888876e-01 | 0.724 | 0 | 0 |
| TRAIL signaling | R-HSA-75158 | 2.620703e-01 | 0.582 | 0 | 0 |
| Epithelial-Mesenchymal Transition (EMT) during gastrulation | R-HSA-9758919 | 2.620703e-01 | 0.582 | 0 | 0 |
| CDH11 homotypic and heterotypic interactions | R-HSA-9833576 | 2.620703e-01 | 0.582 | 0 | 0 |
| SLIT2:ROBO1 increases RHOA activity | R-HSA-8985586 | 2.620703e-01 | 0.582 | 0 | 0 |
| Activation of caspases through apoptosome-mediated cleavage | R-HSA-111459 | 2.620703e-01 | 0.582 | 0 | 0 |
| TWIK related potassium channel (TREK) | R-HSA-1299503 | 3.917151e-01 | 0.407 | 0 | 0 |
| Glycogen storage disease type 0 (muscle GYS1) | R-HSA-3828062 | 3.917151e-01 | 0.407 | 0 | 0 |
| Glycogen storage disease type XV (GYG1) | R-HSA-3814836 | 3.917151e-01 | 0.407 | 0 | 0 |
| Defective SLC6A5 causes hyperekplexia 3 (HKPX3) | R-HSA-5619089 | 3.917151e-01 | 0.407 | 0 | 0 |
| HHAT G278V doesn't palmitoylate Hh-Np | R-HSA-5658034 | 3.917151e-01 | 0.407 | 0 | 0 |
| Mitotic Metaphase/Anaphase Transition | R-HSA-68881 | 3.917151e-01 | 0.407 | 0 | 0 |
| Inactivation of APC/C via direct inhibition of the APC/C complex | R-HSA-141430 | 1.237964e-01 | 0.907 | 0 | 0 |
| Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) | R-HSA-9661069 | 1.636301e-01 | 0.786 | 0 | 0 |
| TICAM1,TRAF6-dependent induction of TAK1 complex | R-HSA-9014325 | 2.205920e-01 | 0.656 | 0 | 0 |
| Synthesis of PIPs at the late endosome membrane | R-HSA-1660517 | 1.420282e-01 | 0.848 | 0 | 0 |
| Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase | R-HSA-176407 | 1.420282e-01 | 0.848 | 0 | 0 |
| STAT5 Activation | R-HSA-9645135 | 3.077007e-01 | 0.512 | 0 | 0 |
| RAS signaling downstream of NF1 loss-of-function variants | R-HSA-6802953 | 3.077007e-01 | 0.512 | 0 | 0 |
| Signaling by EGFR in Cancer | R-HSA-1643713 | 1.080224e-01 | 0.966 | 0 | 0 |
| PCNA-Dependent Long Patch Base Excision Repair | R-HSA-5651801 | 1.613433e-01 | 0.792 | 0 | 0 |
| Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants | R-HSA-9670439 | 1.394961e-01 | 0.855 | 0 | 0 |
| RUNX2 regulates genes involved in cell migration | R-HSA-8941332 | 2.532551e-01 | 0.596 | 0 | 0 |
| NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 | R-HSA-933543 | 2.532551e-01 | 0.596 | 0 | 0 |
| InlA-mediated entry of Listeria monocytogenes into host cells | R-HSA-8876493 | 2.532551e-01 | 0.596 | 0 | 0 |
| Activated NTRK3 signals through RAS | R-HSA-9034864 | 2.532551e-01 | 0.596 | 0 | 0 |
| Tat-mediated HIV elongation arrest and recovery | R-HSA-167243 | 1.212113e-01 | 0.916 | 0 | 0 |
| Pausing and recovery of Tat-mediated HIV elongation | R-HSA-167238 | 1.212113e-01 | 0.916 | 0 | 0 |
| TRAF6-mediated induction of TAK1 complex within TLR4 complex | R-HSA-937072 | 2.130858e-01 | 0.671 | 0 | 0 |
| Impaired BRCA2 binding to PALB2 | R-HSA-9709603 | 1.816448e-01 | 0.741 | 0 | 0 |
| Interleukin receptor SHC signaling | R-HSA-912526 | 1.562058e-01 | 0.806 | 0 | 0 |
| Prefoldin mediated transfer of substrate to CCT/TriC | R-HSA-389957 | 1.562058e-01 | 0.806 | 0 | 0 |
| HIV elongation arrest and recovery | R-HSA-167287 | 1.351840e-01 | 0.869 | 0 | 0 |
| Pausing and recovery of HIV elongation | R-HSA-167290 | 1.351840e-01 | 0.869 | 0 | 0 |
| Transport of the SLBP independent Mature mRNA | R-HSA-159227 | 1.175576e-01 | 0.930 | 0 | 0 |
| Transport of the SLBP Dependant Mature mRNA | R-HSA-159230 | 1.300484e-01 | 0.886 | 0 | 0 |
| Association of TriC/CCT with target proteins during biosynthesis | R-HSA-390471 | 1.300484e-01 | 0.886 | 0 | 0 |
| Downstream signaling of activated FGFR3 | R-HSA-5654708 | 1.499082e-01 | 0.824 | 0 | 0 |
| Late endosomal microautophagy | R-HSA-9615710 | 1.499082e-01 | 0.824 | 0 | 0 |
| Signaling by ERBB2 TMD/JMD mutants | R-HSA-9665686 | 1.737426e-01 | 0.760 | 0 | 0 |
| Co-inhibition by CTLA4 | R-HSA-389513 | 2.028289e-01 | 0.693 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to PALB2 loss of function | R-HSA-9701193 | 2.028289e-01 | 0.693 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function | R-HSA-9704331 | 2.028289e-01 | 0.693 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA1 loss of function | R-HSA-9701192 | 2.028289e-01 | 0.693 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function | R-HSA-9704646 | 2.028289e-01 | 0.693 | 0 | 0 |
| Aberrant regulation of mitotic exit in cancer due to RB1 defects | R-HSA-9687136 | 2.392076e-01 | 0.621 | 0 | 0 |
| Activated NTRK2 signals through RAS | R-HSA-9026519 | 2.865374e-01 | 0.543 | 0 | 0 |
| APOBEC3G mediated resistance to HIV-1 infection | R-HSA-180689 | 2.865374e-01 | 0.543 | 0 | 0 |
| Phosphorylation of CLOCK, acetylation of BMAL1 (ARNTL) at target gene promoters | R-HSA-9931512 | 2.865374e-01 | 0.543 | 0 | 0 |
| Activated NTRK2 signals through CDK5 | R-HSA-9032845 | 3.527483e-01 | 0.453 | 0 | 0 |
| MET activates PI3K/AKT signaling | R-HSA-8851907 | 3.527483e-01 | 0.453 | 0 | 0 |
| Netrin mediated repulsion signals | R-HSA-418886 | 3.527483e-01 | 0.453 | 0 | 0 |
| TRIF-mediated programmed cell death | R-HSA-2562578 | 3.527483e-01 | 0.453 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression linked to triglyceride lipolysis in adipose | R-HSA-9031528 | 3.527483e-01 | 0.453 | 0 | 0 |
| SOS-mediated signalling | R-HSA-112412 | 3.527483e-01 | 0.453 | 0 | 0 |
| Axonal growth stimulation | R-HSA-209563 | 4.628131e-01 | 0.335 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of other transcription factors | R-HSA-8866906 | 4.628131e-01 | 0.335 | 0 | 0 |
| Negative regulation of TCF-dependent signaling by DVL-interacting proteins | R-HSA-5368598 | 4.628131e-01 | 0.335 | 0 | 0 |
| Loss of Function of KMT2D in Kabuki Syndrome | R-HSA-9944971 | 4.628131e-01 | 0.335 | 0 | 0 |
| MET activates PTPN11 | R-HSA-8865999 | 4.628131e-01 | 0.335 | 0 | 0 |
| Defective CYP1B1 causes Glaucoma | R-HSA-5579000 | 4.628131e-01 | 0.335 | 0 | 0 |
| IRAK4 deficiency (TLR5) | R-HSA-5603037 | 4.628131e-01 | 0.335 | 0 | 0 |
| Defective CYP7B1 causes SPG5A and CBAS3 | R-HSA-5579013 | 4.628131e-01 | 0.335 | 0 | 0 |
| Defective GCLC causes HAGGSD | R-HSA-5578999 | 4.628131e-01 | 0.335 | 0 | 0 |
| Loss of Function of KMT2D in MLL4 Complex Formation in Kabuki Syndrome | R-HSA-9944997 | 4.628131e-01 | 0.335 | 0 | 0 |
| Formation of HIV-1 elongation complex containing HIV-1 Tat | R-HSA-167200 | 1.245690e-01 | 0.905 | 0 | 0 |
| Transport of Mature mRNA Derived from an Intronless Transcript | R-HSA-159231 | 1.245690e-01 | 0.905 | 0 | 0 |
| Developmental Lineage of Mammary Gland Alveolar Cells | R-HSA-9927426 | 1.431919e-01 | 0.844 | 0 | 0 |
| Downstream signaling of activated FGFR4 | R-HSA-5654716 | 1.653462e-01 | 0.782 | 0 | 0 |
| RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression | R-HSA-9933387 | 1.653462e-01 | 0.782 | 0 | 0 |
| Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) | R-HSA-5693554 | 1.920418e-01 | 0.717 | 0 | 0 |
| APC-Cdc20 mediated degradation of Nek2A | R-HSA-179409 | 2.247867e-01 | 0.648 | 0 | 0 |
| JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | R-HSA-450321 | 2.247867e-01 | 0.648 | 0 | 0 |
| TNFR1-induced proapoptotic signaling | R-HSA-5357786 | 2.247867e-01 | 0.648 | 0 | 0 |
| HIV Transcription Elongation | R-HSA-167169 | 1.364143e-01 | 0.865 | 0 | 0 |
| Transport of Mature mRNAs Derived from Intronless Transcripts | R-HSA-159234 | 1.364143e-01 | 0.865 | 0 | 0 |
| Tat-mediated elongation of the HIV-1 transcript | R-HSA-167246 | 1.364143e-01 | 0.865 | 0 | 0 |
| Formation of HIV elongation complex in the absence of HIV Tat | R-HSA-167152 | 1.364143e-01 | 0.865 | 0 | 0 |
| Downstream signaling of activated FGFR1 | R-HSA-5654687 | 1.569630e-01 | 0.804 | 0 | 0 |
| POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation | R-HSA-2892247 | 2.660142e-01 | 0.575 | 0 | 0 |
| p75NTR recruits signalling complexes | R-HSA-209543 | 3.201284e-01 | 0.495 | 0 | 0 |
| NOTCH2 intracellular domain regulates transcription | R-HSA-2197563 | 3.201284e-01 | 0.495 | 0 | 0 |
| Leading Strand Synthesis | R-HSA-69109 | 3.201284e-01 | 0.495 | 0 | 0 |
| Polymerase switching | R-HSA-69091 | 3.201284e-01 | 0.495 | 0 | 0 |
| Z-decay: degradation of maternal mRNAs by zygotically expressed factors | R-HSA-9820865 | 3.201284e-01 | 0.495 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in GG-NER | R-HSA-5696397 | 2.474069e-01 | 0.607 | 0 | 0 |
| mRNA 3'-end processing | R-HSA-72187 | 1.335906e-01 | 0.874 | 0 | 0 |
| Formation of the beta-catenin:TCF transactivating complex | R-HSA-201722 | 1.265570e-01 | 0.898 | 0 | 0 |
| Recycling pathway of L1 | R-HSA-437239 | 1.527626e-01 | 0.816 | 0 | 0 |
| TNFR1-induced NF-kappa-B signaling pathway | R-HSA-5357956 | 2.306463e-01 | 0.637 | 0 | 0 |
| PI3K events in ERBB2 signaling | R-HSA-1963642 | 2.933275e-01 | 0.533 | 0 | 0 |
| FGFR1b ligand binding and activation | R-HSA-190370 | 3.967264e-01 | 0.402 | 0 | 0 |
| Activated NTRK2 signals through PI3K | R-HSA-9028335 | 3.967264e-01 | 0.402 | 0 | 0 |
| Activation of AMPK downstream of NMDARs | R-HSA-9619483 | 2.508031e-01 | 0.601 | 0 | 0 |
| Striated Muscle Contraction | R-HSA-390522 | 2.333299e-01 | 0.632 | 0 | 0 |
| Nuclear Receptor transcription pathway | R-HSA-383280 | 1.235528e-01 | 0.908 | 0 | 0 |
| GAB1 signalosome | R-HSA-180292 | 3.209766e-01 | 0.494 | 0 | 0 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | R-HSA-72706 | 1.190738e-01 | 0.924 | 0 | 0 |
| Downstream signaling of activated FGFR2 | R-HSA-5654696 | 2.703380e-01 | 0.568 | 0 | 0 |
| Nuclear Pore Complex (NPC) Disassembly | R-HSA-3301854 | 2.703380e-01 | 0.568 | 0 | 0 |
| Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) | R-HSA-5619107 | 2.924408e-01 | 0.534 | 0 | 0 |
| Formation of tubulin folding intermediates by CCT/TriC | R-HSA-389960 | 3.181194e-01 | 0.497 | 0 | 0 |
| PI-3K cascade:FGFR3 | R-HSA-5654710 | 3.488000e-01 | 0.457 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Cyclin B | R-HSA-174048 | 3.488000e-01 | 0.457 | 0 | 0 |
| Abortive elongation of HIV-1 transcript in the absence of Tat | R-HSA-167242 | 3.488000e-01 | 0.457 | 0 | 0 |
| Formation of the polybromo-BAF (pBAF) complex | R-HSA-9933939 | 3.871521e-01 | 0.412 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation | R-HSA-975163 | 3.871521e-01 | 0.412 | 0 | 0 |
| Formation of the canonical BAF (cBAF) complex | R-HSA-9933937 | 3.871521e-01 | 0.412 | 0 | 0 |
| CRMPs in Sema3A signaling | R-HSA-399956 | 3.871521e-01 | 0.412 | 0 | 0 |
| ARMS-mediated activation | R-HSA-170984 | 4.392699e-01 | 0.357 | 0 | 0 |
| Regulated proteolysis of p75NTR | R-HSA-193692 | 4.392699e-01 | 0.357 | 0 | 0 |
| WNT mediated activation of DVL | R-HSA-201688 | 4.392699e-01 | 0.357 | 0 | 0 |
| 5-Phosphoribose 1-diphosphate biosynthesis | R-HSA-73843 | 4.392699e-01 | 0.357 | 0 | 0 |
| TNFR1-mediated ceramide production | R-HSA-5626978 | 5.256047e-01 | 0.279 | 0 | 0 |
| NADE modulates death signalling | R-HSA-205025 | 5.256047e-01 | 0.279 | 0 | 0 |
| Inhibition of TSC complex formation by PKB | R-HSA-165181 | 5.256047e-01 | 0.279 | 0 | 0 |
| RUNX3 regulates BCL2L11 (BIM) transcription | R-HSA-8952158 | 5.256047e-01 | 0.279 | 0 | 0 |
| ATP sensitive Potassium channels | R-HSA-1296025 | 5.256047e-01 | 0.279 | 0 | 0 |
| Defective LFNG causes SCDO3 | R-HSA-5083630 | 5.256047e-01 | 0.279 | 0 | 0 |
| Signaling by LRP5 mutants | R-HSA-5339717 | 5.256047e-01 | 0.279 | 0 | 0 |
| EGFR downregulation | R-HSA-182971 | 3.137663e-01 | 0.503 | 0 | 0 |
| Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | R-HSA-389958 | 3.137663e-01 | 0.503 | 0 | 0 |
| IP3 and IP4 transport between cytosol and nucleus | R-HSA-1855196 | 3.137663e-01 | 0.503 | 0 | 0 |
| IP6 and IP7 transport between cytosol and nucleus | R-HSA-1855229 | 3.137663e-01 | 0.503 | 0 | 0 |
| PI-3K cascade:FGFR4 | R-HSA-5654720 | 3.766466e-01 | 0.424 | 0 | 0 |
| RNA Polymerase II Transcription Termination | R-HSA-73856 | 2.445296e-01 | 0.612 | 0 | 0 |
| Vpr-mediated nuclear import of PICs | R-HSA-180910 | 3.087594e-01 | 0.510 | 0 | 0 |
| L13a-mediated translational silencing of Ceruloplasmin expression | R-HSA-156827 | 1.735331e-01 | 0.761 | 0 | 0 |
| Transcription of the HIV genome | R-HSA-167172 | 2.416696e-01 | 0.617 | 0 | 0 |
| Developmental Lineage of Multipotent Pancreatic Progenitor Cells | R-HSA-9937080 | 3.353271e-01 | 0.475 | 0 | 0 |
| Spry regulation of FGF signaling | R-HSA-1295596 | 4.201226e-01 | 0.377 | 0 | 0 |
| Formation of the embryonic stem cell BAF (esBAF) complex | R-HSA-9933946 | 4.201226e-01 | 0.377 | 0 | 0 |
| Translesion synthesis by REV1 | R-HSA-110312 | 4.201226e-01 | 0.377 | 0 | 0 |
| SHC1 events in EGFR signaling | R-HSA-180336 | 4.201226e-01 | 0.377 | 0 | 0 |
| mRNA Splicing - Major Pathway | R-HSA-72163 | 1.208875e-01 | 0.918 | 0 | 0 |
| IPs transport between nucleus and cytosol | R-HSA-1855170 | 3.570483e-01 | 0.447 | 0 | 0 |
| Lagging Strand Synthesis | R-HSA-69186 | 4.043772e-01 | 0.393 | 0 | 0 |
| SHC-mediated cascade:FGFR3 | R-HSA-5654704 | 4.043772e-01 | 0.393 | 0 | 0 |
| Formation of apoptosome | R-HSA-111458 | 4.801134e-01 | 0.319 | 0 | 0 |
| Regulation of the apoptosome activity | R-HSA-9627069 | 4.801134e-01 | 0.319 | 0 | 0 |
| Establishment of Sister Chromatid Cohesion | R-HSA-2468052 | 4.801134e-01 | 0.319 | 0 | 0 |
| Activation of Ca-permeable Kainate Receptor | R-HSA-451308 | 4.801134e-01 | 0.319 | 0 | 0 |
| Processive synthesis on the C-strand of the telomere | R-HSA-174414 | 3.908415e-01 | 0.408 | 0 | 0 |
| Formation of a pool of free 40S subunits | R-HSA-72689 | 2.512431e-01 | 0.600 | 0 | 0 |
| NEP/NS2 Interacts with the Cellular Export Machinery | R-HSA-168333 | 3.397444e-01 | 0.469 | 0 | 0 |
| DNA Damage Recognition in GG-NER | R-HSA-5696394 | 3.788571e-01 | 0.422 | 0 | 0 |
| Caspase activation via Death Receptors in the presence of ligand | R-HSA-140534 | 4.524756e-01 | 0.344 | 0 | 0 |
| Translesion synthesis by POLI | R-HSA-5656121 | 4.524756e-01 | 0.344 | 0 | 0 |
| snRNP Assembly | R-HSA-191859 | 3.243255e-01 | 0.489 | 0 | 0 |
| Metabolism of non-coding RNA | R-HSA-194441 | 3.243255e-01 | 0.489 | 0 | 0 |
| Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | R-HSA-975956 | 2.794462e-01 | 0.554 | 0 | 0 |
| SHC-mediated cascade:FGFR4 | R-HSA-5654719 | 4.318650e-01 | 0.365 | 0 | 0 |
| mRNA Splicing | R-HSA-72172 | 1.846669e-01 | 0.734 | 0 | 0 |
| Negative regulation of FGFR3 signaling | R-HSA-5654732 | 4.150625e-01 | 0.382 | 0 | 0 |
| Formation of the HIV-1 Early Elongation Complex | R-HSA-167158 | 4.150625e-01 | 0.382 | 0 | 0 |
| Formation of the Early Elongation Complex | R-HSA-113418 | 4.150625e-01 | 0.382 | 0 | 0 |
| Translation initiation complex formation | R-HSA-72649 | 3.661710e-01 | 0.436 | 0 | 0 |
| Constitutive Signaling by Aberrant PI3K in Cancer | R-HSA-2219530 | 3.167079e-01 | 0.499 | 0 | 0 |
| PERK regulates gene expression | R-HSA-381042 | 4.224614e-01 | 0.374 | 0 | 0 |
| Negative regulation of FGFR4 signaling | R-HSA-5654733 | 4.391255e-01 | 0.357 | 0 | 0 |
| PI-3K cascade:FGFR1 | R-HSA-5654689 | 4.589955e-01 | 0.338 | 0 | 0 |
| GRB2 events in ERBB2 signaling | R-HSA-1963640 | 4.840558e-01 | 0.315 | 0 | 0 |
| The CRY:PER:kinase complex represses transactivation by the BMAL:CLOCK (ARNTL:CLOCK) complex | R-HSA-9931521 | 4.840558e-01 | 0.315 | 0 | 0 |
| Translesion synthesis by POLK | R-HSA-5655862 | 4.840558e-01 | 0.315 | 0 | 0 |
| Phase 2 - plateau phase | R-HSA-5576893 | 4.840558e-01 | 0.315 | 0 | 0 |
| RHOBTB3 ATPase cycle | R-HSA-9706019 | 5.190734e-01 | 0.285 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in TC-NER | R-HSA-6782210 | 4.008517e-01 | 0.397 | 0 | 0 |
| Ribosomal scanning and start codon recognition | R-HSA-72702 | 4.008517e-01 | 0.397 | 0 | 0 |
| PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA | R-HSA-9954714 | 3.639547e-01 | 0.439 | 0 | 0 |
| HSF1 activation | R-HSA-3371511 | 4.441271e-01 | 0.352 | 0 | 0 |
| Response of EIF2AK4 (GCN2) to amino acid deficiency | R-HSA-9633012 | 3.593587e-01 | 0.444 | 0 | 0 |
| Regulation of FZD by ubiquitination | R-HSA-4641263 | 5.147347e-01 | 0.288 | 0 | 0 |
| Removal of the Flap Intermediate from the C-strand | R-HSA-174437 | 5.147347e-01 | 0.288 | 0 | 0 |
| Deadenylation of mRNA | R-HSA-429947 | 5.117906e-01 | 0.291 | 0 | 0 |
| SHC-mediated cascade:FGFR1 | R-HSA-5654688 | 5.117906e-01 | 0.291 | 0 | 0 |
| Transcription-Coupled Nucleotide Excision Repair (TC-NER) | R-HSA-6781827 | 4.562563e-01 | 0.341 | 0 | 0 |
| Formation of the ternary complex, and subsequently, the 43S complex | R-HSA-72695 | 5.064604e-01 | 0.295 | 0 | 0 |
| RNA polymerase II transcribes snRNA genes | R-HSA-6807505 | 5.161996e-01 | 0.287 | 0 | 0 |
| Nuclear events mediated by NFE2L2 | R-HSA-9759194 | 5.108255e-01 | 0.292 | 0 | 0 |
| Transcriptional regulation by RUNX2 | R-HSA-8878166 | 3.903394e-01 | 0.409 | 0 | 0 |
| Signaling by FGFR2 | R-HSA-5654738 | 3.039053e-01 | 0.517 | 0 | 0 |
| FOXO-mediated transcription | R-HSA-9614085 | 1.492950e-01 | 0.826 | 0 | 0 |
| RUNX2 regulates bone development | R-HSA-8941326 | 1.713331e-01 | 0.766 | 0 | 0 |
| RUNX2 regulates osteoblast differentiation | R-HSA-8940973 | 4.150625e-01 | 0.382 | 0 | 0 |
| Eukaryotic Translation Initiation | R-HSA-72613 | 1.978487e-01 | 0.704 | 0 | 0 |
| Signaling by FGFR4 | R-HSA-5654743 | 1.087628e-01 | 0.964 | 0 | 0 |
| Nucleotide Excision Repair | R-HSA-5696398 | 3.846002e-01 | 0.415 | 0 | 0 |
| Cap-dependent Translation Initiation | R-HSA-72737 | 1.978487e-01 | 0.704 | 0 | 0 |
| Transcriptional regulation of pluripotent stem cells | R-HSA-452723 | 1.132998e-01 | 0.946 | 0 | 0 |
| Specification of the neural plate border | R-HSA-9834899 | 1.816448e-01 | 0.741 | 0 | 0 |
| Translocation of SLC2A4 (GLUT4) to the plasma membrane | R-HSA-1445148 | 1.397902e-01 | 0.855 | 0 | 0 |
| HATs acetylate histones | R-HSA-3214847 | 3.943942e-01 | 0.404 | 0 | 0 |
| Negative regulation of FGFR1 signaling | R-HSA-5654726 | 5.323107e-01 | 0.274 | 0 | 0 |
| STAT5 activation downstream of FLT3 ITD mutants | R-HSA-9702518 | 2.660142e-01 | 0.575 | 0 | 0 |
| Extra-nuclear estrogen signaling | R-HSA-9009391 | 2.363531e-01 | 0.626 | 0 | 0 |
| Insulin receptor signalling cascade | R-HSA-74751 | 1.914294e-01 | 0.718 | 0 | 0 |
| Resolution of D-loop Structures through Holliday Junction Intermediates | R-HSA-5693568 | 1.175576e-01 | 0.930 | 0 | 0 |
| NFE2L2 regulating tumorigenic genes | R-HSA-9818030 | 3.537490e-01 | 0.451 | 0 | 0 |
| Apoptosis induced DNA fragmentation | R-HSA-140342 | 4.801134e-01 | 0.319 | 0 | 0 |
| Signaling by FGFR | R-HSA-190236 | 3.812553e-01 | 0.419 | 0 | 0 |
| Germ layer formation at gastrulation | R-HSA-9754189 | 1.816448e-01 | 0.741 | 0 | 0 |
| Ephrin signaling | R-HSA-3928664 | 3.209766e-01 | 0.494 | 0 | 0 |
| Signaling by FGFR3 | R-HSA-5654741 | 1.297568e-01 | 0.887 | 0 | 0 |
| POLB-Dependent Long Patch Base Excision Repair | R-HSA-110362 | 2.865374e-01 | 0.543 | 0 | 0 |
| MET activates RAS signaling | R-HSA-8851805 | 3.201284e-01 | 0.495 | 0 | 0 |
| Telomere Extension By Telomerase | R-HSA-171319 | 2.508031e-01 | 0.601 | 0 | 0 |
| Postmitotic nuclear pore complex (NPC) reformation | R-HSA-9615933 | 3.665482e-01 | 0.436 | 0 | 0 |
| Global Genome Nucleotide Excision Repair (GG-NER) | R-HSA-5696399 | 3.592042e-01 | 0.445 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) | R-HSA-5358565 | 5.147347e-01 | 0.288 | 0 | 0 |
| Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | R-HSA-5693565 | 1.363962e-01 | 0.865 | 0 | 0 |
| Signaling by FGFR1 | R-HSA-5654736 | 1.081167e-01 | 0.966 | 0 | 0 |
| Resolution of AP sites via the multiple-nucleotide patch replacement pathway | R-HSA-110373 | 2.110341e-01 | 0.676 | 0 | 0 |
| Prolonged ERK activation events | R-HSA-169893 | 4.524756e-01 | 0.344 | 0 | 0 |
| Extension of Telomeres | R-HSA-180786 | 2.173186e-01 | 0.663 | 0 | 0 |
| IRS-mediated signalling | R-HSA-112399 | 1.914432e-01 | 0.718 | 0 | 0 |
| Killing mechanisms | R-HSA-9664420 | 4.524756e-01 | 0.344 | 0 | 0 |
| WNT5:FZD7-mediated leishmania damping | R-HSA-9673324 | 4.524756e-01 | 0.344 | 0 | 0 |
| Telomere C-strand (Lagging Strand) Synthesis | R-HSA-174417 | 4.079896e-01 | 0.389 | 0 | 0 |
| Transcriptional regulation of testis differentiation | R-HSA-9690406 | 4.840558e-01 | 0.315 | 0 | 0 |
| ESR-mediated signaling | R-HSA-8939211 | 3.799795e-01 | 0.420 | 0 | 0 |
| G1/S Transition | R-HSA-69206 | 3.812410e-01 | 0.419 | 0 | 0 |
| Interleukin-7 signaling | R-HSA-1266695 | 1.920418e-01 | 0.717 | 0 | 0 |
| DNA Damage Bypass | R-HSA-73893 | 4.136681e-01 | 0.383 | 0 | 0 |
| Epigenetic regulation by WDR5-containing histone modifying complexes | R-HSA-9917777 | 4.748088e-01 | 0.323 | 0 | 0 |
| DNA strand elongation | R-HSA-69190 | 5.096059e-01 | 0.293 | 0 | 0 |
| Estrogen-dependent gene expression | R-HSA-9018519 | 5.320648e-01 | 0.274 | 0 | 0 |
| RIPK1-mediated regulated necrosis | R-HSA-5213460 | 2.017392e-01 | 0.695 | 0 | 0 |
| Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | R-HSA-9027276 | 1.406635e-01 | 0.852 | 0 | 0 |
| Signal attenuation | R-HSA-74749 | 2.205920e-01 | 0.656 | 0 | 0 |
| Energy dependent regulation of mTOR by LKB1-AMPK | R-HSA-380972 | 2.924408e-01 | 0.534 | 0 | 0 |
| Inwardly rectifying K+ channels | R-HSA-1296065 | 3.353271e-01 | 0.475 | 0 | 0 |
| Cellular response to starvation | R-HSA-9711097 | 5.177370e-01 | 0.286 | 0 | 0 |
| Interleukin-9 signaling | R-HSA-8985947 | 1.585068e-01 | 0.800 | 0 | 0 |
| p75NTR signals via NF-kB | R-HSA-193639 | 4.201226e-01 | 0.377 | 0 | 0 |
| Interleukin-3, Interleukin-5 and GM-CSF signaling | R-HSA-512988 | 2.856729e-01 | 0.544 | 0 | 0 |
| Activation of RAC1 downstream of NMDARs | R-HSA-9619229 | 1.888876e-01 | 0.724 | 0 | 0 |
| Estrogen-dependent nuclear events downstream of ESR-membrane signaling | R-HSA-9634638 | 1.562058e-01 | 0.806 | 0 | 0 |
| Signaling by FLT3 ITD and TKD mutants | R-HSA-9703648 | 1.737426e-01 | 0.760 | 0 | 0 |
| IRS-related events triggered by IGF1R | R-HSA-2428928 | 1.572744e-01 | 0.803 | 0 | 0 |
| PI3K Cascade | R-HSA-109704 | 1.907771e-01 | 0.719 | 0 | 0 |
| Recognition of DNA damage by PCNA-containing replication complex | R-HSA-110314 | 3.181194e-01 | 0.497 | 0 | 0 |
| Polymerase switching on the C-strand of the telomere | R-HSA-174411 | 3.422750e-01 | 0.466 | 0 | 0 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | R-HSA-72662 | 4.355895e-01 | 0.361 | 0 | 0 |
| Degradation of beta-catenin by the destruction complex | R-HSA-195253 | 2.684911e-01 | 0.571 | 0 | 0 |
| Mitophagy | R-HSA-5205647 | 4.006837e-01 | 0.397 | 0 | 0 |
| KEAP1-NFE2L2 pathway | R-HSA-9755511 | 3.591363e-01 | 0.445 | 0 | 0 |
| TRAF3-dependent IRF activation pathway | R-HSA-918233 | 4.840558e-01 | 0.315 | 0 | 0 |
| Regulation of necroptotic cell death | R-HSA-5675482 | 1.175576e-01 | 0.930 | 0 | 0 |
| Activation of NOXA and translocation to mitochondria | R-HSA-111448 | 1.717754e-01 | 0.765 | 0 | 0 |
| Activation of the AP-1 family of transcription factors | R-HSA-450341 | 1.888876e-01 | 0.724 | 0 | 0 |
| Regulation of commissural axon pathfinding by SLIT and ROBO | R-HSA-428542 | 1.888876e-01 | 0.724 | 0 | 0 |
| Rev-mediated nuclear export of HIV RNA | R-HSA-165054 | 1.132998e-01 | 0.946 | 0 | 0 |
| Signalling to RAS | R-HSA-167044 | 2.247867e-01 | 0.648 | 0 | 0 |
| VEGFR2 mediated vascular permeability | R-HSA-5218920 | 1.488189e-01 | 0.827 | 0 | 0 |
| Elevation of cytosolic Ca2+ levels | R-HSA-139853 | 2.933275e-01 | 0.533 | 0 | 0 |
| RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | R-HSA-8939243 | 2.154986e-01 | 0.667 | 0 | 0 |
| Regulation of CDH11 function | R-HSA-9762292 | 4.801134e-01 | 0.319 | 0 | 0 |
| PI3K/AKT activation | R-HSA-198203 | 4.801134e-01 | 0.319 | 0 | 0 |
| Peptide chain elongation | R-HSA-156902 | 3.238174e-01 | 0.490 | 0 | 0 |
| Regulation of IFNA/IFNB signaling | R-HSA-912694 | 4.589955e-01 | 0.338 | 0 | 0 |
| G2/M Checkpoints | R-HSA-69481 | 1.763923e-01 | 0.754 | 0 | 0 |
| Cyclin A:Cdk2-associated events at S phase entry | R-HSA-69656 | 2.962354e-01 | 0.528 | 0 | 0 |
| Downregulation of ERBB2 signaling | R-HSA-8863795 | 1.653462e-01 | 0.782 | 0 | 0 |
| Signalling to ERKs | R-HSA-187687 | 1.569630e-01 | 0.804 | 0 | 0 |
| APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway | R-HSA-5649702 | 4.392699e-01 | 0.357 | 0 | 0 |
| Eukaryotic Translation Elongation | R-HSA-156842 | 2.077513e-01 | 0.682 | 0 | 0 |
| Antigen processing: Ubiquitination & Proteasome degradation | R-HSA-983168 | 3.636827e-01 | 0.439 | 0 | 0 |
| Listeria monocytogenes entry into host cells | R-HSA-8876384 | 4.318650e-01 | 0.365 | 0 | 0 |
| Signaling by Insulin receptor | R-HSA-74752 | 3.911363e-01 | 0.408 | 0 | 0 |
| Role of second messengers in netrin-1 signaling | R-HSA-418890 | 1.406635e-01 | 0.852 | 0 | 0 |
| Activation of NIMA Kinases NEK9, NEK6, NEK7 | R-HSA-2980767 | 3.077007e-01 | 0.512 | 0 | 0 |
| Interactions of Rev with host cellular proteins | R-HSA-177243 | 1.364143e-01 | 0.865 | 0 | 0 |
| Advanced glycosylation endproduct receptor signaling | R-HSA-879415 | 3.201284e-01 | 0.495 | 0 | 0 |
| Nef mediated downregulation of MHC class I complex cell surface expression | R-HSA-164940 | 3.967264e-01 | 0.402 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression linked to lipogenesis | R-HSA-9029558 | 3.537490e-01 | 0.451 | 0 | 0 |
| G beta:gamma signalling through PI3Kgamma | R-HSA-392451 | 2.941844e-01 | 0.531 | 0 | 0 |
| cGMP effects | R-HSA-418457 | 3.871521e-01 | 0.412 | 0 | 0 |
| AMPK inhibits chREBP transcriptional activation activity | R-HSA-163680 | 4.392699e-01 | 0.357 | 0 | 0 |
| Regulation of gap junction activity | R-HSA-191650 | 5.256047e-01 | 0.279 | 0 | 0 |
| Negative regulation of MET activity | R-HSA-6807004 | 3.766466e-01 | 0.424 | 0 | 0 |
| DARPP-32 events | R-HSA-180024 | 4.391255e-01 | 0.357 | 0 | 0 |
| Cyclin E associated events during G1/S transition | R-HSA-69202 | 3.784545e-01 | 0.422 | 0 | 0 |
| TRAF6 mediated NF-kB activation | R-HSA-933542 | 5.117906e-01 | 0.291 | 0 | 0 |
| Meiosis | R-HSA-1500620 | 4.870444e-01 | 0.312 | 0 | 0 |
| Signaling by Hippo | R-HSA-2028269 | 1.420282e-01 | 0.848 | 0 | 0 |
| Mitotic G1 phase and G1/S transition | R-HSA-453279 | 2.376096e-01 | 0.624 | 0 | 0 |
| DNA Double Strand Break Response | R-HSA-5693606 | 2.286559e-01 | 0.641 | 0 | 0 |
| S Phase | R-HSA-69242 | 1.411869e-01 | 0.850 | 0 | 0 |
| G1/S DNA Damage Checkpoints | R-HSA-69615 | 3.891857e-01 | 0.410 | 0 | 0 |
| VEGFA-VEGFR2 Pathway | R-HSA-4420097 | 1.326085e-01 | 0.877 | 0 | 0 |
| Resolution of Abasic Sites (AP sites) | R-HSA-73933 | 2.509497e-01 | 0.600 | 0 | 0 |
| Repression of WNT target genes | R-HSA-4641265 | 1.406635e-01 | 0.852 | 0 | 0 |
| Nuclear import of Rev protein | R-HSA-180746 | 2.516285e-01 | 0.599 | 0 | 0 |
| NRIF signals cell death from the nucleus | R-HSA-205043 | 3.871521e-01 | 0.412 | 0 | 0 |
| Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | R-HSA-9673767 | 4.201226e-01 | 0.377 | 0 | 0 |
| Signaling by PDGFRA extracellular domain mutants | R-HSA-9673770 | 4.201226e-01 | 0.377 | 0 | 0 |
| Caspase activation via extrinsic apoptotic signalling pathway | R-HSA-5357769 | 1.080224e-01 | 0.966 | 0 | 0 |
| TP53 Regulates Transcription of Caspase Activators and Caspases | R-HSA-6803207 | 2.392076e-01 | 0.621 | 0 | 0 |
| Defective RIPK1-mediated regulated necrosis | R-HSA-9693928 | 2.205920e-01 | 0.656 | 0 | 0 |
| RNA Polymerase II Transcription | R-HSA-73857 | 2.464939e-01 | 0.608 | 0 | 0 |
| Gene expression (Transcription) | R-HSA-74160 | 3.338462e-01 | 0.476 | 0 | 0 |
| Host Interactions of HIV factors | R-HSA-162909 | 3.582398e-01 | 0.446 | 0 | 0 |
| EPH-Ephrin signaling | R-HSA-2682334 | 2.077513e-01 | 0.682 | 0 | 0 |
| Generic Transcription Pathway | R-HSA-212436 | 3.491034e-01 | 0.457 | 0 | 0 |
| Signaling by WNT | R-HSA-195721 | 3.087962e-01 | 0.510 | 0 | 0 |
| Inositol transporters | R-HSA-429593 | 2.164912e-01 | 0.665 | 0 | 0 |
| Calcineurin activates NFAT | R-HSA-2025928 | 1.888876e-01 | 0.724 | 0 | 0 |
| Transcription from mitochondrial promoters | R-HSA-75944 | 3.917151e-01 | 0.407 | 0 | 0 |
| Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components | R-HSA-141405 | 1.237964e-01 | 0.907 | 0 | 0 |
| Microbial modulation of RIPK1-mediated regulated necrosis | R-HSA-9686347 | 3.527483e-01 | 0.453 | 0 | 0 |
| Ca2+ activated K+ channels | R-HSA-1296052 | 3.527483e-01 | 0.453 | 0 | 0 |
| Signaling by high-kinase activity BRAF mutants | R-HSA-6802948 | 1.862702e-01 | 0.730 | 0 | 0 |
| Astrocytic Glutamate-Glutamine Uptake And Metabolism | R-HSA-210455 | 3.967264e-01 | 0.402 | 0 | 0 |
| Neurotransmitter uptake and metabolism In glial cells | R-HSA-112313 | 3.967264e-01 | 0.402 | 0 | 0 |
| Cellular response to mitochondrial stress | R-HSA-9840373 | 4.392699e-01 | 0.357 | 0 | 0 |
| MAP2K and MAPK activation | R-HSA-5674135 | 2.681488e-01 | 0.572 | 0 | 0 |
| Regulation of PD-L1(CD274) transcription | R-HSA-9909649 | 2.159326e-01 | 0.666 | 0 | 0 |
| Josephin domain DUBs | R-HSA-5689877 | 4.801134e-01 | 0.319 | 0 | 0 |
| Arachidonate production from DAG | R-HSA-426048 | 4.801134e-01 | 0.319 | 0 | 0 |
| Signaling by MET | R-HSA-6806834 | 3.039053e-01 | 0.517 | 0 | 0 |
| Formation of the posterior neural plate | R-HSA-9832991 | 5.190734e-01 | 0.285 | 0 | 0 |
| RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | R-HSA-8936459 | 4.710144e-01 | 0.327 | 0 | 0 |
| Cargo recognition for clathrin-mediated endocytosis | R-HSA-8856825 | 4.603999e-01 | 0.337 | 0 | 0 |
| Signaling by Nuclear Receptors | R-HSA-9006931 | 4.961017e-01 | 0.304 | 0 | 0 |
| Signaling by VEGF | R-HSA-194138 | 2.220501e-01 | 0.654 | 0 | 0 |
| Cilium Assembly | R-HSA-5617833 | 2.376836e-01 | 0.624 | 0 | 0 |
| MyD88:MAL(TIRAP) cascade initiated on plasma membrane | R-HSA-166058 | 2.255452e-01 | 0.647 | 0 | 0 |
| Transcriptional Regulation by NPAS4 | R-HSA-9634815 | 3.318264e-01 | 0.479 | 0 | 0 |
| MyD88 cascade initiated on plasma membrane | R-HSA-975871 | 1.412114e-01 | 0.850 | 0 | 0 |
| Toll Like Receptor TLR6:TLR2 Cascade | R-HSA-168188 | 2.255452e-01 | 0.647 | 0 | 0 |
| Toll Like Receptor TLR1:TLR2 Cascade | R-HSA-168179 | 2.548494e-01 | 0.594 | 0 | 0 |
| MyD88 dependent cascade initiated on endosome | R-HSA-975155 | 2.535474e-01 | 0.596 | 0 | 0 |
| Signaling by FGFR in disease | R-HSA-1226099 | 1.491903e-01 | 0.826 | 0 | 0 |
| Senescence-Associated Secretory Phenotype (SASP) | R-HSA-2559582 | 4.427047e-01 | 0.354 | 0 | 0 |
| DNA Repair | R-HSA-73894 | 1.423674e-01 | 0.847 | 0 | 0 |
| Toll Like Receptor 10 (TLR10) Cascade | R-HSA-168142 | 1.412114e-01 | 0.850 | 0 | 0 |
| Toll Like Receptor 5 (TLR5) Cascade | R-HSA-168176 | 1.412114e-01 | 0.850 | 0 | 0 |
| mTORC1-mediated signalling | R-HSA-166208 | 1.394961e-01 | 0.855 | 0 | 0 |
| Platelet calcium homeostasis | R-HSA-418360 | 1.499082e-01 | 0.824 | 0 | 0 |
| Downregulation of ERBB2:ERBB3 signaling | R-HSA-1358803 | 3.201284e-01 | 0.495 | 0 | 0 |
| HDR through MMEJ (alt-NHEJ) | R-HSA-5685939 | 3.537490e-01 | 0.451 | 0 | 0 |
| Toll Like Receptor 2 (TLR2) Cascade | R-HSA-181438 | 2.548494e-01 | 0.594 | 0 | 0 |
| Signaling by NOTCH1 PEST Domain Mutants in Cancer | R-HSA-2644602 | 1.466384e-01 | 0.834 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | R-HSA-2894862 | 1.466384e-01 | 0.834 | 0 | 0 |
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | R-HSA-2644606 | 1.466384e-01 | 0.834 | 0 | 0 |
| Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | R-HSA-2894858 | 1.466384e-01 | 0.834 | 0 | 0 |
| Signaling by FGFR3 in disease | R-HSA-5655332 | 3.908415e-01 | 0.408 | 0 | 0 |
| Signaling by CSF3 (G-CSF) | R-HSA-9674555 | 4.391255e-01 | 0.357 | 0 | 0 |
| Organelle biogenesis and maintenance | R-HSA-1852241 | 3.001742e-01 | 0.523 | 0 | 0 |
| Signaling by NOTCH1 | R-HSA-1980143 | 1.077076e-01 | 0.968 | 0 | 0 |
| HIV Infection | R-HSA-162906 | 1.888733e-01 | 0.724 | 0 | 0 |
| Deubiquitination | R-HSA-5688426 | 1.776440e-01 | 0.750 | 0 | 0 |
| Response of endothelial cells to shear stress | R-HSA-9860931 | 4.603999e-01 | 0.337 | 0 | 0 |
| Lipophagy | R-HSA-9613354 | 1.888876e-01 | 0.724 | 0 | 0 |
| Formation of intermediate mesoderm | R-HSA-9761174 | 2.205920e-01 | 0.656 | 0 | 0 |
| Mitochondrial calcium ion transport | R-HSA-8949215 | 1.236723e-01 | 0.908 | 0 | 0 |
| Alpha-protein kinase 1 signaling pathway | R-HSA-9645460 | 2.532551e-01 | 0.596 | 0 | 0 |
| Signaling by Erythropoietin | R-HSA-9006335 | 1.499082e-01 | 0.824 | 0 | 0 |
| ATF6 (ATF6-alpha) activates chaperone genes | R-HSA-381183 | 2.865374e-01 | 0.543 | 0 | 0 |
| FasL/ CD95L signaling | R-HSA-75157 | 4.628131e-01 | 0.335 | 0 | 0 |
| Downregulation of ERBB4 signaling | R-HSA-1253288 | 3.967264e-01 | 0.402 | 0 | 0 |
| Regulation of TP53 Expression and Degradation | R-HSA-6806003 | 2.177024e-01 | 0.662 | 0 | 0 |
| SARS-CoV-1-mediated effects on programmed cell death | R-HSA-9692913 | 5.256047e-01 | 0.279 | 0 | 0 |
| Oxidative Stress Induced Senescence | R-HSA-2559580 | 1.750329e-01 | 0.757 | 0 | 0 |
| Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters | R-HSA-164938 | 5.147347e-01 | 0.288 | 0 | 0 |
| Nuclear RNA decay | R-HSA-9930044 | 5.323107e-01 | 0.274 | 0 | 0 |
| HIV Life Cycle | R-HSA-162587 | 1.101631e-01 | 0.958 | 0 | 0 |
| G-protein mediated events | R-HSA-112040 | 3.323274e-01 | 0.478 | 0 | 0 |
| VEGFR2 mediated cell proliferation | R-HSA-5218921 | 3.422750e-01 | 0.466 | 0 | 0 |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | R-HSA-975138 | 2.430323e-01 | 0.614 | 0 | 0 |
| Evasion by RSV of host interferon responses | R-HSA-9833109 | 4.864663e-01 | 0.313 | 0 | 0 |
| Activation of BH3-only proteins | R-HSA-114452 | 1.653462e-01 | 0.782 | 0 | 0 |
| CLEC7A (Dectin-1) signaling | R-HSA-5607764 | 3.551609e-01 | 0.450 | 0 | 0 |
| Toll Like Receptor 4 (TLR4) Cascade | R-HSA-166016 | 2.554575e-01 | 0.593 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of myeloid cells | R-HSA-8939246 | 1.585068e-01 | 0.800 | 0 | 0 |
| M-decay: degradation of maternal mRNAs by maternally stored factors | R-HSA-9820841 | 2.509497e-01 | 0.600 | 0 | 0 |
| Toll Like Receptor 9 (TLR9) Cascade | R-HSA-168138 | 1.803634e-01 | 0.744 | 0 | 0 |
| Cellular responses to stress | R-HSA-2262752 | 3.083434e-01 | 0.511 | 0 | 0 |
| Toll Like Receptor 7/8 (TLR7/8) Cascade | R-HSA-168181 | 2.972496e-01 | 0.527 | 0 | 0 |
| Opioid Signalling | R-HSA-111885 | 3.593587e-01 | 0.444 | 0 | 0 |
| Protein methylation | R-HSA-8876725 | 2.130858e-01 | 0.671 | 0 | 0 |
| Gastrin-CREB signalling pathway via PKC and MAPK | R-HSA-881907 | 1.816448e-01 | 0.741 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | R-HSA-6804114 | 2.660142e-01 | 0.575 | 0 | 0 |
| Toll-like Receptor Cascades | R-HSA-168898 | 3.797033e-01 | 0.421 | 0 | 0 |
| Synthesis of PIPs at the early endosome membrane | R-HSA-1660516 | 1.920418e-01 | 0.717 | 0 | 0 |
| Cellular responses to stimuli | R-HSA-8953897 | 4.400248e-01 | 0.357 | 0 | 0 |
| Regulation of TP53 Degradation | R-HSA-6804757 | 2.894009e-01 | 0.539 | 0 | 0 |
| Nuclear signaling by ERBB4 | R-HSA-1251985 | 2.341198e-01 | 0.631 | 0 | 0 |
| Activation of BIM and translocation to mitochondria | R-HSA-111446 | 1.289484e-01 | 0.890 | 0 | 0 |
| Manipulation of host energy metabolism | R-HSA-9636667 | 3.112125e-01 | 0.507 | 0 | 0 |
| Defective Mismatch Repair Associated With MSH2 | R-HSA-5632928 | 3.112125e-01 | 0.507 | 0 | 0 |
| Phase 3 - rapid repolarisation | R-HSA-5576890 | 1.298329e-01 | 0.887 | 0 | 0 |
| Co-stimulation by ICOS | R-HSA-9927354 | 1.585068e-01 | 0.800 | 0 | 0 |
| Activation of the TFAP2 (AP-2) family of transcription factors | R-HSA-8866907 | 1.888876e-01 | 0.724 | 0 | 0 |
| Defective ABCC8 can cause hypo- and hyper-glycemias | R-HSA-5683177 | 3.917151e-01 | 0.407 | 0 | 0 |
| Localization of the PINCH-ILK-PARVIN complex to focal adhesions | R-HSA-446343 | 3.917151e-01 | 0.407 | 0 | 0 |
| Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects | R-HSA-9659787 | 1.636301e-01 | 0.786 | 0 | 0 |
| Regulation of KIT signaling | R-HSA-1433559 | 1.878317e-01 | 0.726 | 0 | 0 |
| Regulation of MECP2 expression and activity | R-HSA-9022692 | 1.175576e-01 | 0.930 | 0 | 0 |
| Negative regulation of FLT3 | R-HSA-9706369 | 2.392076e-01 | 0.621 | 0 | 0 |
| Phase 4 - resting membrane potential | R-HSA-5576886 | 2.392076e-01 | 0.621 | 0 | 0 |
| Regulation of PTEN localization | R-HSA-8948747 | 3.527483e-01 | 0.453 | 0 | 0 |
| Activation of BMF and translocation to mitochondria | R-HSA-139910 | 4.628131e-01 | 0.335 | 0 | 0 |
| Metalloprotease DUBs | R-HSA-5689901 | 2.110341e-01 | 0.676 | 0 | 0 |
| Signaling by PDGFR in disease | R-HSA-9671555 | 2.474069e-01 | 0.607 | 0 | 0 |
| PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 | R-HSA-8849469 | 3.967264e-01 | 0.402 | 0 | 0 |
| Negative regulation of activity of TFAP2 (AP-2) family transcription factors | R-HSA-8866904 | 3.967264e-01 | 0.402 | 0 | 0 |
| MAP kinase activation | R-HSA-450294 | 1.572744e-01 | 0.803 | 0 | 0 |
| Electric Transmission Across Gap Junctions | R-HSA-112303 | 5.256047e-01 | 0.279 | 0 | 0 |
| Transmission across Electrical Synapses | R-HSA-112307 | 5.256047e-01 | 0.279 | 0 | 0 |
| EGFR Transactivation by Gastrin | R-HSA-2179392 | 4.801134e-01 | 0.319 | 0 | 0 |
| Regulation of glycolysis by fructose 2,6-bisphosphate metabolism | R-HSA-9634600 | 4.524756e-01 | 0.344 | 0 | 0 |
| Interactions of Vpr with host cellular proteins | R-HSA-176033 | 3.680330e-01 | 0.434 | 0 | 0 |
| Smooth Muscle Contraction | R-HSA-445355 | 3.489388e-01 | 0.457 | 0 | 0 |
| Ionotropic activity of kainate receptors | R-HSA-451306 | 5.190734e-01 | 0.285 | 0 | 0 |
| Cholesterol biosynthesis via desmosterol | R-HSA-6807047 | 5.190734e-01 | 0.285 | 0 | 0 |
| The role of Nef in HIV-1 replication and disease pathogenesis | R-HSA-164952 | 4.856671e-01 | 0.314 | 0 | 0 |
| Budding and maturation of HIV virion | R-HSA-162588 | 4.864663e-01 | 0.313 | 0 | 0 |
| Maternal to zygotic transition (MZT) | R-HSA-9816359 | 4.382944e-01 | 0.358 | 0 | 0 |
| Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin | R-HSA-9725554 | 5.078813e-01 | 0.294 | 0 | 0 |
| Retrograde transport at the Trans-Golgi-Network | R-HSA-6811440 | 5.255578e-01 | 0.279 | 0 | 0 |
| Platelet activation, signaling and aggregation | R-HSA-76002 | 1.592483e-01 | 0.798 | 0 | 0 |
| MyD88-independent TLR4 cascade | R-HSA-166166 | 1.912197e-01 | 0.718 | 0 | 0 |
| TRIF (TICAM1)-mediated TLR4 signaling | R-HSA-937061 | 1.912197e-01 | 0.718 | 0 | 0 |
| Ca-dependent events | R-HSA-111996 | 1.752251e-01 | 0.756 | 0 | 0 |
| Transcriptional regulation of granulopoiesis | R-HSA-9616222 | 1.682933e-01 | 0.774 | 0 | 0 |
| Intra-Golgi and retrograde Golgi-to-ER traffic | R-HSA-6811442 | 4.655048e-01 | 0.332 | 0 | 0 |
| Signaling by NTRK3 (TRKC) | R-HSA-9034015 | 1.236723e-01 | 0.908 | 0 | 0 |
| Signaling by PTK6 | R-HSA-8848021 | 5.210040e-01 | 0.283 | 0 | 0 |
| Signaling by Non-Receptor Tyrosine Kinases | R-HSA-9006927 | 5.210040e-01 | 0.283 | 0 | 0 |
| TAK1-dependent IKK and NF-kappa-B activation | R-HSA-445989 | 5.255578e-01 | 0.279 | 0 | 0 |
| PLC beta mediated events | R-HSA-112043 | 2.445296e-01 | 0.612 | 0 | 0 |
| Toll Like Receptor 3 (TLR3) Cascade | R-HSA-168164 | 1.486943e-01 | 0.828 | 0 | 0 |
| Signaling by FGFR4 in disease | R-HSA-5655291 | 1.878317e-01 | 0.726 | 0 | 0 |
| Pyroptosis | R-HSA-5620971 | 1.351840e-01 | 0.869 | 0 | 0 |
| Interleukin-17 signaling | R-HSA-448424 | 2.684911e-01 | 0.571 | 0 | 0 |
| Regulation of NF-kappa B signaling | R-HSA-9758274 | 4.524756e-01 | 0.344 | 0 | 0 |
| Platelet degranulation | R-HSA-114608 | 4.981318e-01 | 0.303 | 0 | 0 |
| PECAM1 interactions | R-HSA-210990 | 2.532551e-01 | 0.596 | 0 | 0 |
| Activated NTRK2 signals through FYN | R-HSA-9032500 | 3.967264e-01 | 0.402 | 0 | 0 |
| Sensory processing of sound by inner hair cells of the cochlea | R-HSA-9662360 | 1.583695e-01 | 0.800 | 0 | 0 |
| Receptor Mediated Mitophagy | R-HSA-8934903 | 4.801134e-01 | 0.319 | 0 | 0 |
| Selenocysteine synthesis | R-HSA-2408557 | 5.271146e-01 | 0.278 | 0 | 0 |
| Signaling by KIT in disease | R-HSA-9669938 | 1.394961e-01 | 0.855 | 0 | 0 |
| NR1H2 and NR1H3-mediated signaling | R-HSA-9024446 | 1.793392e-01 | 0.746 | 0 | 0 |
| Intrinsic Pathway for Apoptosis | R-HSA-109606 | 2.772798e-01 | 0.557 | 0 | 0 |
| Downregulation of SMAD2/3:SMAD4 transcriptional activity | R-HSA-2173795 | 1.981895e-01 | 0.703 | 0 | 0 |
| Transcriptional and post-translational regulation of MITF-M expression and activity | R-HSA-9856649 | 5.191989e-01 | 0.285 | 0 | 0 |
| Muscarinic acetylcholine receptors | R-HSA-390648 | 2.164912e-01 | 0.665 | 0 | 0 |
| G-protein beta:gamma signalling | R-HSA-397795 | 3.570483e-01 | 0.447 | 0 | 0 |
| Regulation of Glucokinase by Glucokinase Regulatory Protein | R-HSA-170822 | 3.788571e-01 | 0.422 | 0 | 0 |
| Export of Viral Ribonucleoproteins from Nucleus | R-HSA-168274 | 3.581177e-01 | 0.446 | 0 | 0 |
| Cytokine Signaling in Immune system | R-HSA-1280215 | 2.810244e-01 | 0.551 | 0 | 0 |
| Growth hormone receptor signaling | R-HSA-982772 | 4.856671e-01 | 0.314 | 0 | 0 |
| Signaling by Interleukins | R-HSA-449147 | 1.737052e-01 | 0.760 | 0 | 0 |
| Glycolysis | R-HSA-70171 | 2.258081e-01 | 0.646 | 0 | 0 |
| Golgi-to-ER retrograde transport | R-HSA-8856688 | 4.744551e-01 | 0.324 | 0 | 0 |
| Signaling by NOTCH1 in Cancer | R-HSA-2644603 | 1.466384e-01 | 0.834 | 0 | 0 |
| Sensory processing of sound | R-HSA-9659379 | 2.009725e-01 | 0.697 | 0 | 0 |
| Transcriptional Regulation by VENTX | R-HSA-8853884 | 3.880032e-01 | 0.411 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex | R-HSA-170834 | 1.333822e-01 | 0.875 | 0 | 0 |
| PI5P Regulates TP53 Acetylation | R-HSA-6811555 | 3.537490e-01 | 0.451 | 0 | 0 |
| ISG15 antiviral mechanism | R-HSA-1169408 | 1.589205e-01 | 0.799 | 0 | 0 |
| Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 | R-HSA-1362300 | 4.524756e-01 | 0.344 | 0 | 0 |
| Cyclin A/B1/B2 associated events during G2/M transition | R-HSA-69273 | 2.154986e-01 | 0.667 | 0 | 0 |
| Formation of the nephric duct | R-HSA-9830364 | 1.920418e-01 | 0.717 | 0 | 0 |
| Signaling by Leptin | R-HSA-2586552 | 4.801134e-01 | 0.319 | 0 | 0 |
| Interleukin-2 signaling | R-HSA-9020558 | 5.190734e-01 | 0.285 | 0 | 0 |
| Amine ligand-binding receptors | R-HSA-375280 | 3.215159e-01 | 0.493 | 0 | 0 |
| GPVI-mediated activation cascade | R-HSA-114604 | 4.441271e-01 | 0.352 | 0 | 0 |
| Tie2 Signaling | R-HSA-210993 | 3.209766e-01 | 0.494 | 0 | 0 |
| TBC/RABGAPs | R-HSA-8854214 | 3.034770e-01 | 0.518 | 0 | 0 |
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | R-HSA-2173793 | 1.790571e-01 | 0.747 | 0 | 0 |
| Interleukin-6 signaling | R-HSA-1059683 | 3.537490e-01 | 0.451 | 0 | 0 |
| Signaling by TGFBR3 | R-HSA-9839373 | 5.064604e-01 | 0.295 | 0 | 0 |
| SARS-CoV-2 activates/modulates innate and adaptive immune responses | R-HSA-9705671 | 4.303737e-01 | 0.366 | 0 | 0 |
| SMAC(DIABLO)-mediated dissociation of IAP:caspase complexes | R-HSA-111464 | 2.164912e-01 | 0.665 | 0 | 0 |
| DSCAM interactions | R-HSA-376172 | 3.917151e-01 | 0.407 | 0 | 0 |
| Synthesis of PI | R-HSA-1483226 | 2.532551e-01 | 0.596 | 0 | 0 |
| Glutamate binding, activation of AMPA receptors and synaptic plasticity | R-HSA-399721 | 1.175576e-01 | 0.930 | 0 | 0 |
| Reduction of cytosolic Ca++ levels | R-HSA-418359 | 2.865374e-01 | 0.543 | 0 | 0 |
| Diseases of Mismatch Repair (MMR) | R-HSA-5423599 | 4.628131e-01 | 0.335 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9683610 | 3.537490e-01 | 0.451 | 0 | 0 |
| Regulation of gene expression in beta cells | R-HSA-210745 | 2.714272e-01 | 0.566 | 0 | 0 |
| Zinc influx into cells by the SLC39 gene family | R-HSA-442380 | 4.392699e-01 | 0.357 | 0 | 0 |
| p75NTR negatively regulates cell cycle via SC1 | R-HSA-193670 | 5.256047e-01 | 0.279 | 0 | 0 |
| Factors involved in megakaryocyte development and platelet production | R-HSA-983231 | 2.380003e-01 | 0.623 | 0 | 0 |
| Signaling by PDGF | R-HSA-186797 | 5.042020e-01 | 0.297 | 0 | 0 |
| PTEN Regulation | R-HSA-6807070 | 4.745960e-01 | 0.324 | 0 | 0 |
| Signaling by TGFB family members | R-HSA-9006936 | 3.718230e-01 | 0.430 | 0 | 0 |
| MITF-M-regulated melanocyte development | R-HSA-9730414 | 1.125195e-01 | 0.949 | 0 | 0 |
| Apoptotic cleavage of cell adhesion proteins | R-HSA-351906 | 1.585068e-01 | 0.800 | 0 | 0 |
| ATF6 (ATF6-alpha) activates chaperones | R-HSA-381033 | 3.537490e-01 | 0.451 | 0 | 0 |
| Glucose metabolism | R-HSA-70326 | 4.617494e-01 | 0.336 | 0 | 0 |
| Zygotic genome activation (ZGA) | R-HSA-9819196 | 2.247867e-01 | 0.648 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9694631 | 3.488000e-01 | 0.457 | 0 | 0 |
| Positive Regulation of CDH1 Gene Transcription | R-HSA-9764790 | 4.801134e-01 | 0.319 | 0 | 0 |
| Suppression of apoptosis | R-HSA-9635465 | 5.190734e-01 | 0.285 | 0 | 0 |
| Stimuli-sensing channels | R-HSA-2672351 | 5.256067e-01 | 0.279 | 0 | 0 |
| NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | R-HSA-9029569 | 4.355895e-01 | 0.361 | 0 | 0 |
| Syndecan interactions | R-HSA-3000170 | 2.941844e-01 | 0.531 | 0 | 0 |
| Formation of the anterior neural plate | R-HSA-9823739 | 4.201226e-01 | 0.377 | 0 | 0 |
| SMAC (DIABLO) binds to IAPs | R-HSA-111463 | 2.164912e-01 | 0.665 | 0 | 0 |
| MECP2 regulates transcription factors | R-HSA-9022707 | 3.527483e-01 | 0.453 | 0 | 0 |
| Regulation of MITF-M dependent genes involved in metabolism | R-HSA-9854907 | 4.628131e-01 | 0.335 | 0 | 0 |
| Sodium/Proton exchangers | R-HSA-425986 | 3.967264e-01 | 0.402 | 0 | 0 |
| Synthesis of IP3 and IP4 in the cytosol | R-HSA-1855204 | 2.154986e-01 | 0.667 | 0 | 0 |
| Regulation of HMOX1 expression and activity | R-HSA-9707587 | 5.256047e-01 | 0.279 | 0 | 0 |
| Dopamine receptors | R-HSA-390651 | 5.256047e-01 | 0.279 | 0 | 0 |
| Sensory processing of sound by outer hair cells of the cochlea | R-HSA-9662361 | 2.772798e-01 | 0.557 | 0 | 0 |
| Maturation of spike protein | R-HSA-9683686 | 4.801134e-01 | 0.319 | 0 | 0 |
| Assembly and release of respiratory syncytial virus (RSV) virions | R-HSA-9820962 | 4.801134e-01 | 0.319 | 0 | 0 |
| Bicarbonate transporters | R-HSA-425381 | 5.190734e-01 | 0.285 | 0 | 0 |
| Inositol phosphate metabolism | R-HSA-1483249 | 4.738456e-01 | 0.324 | 0 | 0 |
| Antiviral mechanism by IFN-stimulated genes | R-HSA-1169410 | 4.748088e-01 | 0.323 | 0 | 0 |
| Metal ion SLC transporters | R-HSA-425410 | 2.653053e-01 | 0.576 | 0 | 0 |
| Interleukin-12 family signaling | R-HSA-447115 | 5.306023e-01 | 0.275 | 0 | 0 |
| SMAC, XIAP-regulated apoptotic response | R-HSA-111469 | 2.620703e-01 | 0.582 | 0 | 0 |
| Regulation of CDH19 Expression and Function | R-HSA-9764302 | 2.620703e-01 | 0.582 | 0 | 0 |
| Uptake and function of diphtheria toxin | R-HSA-5336415 | 3.527483e-01 | 0.453 | 0 | 0 |
| OAS antiviral response | R-HSA-8983711 | 3.201284e-01 | 0.495 | 0 | 0 |
| Respiratory syncytial virus genome replication | R-HSA-9834752 | 4.392699e-01 | 0.357 | 0 | 0 |
| Interleukin-38 signaling | R-HSA-9007892 | 5.256047e-01 | 0.279 | 0 | 0 |
| Unfolded Protein Response (UPR) | R-HSA-381119 | 4.745960e-01 | 0.324 | 0 | 0 |
| Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | R-HSA-8950505 | 3.022306e-01 | 0.520 | 0 | 0 |
| NS1 Mediated Effects on Host Pathways | R-HSA-168276 | 5.078813e-01 | 0.294 | 0 | 0 |
| XBP1(S) activates chaperone genes | R-HSA-381038 | 5.161996e-01 | 0.287 | 0 | 0 |
| NOTCH4 Intracellular Domain Regulates Transcription | R-HSA-9013695 | 2.247867e-01 | 0.648 | 0 | 0 |
| Interleukin-12 signaling | R-HSA-9020591 | 4.717362e-01 | 0.326 | 0 | 0 |
| Interleukin-37 signaling | R-HSA-9008059 | 2.924408e-01 | 0.534 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9694676 | 1.394961e-01 | 0.855 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9679504 | 1.613433e-01 | 0.792 | 0 | 0 |
| High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells | R-HSA-9856530 | 5.326496e-01 | 0.274 | 0 | 0 |
| ATP-dependent chromatin remodelers | R-HSA-9932444 | 5.372890e-01 | 0.270 | 0 | 0 |
| SWI/SNF chromatin remodelers | R-HSA-9932451 | 5.372890e-01 | 0.270 | 0 | 0 |
| PI-3K cascade:FGFR2 | R-HSA-5654695 | 5.372890e-01 | 0.270 | 0 | 0 |
| Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits | R-HSA-997272 | 5.372890e-01 | 0.270 | 0 | 0 |
| Activation of G protein gated Potassium channels | R-HSA-1296041 | 5.372890e-01 | 0.270 | 0 | 0 |
| G protein gated Potassium channels | R-HSA-1296059 | 5.372890e-01 | 0.270 | 0 | 0 |
| Glycogen breakdown (glycogenolysis) | R-HSA-70221 | 5.372890e-01 | 0.270 | 0 | 0 |
| TGFBR3 expression | R-HSA-9839394 | 5.372890e-01 | 0.270 | 0 | 0 |
| Neutrophil degranulation | R-HSA-6798695 | 5.389396e-01 | 0.268 | 0 | 0 |
| TNF signaling | R-HSA-75893 | 5.406985e-01 | 0.267 | 0 | 0 |
| ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA | R-HSA-9954716 | 5.424908e-01 | 0.266 | 0 | 0 |
| Regulation of TP53 Activity through Methylation | R-HSA-6804760 | 5.444091e-01 | 0.264 | 0 | 0 |
| Apoptotic factor-mediated response | R-HSA-111471 | 5.444091e-01 | 0.264 | 0 | 0 |
| Mismatch Repair | R-HSA-5358508 | 5.444091e-01 | 0.264 | 0 | 0 |
| Transcriptional activation of mitochondrial biogenesis | R-HSA-2151201 | 5.475277e-01 | 0.262 | 0 | 0 |
| Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template | R-HSA-110313 | 5.488508e-01 | 0.261 | 0 | 0 |
| Transport of Ribonucleoproteins into the Host Nucleus | R-HSA-168271 | 5.488508e-01 | 0.261 | 0 | 0 |
| TCR signaling | R-HSA-202403 | 5.510949e-01 | 0.259 | 0 | 0 |
| Developmental Biology | R-HSA-1266738 | 5.522643e-01 | 0.258 | 0 | 0 |
| Cytochrome c-mediated apoptotic response | R-HSA-111461 | 5.560320e-01 | 0.255 | 0 | 0 |
| Sema4D mediated inhibition of cell attachment and migration | R-HSA-416550 | 5.560320e-01 | 0.255 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression to control bile acid homeostasis | R-HSA-9623433 | 5.560320e-01 | 0.255 | 0 | 0 |
| Regulation of gene expression by Hypoxia-inducible Factor | R-HSA-1234158 | 5.560320e-01 | 0.255 | 0 | 0 |
| NF-kB is activated and signals survival | R-HSA-209560 | 5.560320e-01 | 0.255 | 0 | 0 |
| Eukaryotic Translation Termination | R-HSA-72764 | 5.560752e-01 | 0.255 | 0 | 0 |
| Nuclear Envelope Breakdown | R-HSA-2980766 | 5.580449e-01 | 0.253 | 0 | 0 |
| Mitochondrial biogenesis | R-HSA-1592230 | 5.611258e-01 | 0.251 | 0 | 0 |
| Phosphorylated BMAL1:CLOCK (ARNTL:CLOCK) activates expression of core clock genes | R-HSA-9931510 | 5.620969e-01 | 0.250 | 0 | 0 |
| Myogenesis | R-HSA-525793 | 5.620969e-01 | 0.250 | 0 | 0 |
| Activated NOTCH1 Transmits Signal to the Nucleus | R-HSA-2122948 | 5.620969e-01 | 0.250 | 0 | 0 |
| Synthesis of PIPs at the Golgi membrane | R-HSA-1660514 | 5.620969e-01 | 0.250 | 0 | 0 |
| FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | R-HSA-9615017 | 5.687489e-01 | 0.245 | 0 | 0 |
| Transcriptional regulation of white adipocyte differentiation | R-HSA-381340 | 5.695102e-01 | 0.244 | 0 | 0 |
| COPI-dependent Golgi-to-ER retrograde traffic | R-HSA-6811434 | 5.695102e-01 | 0.244 | 0 | 0 |
| Influenza Viral RNA Transcription and Replication | R-HSA-168273 | 5.722549e-01 | 0.242 | 0 | 0 |
| IKK complex recruitment mediated by RIP1 | R-HSA-937041 | 5.729981e-01 | 0.242 | 0 | 0 |
| Translesion Synthesis by POLH | R-HSA-110320 | 5.729981e-01 | 0.242 | 0 | 0 |
| The NLRP3 inflammasome | R-HSA-844456 | 5.729981e-01 | 0.242 | 0 | 0 |
| Early SARS-CoV-2 Infection Events | R-HSA-9772572 | 5.751064e-01 | 0.240 | 0 | 0 |
| Nonsense-Mediated Decay (NMD) | R-HSA-927802 | 5.761029e-01 | 0.239 | 0 | 0 |
| Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | R-HSA-975957 | 5.761029e-01 | 0.239 | 0 | 0 |
| Negative regulation of FGFR2 signaling | R-HSA-5654727 | 5.762145e-01 | 0.239 | 0 | 0 |
| Dual Incision in GG-NER | R-HSA-5696400 | 5.762145e-01 | 0.239 | 0 | 0 |
| NOD1/2 Signaling Pathway | R-HSA-168638 | 5.762145e-01 | 0.239 | 0 | 0 |
| Response to elevated platelet cytosolic Ca2+ | R-HSA-76005 | 5.794121e-01 | 0.237 | 0 | 0 |
| Trafficking of myristoylated proteins to the cilium | R-HSA-5624138 | 5.810598e-01 | 0.236 | 0 | 0 |
| NFE2L2 regulating TCA cycle genes | R-HSA-9818025 | 5.810598e-01 | 0.236 | 0 | 0 |
| IRS activation | R-HSA-74713 | 5.810598e-01 | 0.236 | 0 | 0 |
| Defective CYP17A1 causes AH5 | R-HSA-5579028 | 5.810598e-01 | 0.236 | 0 | 0 |
| NOSIP mediated eNOS trafficking | R-HSA-203754 | 5.810598e-01 | 0.236 | 0 | 0 |
| Defective F9 activation | R-HSA-9673221 | 5.810598e-01 | 0.236 | 0 | 0 |
| FLT3 signaling by CBL mutants | R-HSA-9706377 | 5.810598e-01 | 0.236 | 0 | 0 |
| Enhanced binding of GP1BA variant to VWF multimer:collagen | R-HSA-9845620 | 5.810598e-01 | 0.236 | 0 | 0 |
| Defective binding of VWF variant to GPIb:IX:V | R-HSA-9846298 | 5.810598e-01 | 0.236 | 0 | 0 |
| Phosphorylation and nuclear translocation of BMAL1 (ARNTL) and CLOCK | R-HSA-9931529 | 5.810598e-01 | 0.236 | 0 | 0 |
| PTK6 Down-Regulation | R-HSA-8849472 | 5.810598e-01 | 0.236 | 0 | 0 |
| Activation of AKT2 | R-HSA-165158 | 5.810598e-01 | 0.236 | 0 | 0 |
| DEx/H-box helicases activate type I IFN and inflammatory cytokines production | R-HSA-3134963 | 5.810598e-01 | 0.236 | 0 | 0 |
| Activation of C3 and C5 | R-HSA-174577 | 5.810598e-01 | 0.236 | 0 | 0 |
| PTK6 Regulates Proteins Involved in RNA Processing | R-HSA-8849468 | 5.810598e-01 | 0.236 | 0 | 0 |
| Telomere Maintenance | R-HSA-157579 | 5.827832e-01 | 0.234 | 0 | 0 |
| SHC-mediated cascade:FGFR2 | R-HSA-5654699 | 5.861598e-01 | 0.232 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in Cytochrome C Release | R-HSA-6803204 | 5.861598e-01 | 0.232 | 0 | 0 |
| Mitochondrial unfolded protein response (UPRmt) | R-HSA-9841251 | 5.861598e-01 | 0.232 | 0 | 0 |
| RUNX3 regulates p14-ARF | R-HSA-8951936 | 5.909248e-01 | 0.228 | 0 | 0 |
| IRAK1 recruits IKK complex | R-HSA-937039 | 5.909248e-01 | 0.228 | 0 | 0 |
| IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation | R-HSA-975144 | 5.909248e-01 | 0.228 | 0 | 0 |
| GRB2 events in EGFR signaling | R-HSA-179812 | 5.909248e-01 | 0.228 | 0 | 0 |
| Scavenging by Class F Receptors | R-HSA-3000484 | 5.909248e-01 | 0.228 | 0 | 0 |
| Regulation of IFNG signaling | R-HSA-877312 | 5.909248e-01 | 0.228 | 0 | 0 |
| Activated NTRK2 signals through FRS2 and FRS3 | R-HSA-9028731 | 5.909248e-01 | 0.228 | 0 | 0 |
| RUNX3 regulates NOTCH signaling | R-HSA-8941856 | 5.909248e-01 | 0.228 | 0 | 0 |
| Regulation of beta-cell development | R-HSA-186712 | 5.918600e-01 | 0.228 | 0 | 0 |
| Phospholipid metabolism | R-HSA-1483257 | 5.951813e-01 | 0.225 | 0 | 0 |
| Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells | R-HSA-9860927 | 5.973292e-01 | 0.224 | 0 | 0 |
| Meiotic recombination | R-HSA-912446 | 5.987716e-01 | 0.223 | 0 | 0 |
| IRE1alpha activates chaperones | R-HSA-381070 | 6.002404e-01 | 0.222 | 0 | 0 |
| Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | R-HSA-9609523 | 6.004417e-01 | 0.222 | 0 | 0 |
| Formation of neuronal progenitor and neuronal BAF (npBAF and nBAF) | R-HSA-9934037 | 6.004417e-01 | 0.222 | 0 | 0 |
| Formation of definitive endoderm | R-HSA-9823730 | 6.004417e-01 | 0.222 | 0 | 0 |
| Cellular responses to mechanical stimuli | R-HSA-9855142 | 6.005482e-01 | 0.221 | 0 | 0 |
| TGF-beta receptor signaling activates SMADs | R-HSA-2173789 | 6.072044e-01 | 0.217 | 0 | 0 |
| GABA receptor activation | R-HSA-977443 | 6.082851e-01 | 0.216 | 0 | 0 |
| Chromosome Maintenance | R-HSA-73886 | 6.086301e-01 | 0.216 | 0 | 0 |
| PINK1-PRKN Mediated Mitophagy | R-HSA-5205685 | 6.094338e-01 | 0.215 | 0 | 0 |
| Clathrin-mediated endocytosis | R-HSA-8856828 | 6.199584e-01 | 0.208 | 0 | 0 |
| Transmission across Chemical Synapses | R-HSA-112315 | 6.203064e-01 | 0.207 | 0 | 0 |
| Frs2-mediated activation | R-HSA-170968 | 6.237298e-01 | 0.205 | 0 | 0 |
| Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | R-HSA-75035 | 6.237298e-01 | 0.205 | 0 | 0 |
| FGFR1c ligand binding and activation | R-HSA-190373 | 6.237298e-01 | 0.205 | 0 | 0 |
| Chylomicron remodeling | R-HSA-8963901 | 6.237298e-01 | 0.205 | 0 | 0 |
| Membrane binding and targetting of GAG proteins | R-HSA-174490 | 6.237298e-01 | 0.205 | 0 | 0 |
| Formation of Senescence-Associated Heterochromatin Foci (SAHF) | R-HSA-2559584 | 6.237298e-01 | 0.205 | 0 | 0 |
| Processing of SMDT1 | R-HSA-8949664 | 6.237298e-01 | 0.205 | 0 | 0 |
| Regulation of RUNX2 expression and activity | R-HSA-8939902 | 6.243635e-01 | 0.205 | 0 | 0 |
| RMTs methylate histone arginines | R-HSA-3214858 | 6.257070e-01 | 0.204 | 0 | 0 |
| G1 Phase | R-HSA-69236 | 6.257070e-01 | 0.204 | 0 | 0 |
| Cyclin D associated events in G1 | R-HSA-69231 | 6.257070e-01 | 0.204 | 0 | 0 |
| MyD88 deficiency (TLR2/4) | R-HSA-5602498 | 6.266977e-01 | 0.203 | 0 | 0 |
| Basigin interactions | R-HSA-210991 | 6.266977e-01 | 0.203 | 0 | 0 |
| ERK/MAPK targets | R-HSA-198753 | 6.266977e-01 | 0.203 | 0 | 0 |
| Interleukin-1 family signaling | R-HSA-446652 | 6.268889e-01 | 0.203 | 0 | 0 |
| Nef Mediated CD8 Down-regulation | R-HSA-182218 | 6.300352e-01 | 0.201 | 0 | 0 |
| PDE3B signalling | R-HSA-165160 | 6.300352e-01 | 0.201 | 0 | 0 |
| PTK6 Regulates Cell Cycle | R-HSA-8849470 | 6.300352e-01 | 0.201 | 0 | 0 |
| PKB-mediated events | R-HSA-109703 | 6.300352e-01 | 0.201 | 0 | 0 |
| Inhibition of Signaling by Overexpressed EGFR | R-HSA-5638303 | 6.300352e-01 | 0.201 | 0 | 0 |
| Signaling by Overexpressed Wild-Type EGFR in Cancer | R-HSA-5638302 | 6.300352e-01 | 0.201 | 0 | 0 |
| Phase 1 - inactivation of fast Na+ channels | R-HSA-5576894 | 6.300352e-01 | 0.201 | 0 | 0 |
| Defective CSF2RA causes SMDP4 | R-HSA-5688890 | 6.300352e-01 | 0.201 | 0 | 0 |
| Defective CSF2RB causes SMDP5 | R-HSA-5688849 | 6.300352e-01 | 0.201 | 0 | 0 |
| Signaling by RNF43 mutants | R-HSA-5340588 | 6.300352e-01 | 0.201 | 0 | 0 |
| Loss of MECP2 binding ability to the NCoR/SMRT complex | R-HSA-9022537 | 6.300352e-01 | 0.201 | 0 | 0 |
| CLEC7A/inflammasome pathway | R-HSA-5660668 | 6.300352e-01 | 0.201 | 0 | 0 |
| Aryl hydrocarbon receptor signalling | R-HSA-8937144 | 6.300352e-01 | 0.201 | 0 | 0 |
| NGF-independant TRKA activation | R-HSA-187024 | 6.300352e-01 | 0.201 | 0 | 0 |
| Pentose phosphate pathway disease | R-HSA-6791465 | 6.300352e-01 | 0.201 | 0 | 0 |
| CDC6 association with the ORC:origin complex | R-HSA-68689 | 6.300352e-01 | 0.201 | 0 | 0 |
| Ceramide signalling | R-HSA-193681 | 6.300352e-01 | 0.201 | 0 | 0 |
| Phosphorylation of Emi1 | R-HSA-176417 | 6.300352e-01 | 0.201 | 0 | 0 |
| Formation of the Editosome | R-HSA-75094 | 6.300352e-01 | 0.201 | 0 | 0 |
| Release of Hh-Np from the secreting cell | R-HSA-5362798 | 6.300352e-01 | 0.201 | 0 | 0 |
| Defects of platelet adhesion to exposed collagen | R-HSA-9823587 | 6.300352e-01 | 0.201 | 0 | 0 |
| Sodium-coupled phosphate cotransporters | R-HSA-427652 | 6.300352e-01 | 0.201 | 0 | 0 |
| Release of apoptotic factors from the mitochondria | R-HSA-111457 | 6.300352e-01 | 0.201 | 0 | 0 |
| Acetylcholine inhibits contraction of outer hair cells | R-HSA-9667769 | 6.300352e-01 | 0.201 | 0 | 0 |
| Regulation of cytoskeletal remodeling and cell spreading by IPP complex components | R-HSA-446388 | 6.300352e-01 | 0.201 | 0 | 0 |
| TYSND1 cleaves peroxisomal proteins | R-HSA-9033500 | 6.300352e-01 | 0.201 | 0 | 0 |
| Endosomal Sorting Complex Required For Transport (ESCRT) | R-HSA-917729 | 6.318843e-01 | 0.199 | 0 | 0 |
| Termination of translesion DNA synthesis | R-HSA-5656169 | 6.318843e-01 | 0.199 | 0 | 0 |
| Nitric oxide stimulates guanylate cyclase | R-HSA-392154 | 6.318843e-01 | 0.199 | 0 | 0 |
| Regulation of CDH1 Gene Transcription | R-HSA-9764560 | 6.320035e-01 | 0.199 | 0 | 0 |
| Meiotic synapsis | R-HSA-1221632 | 6.331001e-01 | 0.199 | 0 | 0 |
| Vesicle-mediated transport | R-HSA-5653656 | 6.338836e-01 | 0.198 | 0 | 0 |
| Interleukin-1 signaling | R-HSA-9020702 | 6.340320e-01 | 0.198 | 0 | 0 |
| SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | R-HSA-2173796 | 6.377194e-01 | 0.195 | 0 | 0 |
| NCAM signaling for neurite out-growth | R-HSA-375165 | 6.400787e-01 | 0.194 | 0 | 0 |
| Interferon Signaling | R-HSA-913531 | 6.431106e-01 | 0.192 | 0 | 0 |
| APC/C-mediated degradation of cell cycle proteins | R-HSA-174143 | 6.466937e-01 | 0.189 | 0 | 0 |
| Regulation of mitotic cell cycle | R-HSA-453276 | 6.466937e-01 | 0.189 | 0 | 0 |
| FRS-mediated FGFR3 signaling | R-HSA-5654706 | 6.517402e-01 | 0.186 | 0 | 0 |
| IRAK4 deficiency (TLR2/4) | R-HSA-5603041 | 6.517402e-01 | 0.186 | 0 | 0 |
| Inactivation of CSF3 (G-CSF) signaling | R-HSA-9705462 | 6.517402e-01 | 0.186 | 0 | 0 |
| activated TAK1 mediates p38 MAPK activation | R-HSA-450302 | 6.517402e-01 | 0.186 | 0 | 0 |
| DDX58/IFIH1-mediated induction of interferon-alpha/beta | R-HSA-168928 | 6.523198e-01 | 0.186 | 0 | 0 |
| Activation of the pre-replicative complex | R-HSA-68962 | 6.534858e-01 | 0.185 | 0 | 0 |
| DAP12 signaling | R-HSA-2424491 | 6.534858e-01 | 0.185 | 0 | 0 |
| ERBB2 Activates PTK6 Signaling | R-HSA-8847993 | 6.544582e-01 | 0.184 | 0 | 0 |
| Regulation of CDH1 mRNA translation by microRNAs | R-HSA-9764562 | 6.544582e-01 | 0.184 | 0 | 0 |
| Synthesis And Processing Of GAG, GAGPOL Polyproteins | R-HSA-174495 | 6.544582e-01 | 0.184 | 0 | 0 |
| Prolactin receptor signaling | R-HSA-1170546 | 6.544582e-01 | 0.184 | 0 | 0 |
| Signal regulatory protein family interactions | R-HSA-391160 | 6.544582e-01 | 0.184 | 0 | 0 |
| P2Y receptors | R-HSA-417957 | 6.544582e-01 | 0.184 | 0 | 0 |
| Zinc transporters | R-HSA-435354 | 6.544582e-01 | 0.184 | 0 | 0 |
| YAP1- and WWTR1 (TAZ)-stimulated gene expression | R-HSA-2032785 | 6.544582e-01 | 0.184 | 0 | 0 |
| Influenza Infection | R-HSA-168255 | 6.551927e-01 | 0.184 | 0 | 0 |
| MET promotes cell motility | R-HSA-8875878 | 6.569466e-01 | 0.182 | 0 | 0 |
| SLC-mediated transport of inorganic anions | R-HSA-9958790 | 6.569466e-01 | 0.182 | 0 | 0 |
| Viral mRNA Translation | R-HSA-192823 | 6.584152e-01 | 0.182 | 0 | 0 |
| Regulation of TNFR1 signaling | R-HSA-5357905 | 6.611551e-01 | 0.180 | 0 | 0 |
| Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide | R-HSA-9954709 | 6.647476e-01 | 0.177 | 0 | 0 |
| COPI-independent Golgi-to-ER retrograde traffic | R-HSA-6811436 | 6.656951e-01 | 0.177 | 0 | 0 |
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | R-HSA-168643 | 6.703651e-01 | 0.174 | 0 | 0 |
| PTK6 promotes HIF1A stabilization | R-HSA-8857538 | 6.732878e-01 | 0.172 | 0 | 0 |
| Erythropoietin activates STAT5 | R-HSA-9027283 | 6.732878e-01 | 0.172 | 0 | 0 |
| Autointegration results in viral DNA circles | R-HSA-177539 | 6.732878e-01 | 0.172 | 0 | 0 |
| Highly sodium permeable postsynaptic acetylcholine nicotinic receptors | R-HSA-629587 | 6.732878e-01 | 0.172 | 0 | 0 |
| E2F-enabled inhibition of pre-replication complex formation | R-HSA-113507 | 6.732878e-01 | 0.172 | 0 | 0 |
| Hydrolysis of LPE | R-HSA-1483152 | 6.732878e-01 | 0.172 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in WNT signaling | R-HSA-8939256 | 6.732878e-01 | 0.172 | 0 | 0 |
| Neurofascin interactions | R-HSA-447043 | 6.732878e-01 | 0.172 | 0 | 0 |
| Integration of viral DNA into host genomic DNA | R-HSA-175567 | 6.732878e-01 | 0.172 | 0 | 0 |
| Signaling by LTK in cancer | R-HSA-9842640 | 6.732878e-01 | 0.172 | 0 | 0 |
| HDL clearance | R-HSA-8964011 | 6.732878e-01 | 0.172 | 0 | 0 |
| Leukotriene receptors | R-HSA-391906 | 6.732878e-01 | 0.172 | 0 | 0 |
| Nef and signal transduction | R-HSA-164944 | 6.732878e-01 | 0.172 | 0 | 0 |
| FRS-mediated FGFR4 signaling | R-HSA-5654712 | 6.755570e-01 | 0.170 | 0 | 0 |
| FGFR2 alternative splicing | R-HSA-6803529 | 6.755570e-01 | 0.170 | 0 | 0 |
| TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | R-HSA-6804115 | 6.755570e-01 | 0.170 | 0 | 0 |
| TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain | R-HSA-6803205 | 6.755570e-01 | 0.170 | 0 | 0 |
| Dopamine Neurotransmitter Release Cycle | R-HSA-212676 | 6.755570e-01 | 0.170 | 0 | 0 |
| Cholesterol biosynthesis via lathosterol | R-HSA-6807062 | 6.755570e-01 | 0.170 | 0 | 0 |
| Downregulation of TGF-beta receptor signaling | R-HSA-2173788 | 6.755570e-01 | 0.170 | 0 | 0 |
| NOTCH3 Activation and Transmission of Signal to the Nucleus | R-HSA-9013507 | 6.755570e-01 | 0.170 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in lysosome biogenesis and autophagy | R-HSA-9857377 | 6.755570e-01 | 0.170 | 0 | 0 |
| Ub-specific processing proteases | R-HSA-5689880 | 6.771346e-01 | 0.169 | 0 | 0 |
| Signaling by NOTCH | R-HSA-157118 | 6.830686e-01 | 0.166 | 0 | 0 |
| Processive synthesis on the lagging strand | R-HSA-69183 | 6.831472e-01 | 0.165 | 0 | 0 |
| TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | R-HSA-2173791 | 6.831472e-01 | 0.165 | 0 | 0 |
| TICAM1, RIP1-mediated IKK complex recruitment | R-HSA-168927 | 6.831472e-01 | 0.165 | 0 | 0 |
| ERBB2 Regulates Cell Motility | R-HSA-6785631 | 6.831472e-01 | 0.165 | 0 | 0 |
| Erythropoietin activates RAS | R-HSA-9027284 | 6.831472e-01 | 0.165 | 0 | 0 |
| RIP-mediated NFkB activation via ZBP1 | R-HSA-1810476 | 6.831472e-01 | 0.165 | 0 | 0 |
| Telomere C-strand synthesis initiation | R-HSA-174430 | 6.831472e-01 | 0.165 | 0 | 0 |
| p38MAPK events | R-HSA-171007 | 6.831472e-01 | 0.165 | 0 | 0 |
| SARS-CoV-2 targets host intracellular signalling and regulatory pathways | R-HSA-9755779 | 6.831472e-01 | 0.165 | 0 | 0 |
| SARS-CoV-1 targets host intracellular signalling and regulatory pathways | R-HSA-9735871 | 6.831472e-01 | 0.165 | 0 | 0 |
| Downstream TCR signaling | R-HSA-202424 | 6.843211e-01 | 0.165 | 0 | 0 |
| Base Excision Repair | R-HSA-73884 | 6.843211e-01 | 0.165 | 0 | 0 |
| Cell-Cell communication | R-HSA-1500931 | 6.879061e-01 | 0.162 | 0 | 0 |
| Transcriptional regulation by RUNX3 | R-HSA-8878159 | 6.888381e-01 | 0.162 | 0 | 0 |
| Attenuation phase | R-HSA-3371568 | 6.933835e-01 | 0.159 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation by EBF2 | R-HSA-9844594 | 6.933835e-01 | 0.159 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation | R-HSA-9843743 | 6.933835e-01 | 0.159 | 0 | 0 |
| Formation of Incision Complex in GG-NER | R-HSA-5696395 | 6.933835e-01 | 0.159 | 0 | 0 |
| Glycogen metabolism | R-HSA-8982491 | 6.933835e-01 | 0.159 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected purine | R-HSA-110330 | 6.940791e-01 | 0.159 | 0 | 0 |
| Class I MHC mediated antigen processing & presentation | R-HSA-983169 | 6.959292e-01 | 0.157 | 0 | 0 |
| Response of EIF2AK1 (HRI) to heme deficiency | R-HSA-9648895 | 6.981480e-01 | 0.156 | 0 | 0 |
| Interleukin-20 family signaling | R-HSA-8854691 | 6.981480e-01 | 0.156 | 0 | 0 |
| SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | R-HSA-399955 | 7.098535e-01 | 0.149 | 0 | 0 |
| Activation of SMO | R-HSA-5635838 | 7.098535e-01 | 0.149 | 0 | 0 |
| Attachment and Entry | R-HSA-9678110 | 7.098535e-01 | 0.149 | 0 | 0 |
| Differentiation of T cells | R-HSA-9945266 | 7.098535e-01 | 0.149 | 0 | 0 |
| Differentiation of naive CD+ T cells to T helper 1 cells (Th1 cells) | R-HSA-9942503 | 7.098535e-01 | 0.149 | 0 | 0 |
| Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells | R-HSA-210744 | 7.098535e-01 | 0.149 | 0 | 0 |
| Serotonin and melatonin biosynthesis | R-HSA-209931 | 7.098535e-01 | 0.149 | 0 | 0 |
| Integration of energy metabolism | R-HSA-163685 | 7.100145e-01 | 0.149 | 0 | 0 |
| Maturation of spike protein | R-HSA-9694548 | 7.105747e-01 | 0.148 | 0 | 0 |
| Dual incision in TC-NER | R-HSA-6782135 | 7.111164e-01 | 0.148 | 0 | 0 |
| RUNX1 regulates estrogen receptor mediated transcription | R-HSA-8931987 | 7.114860e-01 | 0.148 | 0 | 0 |
| PP2A-mediated dephosphorylation of key metabolic factors | R-HSA-163767 | 7.114860e-01 | 0.148 | 0 | 0 |
| Defective HLCS causes multiple carboxylase deficiency | R-HSA-3371599 | 7.114860e-01 | 0.148 | 0 | 0 |
| SLBP independent Processing of Histone Pre-mRNAs | R-HSA-111367 | 7.114860e-01 | 0.148 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression linked to gluconeogenesis | R-HSA-9632974 | 7.114860e-01 | 0.148 | 0 | 0 |
| Recycling of eIF2:GDP | R-HSA-72731 | 7.114860e-01 | 0.148 | 0 | 0 |
| Pre-NOTCH Processing in the Endoplasmic Reticulum | R-HSA-1912399 | 7.114860e-01 | 0.148 | 0 | 0 |
| Cohesin Loading onto Chromatin | R-HSA-2470946 | 7.114860e-01 | 0.148 | 0 | 0 |
| mRNA Editing: C to U Conversion | R-HSA-72200 | 7.114860e-01 | 0.148 | 0 | 0 |
| Nef Mediated CD4 Down-regulation | R-HSA-167590 | 7.114860e-01 | 0.148 | 0 | 0 |
| VLDL clearance | R-HSA-8964046 | 7.114860e-01 | 0.148 | 0 | 0 |
| Insulin effects increased synthesis of Xylulose-5-Phosphate | R-HSA-163754 | 7.114860e-01 | 0.148 | 0 | 0 |
| TGFBR3 regulates TGF-beta signaling | R-HSA-9839389 | 7.114860e-01 | 0.148 | 0 | 0 |
| Activation of TRKA receptors | R-HSA-187015 | 7.114860e-01 | 0.148 | 0 | 0 |
| Cation-coupled Chloride cotransporters | R-HSA-426117 | 7.114860e-01 | 0.148 | 0 | 0 |
| CHL1 interactions | R-HSA-447041 | 7.114860e-01 | 0.148 | 0 | 0 |
| Displacement of DNA glycosylase by APEX1 | R-HSA-110357 | 7.114860e-01 | 0.148 | 0 | 0 |
| Maturation of replicase proteins | R-HSA-9694301 | 7.114860e-01 | 0.148 | 0 | 0 |
| Kidney development | R-HSA-9830369 | 7.127820e-01 | 0.147 | 0 | 0 |
| Sealing of the nuclear envelope (NE) by ESCRT-III | R-HSA-9668328 | 7.130571e-01 | 0.147 | 0 | 0 |
| Cardiogenesis | R-HSA-9733709 | 7.130571e-01 | 0.147 | 0 | 0 |
| SRP-dependent cotranslational protein targeting to membrane | R-HSA-1799339 | 7.152802e-01 | 0.146 | 0 | 0 |
| Complex III assembly | R-HSA-9865881 | 7.195235e-01 | 0.143 | 0 | 0 |
| Assembly of active LPL and LIPC lipase complexes | R-HSA-8963889 | 7.195235e-01 | 0.143 | 0 | 0 |
| Interleukin-6 family signaling | R-HSA-6783589 | 7.195235e-01 | 0.143 | 0 | 0 |
| SARS-CoV-2-host interactions | R-HSA-9705683 | 7.201574e-01 | 0.143 | 0 | 0 |
| Deadenylation-dependent mRNA decay | R-HSA-429914 | 7.253000e-01 | 0.139 | 0 | 0 |
| Signaling by FGFR2 in disease | R-HSA-5655253 | 7.254501e-01 | 0.139 | 0 | 0 |
| HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand | R-HSA-3371497 | 7.260897e-01 | 0.139 | 0 | 0 |
| Negative regulation of MAPK pathway | R-HSA-5675221 | 7.270757e-01 | 0.138 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9683701 | 7.270757e-01 | 0.138 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9694635 | 7.275023e-01 | 0.138 | 0 | 0 |
| Regulation of CDH1 posttranslational processing and trafficking to plasma membrane | R-HSA-9768727 | 7.311570e-01 | 0.136 | 0 | 0 |
| Miscellaneous transport and binding events | R-HSA-5223345 | 7.311570e-01 | 0.136 | 0 | 0 |
| Processing of Intronless Pre-mRNAs | R-HSA-77595 | 7.346486e-01 | 0.134 | 0 | 0 |
| SHC1 events in ERBB4 signaling | R-HSA-1250347 | 7.346486e-01 | 0.134 | 0 | 0 |
| mRNA decay by 5' to 3' exoribonuclease | R-HSA-430039 | 7.346486e-01 | 0.134 | 0 | 0 |
| TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling | R-HSA-975110 | 7.346486e-01 | 0.134 | 0 | 0 |
| Disorders of Developmental Biology | R-HSA-9675151 | 7.346486e-01 | 0.134 | 0 | 0 |
| Synthesis of PG | R-HSA-1483148 | 7.346486e-01 | 0.134 | 0 | 0 |
| Adipogenesis | R-HSA-9843745 | 7.349499e-01 | 0.134 | 0 | 0 |
| SARS-CoV-2 Infection | R-HSA-9694516 | 7.377909e-01 | 0.132 | 0 | 0 |
| Developmental Lineage of Pancreatic Ductal Cells | R-HSA-9925563 | 7.389752e-01 | 0.131 | 0 | 0 |
| Sphingolipid de novo biosynthesis | R-HSA-1660661 | 7.389988e-01 | 0.131 | 0 | 0 |
| Negative Regulation of CDH1 Gene Transcription | R-HSA-9764725 | 7.389988e-01 | 0.131 | 0 | 0 |
| FRS-mediated FGFR1 signaling | R-HSA-5654693 | 7.397022e-01 | 0.131 | 0 | 0 |
| GABA B receptor activation | R-HSA-977444 | 7.428871e-01 | 0.129 | 0 | 0 |
| Activation of GABAB receptors | R-HSA-991365 | 7.428871e-01 | 0.129 | 0 | 0 |
| Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | R-HSA-381676 | 7.428871e-01 | 0.129 | 0 | 0 |
| ROBO receptors bind AKAP5 | R-HSA-9010642 | 7.452201e-01 | 0.128 | 0 | 0 |
| EGFR interacts with phospholipase C-gamma | R-HSA-212718 | 7.452201e-01 | 0.128 | 0 | 0 |
| SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs | R-HSA-77588 | 7.452201e-01 | 0.128 | 0 | 0 |
| MET receptor recycling | R-HSA-8875656 | 7.452201e-01 | 0.128 | 0 | 0 |
| Myoclonic epilepsy of Lafora | R-HSA-3785653 | 7.452201e-01 | 0.128 | 0 | 0 |
| Formation of annular gap junctions | R-HSA-196025 | 7.452201e-01 | 0.128 | 0 | 0 |
| Highly calcium permeable nicotinic acetylcholine receptors | R-HSA-629597 | 7.452201e-01 | 0.128 | 0 | 0 |
| Axonal growth inhibition (RHOA activation) | R-HSA-193634 | 7.452201e-01 | 0.128 | 0 | 0 |
| Formyl peptide receptors bind formyl peptides and many other ligands | R-HSA-444473 | 7.452201e-01 | 0.128 | 0 | 0 |
| TGFBR3 PTM regulation | R-HSA-9839383 | 7.452201e-01 | 0.128 | 0 | 0 |
| Alpha-defensins | R-HSA-1462054 | 7.452201e-01 | 0.128 | 0 | 0 |
| BMAL1:CLOCK,NPAS2 activates circadian expression | R-HSA-1368108 | 7.483860e-01 | 0.126 | 0 | 0 |
| Signaling by NOTCH2 | R-HSA-1980145 | 7.483860e-01 | 0.126 | 0 | 0 |
| Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding | R-HSA-6814122 | 7.483860e-01 | 0.126 | 0 | 0 |
| SARS-CoV-1 modulates host translation machinery | R-HSA-9735869 | 7.483860e-01 | 0.126 | 0 | 0 |
| Downstream signaling events of B Cell Receptor (BCR) | R-HSA-1168372 | 7.514369e-01 | 0.124 | 0 | 0 |
| Chaperonin-mediated protein folding | R-HSA-390466 | 7.521469e-01 | 0.124 | 0 | 0 |
| Modulation of host responses by IFN-stimulated genes | R-HSA-9909505 | 7.576141e-01 | 0.121 | 0 | 0 |
| Uptake and function of anthrax toxins | R-HSA-5210891 | 7.576141e-01 | 0.121 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) | R-HSA-5358606 | 7.576141e-01 | 0.121 | 0 | 0 |
| Specification of primordial germ cells | R-HSA-9827857 | 7.576141e-01 | 0.121 | 0 | 0 |
| Adrenaline,noradrenaline inhibits insulin secretion | R-HSA-400042 | 7.587099e-01 | 0.120 | 0 | 0 |
| Nuclear Envelope (NE) Reassembly | R-HSA-2995410 | 7.629283e-01 | 0.118 | 0 | 0 |
| Oncogene Induced Senescence | R-HSA-2559585 | 7.647560e-01 | 0.116 | 0 | 0 |
| Regulation of APC/C activators between G1/S and early anaphase | R-HSA-176408 | 7.649395e-01 | 0.116 | 0 | 0 |
| DNA Damage/Telomere Stress Induced Senescence | R-HSA-2559586 | 7.649395e-01 | 0.116 | 0 | 0 |
| tRNA processing in the nucleus | R-HSA-6784531 | 7.649395e-01 | 0.116 | 0 | 0 |
| SARS-CoV-1 Infection | R-HSA-9678108 | 7.654976e-01 | 0.116 | 0 | 0 |
| Transcriptional regulation by RUNX1 | R-HSA-8878171 | 7.668247e-01 | 0.115 | 0 | 0 |
| APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | R-HSA-174178 | 7.677200e-01 | 0.115 | 0 | 0 |
| Amino acids regulate mTORC1 | R-HSA-9639288 | 7.677200e-01 | 0.115 | 0 | 0 |
| Interferon gamma signaling | R-HSA-877300 | 7.685542e-01 | 0.114 | 0 | 0 |
| COPI-mediated anterograde transport | R-HSA-6807878 | 7.737526e-01 | 0.111 | 0 | 0 |
| Estrogen-stimulated signaling through PRKCZ | R-HSA-9634635 | 7.750116e-01 | 0.111 | 0 | 0 |
| Gap junction degradation | R-HSA-190873 | 7.750116e-01 | 0.111 | 0 | 0 |
| p75NTR regulates axonogenesis | R-HSA-193697 | 7.750116e-01 | 0.111 | 0 | 0 |
| MASTL Facilitates Mitotic Progression | R-HSA-2465910 | 7.750116e-01 | 0.111 | 0 | 0 |
| Defects in biotin (Btn) metabolism | R-HSA-3323169 | 7.750116e-01 | 0.111 | 0 | 0 |
| Unwinding of DNA | R-HSA-176974 | 7.750116e-01 | 0.111 | 0 | 0 |
| Interleukin-1 processing | R-HSA-448706 | 7.750116e-01 | 0.111 | 0 | 0 |
| mRNA Editing | R-HSA-75072 | 7.750116e-01 | 0.111 | 0 | 0 |
| Regulation of CDH11 gene transcription | R-HSA-9762293 | 7.750116e-01 | 0.111 | 0 | 0 |
| Transcriptional regulation by small RNAs | R-HSA-5578749 | 7.750893e-01 | 0.111 | 0 | 0 |
| Mitotic Prophase | R-HSA-68875 | 7.762984e-01 | 0.110 | 0 | 0 |
| EPHA-mediated growth cone collapse | R-HSA-3928663 | 7.765785e-01 | 0.110 | 0 | 0 |
| Packaging Of Telomere Ends | R-HSA-171306 | 7.765785e-01 | 0.110 | 0 | 0 |
| Insulin processing | R-HSA-264876 | 7.765785e-01 | 0.110 | 0 | 0 |
| Activation of gene expression by SREBF (SREBP) | R-HSA-2426168 | 7.771849e-01 | 0.109 | 0 | 0 |
| Cytosolic iron-sulfur cluster assembly | R-HSA-2564830 | 7.788389e-01 | 0.109 | 0 | 0 |
| FGFR1 ligand binding and activation | R-HSA-190242 | 7.788389e-01 | 0.109 | 0 | 0 |
| Serotonin Neurotransmitter Release Cycle | R-HSA-181429 | 7.788389e-01 | 0.109 | 0 | 0 |
| ZBP1(DAI) mediated induction of type I IFNs | R-HSA-1606322 | 7.788389e-01 | 0.109 | 0 | 0 |
| Nucleotide-like (purinergic) receptors | R-HSA-418038 | 7.788389e-01 | 0.109 | 0 | 0 |
| Nephron development | R-HSA-9831926 | 7.788389e-01 | 0.109 | 0 | 0 |
| Platelet sensitization by LDL | R-HSA-432142 | 7.788389e-01 | 0.109 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition | R-HSA-9926550 | 7.788389e-01 | 0.109 | 0 | 0 |
| Developmental Cell Lineages | R-HSA-9734767 | 7.834886e-01 | 0.106 | 0 | 0 |
| Epigenetic regulation of gene expression | R-HSA-212165 | 7.835082e-01 | 0.106 | 0 | 0 |
| p53-Independent G1/S DNA Damage Checkpoint | R-HSA-69613 | 7.862383e-01 | 0.104 | 0 | 0 |
| Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A | R-HSA-69601 | 7.862383e-01 | 0.104 | 0 | 0 |
| Ca2+ pathway | R-HSA-4086398 | 7.862836e-01 | 0.104 | 0 | 0 |
| Ion transport by P-type ATPases | R-HSA-936837 | 7.889517e-01 | 0.103 | 0 | 0 |
| Platelet homeostasis | R-HSA-418346 | 7.928698e-01 | 0.101 | 0 | 0 |
| HDACs deacetylate histones | R-HSA-3214815 | 7.930889e-01 | 0.101 | 0 | 0 |
| Signaling by NOTCH3 | R-HSA-9012852 | 7.930889e-01 | 0.101 | 0 | 0 |
| FRS-mediated FGFR2 signaling | R-HSA-5654700 | 7.933443e-01 | 0.101 | 0 | 0 |
| ATF4 activates genes in response to endoplasmic reticulum stress | R-HSA-380994 | 7.933443e-01 | 0.101 | 0 | 0 |
| Inflammasomes | R-HSA-622312 | 7.933443e-01 | 0.101 | 0 | 0 |
| Pre-NOTCH Transcription and Translation | R-HSA-1912408 | 7.937012e-01 | 0.100 | 0 | 0 |
| TRAF6 mediated IRF7 activation | R-HSA-933541 | 7.949847e-01 | 0.100 | 0 | 0 |
| Cleavage of the damaged purine | R-HSA-110331 | 7.949847e-01 | 0.100 | 0 | 0 |
| Regulation of signaling by CBL | R-HSA-912631 | 7.984160e-01 | 0.098 | 0 | 0 |
| Signaling by FGFR2 IIIa TM | R-HSA-8851708 | 7.984160e-01 | 0.098 | 0 | 0 |
| E2F mediated regulation of DNA replication | R-HSA-113510 | 7.984160e-01 | 0.098 | 0 | 0 |
| Mechanical load activates signaling by PIEZO1 and integrins in osteocytes | R-HSA-9856532 | 7.984160e-01 | 0.098 | 0 | 0 |
| Condensation of Prophase Chromosomes | R-HSA-2299718 | 7.993591e-01 | 0.097 | 0 | 0 |
| Formation of TC-NER Pre-Incision Complex | R-HSA-6781823 | 7.993591e-01 | 0.097 | 0 | 0 |
| Highly calcium permeable postsynaptic nicotinic acetylcholine receptors | R-HSA-629594 | 8.013212e-01 | 0.096 | 0 | 0 |
| TET1,2,3 and TDG demethylate DNA | R-HSA-5221030 | 8.013212e-01 | 0.096 | 0 | 0 |
| Ion influx/efflux at host-pathogen interface | R-HSA-6803544 | 8.013212e-01 | 0.096 | 0 | 0 |
| WNT5A-dependent internalization of FZD2, FZD5 and ROR2 | R-HSA-5140745 | 8.013212e-01 | 0.096 | 0 | 0 |
| 2-LTR circle formation | R-HSA-164843 | 8.013212e-01 | 0.096 | 0 | 0 |
| Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RNA | R-HSA-428359 | 8.013212e-01 | 0.096 | 0 | 0 |
| Cross-presentation of particulate exogenous antigens (phagosomes) | R-HSA-1236973 | 8.013212e-01 | 0.096 | 0 | 0 |
| Interleukin-27 signaling | R-HSA-9020956 | 8.013212e-01 | 0.096 | 0 | 0 |
| MECP2 regulates transcription of neuronal ligands | R-HSA-9022702 | 8.013212e-01 | 0.096 | 0 | 0 |
| Sperm Motility And Taxes | R-HSA-1300642 | 8.013212e-01 | 0.096 | 0 | 0 |
| Defective factor IX causes hemophilia B | R-HSA-9668250 | 8.013212e-01 | 0.096 | 0 | 0 |
| Metal sequestration by antimicrobial proteins | R-HSA-6799990 | 8.013212e-01 | 0.096 | 0 | 0 |
| Serotonin receptors | R-HSA-390666 | 8.013212e-01 | 0.096 | 0 | 0 |
| Reproduction | R-HSA-1474165 | 8.022913e-01 | 0.096 | 0 | 0 |
| Ribosome-associated quality control | R-HSA-9948299 | 8.029649e-01 | 0.095 | 0 | 0 |
| Ion channel transport | R-HSA-983712 | 8.031322e-01 | 0.095 | 0 | 0 |
| Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176814 | 8.049502e-01 | 0.094 | 0 | 0 |
| Detoxification of Reactive Oxygen Species | R-HSA-3299685 | 8.049502e-01 | 0.094 | 0 | 0 |
| TP53 Regulates Transcription of Cell Death Genes | R-HSA-5633008 | 8.074254e-01 | 0.093 | 0 | 0 |
| Non-integrin membrane-ECM interactions | R-HSA-3000171 | 8.074254e-01 | 0.093 | 0 | 0 |
| Depurination | R-HSA-73927 | 8.088839e-01 | 0.092 | 0 | 0 |
| mRNA Capping | R-HSA-72086 | 8.090471e-01 | 0.092 | 0 | 0 |
| Regulation of CDH11 Expression and Function | R-HSA-9759475 | 8.090471e-01 | 0.092 | 0 | 0 |
| Cellular response to chemical stress | R-HSA-9711123 | 8.124469e-01 | 0.090 | 0 | 0 |
| Protein folding | R-HSA-391251 | 8.124661e-01 | 0.090 | 0 | 0 |
| Late SARS-CoV-2 Infection Events | R-HSA-9772573 | 8.124661e-01 | 0.090 | 0 | 0 |
| MAPK6/MAPK4 signaling | R-HSA-5687128 | 8.144864e-01 | 0.089 | 0 | 0 |
| Glycogen synthesis | R-HSA-3322077 | 8.164404e-01 | 0.088 | 0 | 0 |
| Acyl chain remodelling of PI | R-HSA-1482922 | 8.164404e-01 | 0.088 | 0 | 0 |
| Mitochondrial iron-sulfur cluster biogenesis | R-HSA-1362409 | 8.164404e-01 | 0.088 | 0 | 0 |
| Protein hydroxylation | R-HSA-9629569 | 8.164404e-01 | 0.088 | 0 | 0 |
| BBSome-mediated cargo-targeting to cilium | R-HSA-5620922 | 8.164404e-01 | 0.088 | 0 | 0 |
| Signal transduction by L1 | R-HSA-445144 | 8.164404e-01 | 0.088 | 0 | 0 |
| GPER1 signaling | R-HSA-9634597 | 8.236859e-01 | 0.084 | 0 | 0 |
| NOTCH3 Intracellular Domain Regulates Transcription | R-HSA-9013508 | 8.237296e-01 | 0.084 | 0 | 0 |
| Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | R-HSA-1474151 | 8.237296e-01 | 0.084 | 0 | 0 |
| FGFR2b ligand binding and activation | R-HSA-190377 | 8.245555e-01 | 0.084 | 0 | 0 |
| vRNP Assembly | R-HSA-192905 | 8.245555e-01 | 0.084 | 0 | 0 |
| FGFRL1 modulation of FGFR1 signaling | R-HSA-5658623 | 8.245555e-01 | 0.084 | 0 | 0 |
| vRNA Synthesis | R-HSA-192814 | 8.245555e-01 | 0.084 | 0 | 0 |
| CD163 mediating an anti-inflammatory response | R-HSA-9662834 | 8.245555e-01 | 0.084 | 0 | 0 |
| Chylomicron assembly | R-HSA-8963888 | 8.245555e-01 | 0.084 | 0 | 0 |
| Inorganic anion exchange by SLC26 transporters | R-HSA-427601 | 8.245555e-01 | 0.084 | 0 | 0 |
| Regulation of HSF1-mediated heat shock response | R-HSA-3371453 | 8.279957e-01 | 0.082 | 0 | 0 |
| Potential therapeutics for SARS | R-HSA-9679191 | 8.319264e-01 | 0.080 | 0 | 0 |
| NOTCH2 Activation and Transmission of Signal to the Nucleus | R-HSA-2979096 | 8.330074e-01 | 0.079 | 0 | 0 |
| PKA-mediated phosphorylation of CREB | R-HSA-111931 | 8.330074e-01 | 0.079 | 0 | 0 |
| Early Phase of HIV Life Cycle | R-HSA-162594 | 8.330074e-01 | 0.079 | 0 | 0 |
| RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | R-HSA-73779 | 8.343708e-01 | 0.079 | 0 | 0 |
| Inhibition of DNA recombination at telomere | R-HSA-9670095 | 8.343708e-01 | 0.079 | 0 | 0 |
| p53-Dependent G1 DNA Damage Response | R-HSA-69563 | 8.349242e-01 | 0.078 | 0 | 0 |
| p53-Dependent G1/S DNA damage checkpoint | R-HSA-69580 | 8.349242e-01 | 0.078 | 0 | 0 |
| Fc epsilon receptor (FCERI) signaling | R-HSA-2454202 | 8.351989e-01 | 0.078 | 0 | 0 |
| Negative regulators of DDX58/IFIH1 signaling | R-HSA-936440 | 8.374361e-01 | 0.077 | 0 | 0 |
| Formation of the dystrophin-glycoprotein complex (DGC) | R-HSA-9913351 | 8.374361e-01 | 0.077 | 0 | 0 |
| Regulation of T cell activation by CD28 family | R-HSA-388841 | 8.412102e-01 | 0.075 | 0 | 0 |
| Regulation of expression of SLITs and ROBOs | R-HSA-9010553 | 8.448136e-01 | 0.073 | 0 | 0 |
| Regulation of cholesterol biosynthesis by SREBP (SREBF) | R-HSA-1655829 | 8.448805e-01 | 0.073 | 0 | 0 |
| Presynaptic nicotinic acetylcholine receptors | R-HSA-622323 | 8.450739e-01 | 0.073 | 0 | 0 |
| PI3K events in ERBB4 signaling | R-HSA-1250342 | 8.450739e-01 | 0.073 | 0 | 0 |
| Integration of provirus | R-HSA-162592 | 8.450739e-01 | 0.073 | 0 | 0 |
| Negative regulation of TCF-dependent signaling by WNT ligand antagonists | R-HSA-3772470 | 8.450739e-01 | 0.073 | 0 | 0 |
| Signaling by activated point mutants of FGFR1 | R-HSA-1839122 | 8.450739e-01 | 0.073 | 0 | 0 |
| Plasmalogen biosynthesis | R-HSA-75896 | 8.450739e-01 | 0.073 | 0 | 0 |
| ERKs are inactivated | R-HSA-202670 | 8.450739e-01 | 0.073 | 0 | 0 |
| Inhibition of replication initiation of damaged DNA by RB1/E2F1 | R-HSA-113501 | 8.450739e-01 | 0.073 | 0 | 0 |
| Synthesis of diphthamide-EEF2 | R-HSA-5358493 | 8.450739e-01 | 0.073 | 0 | 0 |
| Regulation of RAS by GAPs | R-HSA-5658442 | 8.455696e-01 | 0.073 | 0 | 0 |
| Chromatin modifications during the maternal to zygotic transition (MZT) | R-HSA-9821002 | 8.460111e-01 | 0.073 | 0 | 0 |
| Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs) | R-HSA-9845323 | 8.471511e-01 | 0.072 | 0 | 0 |
| Attachment and Entry | R-HSA-9694614 | 8.482115e-01 | 0.071 | 0 | 0 |
| Metabolism of Angiotensinogen to Angiotensins | R-HSA-2022377 | 8.482115e-01 | 0.071 | 0 | 0 |
| Assembly Of The HIV Virion | R-HSA-175474 | 8.482115e-01 | 0.071 | 0 | 0 |
| Activation of HOX genes during differentiation | R-HSA-5619507 | 8.511241e-01 | 0.070 | 0 | 0 |
| Activation of anterior HOX genes in hindbrain development during early embryogenesis | R-HSA-5617472 | 8.511241e-01 | 0.070 | 0 | 0 |
| Activation of NF-kappaB in B cells | R-HSA-1169091 | 8.556410e-01 | 0.068 | 0 | 0 |
| Viral Messenger RNA Synthesis | R-HSA-168325 | 8.564536e-01 | 0.067 | 0 | 0 |
| RNA Polymerase II HIV Promoter Escape | R-HSA-167162 | 8.569530e-01 | 0.067 | 0 | 0 |
| Degradation of GLI2 by the proteasome | R-HSA-5610783 | 8.569530e-01 | 0.067 | 0 | 0 |
| HIV Transcription Initiation | R-HSA-167161 | 8.569530e-01 | 0.067 | 0 | 0 |
| RNA Polymerase II Transcription Initiation | R-HSA-75953 | 8.569530e-01 | 0.067 | 0 | 0 |
| Intra-Golgi traffic | R-HSA-6811438 | 8.569530e-01 | 0.067 | 0 | 0 |
| Hedgehog 'on' state | R-HSA-5632684 | 8.585088e-01 | 0.066 | 0 | 0 |
| Cargo trafficking to the periciliary membrane | R-HSA-5620920 | 8.585088e-01 | 0.066 | 0 | 0 |
| Regulation of Expression and Function of Type II Classical Cadherins | R-HSA-9764260 | 8.621041e-01 | 0.064 | 0 | 0 |
| LDL clearance | R-HSA-8964038 | 8.621446e-01 | 0.064 | 0 | 0 |
| VLDLR internalisation and degradation | R-HSA-8866427 | 8.631937e-01 | 0.064 | 0 | 0 |
| Interleukin-35 Signalling | R-HSA-8984722 | 8.631937e-01 | 0.064 | 0 | 0 |
| Trafficking and processing of endosomal TLR | R-HSA-1679131 | 8.631937e-01 | 0.064 | 0 | 0 |
| Diseases associated with surfactant metabolism | R-HSA-5687613 | 8.631937e-01 | 0.064 | 0 | 0 |
| Pervasive developmental disorders | R-HSA-9005895 | 8.631937e-01 | 0.064 | 0 | 0 |
| Disorders of Nervous System Development | R-HSA-9697154 | 8.631937e-01 | 0.064 | 0 | 0 |
| Loss of function of MECP2 in Rett syndrome | R-HSA-9005891 | 8.631937e-01 | 0.064 | 0 | 0 |
| Signaling by NOTCH1 HD Domain Mutants in Cancer | R-HSA-2691230 | 8.631937e-01 | 0.064 | 0 | 0 |
| Erythrocytes take up oxygen and release carbon dioxide | R-HSA-1247673 | 8.631937e-01 | 0.064 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD Domain Mutants | R-HSA-2691232 | 8.631937e-01 | 0.064 | 0 | 0 |
| Signaling by Hedgehog | R-HSA-5358351 | 8.643994e-01 | 0.063 | 0 | 0 |
| Cdc20:Phospho-APC/C mediated degradation of Cyclin A | R-HSA-174184 | 8.651581e-01 | 0.063 | 0 | 0 |
| Uptake and actions of bacterial toxins | R-HSA-5339562 | 8.651581e-01 | 0.063 | 0 | 0 |
| The role of GTSE1 in G2/M progression after G2 checkpoint | R-HSA-8852276 | 8.652851e-01 | 0.063 | 0 | 0 |
| RNA Polymerase I Transcription Initiation | R-HSA-73762 | 8.672252e-01 | 0.062 | 0 | 0 |
| MHC class II antigen presentation | R-HSA-2132295 | 8.672502e-01 | 0.062 | 0 | 0 |
| Regulation of Expression and Function of Type I Classical Cadherins | R-HSA-9764274 | 8.672857e-01 | 0.062 | 0 | 0 |
| Regulation of CDH1 Expression and Function | R-HSA-9764265 | 8.672857e-01 | 0.062 | 0 | 0 |
| Synthesis of DNA | R-HSA-69239 | 8.717458e-01 | 0.060 | 0 | 0 |
| Fcgamma receptor (FCGR) dependent phagocytosis | R-HSA-2029480 | 8.724945e-01 | 0.059 | 0 | 0 |
| Vitamin B5 (pantothenate) metabolism | R-HSA-199220 | 8.731579e-01 | 0.059 | 0 | 0 |
| APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | R-HSA-179419 | 8.741413e-01 | 0.058 | 0 | 0 |
| Regulation of PTEN stability and activity | R-HSA-8948751 | 8.741413e-01 | 0.058 | 0 | 0 |
| Switching of origins to a post-replicative state | R-HSA-69052 | 8.745495e-01 | 0.058 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE | R-HSA-77075 | 8.748960e-01 | 0.058 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | R-HSA-167160 | 8.748960e-01 | 0.058 | 0 | 0 |
| Synthesis of UDP-N-acetyl-glucosamine | R-HSA-446210 | 8.748960e-01 | 0.058 | 0 | 0 |
| Synthesis of pyrophosphates in the cytosol | R-HSA-1855167 | 8.748960e-01 | 0.058 | 0 | 0 |
| Carnitine shuttle | R-HSA-200425 | 8.748960e-01 | 0.058 | 0 | 0 |
| RNA Polymerase II Promoter Escape | R-HSA-73776 | 8.768568e-01 | 0.057 | 0 | 0 |
| Defective pyroptosis | R-HSA-9710421 | 8.768568e-01 | 0.057 | 0 | 0 |
| Response of Mtb to phagocytosis | R-HSA-9637690 | 8.768568e-01 | 0.057 | 0 | 0 |
| G alpha (q) signalling events | R-HSA-416476 | 8.778840e-01 | 0.057 | 0 | 0 |
| Signaling by the B Cell Receptor (BCR) | R-HSA-983705 | 8.789952e-01 | 0.056 | 0 | 0 |
| Acetylcholine binding and downstream events | R-HSA-181431 | 8.791952e-01 | 0.056 | 0 | 0 |
| Adenylate cyclase activating pathway | R-HSA-170660 | 8.791952e-01 | 0.056 | 0 | 0 |
| Postsynaptic nicotinic acetylcholine receptors | R-HSA-622327 | 8.791952e-01 | 0.056 | 0 | 0 |
| FGFR2c ligand binding and activation | R-HSA-190375 | 8.791952e-01 | 0.056 | 0 | 0 |
| Formation of the non-canonical BAF (ncBAF) complex | R-HSA-9933947 | 8.791952e-01 | 0.056 | 0 | 0 |
| Golgi Cisternae Pericentriolar Stack Reorganization | R-HSA-162658 | 8.791952e-01 | 0.056 | 0 | 0 |
| FGFR4 ligand binding and activation | R-HSA-190322 | 8.791952e-01 | 0.056 | 0 | 0 |
| Signaling by activated point mutants of FGFR3 | R-HSA-1839130 | 8.791952e-01 | 0.056 | 0 | 0 |
| Mtb iron assimilation by chelation | R-HSA-1222449 | 8.791952e-01 | 0.056 | 0 | 0 |
| Formation of axial mesoderm | R-HSA-9796292 | 8.791952e-01 | 0.056 | 0 | 0 |
| FGFR3 mutant receptor activation | R-HSA-2033514 | 8.791952e-01 | 0.056 | 0 | 0 |
| rRNA modification in the mitochondrion | R-HSA-6793080 | 8.791952e-01 | 0.056 | 0 | 0 |
| CREB1 phosphorylation through the activation of Adenylate Cyclase | R-HSA-442720 | 8.791952e-01 | 0.056 | 0 | 0 |
| RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs) | R-HSA-8877330 | 8.791952e-01 | 0.056 | 0 | 0 |
| Acyl chain remodeling of DAG and TAG | R-HSA-1482883 | 8.791952e-01 | 0.056 | 0 | 0 |
| Platelet Adhesion to exposed collagen | R-HSA-75892 | 8.791952e-01 | 0.056 | 0 | 0 |
| Gastrulation | R-HSA-9758941 | 8.800384e-01 | 0.055 | 0 | 0 |
| Hedgehog 'off' state | R-HSA-5610787 | 8.812827e-01 | 0.055 | 0 | 0 |
| Signaling by NOTCH4 | R-HSA-9013694 | 8.819874e-01 | 0.055 | 0 | 0 |
| SARS-CoV-2 modulates host translation machinery | R-HSA-9754678 | 8.826111e-01 | 0.054 | 0 | 0 |
| Metabolism of RNA | R-HSA-8953854 | 8.828342e-01 | 0.054 | 0 | 0 |
| Regulation of endogenous retroelements by the Human Silencing Hub (HUSH) complex | R-HSA-9843970 | 8.834195e-01 | 0.054 | 0 | 0 |
| Antigen Presentation: Folding, assembly and peptide loading of class I MHC | R-HSA-983170 | 8.834195e-01 | 0.054 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected pyrimidine | R-HSA-110328 | 8.834195e-01 | 0.054 | 0 | 0 |
| MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis | R-HSA-9841922 | 8.848637e-01 | 0.053 | 0 | 0 |
| Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes | R-HSA-9851695 | 8.848637e-01 | 0.053 | 0 | 0 |
| Epigenetic regulation of gene expression by MLL3 and MLL4 complexes | R-HSA-9818564 | 8.848637e-01 | 0.053 | 0 | 0 |
| DAP12 interactions | R-HSA-2172127 | 8.858771e-01 | 0.053 | 0 | 0 |
| Processing of Capped Intronless Pre-mRNA | R-HSA-75067 | 8.865516e-01 | 0.052 | 0 | 0 |
| Replacement of protamines by nucleosomes in the male pronucleus | R-HSA-9821993 | 8.865516e-01 | 0.052 | 0 | 0 |
| CD209 (DC-SIGN) signaling | R-HSA-5621575 | 8.865516e-01 | 0.052 | 0 | 0 |
| TNFs bind their physiological receptors | R-HSA-5669034 | 8.865516e-01 | 0.052 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176409 | 8.905885e-01 | 0.050 | 0 | 0 |
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | R-HSA-983695 | 8.914498e-01 | 0.050 | 0 | 0 |
| Removal of the Flap Intermediate | R-HSA-69166 | 8.933259e-01 | 0.049 | 0 | 0 |
| Phospholipase C-mediated cascade; FGFR3 | R-HSA-5654227 | 8.933259e-01 | 0.049 | 0 | 0 |
| Retrograde neurotrophin signalling | R-HSA-177504 | 8.933259e-01 | 0.049 | 0 | 0 |
| FGFR3c ligand binding and activation | R-HSA-190372 | 8.933259e-01 | 0.049 | 0 | 0 |
| Transport of fatty acids | R-HSA-804914 | 8.933259e-01 | 0.049 | 0 | 0 |
| Hydrolysis of LPC | R-HSA-1483115 | 8.933259e-01 | 0.049 | 0 | 0 |
| MAP3K8 (TPL2)-dependent MAPK1/3 activation | R-HSA-5684264 | 8.933259e-01 | 0.049 | 0 | 0 |
| Physiological factors | R-HSA-5578768 | 8.933259e-01 | 0.049 | 0 | 0 |
| RNA Polymerase II Transcription Initiation And Promoter Clearance | R-HSA-76042 | 8.943153e-01 | 0.049 | 0 | 0 |
| Nucleosome assembly | R-HSA-774815 | 8.943153e-01 | 0.049 | 0 | 0 |
| Deposition of new CENPA-containing nucleosomes at the centromere | R-HSA-606279 | 8.943153e-01 | 0.049 | 0 | 0 |
| Fanconi Anemia Pathway | R-HSA-6783310 | 8.943153e-01 | 0.049 | 0 | 0 |
| Major pathway of rRNA processing in the nucleolus and cytosol | R-HSA-6791226 | 8.971320e-01 | 0.047 | 0 | 0 |
| Tight junction interactions | R-HSA-420029 | 8.971930e-01 | 0.047 | 0 | 0 |
| Laminin interactions | R-HSA-3000157 | 8.971930e-01 | 0.047 | 0 | 0 |
| Cell junction organization | R-HSA-446728 | 8.973919e-01 | 0.047 | 0 | 0 |
| Mitochondrial protein degradation | R-HSA-9837999 | 8.974326e-01 | 0.047 | 0 | 0 |
| G alpha (s) signalling events | R-HSA-418555 | 9.014806e-01 | 0.045 | 0 | 0 |
| C-type lectin receptors (CLRs) | R-HSA-5621481 | 9.014806e-01 | 0.045 | 0 | 0 |
| Vif-mediated degradation of APOBEC3G | R-HSA-180585 | 9.017451e-01 | 0.045 | 0 | 0 |
| Triglyceride catabolism | R-HSA-163560 | 9.017451e-01 | 0.045 | 0 | 0 |
| mRNA Splicing - Minor Pathway | R-HSA-72165 | 9.022002e-01 | 0.045 | 0 | 0 |
| Autodegradation of Cdh1 by Cdh1:APC/C | R-HSA-174084 | 9.022002e-01 | 0.045 | 0 | 0 |
| Cell recruitment (pro-inflammatory response) | R-HSA-9664424 | 9.022002e-01 | 0.045 | 0 | 0 |
| Purinergic signaling in leishmaniasis infection | R-HSA-9660826 | 9.022002e-01 | 0.045 | 0 | 0 |
| Regulation of CDH1 Function | R-HSA-9764561 | 9.051492e-01 | 0.043 | 0 | 0 |
| Regulation of PD-L1(CD274) expression | R-HSA-9909648 | 9.056791e-01 | 0.043 | 0 | 0 |
| Adenylate cyclase inhibitory pathway | R-HSA-170670 | 9.058045e-01 | 0.043 | 0 | 0 |
| G beta:gamma signalling through BTK | R-HSA-8964315 | 9.058045e-01 | 0.043 | 0 | 0 |
| Phospholipase C-mediated cascade; FGFR4 | R-HSA-5654228 | 9.058045e-01 | 0.043 | 0 | 0 |
| InlB-mediated entry of Listeria monocytogenes into host cell | R-HSA-8875360 | 9.058045e-01 | 0.043 | 0 | 0 |
| Lysosphingolipid and LPA receptors | R-HSA-419408 | 9.058045e-01 | 0.043 | 0 | 0 |
| Biotin transport and metabolism | R-HSA-196780 | 9.058045e-01 | 0.043 | 0 | 0 |
| FGFR3 ligand binding and activation | R-HSA-190239 | 9.058045e-01 | 0.043 | 0 | 0 |
| Protein repair | R-HSA-5676934 | 9.058045e-01 | 0.043 | 0 | 0 |
| Activation of BAD and translocation to mitochondria | R-HSA-111447 | 9.058045e-01 | 0.043 | 0 | 0 |
| Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA | R-HSA-450385 | 9.058045e-01 | 0.043 | 0 | 0 |
| STAT3 nuclear events downstream of ALK signaling | R-HSA-9701898 | 9.058045e-01 | 0.043 | 0 | 0 |
| Glutamate Neurotransmitter Release Cycle | R-HSA-210500 | 9.068981e-01 | 0.042 | 0 | 0 |
| Synthesis of IP2, IP, and Ins in the cytosol | R-HSA-1855183 | 9.068981e-01 | 0.042 | 0 | 0 |
| Regulation of RUNX1 Expression and Activity | R-HSA-8934593 | 9.068981e-01 | 0.042 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Securin | R-HSA-174154 | 9.095604e-01 | 0.041 | 0 | 0 |
| GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2 | R-HSA-9762114 | 9.098961e-01 | 0.041 | 0 | 0 |
| NCAM1 interactions | R-HSA-419037 | 9.098961e-01 | 0.041 | 0 | 0 |
| Adaptive Immune System | R-HSA-1280218 | 9.143213e-01 | 0.039 | 0 | 0 |
| Cristae formation | R-HSA-8949613 | 9.157403e-01 | 0.038 | 0 | 0 |
| RNA Polymerase I Promoter Opening | R-HSA-73728 | 9.157403e-01 | 0.038 | 0 | 0 |
| RNA Polymerase I Transcription Termination | R-HSA-73863 | 9.157403e-01 | 0.038 | 0 | 0 |
| Synthesis of active ubiquitin: roles of E1 and E2 enzymes | R-HSA-8866652 | 9.157403e-01 | 0.038 | 0 | 0 |
| Synthesis of bile acids and bile salts via 27-hydroxycholesterol | R-HSA-193807 | 9.157403e-01 | 0.038 | 0 | 0 |
| Intraflagellar transport | R-HSA-5620924 | 9.164238e-01 | 0.038 | 0 | 0 |
| Nuclear events stimulated by ALK signaling in cancer | R-HSA-9725371 | 9.164238e-01 | 0.038 | 0 | 0 |
| Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE) | R-HSA-2142816 | 9.168239e-01 | 0.038 | 0 | 0 |
| Defective GALNT3 causes HFTC | R-HSA-5083625 | 9.168239e-01 | 0.038 | 0 | 0 |
| Defective GALNT12 causes CRCS1 | R-HSA-5083636 | 9.168239e-01 | 0.038 | 0 | 0 |
| Class I peroxisomal membrane protein import | R-HSA-9603798 | 9.168239e-01 | 0.038 | 0 | 0 |
| Induction of Cell-Cell Fusion | R-HSA-9733458 | 9.168239e-01 | 0.038 | 0 | 0 |
| WNT5A-dependent internalization of FZD4 | R-HSA-5099900 | 9.168239e-01 | 0.038 | 0 | 0 |
| KSRP (KHSRP) binds and destabilizes mRNA | R-HSA-450604 | 9.168239e-01 | 0.038 | 0 | 0 |
| Receptor-type tyrosine-protein phosphatases | R-HSA-388844 | 9.168239e-01 | 0.038 | 0 | 0 |
| Synthesis of wybutosine at G37 of tRNA(Phe) | R-HSA-6782861 | 9.168239e-01 | 0.038 | 0 | 0 |
| Metabolism of nitric oxide: NOS3 activation and regulation | R-HSA-202131 | 9.174284e-01 | 0.037 | 0 | 0 |
| PKR-mediated signaling | R-HSA-9833482 | 9.192503e-01 | 0.037 | 0 | 0 |
| Hemostasis | R-HSA-109582 | 9.197994e-01 | 0.036 | 0 | 0 |
| TP53 Regulates Metabolic Genes | R-HSA-5628897 | 9.201580e-01 | 0.036 | 0 | 0 |
| Cytosolic sensors of pathogen-associated DNA | R-HSA-1834949 | 9.208484e-01 | 0.036 | 0 | 0 |
| Circadian clock | R-HSA-9909396 | 9.227449e-01 | 0.035 | 0 | 0 |
| Gap junction trafficking and regulation | R-HSA-157858 | 9.228176e-01 | 0.035 | 0 | 0 |
| N-glycan trimming in the ER and Calnexin/Calreticulin cycle | R-HSA-532668 | 9.228176e-01 | 0.035 | 0 | 0 |
| Regulation of insulin secretion | R-HSA-422356 | 9.233550e-01 | 0.035 | 0 | 0 |
| Insulin receptor recycling | R-HSA-77387 | 9.237885e-01 | 0.034 | 0 | 0 |
| Activation of kainate receptors upon glutamate binding | R-HSA-451326 | 9.237885e-01 | 0.034 | 0 | 0 |
| RAB geranylgeranylation | R-HSA-8873719 | 9.238143e-01 | 0.034 | 0 | 0 |
| Plasma lipoprotein clearance | R-HSA-8964043 | 9.243818e-01 | 0.034 | 0 | 0 |
| Pentose phosphate pathway | R-HSA-71336 | 9.243818e-01 | 0.034 | 0 | 0 |
| Respiratory syncytial virus (RSV) genome replication, transcription and translation | R-HSA-9820965 | 9.243818e-01 | 0.034 | 0 | 0 |
| Positive epigenetic regulation of rRNA expression | R-HSA-5250913 | 9.261451e-01 | 0.033 | 0 | 0 |
| Acetylcholine regulates insulin secretion | R-HSA-399997 | 9.265549e-01 | 0.033 | 0 | 0 |
| Regulation of innate immune responses to cytosolic DNA | R-HSA-3134975 | 9.265549e-01 | 0.033 | 0 | 0 |
| Galactose catabolism | R-HSA-70370 | 9.265549e-01 | 0.033 | 0 | 0 |
| tRNA modification in the mitochondrion | R-HSA-6787450 | 9.265549e-01 | 0.033 | 0 | 0 |
| Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE) | R-HSA-936964 | 9.265549e-01 | 0.033 | 0 | 0 |
| Defects of contact activation system (CAS) and kallikrein/kinin system (KKS) | R-HSA-9651496 | 9.265549e-01 | 0.033 | 0 | 0 |
| rRNA processing in the nucleus and cytosol | R-HSA-8868773 | 9.298270e-01 | 0.032 | 0 | 0 |
| ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | R-HSA-427389 | 9.307945e-01 | 0.031 | 0 | 0 |
| Maturation of TCA enzymes and regulation of TCA cycle | R-HSA-9854311 | 9.307945e-01 | 0.031 | 0 | 0 |
| Diseases of Immune System | R-HSA-5260271 | 9.307945e-01 | 0.031 | 0 | 0 |
| Diseases associated with the TLR signaling cascade | R-HSA-5602358 | 9.307945e-01 | 0.031 | 0 | 0 |
| Generation of second messenger molecules | R-HSA-202433 | 9.307945e-01 | 0.031 | 0 | 0 |
| Activation of Matrix Metalloproteinases | R-HSA-1592389 | 9.311075e-01 | 0.031 | 0 | 0 |
| Glucagon-type ligand receptors | R-HSA-420092 | 9.311075e-01 | 0.031 | 0 | 0 |
| Regulation of mRNA stability by proteins that bind AU-rich elements | R-HSA-450531 | 9.311273e-01 | 0.031 | 0 | 0 |
| GPCR downstream signalling | R-HSA-388396 | 9.324691e-01 | 0.030 | 0 | 0 |
| Mitochondrial protein import | R-HSA-1268020 | 9.343736e-01 | 0.029 | 0 | 0 |
| Phospholipase C-mediated cascade: FGFR1 | R-HSA-5654219 | 9.351479e-01 | 0.029 | 0 | 0 |
| Defective C1GALT1C1 causes TNPS | R-HSA-5083632 | 9.351479e-01 | 0.029 | 0 | 0 |
| Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane | R-HSA-190840 | 9.351479e-01 | 0.029 | 0 | 0 |
| Glycogen storage diseases | R-HSA-3229121 | 9.351479e-01 | 0.029 | 0 | 0 |
| RNA Polymerase III Transcription Initiation | R-HSA-76046 | 9.377577e-01 | 0.028 | 0 | 0 |
| rRNA modification in the nucleus and cytosol | R-HSA-6790901 | 9.391453e-01 | 0.027 | 0 | 0 |
| AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274) | R-HSA-9931269 | 9.394423e-01 | 0.027 | 0 | 0 |
| Assembly of the pre-replicative complex | R-HSA-68867 | 9.406200e-01 | 0.027 | 0 | 0 |
| Degradation of GLI1 by the proteasome | R-HSA-5610780 | 9.421423e-01 | 0.026 | 0 | 0 |
| GLI3 is processed to GLI3R by the proteasome | R-HSA-5610785 | 9.421423e-01 | 0.026 | 0 | 0 |
| Trafficking of GluR2-containing AMPA receptors | R-HSA-416993 | 9.427359e-01 | 0.026 | 0 | 0 |
| Activated point mutants of FGFR2 | R-HSA-2033519 | 9.427359e-01 | 0.026 | 0 | 0 |
| Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET) | R-HSA-2142670 | 9.427359e-01 | 0.026 | 0 | 0 |
| PKA activation in glucagon signalling | R-HSA-164378 | 9.427359e-01 | 0.026 | 0 | 0 |
| Transport of connexons to the plasma membrane | R-HSA-190872 | 9.427359e-01 | 0.026 | 0 | 0 |
| PKA activation | R-HSA-163615 | 9.427359e-01 | 0.026 | 0 | 0 |
| Molecules associated with elastic fibres | R-HSA-2129379 | 9.437954e-01 | 0.025 | 0 | 0 |
| Cargo concentration in the ER | R-HSA-5694530 | 9.437954e-01 | 0.025 | 0 | 0 |
| Respiratory syncytial virus (RSV) attachment and entry | R-HSA-9820960 | 9.437954e-01 | 0.025 | 0 | 0 |
| B-WICH complex positively regulates rRNA expression | R-HSA-5250924 | 9.442141e-01 | 0.025 | 0 | 0 |
| Golgi Associated Vesicle Biogenesis | R-HSA-432722 | 9.442141e-01 | 0.025 | 0 | 0 |
| Pre-NOTCH Expression and Processing | R-HSA-1912422 | 9.463305e-01 | 0.024 | 0 | 0 |
| Cleavage of the damaged pyrimidine | R-HSA-110329 | 9.471451e-01 | 0.024 | 0 | 0 |
| Depyrimidination | R-HSA-73928 | 9.471451e-01 | 0.024 | 0 | 0 |
| UCH proteinases | R-HSA-5689603 | 9.482047e-01 | 0.023 | 0 | 0 |
| CDK-mediated phosphorylation and removal of Cdc6 | R-HSA-69017 | 9.486397e-01 | 0.023 | 0 | 0 |
| Base-Excision Repair, AP Site Formation | R-HSA-73929 | 9.486397e-01 | 0.023 | 0 | 0 |
| Pre-NOTCH Processing in Golgi | R-HSA-1912420 | 9.494365e-01 | 0.023 | 0 | 0 |
| Pyrimidine biosynthesis | R-HSA-500753 | 9.494365e-01 | 0.023 | 0 | 0 |
| mRNA decay by 3' to 5' exoribonuclease | R-HSA-429958 | 9.494365e-01 | 0.023 | 0 | 0 |
| O2/CO2 exchange in erythrocytes | R-HSA-1480926 | 9.494365e-01 | 0.023 | 0 | 0 |
| Diseases of hemostasis | R-HSA-9671793 | 9.494365e-01 | 0.023 | 0 | 0 |
| Erythrocytes take up carbon dioxide and release oxygen | R-HSA-1237044 | 9.494365e-01 | 0.023 | 0 | 0 |
| HDL remodeling | R-HSA-8964058 | 9.494365e-01 | 0.023 | 0 | 0 |
| Strand-asynchronous mitochondrial DNA replication | R-HSA-9913635 | 9.494365e-01 | 0.023 | 0 | 0 |
| Regulation of Homotypic Cell-Cell Adhesion | R-HSA-9759476 | 9.515551e-01 | 0.022 | 0 | 0 |
| G alpha (z) signalling events | R-HSA-418597 | 9.527410e-01 | 0.021 | 0 | 0 |
| Assembly of the ORC complex at the origin of replication | R-HSA-68616 | 9.542383e-01 | 0.020 | 0 | 0 |
| Recycling of bile acids and salts | R-HSA-159418 | 9.542383e-01 | 0.020 | 0 | 0 |
| Diseases associated with glycosylation precursor biosynthesis | R-HSA-5609975 | 9.542383e-01 | 0.020 | 0 | 0 |
| Formation of ATP by chemiosmotic coupling | R-HSA-163210 | 9.553534e-01 | 0.020 | 0 | 0 |
| Phospholipase C-mediated cascade; FGFR2 | R-HSA-5654221 | 9.553534e-01 | 0.020 | 0 | 0 |
| Post-chaperonin tubulin folding pathway | R-HSA-389977 | 9.553534e-01 | 0.020 | 0 | 0 |
| VxPx cargo-targeting to cilium | R-HSA-5620916 | 9.553534e-01 | 0.020 | 0 | 0 |
| Wax and plasmalogen biosynthesis | R-HSA-8848584 | 9.553534e-01 | 0.020 | 0 | 0 |
| Pregnenolone biosynthesis | R-HSA-196108 | 9.553534e-01 | 0.020 | 0 | 0 |
| Signaling by NODAL | R-HSA-1181150 | 9.553534e-01 | 0.020 | 0 | 0 |
| Eicosanoid ligand-binding receptors | R-HSA-391903 | 9.553534e-01 | 0.020 | 0 | 0 |
| Gap junction trafficking | R-HSA-190828 | 9.559647e-01 | 0.020 | 0 | 0 |
| Surfactant metabolism | R-HSA-5683826 | 9.559647e-01 | 0.020 | 0 | 0 |
| SARS-CoV-1-host interactions | R-HSA-9692914 | 9.560162e-01 | 0.020 | 0 | 0 |
| Interferon alpha/beta signaling | R-HSA-909733 | 9.579260e-01 | 0.019 | 0 | 0 |
| Acyl chain remodelling of PC | R-HSA-1482788 | 9.587368e-01 | 0.018 | 0 | 0 |
| Gene Silencing by RNA | R-HSA-211000 | 9.587433e-01 | 0.018 | 0 | 0 |
| FGFR2 ligand binding and activation | R-HSA-190241 | 9.605783e-01 | 0.017 | 0 | 0 |
| Acetylcholine Neurotransmitter Release Cycle | R-HSA-264642 | 9.605783e-01 | 0.017 | 0 | 0 |
| Intrinsic Pathway of Fibrin Clot Formation | R-HSA-140837 | 9.605783e-01 | 0.017 | 0 | 0 |
| Prevention of phagosomal-lysosomal fusion | R-HSA-9636383 | 9.605783e-01 | 0.017 | 0 | 0 |
| Negative epigenetic regulation of rRNA expression | R-HSA-5250941 | 9.613759e-01 | 0.017 | 0 | 0 |
| DNA Replication | R-HSA-69306 | 9.618543e-01 | 0.017 | 0 | 0 |
| eNOS activation | R-HSA-203615 | 9.628094e-01 | 0.016 | 0 | 0 |
| Calnexin/calreticulin cycle | R-HSA-901042 | 9.628094e-01 | 0.016 | 0 | 0 |
| Regulation of TLR by endogenous ligand | R-HSA-5686938 | 9.628094e-01 | 0.016 | 0 | 0 |
| Gap junction assembly | R-HSA-190861 | 9.628094e-01 | 0.016 | 0 | 0 |
| Inactivation, recovery and regulation of the phototransduction cascade | R-HSA-2514859 | 9.633909e-01 | 0.016 | 0 | 0 |
| DNA Replication Pre-Initiation | R-HSA-69002 | 9.637482e-01 | 0.016 | 0 | 0 |
| Selenoamino acid metabolism | R-HSA-2408522 | 9.640415e-01 | 0.016 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 2 Promoter | R-HSA-76066 | 9.651919e-01 | 0.015 | 0 | 0 |
| Androgen biosynthesis | R-HSA-193048 | 9.651919e-01 | 0.015 | 0 | 0 |
| Molybdenum cofactor biosynthesis | R-HSA-947581 | 9.651919e-01 | 0.015 | 0 | 0 |
| Serine metabolism | R-HSA-977347 | 9.651919e-01 | 0.015 | 0 | 0 |
| Glutathione synthesis and recycling | R-HSA-174403 | 9.651919e-01 | 0.015 | 0 | 0 |
| Glucocorticoid biosynthesis | R-HSA-194002 | 9.651919e-01 | 0.015 | 0 | 0 |
| Assembly of collagen fibrils and other multimeric structures | R-HSA-2022090 | 9.663046e-01 | 0.015 | 0 | 0 |
| Acyl chain remodelling of PE | R-HSA-1482839 | 9.664943e-01 | 0.015 | 0 | 0 |
| EPH-ephrin mediated repulsion of cells | R-HSA-3928665 | 9.666456e-01 | 0.015 | 0 | 0 |
| Synthesis of PC | R-HSA-1483191 | 9.666456e-01 | 0.015 | 0 | 0 |
| NoRC negatively regulates rRNA expression | R-HSA-427413 | 9.673846e-01 | 0.014 | 0 | 0 |
| Respiratory Syncytial Virus Infection Pathway | R-HSA-9820952 | 9.680946e-01 | 0.014 | 0 | 0 |
| SARS-CoV Infections | R-HSA-9679506 | 9.687480e-01 | 0.014 | 0 | 0 |
| Cytoprotection by HMOX1 | R-HSA-9707564 | 9.691661e-01 | 0.014 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 3 Promoter | R-HSA-76071 | 9.692658e-01 | 0.014 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 1 Promoter | R-HSA-76061 | 9.692658e-01 | 0.014 | 0 | 0 |
| WNT ligand biogenesis and trafficking | R-HSA-3238698 | 9.692658e-01 | 0.014 | 0 | 0 |
| Cellular hexose transport | R-HSA-189200 | 9.692658e-01 | 0.014 | 0 | 0 |
| Regulation of endogenous retroelements | R-HSA-9842860 | 9.695178e-01 | 0.013 | 0 | 0 |
| Plasma lipoprotein remodeling | R-HSA-8963899 | 9.696257e-01 | 0.013 | 0 | 0 |
| Gluconeogenesis | R-HSA-70263 | 9.696257e-01 | 0.013 | 0 | 0 |
| ER to Golgi Anterograde Transport | R-HSA-199977 | 9.696380e-01 | 0.013 | 0 | 0 |
| PRC2 methylates histones and DNA | R-HSA-212300 | 9.698264e-01 | 0.013 | 0 | 0 |
| Lysosome Vesicle Biogenesis | R-HSA-432720 | 9.698264e-01 | 0.013 | 0 | 0 |
| RNA Polymerase III Transcription | R-HSA-74158 | 9.698264e-01 | 0.013 | 0 | 0 |
| RNA Polymerase III Abortive And Retractive Initiation | R-HSA-749476 | 9.698264e-01 | 0.013 | 0 | 0 |
| FGFR2 mutant receptor activation | R-HSA-1839126 | 9.698264e-01 | 0.013 | 0 | 0 |
| trans-Golgi Network Vesicle Budding | R-HSA-199992 | 9.699003e-01 | 0.013 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of HSCs | R-HSA-8939236 | 9.714235e-01 | 0.013 | 0 | 0 |
| Collagen degradation | R-HSA-1442490 | 9.716348e-01 | 0.012 | 0 | 0 |
| Degradation of CDH1 | R-HSA-9766229 | 9.723527e-01 | 0.012 | 0 | 0 |
| Degradation of DVL | R-HSA-4641258 | 9.728377e-01 | 0.012 | 0 | 0 |
| SIRT1 negatively regulates rRNA expression | R-HSA-427359 | 9.728377e-01 | 0.012 | 0 | 0 |
| SLC-mediated transport of organic cations | R-HSA-549127 | 9.728377e-01 | 0.012 | 0 | 0 |
| Termination of O-glycan biosynthesis | R-HSA-977068 | 9.728632e-01 | 0.012 | 0 | 0 |
| Formation of the ureteric bud | R-HSA-9830674 | 9.728632e-01 | 0.012 | 0 | 0 |
| ABC transporters in lipid homeostasis | R-HSA-1369062 | 9.728632e-01 | 0.012 | 0 | 0 |
| Regulation of PD-L1(CD274) Post-translational modification | R-HSA-9909615 | 9.754882e-01 | 0.011 | 0 | 0 |
| Elastic fibre formation | R-HSA-1566948 | 9.755577e-01 | 0.011 | 0 | 0 |
| Co-inhibition by PD-1 | R-HSA-389948 | 9.756734e-01 | 0.011 | 0 | 0 |
| Norepinephrine Neurotransmitter Release Cycle | R-HSA-181430 | 9.760396e-01 | 0.011 | 0 | 0 |
| Translocation of ZAP-70 to Immunological synapse | R-HSA-202430 | 9.760396e-01 | 0.011 | 0 | 0 |
| ADP signalling through P2Y purinoceptor 1 | R-HSA-418592 | 9.760396e-01 | 0.011 | 0 | 0 |
| Mitochondrial RNA degradation | R-HSA-9836573 | 9.760396e-01 | 0.011 | 0 | 0 |
| Plasma lipoprotein assembly | R-HSA-8963898 | 9.760396e-01 | 0.011 | 0 | 0 |
| Protein ubiquitination | R-HSA-8852135 | 9.764087e-01 | 0.010 | 0 | 0 |
| Citric acid cycle (TCA cycle) | R-HSA-71403 | 9.764087e-01 | 0.010 | 0 | 0 |
| Hedgehog ligand biogenesis | R-HSA-5358346 | 9.771253e-01 | 0.010 | 0 | 0 |
| The phototransduction cascade | R-HSA-2514856 | 9.771253e-01 | 0.010 | 0 | 0 |
| GSK3B-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929356 | 9.780133e-01 | 0.010 | 0 | 0 |
| RAS processing | R-HSA-9648002 | 9.780133e-01 | 0.010 | 0 | 0 |
| RNA Polymerase I Promoter Clearance | R-HSA-73854 | 9.782687e-01 | 0.010 | 0 | 0 |
| MicroRNA (miRNA) biogenesis | R-HSA-203927 | 9.788444e-01 | 0.009 | 0 | 0 |
| Acyl chain remodelling of PS | R-HSA-1482801 | 9.788444e-01 | 0.009 | 0 | 0 |
| Fertilization | R-HSA-1187000 | 9.788444e-01 | 0.009 | 0 | 0 |
| Beta-oxidation of pristanoyl-CoA | R-HSA-389887 | 9.788444e-01 | 0.009 | 0 | 0 |
| PIWI-interacting RNA (piRNA) biogenesis | R-HSA-5601884 | 9.788444e-01 | 0.009 | 0 | 0 |
| Orc1 removal from chromatin | R-HSA-68949 | 9.792069e-01 | 0.009 | 0 | 0 |
| RNA Polymerase I Promoter Escape | R-HSA-73772 | 9.792069e-01 | 0.009 | 0 | 0 |
| E3 ubiquitin ligases ubiquitinate target proteins | R-HSA-8866654 | 9.792069e-01 | 0.009 | 0 | 0 |
| Regulation of RUNX3 expression and activity | R-HSA-8941858 | 9.802291e-01 | 0.009 | 0 | 0 |
| Negative regulation of NOTCH4 signaling | R-HSA-9604323 | 9.802291e-01 | 0.009 | 0 | 0 |
| PPARA activates gene expression | R-HSA-1989781 | 9.811385e-01 | 0.008 | 0 | 0 |
| MET activates PTK2 signaling | R-HSA-8874081 | 9.813211e-01 | 0.008 | 0 | 0 |
| Urea cycle | R-HSA-70635 | 9.813211e-01 | 0.008 | 0 | 0 |
| Suppression of phagosomal maturation | R-HSA-9637687 | 9.813211e-01 | 0.008 | 0 | 0 |
| RNA Polymerase I Transcription | R-HSA-73864 | 9.815846e-01 | 0.008 | 0 | 0 |
| tRNA modification in the nucleus and cytosol | R-HSA-6782315 | 9.817073e-01 | 0.008 | 0 | 0 |
| Beta-catenin independent WNT signaling | R-HSA-3858494 | 9.821946e-01 | 0.008 | 0 | 0 |
| Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | R-HSA-5625886 | 9.822277e-01 | 0.008 | 0 | 0 |
| SLC-mediated transport of amino acids | R-HSA-9958863 | 9.832658e-01 | 0.007 | 0 | 0 |
| Regulation of lipid metabolism by PPARalpha | R-HSA-400206 | 9.833112e-01 | 0.007 | 0 | 0 |
| HCMV Late Events | R-HSA-9610379 | 9.833112e-01 | 0.007 | 0 | 0 |
| ER Quality Control Compartment (ERQC) | R-HSA-901032 | 9.835079e-01 | 0.007 | 0 | 0 |
| Phosphorylation of CD3 and TCR zeta chains | R-HSA-202427 | 9.835079e-01 | 0.007 | 0 | 0 |
| Synthesis of PE | R-HSA-1483213 | 9.835079e-01 | 0.007 | 0 | 0 |
| Signaling by BMP | R-HSA-201451 | 9.835079e-01 | 0.007 | 0 | 0 |
| Maturation of hRSV A proteins | R-HSA-9828806 | 9.835079e-01 | 0.007 | 0 | 0 |
| SLC-mediated transport of neurotransmitters | R-HSA-442660 | 9.840294e-01 | 0.007 | 0 | 0 |
| Adherens junctions interactions | R-HSA-418990 | 9.850118e-01 | 0.007 | 0 | 0 |
| Pyrimidine salvage | R-HSA-73614 | 9.854388e-01 | 0.006 | 0 | 0 |
| Cytosolic tRNA aminoacylation | R-HSA-379716 | 9.856530e-01 | 0.006 | 0 | 0 |
| Plasma lipoprotein assembly, remodeling, and clearance | R-HSA-174824 | 9.869562e-01 | 0.006 | 0 | 0 |
| Hh mutants abrogate ligand secretion | R-HSA-5387390 | 9.871154e-01 | 0.006 | 0 | 0 |
| DNA methylation | R-HSA-5334118 | 9.871437e-01 | 0.006 | 0 | 0 |
| Regulation of actin dynamics for phagocytic cup formation | R-HSA-2029482 | 9.871781e-01 | 0.006 | 0 | 0 |
| Immune System | R-HSA-168256 | 9.876029e-01 | 0.005 | 0 | 0 |
| rRNA processing | R-HSA-72312 | 9.879200e-01 | 0.005 | 0 | 0 |
| Developmental Cell Lineages of the Exocrine Pancreas | R-HSA-9820448 | 9.882336e-01 | 0.005 | 0 | 0 |
| SCF(Skp2)-mediated degradation of p27/p21 | R-HSA-187577 | 9.884322e-01 | 0.005 | 0 | 0 |
| Thrombin signalling through proteinase activated receptors (PARs) | R-HSA-456926 | 9.886491e-01 | 0.005 | 0 | 0 |
| GABA synthesis, release, reuptake and degradation | R-HSA-888590 | 9.886491e-01 | 0.005 | 0 | 0 |
| Formation of the cornified envelope | R-HSA-6809371 | 9.886838e-01 | 0.005 | 0 | 0 |
| Protein localization | R-HSA-9609507 | 9.889761e-01 | 0.005 | 0 | 0 |
| RSV-host interactions | R-HSA-9833110 | 9.891852e-01 | 0.005 | 0 | 0 |
| Peroxisomal protein import | R-HSA-9033241 | 9.894558e-01 | 0.005 | 0 | 0 |
| Triglyceride metabolism | R-HSA-8979227 | 9.894558e-01 | 0.005 | 0 | 0 |
| Amino acid transport across the plasma membrane | R-HSA-352230 | 9.894558e-01 | 0.005 | 0 | 0 |
| Defective CFTR causes cystic fibrosis | R-HSA-5678895 | 9.896174e-01 | 0.005 | 0 | 0 |
| ADORA2B mediated anti-inflammatory cytokines production | R-HSA-9660821 | 9.896174e-01 | 0.005 | 0 | 0 |
| Vasopressin regulates renal water homeostasis via Aquaporins | R-HSA-432040 | 9.896174e-01 | 0.005 | 0 | 0 |
| Synthesis of glycosylphosphatidylinositol (GPI) | R-HSA-162710 | 9.899783e-01 | 0.004 | 0 | 0 |
| HCMV Early Events | R-HSA-9609690 | 9.902470e-01 | 0.004 | 0 | 0 |
| FCERI mediated Ca+2 mobilization | R-HSA-2871809 | 9.903899e-01 | 0.004 | 0 | 0 |
| Signaling by Retinoic Acid | R-HSA-5362517 | 9.904448e-01 | 0.004 | 0 | 0 |
| ROS and RNS production in phagocytes | R-HSA-1222556 | 9.911276e-01 | 0.004 | 0 | 0 |
| Formation of paraxial mesoderm | R-HSA-9793380 | 9.913439e-01 | 0.004 | 0 | 0 |
| Endogenous sterols | R-HSA-211976 | 9.913439e-01 | 0.004 | 0 | 0 |
| Signaling by GPCR | R-HSA-372790 | 9.917076e-01 | 0.004 | 0 | 0 |
| HCMV Infection | R-HSA-9609646 | 9.921737e-01 | 0.003 | 0 | 0 |
| Cell-cell junction organization | R-HSA-421270 | 9.925956e-01 | 0.003 | 0 | 0 |
| Post-translational protein phosphorylation | R-HSA-8957275 | 9.926416e-01 | 0.003 | 0 | 0 |
| Vpu mediated degradation of CD4 | R-HSA-180534 | 9.931031e-01 | 0.003 | 0 | 0 |
| Glucagon signaling in metabolic regulation | R-HSA-163359 | 9.931031e-01 | 0.003 | 0 | 0 |
| Heme degradation | R-HSA-189483 | 9.931031e-01 | 0.003 | 0 | 0 |
| Synthesis of bile acids and bile salts | R-HSA-192105 | 9.932291e-01 | 0.003 | 0 | 0 |
| Bile acid and bile salt metabolism | R-HSA-194068 | 9.932582e-01 | 0.003 | 0 | 0 |
| ABC-family proteins mediated transport | R-HSA-382556 | 9.937719e-01 | 0.003 | 0 | 0 |
| Interleukin-10 signaling | R-HSA-6783783 | 9.938755e-01 | 0.003 | 0 | 0 |
| Ubiquitin-dependent degradation of Cyclin D | R-HSA-75815 | 9.939109e-01 | 0.003 | 0 | 0 |
| Autodegradation of the E3 ubiquitin ligase COP1 | R-HSA-349425 | 9.939109e-01 | 0.003 | 0 | 0 |
| RA biosynthesis pathway | R-HSA-5365859 | 9.939109e-01 | 0.003 | 0 | 0 |
| Hyaluronan metabolism | R-HSA-2142845 | 9.939109e-01 | 0.003 | 0 | 0 |
| Signal amplification | R-HSA-392518 | 9.939109e-01 | 0.003 | 0 | 0 |
| Developmental Lineage of Pancreatic Acinar Cells | R-HSA-9925561 | 9.944222e-01 | 0.002 | 0 | 0 |
| Metabolic disorders of biological oxidation enzymes | R-HSA-5579029 | 9.944222e-01 | 0.002 | 0 | 0 |
| SCF-beta-TrCP mediated degradation of Emi1 | R-HSA-174113 | 9.946242e-01 | 0.002 | 0 | 0 |
| Defects in vitamin and cofactor metabolism | R-HSA-3296482 | 9.946242e-01 | 0.002 | 0 | 0 |
| Transferrin endocytosis and recycling | R-HSA-917977 | 9.946242e-01 | 0.002 | 0 | 0 |
| SARS-CoV-1 activates/modulates innate immune responses | R-HSA-9692916 | 9.951634e-01 | 0.002 | 0 | 0 |
| Nicotinate metabolism | R-HSA-196807 | 9.952481e-01 | 0.002 | 0 | 0 |
| Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol | R-HSA-193368 | 9.952481e-01 | 0.002 | 0 | 0 |
| AUF1 (hnRNP D0) binds and destabilizes mRNA | R-HSA-450408 | 9.952539e-01 | 0.002 | 0 | 0 |
| Formation of Fibrin Clot (Clotting Cascade) | R-HSA-140877 | 9.952539e-01 | 0.002 | 0 | 0 |
| Amyloid fiber formation | R-HSA-977225 | 9.953781e-01 | 0.002 | 0 | 0 |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | R-HSA-381426 | 9.954948e-01 | 0.002 | 0 | 0 |
| FCERI mediated NF-kB activation | R-HSA-2871837 | 9.955211e-01 | 0.002 | 0 | 0 |
| Nucleotide biosynthesis | R-HSA-8956320 | 9.956675e-01 | 0.002 | 0 | 0 |
| Degradation of AXIN | R-HSA-4641257 | 9.958099e-01 | 0.002 | 0 | 0 |
| Beta-oxidation of very long chain fatty acids | R-HSA-390247 | 9.958099e-01 | 0.002 | 0 | 0 |
| Metabolism of folate and pterines | R-HSA-196757 | 9.958099e-01 | 0.002 | 0 | 0 |
| Collagen chain trimerization | R-HSA-8948216 | 9.958099e-01 | 0.002 | 0 | 0 |
| Collagen formation | R-HSA-1474290 | 9.961292e-01 | 0.002 | 0 | 0 |
| Role of phospholipids in phagocytosis | R-HSA-2029485 | 9.961742e-01 | 0.002 | 0 | 0 |
| alpha-linolenic acid (ALA) metabolism | R-HSA-2046106 | 9.963008e-01 | 0.002 | 0 | 0 |
| Mitochondrial Fatty Acid Beta-Oxidation | R-HSA-77289 | 9.964620e-01 | 0.002 | 0 | 0 |
| Regulation of endogenous retroelements by KRAB-ZFP proteins | R-HSA-9843940 | 9.964933e-01 | 0.002 | 0 | 0 |
| COPII-mediated vesicle transport | R-HSA-204005 | 9.964933e-01 | 0.002 | 0 | 0 |
| Stabilization of p53 | R-HSA-69541 | 9.967342e-01 | 0.001 | 0 | 0 |
| Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) | R-HSA-381771 | 9.967342e-01 | 0.001 | 0 | 0 |
| Diseases associated with N-glycosylation of proteins | R-HSA-3781860 | 9.967342e-01 | 0.001 | 0 | 0 |
| tRNA processing | R-HSA-72306 | 9.967604e-01 | 0.001 | 0 | 0 |
| Metabolism of cofactors | R-HSA-8978934 | 9.968328e-01 | 0.001 | 0 | 0 |
| Metabolism of amine-derived hormones | R-HSA-209776 | 9.968900e-01 | 0.001 | 0 | 0 |
| Role of LAT2/NTAL/LAB on calcium mobilization | R-HSA-2730905 | 9.970469e-01 | 0.001 | 0 | 0 |
| rRNA processing in the mitochondrion | R-HSA-8868766 | 9.971169e-01 | 0.001 | 0 | 0 |
| Interconversion of nucleotide di- and triphosphates | R-HSA-499943 | 9.971402e-01 | 0.001 | 0 | 0 |
| Synthesis of PA | R-HSA-1483166 | 9.972165e-01 | 0.001 | 0 | 0 |
| FCGR3A-mediated phagocytosis | R-HSA-9664422 | 9.972639e-01 | 0.001 | 0 | 0 |
| Leishmania phagocytosis | R-HSA-9664417 | 9.972639e-01 | 0.001 | 0 | 0 |
| Parasite infection | R-HSA-9664407 | 9.972639e-01 | 0.001 | 0 | 0 |
| Hh mutants are degraded by ERAD | R-HSA-5362768 | 9.974547e-01 | 0.001 | 0 | 0 |
| NIK-->noncanonical NF-kB signaling | R-HSA-5676590 | 9.974547e-01 | 0.001 | 0 | 0 |
| Purine ribonucleoside monophosphate biosynthesis | R-HSA-73817 | 9.974547e-01 | 0.001 | 0 | 0 |
| Degradation of CRY and PER proteins | R-HSA-9932298 | 9.977530e-01 | 0.001 | 0 | 0 |
| Scavenging by Class A Receptors | R-HSA-3000480 | 9.977530e-01 | 0.001 | 0 | 0 |
| tRNA Aminoacylation | R-HSA-379724 | 9.980067e-01 | 0.001 | 0 | 0 |
| Incretin synthesis, secretion, and inactivation | R-HSA-400508 | 9.980163e-01 | 0.001 | 0 | 0 |
| SLC transporter disorders | R-HSA-5619102 | 9.980959e-01 | 0.001 | 0 | 0 |
| Neddylation | R-HSA-8951664 | 9.981135e-01 | 0.001 | 0 | 0 |
| Aquaporin-mediated transport | R-HSA-445717 | 9.982173e-01 | 0.001 | 0 | 0 |
| Neurotransmitter release cycle | R-HSA-112310 | 9.982263e-01 | 0.001 | 0 | 0 |
| Defensins | R-HSA-1461973 | 9.982488e-01 | 0.001 | 0 | 0 |
| Integrin cell surface interactions | R-HSA-216083 | 9.984583e-01 | 0.001 | 0 | 0 |
| ABC transporter disorders | R-HSA-5619084 | 9.984583e-01 | 0.001 | 0 | 0 |
| PCP/CE pathway | R-HSA-4086400 | 9.984583e-01 | 0.001 | 0 | 0 |
| Cholesterol biosynthesis | R-HSA-191273 | 9.984583e-01 | 0.001 | 0 | 0 |
| Glycerophospholipid biosynthesis | R-HSA-1483206 | 9.984684e-01 | 0.001 | 0 | 0 |
| Somitogenesis | R-HSA-9824272 | 9.986352e-01 | 0.001 | 0 | 0 |
| Dectin-1 mediated noncanonical NF-kB signaling | R-HSA-5607761 | 9.986352e-01 | 0.001 | 0 | 0 |
| Leishmania infection | R-HSA-9658195 | 9.987351e-01 | 0.001 | 0 | 0 |
| Parasitic Infection Pathways | R-HSA-9824443 | 9.987351e-01 | 0.001 | 0 | 0 |
| Regulation of pyruvate metabolism | R-HSA-9861718 | 9.987952e-01 | 0.001 | 0 | 0 |
| Cellular response to hypoxia | R-HSA-1234174 | 9.988615e-01 | 0.000 | 0 | 0 |
| Peptide hormone metabolism | R-HSA-2980736 | 9.989022e-01 | 0.000 | 0 | 0 |
| Carboxyterminal post-translational modifications of tubulin | R-HSA-8955332 | 9.989364e-01 | 0.000 | 0 | 0 |
| alpha-linolenic (omega3) and linoleic (omega6) acid metabolism | R-HSA-2046104 | 9.989364e-01 | 0.000 | 0 | 0 |
| TNFR2 non-canonical NF-kB pathway | R-HSA-5668541 | 9.990846e-01 | 0.000 | 0 | 0 |
| Metabolism of steroid hormones | R-HSA-196071 | 9.990910e-01 | 0.000 | 0 | 0 |
| O-linked glycosylation of mucins | R-HSA-913709 | 9.991880e-01 | 0.000 | 0 | 0 |
| Collagen biosynthesis and modifying enzymes | R-HSA-1650814 | 9.991880e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation elongation | R-HSA-5389840 | 9.991911e-01 | 0.000 | 0 | 0 |
| Viral Infection Pathways | R-HSA-9824446 | 9.992403e-01 | 0.000 | 0 | 0 |
| Synthesis of Prostaglandins (PG) and Thromboxanes (TX) | R-HSA-2162123 | 9.992684e-01 | 0.000 | 0 | 0 |
| Transport to the Golgi and subsequent modification | R-HSA-948021 | 9.992720e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation initiation | R-HSA-5368286 | 9.993369e-01 | 0.000 | 0 | 0 |
| Fatty acyl-CoA biosynthesis | R-HSA-75105 | 9.993523e-01 | 0.000 | 0 | 0 |
| FCERI mediated MAPK activation | R-HSA-2871796 | 9.993918e-01 | 0.000 | 0 | 0 |
| Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation | R-HSA-163841 | 9.993990e-01 | 0.000 | 0 | 0 |
| Diseases associated with O-glycosylation of proteins | R-HSA-3906995 | 9.994217e-01 | 0.000 | 0 | 0 |
| Retinoid metabolism and transport | R-HSA-975634 | 9.994217e-01 | 0.000 | 0 | 0 |
| ECM proteoglycans | R-HSA-3000178 | 9.994217e-01 | 0.000 | 0 | 0 |
| Diseases of carbohydrate metabolism | R-HSA-5663084 | 9.995391e-01 | 0.000 | 0 | 0 |
| ER-Phagosome pathway | R-HSA-1236974 | 9.995625e-01 | 0.000 | 0 | 0 |
| Mitochondrial ribosome-associated quality control | R-HSA-9937383 | 9.995980e-01 | 0.000 | 0 | 0 |
| Innate Immune System | R-HSA-168249 | 9.996204e-01 | 0.000 | 0 | 0 |
| Digestion | R-HSA-8935690 | 9.996539e-01 | 0.000 | 0 | 0 |
| Dectin-2 family | R-HSA-5621480 | 9.996945e-01 | 0.000 | 0 | 0 |
| Sialic acid metabolism | R-HSA-4085001 | 9.997619e-01 | 0.000 | 0 | 0 |
| Degradation of the extracellular matrix | R-HSA-1474228 | 9.997686e-01 | 0.000 | 0 | 0 |
| Antigen processing-Cross presentation | R-HSA-1236975 | 9.997809e-01 | 0.000 | 0 | 0 |
| Infection with Mycobacterium tuberculosis | R-HSA-9635486 | 9.997890e-01 | 0.000 | 0 | 0 |
| Glutathione conjugation | R-HSA-156590 | 9.997899e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation termination | R-HSA-5419276 | 9.998022e-01 | 0.000 | 0 | 0 |
| Nucleotide salvage | R-HSA-8956321 | 9.998145e-01 | 0.000 | 0 | 0 |
| Metabolism of fat-soluble vitamins | R-HSA-6806667 | 9.998150e-01 | 0.000 | 0 | 0 |
| Translation | R-HSA-72766 | 9.998282e-01 | 0.000 | 0 | 0 |
| Complex I biogenesis | R-HSA-6799198 | 9.998555e-01 | 0.000 | 0 | 0 |
| Digestion and absorption | R-HSA-8963743 | 9.998555e-01 | 0.000 | 0 | 0 |
| CD22 mediated BCR regulation | R-HSA-5690714 | 9.998724e-01 | 0.000 | 0 | 0 |
| Glycosphingolipid biosynthesis | R-HSA-9840309 | 9.998724e-01 | 0.000 | 0 | 0 |
| FCGR3A-mediated IL10 synthesis | R-HSA-9664323 | 9.998828e-01 | 0.000 | 0 | 0 |
| Latent infection - Other responses of Mtb to phagocytosis | R-HSA-1222499 | 9.998874e-01 | 0.000 | 0 | 0 |
| Pyruvate metabolism | R-HSA-70268 | 9.999173e-01 | 0.000 | 0 | 0 |
| Post-translational modification: synthesis of GPI-anchored proteins | R-HSA-163125 | 9.999370e-01 | 0.000 | 0 | 0 |
| Glycosphingolipid catabolism | R-HSA-9840310 | 9.999397e-01 | 0.000 | 0 | 0 |
| Class B/2 (Secretin family receptors) | R-HSA-373080 | 9.999415e-01 | 0.000 | 0 | 0 |
| Metabolism of porphyrins | R-HSA-189445 | 9.999468e-01 | 0.000 | 0 | 0 |
| Disorders of transmembrane transporters | R-HSA-5619115 | 9.999468e-01 | 0.000 | 0 | 0 |
| Purine catabolism | R-HSA-74259 | 9.999530e-01 | 0.000 | 0 | 0 |
| Transport of vitamins, nucleosides, and related molecules | R-HSA-425397 | 9.999634e-01 | 0.000 | 0 | 0 |
| Iron uptake and transport | R-HSA-917937 | 9.999677e-01 | 0.000 | 0 | 0 |
| Antimicrobial peptides | R-HSA-6803157 | 9.999707e-01 | 0.000 | 0 | 0 |
| G alpha (i) signalling events | R-HSA-418594 | 9.999771e-01 | 0.000 | 0 | 0 |
| SLC-mediated transmembrane transport | R-HSA-425407 | 9.999787e-01 | 0.000 | 0 | 0 |
| Cell surface interactions at the vascular wall | R-HSA-202733 | 9.999841e-01 | 0.000 | 0 | 0 |
| Sphingolipid metabolism | R-HSA-428157 | 9.999869e-01 | 0.000 | 0 | 0 |
| Visual phototransduction | R-HSA-2187338 | 9.999895e-01 | 0.000 | 0 | 0 |
| Peroxisomal lipid metabolism | R-HSA-390918 | 9.999895e-01 | 0.000 | 0 | 0 |
| Extracellular matrix organization | R-HSA-1474244 | 9.999918e-01 | 0.000 | 0 | 0 |
| Keratinization | R-HSA-6805567 | 9.999924e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation | R-HSA-5368287 | 9.999944e-01 | 0.000 | 0 | 0 |
| Class C/3 (Metabotropic glutamate/pheromone receptors) | R-HSA-420499 | 9.999944e-01 | 0.000 | 0 | 0 |
| Metabolism of steroids | R-HSA-8957322 | 9.999944e-01 | 0.000 | 0 | 0 |
| Anti-inflammatory response favouring Leishmania parasite infection | R-HSA-9662851 | 9.999968e-01 | 0.000 | 0 | 0 |
| Leishmania parasite growth and survival | R-HSA-9664433 | 9.999968e-01 | 0.000 | 0 | 0 |
| FCGR activation | R-HSA-2029481 | 9.999973e-01 | 0.000 | 0 | 0 |
| Synthesis of substrates in N-glycan biosythesis | R-HSA-446219 | 9.999980e-01 | 0.000 | 0 | 0 |
| Respiratory electron transport | R-HSA-611105 | 9.999981e-01 | 0.000 | 0 | 0 |
| Metabolism of water-soluble vitamins and cofactors | R-HSA-196849 | 9.999992e-01 | 0.000 | 0 | 0 |
| Glycosphingolipid metabolism | R-HSA-1660662 | 9.999993e-01 | 0.000 | 0 | 0 |
| Disease | R-HSA-1643685 | 9.999995e-01 | 0.000 | 0 | 0 |
| Metabolism of carbohydrates and carbohydrate derivatives | R-HSA-71387 | 9.999997e-01 | 0.000 | 0 | 0 |
| Diseases of glycosylation | R-HSA-3781865 | 9.999998e-01 | 0.000 | 0 | 0 |
| Binding and Uptake of Ligands by Scavenger Receptors | R-HSA-2173782 | 9.999998e-01 | 0.000 | 0 | 0 |
| Initial triggering of complement | R-HSA-166663 | 9.999999e-01 | 0.000 | 0 | 0 |
| O-linked glycosylation | R-HSA-5173105 | 9.999999e-01 | 0.000 | 0 | 0 |
| Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein | R-HSA-446193 | 9.999999e-01 | 0.000 | 0 | 0 |
| Sensory perception of sweet, bitter, and umami (glutamate) taste | R-HSA-9717207 | 1.000000e+00 | 0.000 | 0 | 0 |
| Regulation of Complement cascade | R-HSA-977606 | 1.000000e+00 | 0.000 | 0 | 0 |
| Cytochrome P450 - arranged by substrate type | R-HSA-211897 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of nucleotides | R-HSA-15869 | 1.000000e+00 | 0.000 | 0 | 0 |
| Transport of small molecules | R-HSA-382551 | 1.000000e+00 | 0.000 | 0 | 0 |
| Nucleotide catabolism | R-HSA-8956319 | 1.000000e+00 | 0.000 | 0 | 0 |
| Arachidonate metabolism | R-HSA-2142753 | 1.000000e+00 | 0.000 | 0 | 0 |
| Asparagine N-linked glycosylation | R-HSA-446203 | 1.000000e+00 | 0.000 | 0 | 0 |
| Sensory perception of taste | R-HSA-9717189 | 1.000000e+00 | 0.000 | 0 | 0 |
| Post-translational protein modification | R-HSA-597592 | 1.000000e+00 | 0.000 | 0 | 0 |
| Peptide ligand-binding receptors | R-HSA-375276 | 1.000000e+00 | 0.000 | 0 | 0 |
| Complement cascade | R-HSA-166658 | 1.000000e+00 | 0.000 | 0 | 0 |
| Infectious disease | R-HSA-5663205 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of vitamins and cofactors | R-HSA-196854 | 1.000000e+00 | 0.000 | 0 | 0 |
| Class A/1 (Rhodopsin-like receptors) | R-HSA-373076 | 1.000000e+00 | 0.000 | 0 | 0 |
| Aerobic respiration and respiratory electron transport | R-HSA-1428517 | 1.000000e+00 | 0.000 | 0 | 0 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | R-HSA-198933 | 1.000000e+00 | 0.000 | 0 | 0 |
| Bacterial Infection Pathways | R-HSA-9824439 | 1.000000e+00 | 0.000 | 0 | 0 |
| Glycosaminoglycan metabolism | R-HSA-1630316 | 1.000000e+00 | 0.000 | 0 | 0 |
| Fatty acid metabolism | R-HSA-8978868 | 1.000000e+00 | 0.000 | 0 | 0 |
| Diseases of metabolism | R-HSA-5668914 | 1.000000e+00 | 0.000 | 0 | 0 |
| Phase I - Functionalization of compounds | R-HSA-211945 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of proteins | R-HSA-392499 | 1.000000e+00 | 0.000 | 0 | 0 |
| Phase II - Conjugation of compounds | R-HSA-156580 | 1.000000e+00 | 0.000 | 0 | 0 |
| GPCR ligand binding | R-HSA-500792 | 1.000000e+00 | 0.000 | 0 | 0 |
| Expression and translocation of olfactory receptors | R-HSA-9752946 | 1.000000e+00 | -0.000 | 0 | 0 |
| Metabolism of lipids | R-HSA-556833 | 1.000000e+00 | -0.000 | 0 | 0 |
| Metabolism | R-HSA-1430728 | 1.000000e+00 | -0.000 | 0 | 0 |
| Sensory Perception | R-HSA-9709957 | 1.000000e+00 | -0.000 | 0 | 0 |
| Olfactory Signaling Pathway | R-HSA-381753 | 1.000000e+00 | -0.000 | 0 | 0 |
| Biological oxidations | R-HSA-211859 | 1.000000e+00 | -0.000 | 0 | 0 |
| Metabolism of amino acids and derivatives | R-HSA-71291 | 1.000000e+00 | -0.000 | 0 | 0 |
Top15 pathways (red highlights are reference pathways)
Compared with reference pathways
Motif of predicted substrate sequence
Reactome pathways of predicted substrates
Download
| name | reactome_id | p | -log10p | ref_path | ref_path_lowest |
|---|---|---|---|---|---|
| Cell Cycle | R-HSA-1640170 | 3.910192e-08 | 7.408 | 0 | 0 |
| Cell Cycle, Mitotic | R-HSA-69278 | 6.274009e-08 | 7.202 | 0 | 0 |
| Processing of Capped Intron-Containing Pre-mRNA | R-HSA-72203 | 2.452133e-07 | 6.610 | 0 | 0 |
| Metabolism of RNA | R-HSA-8953854 | 4.294370e-07 | 6.367 | 0 | 0 |
| Apoptotic execution phase | R-HSA-75153 | 4.877981e-07 | 6.312 | 0 | 0 |
| Chromatin organization | R-HSA-4839726 | 7.594410e-07 | 6.120 | 0 | 0 |
| Apoptotic cleavage of cellular proteins | R-HSA-111465 | 9.215894e-07 | 6.035 | 0 | 0 |
| Ribosomal scanning and start codon recognition | R-HSA-72702 | 6.562878e-06 | 5.183 | 0 | 0 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | R-HSA-72706 | 6.530320e-06 | 5.185 | 0 | 0 |
| M Phase | R-HSA-68886 | 6.379037e-06 | 5.195 | 0 | 0 |
| Chromatin modifying enzymes | R-HSA-3247509 | 1.187626e-05 | 4.925 | 0 | 0 |
| Translation initiation complex formation | R-HSA-72649 | 1.367605e-05 | 4.864 | 0 | 0 |
| Formation of the ternary complex, and subsequently, the 43S complex | R-HSA-72695 | 2.371443e-05 | 4.625 | 0 | 0 |
| Downregulation of ERBB4 signaling | R-HSA-1253288 | 2.620742e-05 | 4.582 | 0 | 0 |
| Eukaryotic Translation Initiation | R-HSA-72613 | 2.936644e-05 | 4.532 | 0 | 0 |
| Cap-dependent Translation Initiation | R-HSA-72737 | 2.936644e-05 | 4.532 | 0 | 0 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | R-HSA-72662 | 3.247797e-05 | 4.488 | 0 | 0 |
| ISG15 antiviral mechanism | R-HSA-1169408 | 3.411858e-05 | 4.467 | 0 | 0 |
| Downregulation of ERBB2 signaling | R-HSA-8863795 | 3.717905e-05 | 4.430 | 0 | 0 |
| L13a-mediated translational silencing of Ceruloplasmin expression | R-HSA-156827 | 4.142628e-05 | 4.383 | 0 | 0 |
| mRNA Splicing - Major Pathway | R-HSA-72163 | 4.909313e-05 | 4.309 | 0 | 0 |
| TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation | R-HSA-8869496 | 5.490706e-05 | 4.260 | 0 | 0 |
| mRNA Splicing | R-HSA-72172 | 7.427139e-05 | 4.129 | 0 | 0 |
| Axon guidance | R-HSA-422475 | 7.203376e-05 | 4.142 | 0 | 0 |
| Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RNA | R-HSA-428359 | 8.318764e-05 | 4.080 | 0 | 0 |
| Cell-Cell communication | R-HSA-1500931 | 1.077656e-04 | 3.968 | 0 | 0 |
| Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | R-HSA-8950505 | 1.243845e-04 | 3.905 | 0 | 0 |
| SWI/SNF chromatin remodelers | R-HSA-9932451 | 1.356561e-04 | 3.868 | 0 | 0 |
| ATP-dependent chromatin remodelers | R-HSA-9932444 | 1.356561e-04 | 3.868 | 0 | 0 |
| Formation of the polybromo-BAF (pBAF) complex | R-HSA-9933939 | 1.448012e-04 | 3.839 | 0 | 0 |
| Formation of a pool of free 40S subunits | R-HSA-72689 | 1.942366e-04 | 3.712 | 0 | 0 |
| Formation of the embryonic stem cell BAF (esBAF) complex | R-HSA-9933946 | 2.149941e-04 | 3.668 | 0 | 0 |
| Nervous system development | R-HSA-9675108 | 2.396610e-04 | 3.620 | 0 | 0 |
| Transport of Mature Transcript to Cytoplasm | R-HSA-72202 | 2.835166e-04 | 3.547 | 0 | 0 |
| Regulation of CDH1 Gene Transcription | R-HSA-9764560 | 2.896160e-04 | 3.538 | 0 | 0 |
| Interleukin-12 signaling | R-HSA-9020591 | 2.882908e-04 | 3.540 | 0 | 0 |
| Formation of neuronal progenitor and neuronal BAF (npBAF and nBAF) | R-HSA-9934037 | 3.706475e-04 | 3.431 | 0 | 0 |
| Developmental Lineage of Mammary Gland Myoepithelial Cells | R-HSA-9927432 | 4.007060e-04 | 3.397 | 0 | 0 |
| Signaling by ERBB2 | R-HSA-1227986 | 3.940859e-04 | 3.404 | 0 | 0 |
| Membrane Trafficking | R-HSA-199991 | 3.943403e-04 | 3.404 | 0 | 0 |
| Signaling by ROBO receptors | R-HSA-376176 | 4.366750e-04 | 3.360 | 0 | 0 |
| Transcriptional Regulation by E2F6 | R-HSA-8953750 | 4.476632e-04 | 3.349 | 0 | 0 |
| Signaling by ALK fusions and activated point mutants | R-HSA-9725370 | 4.577885e-04 | 3.339 | 0 | 0 |
| Signaling by ALK in cancer | R-HSA-9700206 | 4.577885e-04 | 3.339 | 0 | 0 |
| TICAM1,TRAF6-dependent induction of TAK1 complex | R-HSA-9014325 | 5.043292e-04 | 3.297 | 0 | 0 |
| Major pathway of rRNA processing in the nucleolus and cytosol | R-HSA-6791226 | 5.516231e-04 | 3.258 | 0 | 0 |
| Mitotic Prophase | R-HSA-68875 | 5.608810e-04 | 3.251 | 0 | 0 |
| Regulation of CDH1 Expression and Function | R-HSA-9764265 | 7.256124e-04 | 3.139 | 0 | 0 |
| Regulation of Expression and Function of Type I Classical Cadherins | R-HSA-9764274 | 7.256124e-04 | 3.139 | 0 | 0 |
| rRNA processing in the nucleus and cytosol | R-HSA-8868773 | 7.700205e-04 | 3.113 | 0 | 0 |
| Chaperone Mediated Autophagy | R-HSA-9613829 | 8.336371e-04 | 3.079 | 0 | 0 |
| Deactivation of the beta-catenin transactivating complex | R-HSA-3769402 | 9.177605e-04 | 3.037 | 0 | 0 |
| Regulation of PLK1 Activity at G2/M Transition | R-HSA-2565942 | 9.042378e-04 | 3.044 | 0 | 0 |
| FLT3 signaling by CBL mutants | R-HSA-9706377 | 9.307657e-04 | 3.031 | 0 | 0 |
| Cell-extracellular matrix interactions | R-HSA-446353 | 1.008195e-03 | 2.996 | 0 | 0 |
| Activation of ATR in response to replication stress | R-HSA-176187 | 1.012137e-03 | 2.995 | 0 | 0 |
| Negative Regulation of CDH1 Gene Transcription | R-HSA-9764725 | 1.039623e-03 | 2.983 | 0 | 0 |
| Clathrin-mediated endocytosis | R-HSA-8856828 | 1.086036e-03 | 2.964 | 0 | 0 |
| Diseases of signal transduction by growth factor receptors and second messengers | R-HSA-5663202 | 1.088469e-03 | 2.963 | 0 | 0 |
| Transport of Mature mRNA derived from an Intron-Containing Transcript | R-HSA-159236 | 1.138139e-03 | 2.944 | 0 | 0 |
| Regulation of TBK1, IKKε-mediated activation of IRF3, IRF7 upon TLR3 ligation | R-HSA-9828211 | 1.174477e-03 | 2.930 | 0 | 0 |
| Apoptotic cleavage of cell adhesion proteins | R-HSA-351906 | 1.174477e-03 | 2.930 | 0 | 0 |
| DNA Replication Pre-Initiation | R-HSA-69002 | 1.248240e-03 | 2.904 | 0 | 0 |
| Nephrin family interactions | R-HSA-373753 | 1.472580e-03 | 2.832 | 0 | 0 |
| Interleukin-12 family signaling | R-HSA-447115 | 1.507423e-03 | 2.822 | 0 | 0 |
| Cell junction organization | R-HSA-446728 | 1.536857e-03 | 2.813 | 0 | 0 |
| Regulation of CDH1 Function | R-HSA-9764561 | 1.675259e-03 | 2.776 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex | R-HSA-937042 | 1.814993e-03 | 2.741 | 0 | 0 |
| Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | R-HSA-1236382 | 1.914489e-03 | 2.718 | 0 | 0 |
| Signaling by Ligand-Responsive EGFR Variants in Cancer | R-HSA-5637815 | 1.914489e-03 | 2.718 | 0 | 0 |
| Cell Cycle Checkpoints | R-HSA-69620 | 1.864746e-03 | 2.729 | 0 | 0 |
| mRNA 3'-end processing | R-HSA-72187 | 1.987665e-03 | 2.702 | 0 | 0 |
| Formation of Senescence-Associated Heterochromatin Foci (SAHF) | R-HSA-2559584 | 2.314794e-03 | 2.635 | 0 | 0 |
| Formation of the non-canonical BAF (ncBAF) complex | R-HSA-9933947 | 2.314794e-03 | 2.635 | 0 | 0 |
| Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs) | R-HSA-9845323 | 2.599475e-03 | 2.585 | 0 | 0 |
| Factors involved in megakaryocyte development and platelet production | R-HSA-983231 | 2.902272e-03 | 2.537 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation | R-HSA-975163 | 3.162419e-03 | 2.500 | 0 | 0 |
| Assembly of the pre-replicative complex | R-HSA-68867 | 3.388349e-03 | 2.470 | 0 | 0 |
| Spry regulation of FGF signaling | R-HSA-1295596 | 4.228654e-03 | 2.374 | 0 | 0 |
| TRAF6-mediated induction of TAK1 complex within TLR4 complex | R-HSA-937072 | 4.228654e-03 | 2.374 | 0 | 0 |
| Regulation of signaling by CBL | R-HSA-912631 | 4.178217e-03 | 2.379 | 0 | 0 |
| DNA Damage Recognition in GG-NER | R-HSA-5696394 | 3.750621e-03 | 2.426 | 0 | 0 |
| Striated Muscle Contraction | R-HSA-390522 | 3.750621e-03 | 2.426 | 0 | 0 |
| Transport of Mature mRNA Derived from an Intronless Transcript | R-HSA-159231 | 3.839347e-03 | 2.416 | 0 | 0 |
| ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA | R-HSA-9954716 | 4.194331e-03 | 2.377 | 0 | 0 |
| RMTs methylate histone arginines | R-HSA-3214858 | 3.824612e-03 | 2.417 | 0 | 0 |
| DCC mediated attractive signaling | R-HSA-418885 | 4.228654e-03 | 2.374 | 0 | 0 |
| Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | R-HSA-8864260 | 3.824612e-03 | 2.417 | 0 | 0 |
| Nuclear Envelope Breakdown | R-HSA-2980766 | 4.133297e-03 | 2.384 | 0 | 0 |
| NS1 Mediated Effects on Host Pathways | R-HSA-168276 | 3.839347e-03 | 2.416 | 0 | 0 |
| Alpha-protein kinase 1 signaling pathway | R-HSA-9645460 | 3.849554e-03 | 2.415 | 0 | 0 |
| Influenza Infection | R-HSA-168255 | 3.940668e-03 | 2.404 | 0 | 0 |
| Late endosomal microautophagy | R-HSA-9615710 | 4.297333e-03 | 2.367 | 0 | 0 |
| SARS-CoV-1 modulates host translation machinery | R-HSA-9735869 | 4.490411e-03 | 2.348 | 0 | 0 |
| Transport of Mature mRNAs Derived from Intronless Transcripts | R-HSA-159234 | 4.532170e-03 | 2.344 | 0 | 0 |
| Regulation of Homotypic Cell-Cell Adhesion | R-HSA-9759476 | 4.543528e-03 | 2.343 | 0 | 0 |
| Glycogen synthesis | R-HSA-3322077 | 5.298657e-03 | 2.276 | 0 | 0 |
| Activation of the pre-replicative complex | R-HSA-68962 | 5.201156e-03 | 2.284 | 0 | 0 |
| Regulation of TBK1, IKKε (IKBKE)-mediated activation of IRF3, IRF7 | R-HSA-9824878 | 5.342547e-03 | 2.272 | 0 | 0 |
| TICAM1-dependent activation of IRF3/IRF7 | R-HSA-9013973 | 5.342547e-03 | 2.272 | 0 | 0 |
| Influenza Viral RNA Transcription and Replication | R-HSA-168273 | 5.668604e-03 | 2.247 | 0 | 0 |
| Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | R-HSA-975956 | 5.671957e-03 | 2.246 | 0 | 0 |
| Loss of phosphorylation of MECP2 at T308 | R-HSA-9022535 | 6.573921e-03 | 2.182 | 0 | 0 |
| ROBO receptors bind AKAP5 | R-HSA-9010642 | 6.363945e-03 | 2.196 | 0 | 0 |
| Myoclonic epilepsy of Lafora | R-HSA-3785653 | 6.363945e-03 | 2.196 | 0 | 0 |
| APC-Cdc20 mediated degradation of Nek2A | R-HSA-179409 | 6.635016e-03 | 2.178 | 0 | 0 |
| Long-term potentiation | R-HSA-9620244 | 5.939228e-03 | 2.226 | 0 | 0 |
| CaM pathway | R-HSA-111997 | 6.315266e-03 | 2.200 | 0 | 0 |
| Calmodulin induced events | R-HSA-111933 | 6.315266e-03 | 2.200 | 0 | 0 |
| Mitotic Prometaphase | R-HSA-68877 | 6.247597e-03 | 2.204 | 0 | 0 |
| Eukaryotic Translation Elongation | R-HSA-156842 | 6.282572e-03 | 2.202 | 0 | 0 |
| Smooth Muscle Contraction | R-HSA-445355 | 5.725012e-03 | 2.242 | 0 | 0 |
| FLT3 signaling in disease | R-HSA-9682385 | 6.315266e-03 | 2.200 | 0 | 0 |
| PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 | R-HSA-8849469 | 6.363945e-03 | 2.196 | 0 | 0 |
| rRNA processing | R-HSA-72312 | 6.865814e-03 | 2.163 | 0 | 0 |
| RNA Polymerase II Transcription Termination | R-HSA-73856 | 6.967853e-03 | 2.157 | 0 | 0 |
| VLDLR internalisation and degradation | R-HSA-8866427 | 7.220524e-03 | 2.141 | 0 | 0 |
| Signaling by EGFR in Cancer | R-HSA-1643713 | 7.224856e-03 | 2.141 | 0 | 0 |
| Interleukin-3, Interleukin-5 and GM-CSF signaling | R-HSA-512988 | 7.226376e-03 | 2.141 | 0 | 0 |
| SARS-CoV-1-host interactions | R-HSA-9692914 | 7.530684e-03 | 2.123 | 0 | 0 |
| Drug resistance in ERBB2 KD mutants | R-HSA-9665230 | 8.804774e-03 | 2.055 | 0 | 0 |
| Drug-mediated inhibition of ERBB2 signaling | R-HSA-9652282 | 8.804774e-03 | 2.055 | 0 | 0 |
| Resistance of ERBB2 KD mutants to AEE788 | R-HSA-9665250 | 8.804774e-03 | 2.055 | 0 | 0 |
| Resistance of ERBB2 KD mutants to afatinib | R-HSA-9665249 | 8.804774e-03 | 2.055 | 0 | 0 |
| Resistance of ERBB2 KD mutants to trastuzumab | R-HSA-9665233 | 8.804774e-03 | 2.055 | 0 | 0 |
| Resistance of ERBB2 KD mutants to lapatinib | R-HSA-9665251 | 8.804774e-03 | 2.055 | 0 | 0 |
| Drug resistance in ERBB2 TMD/JMD mutants | R-HSA-9665737 | 8.804774e-03 | 2.055 | 0 | 0 |
| Resistance of ERBB2 KD mutants to sapitinib | R-HSA-9665244 | 8.804774e-03 | 2.055 | 0 | 0 |
| Resistance of ERBB2 KD mutants to osimertinib | R-HSA-9665247 | 8.804774e-03 | 2.055 | 0 | 0 |
| Resistance of ERBB2 KD mutants to neratinib | R-HSA-9665246 | 8.804774e-03 | 2.055 | 0 | 0 |
| Resistance of ERBB2 KD mutants to tesevatinib | R-HSA-9665245 | 8.804774e-03 | 2.055 | 0 | 0 |
| Interaction between L1 and Ankyrins | R-HSA-445095 | 8.712997e-03 | 2.060 | 0 | 0 |
| Transport of the SLBP independent Mature mRNA | R-HSA-159227 | 8.824580e-03 | 2.054 | 0 | 0 |
| Peptide chain elongation | R-HSA-156902 | 7.665439e-03 | 2.115 | 0 | 0 |
| Unwinding of DNA | R-HSA-176974 | 9.042590e-03 | 2.044 | 0 | 0 |
| Caspase-mediated cleavage of cytoskeletal proteins | R-HSA-264870 | 9.042590e-03 | 2.044 | 0 | 0 |
| Adherens junctions interactions | R-HSA-418990 | 7.557896e-03 | 2.122 | 0 | 0 |
| Regulation of expression of SLITs and ROBOs | R-HSA-9010553 | 7.946663e-03 | 2.100 | 0 | 0 |
| Signaling by Non-Receptor Tyrosine Kinases | R-HSA-9006927 | 8.877955e-03 | 2.052 | 0 | 0 |
| Signaling by PTK6 | R-HSA-8848021 | 8.877955e-03 | 2.052 | 0 | 0 |
| G2/M Checkpoints | R-HSA-69481 | 9.095330e-03 | 2.041 | 0 | 0 |
| Apoptosis | R-HSA-109581 | 9.494192e-03 | 2.023 | 0 | 0 |
| Membrane binding and targetting of GAG proteins | R-HSA-174490 | 9.534138e-03 | 2.021 | 0 | 0 |
| S Phase | R-HSA-69242 | 1.029548e-02 | 1.987 | 0 | 0 |
| PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA | R-HSA-9954714 | 1.030292e-02 | 1.987 | 0 | 0 |
| Regulation of cytoskeletal remodeling and cell spreading by IPP complex components | R-HSA-446388 | 1.034488e-02 | 1.985 | 0 | 0 |
| Maturation of protein E | R-HSA-9683683 | 1.034488e-02 | 1.985 | 0 | 0 |
| Maturation of protein E | R-HSA-9694493 | 1.034488e-02 | 1.985 | 0 | 0 |
| Transport of the SLBP Dependant Mature mRNA | R-HSA-159230 | 1.038507e-02 | 1.984 | 0 | 0 |
| G2/M Transition | R-HSA-69275 | 1.087658e-02 | 1.964 | 0 | 0 |
| Cargo recognition for clathrin-mediated endocytosis | R-HSA-8856825 | 1.096506e-02 | 1.960 | 0 | 0 |
| Response of EIF2AK4 (GCN2) to amino acid deficiency | R-HSA-9633012 | 1.096506e-02 | 1.960 | 0 | 0 |
| DAG and IP3 signaling | R-HSA-1489509 | 1.104375e-02 | 1.957 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in pigmentation | R-HSA-9824585 | 1.104375e-02 | 1.957 | 0 | 0 |
| Developmental Lineages of the Mammary Gland | R-HSA-9924644 | 1.137161e-02 | 1.944 | 0 | 0 |
| Formation of the canonical BAF (cBAF) complex | R-HSA-9933937 | 1.233259e-02 | 1.909 | 0 | 0 |
| Synthesis And Processing Of GAG, GAGPOL Polyproteins | R-HSA-174495 | 1.233259e-02 | 1.909 | 0 | 0 |
| Cellular Senescence | R-HSA-2559583 | 1.216209e-02 | 1.915 | 0 | 0 |
| Mitotic G2-G2/M phases | R-HSA-453274 | 1.235597e-02 | 1.908 | 0 | 0 |
| Regulation of PD-L1(CD274) transcription | R-HSA-9909649 | 1.249613e-02 | 1.903 | 0 | 0 |
| Nonsense-Mediated Decay (NMD) | R-HSA-927802 | 1.268422e-02 | 1.897 | 0 | 0 |
| Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | R-HSA-975957 | 1.268422e-02 | 1.897 | 0 | 0 |
| Nucleotide Excision Repair | R-HSA-5696398 | 1.303348e-02 | 1.885 | 0 | 0 |
| HATs acetylate histones | R-HSA-3214847 | 1.334924e-02 | 1.875 | 0 | 0 |
| PKMTs methylate histone lysines | R-HSA-3214841 | 1.343202e-02 | 1.872 | 0 | 0 |
| FLT3 Signaling | R-HSA-9607240 | 1.343202e-02 | 1.872 | 0 | 0 |
| Ribosome-associated quality control | R-HSA-9948299 | 1.386821e-02 | 1.858 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Cyclin B | R-HSA-174048 | 1.401589e-02 | 1.853 | 0 | 0 |
| Signaling by ERBB2 TMD/JMD mutants | R-HSA-9665686 | 1.463296e-02 | 1.835 | 0 | 0 |
| Recognition of DNA damage by PCNA-containing replication complex | R-HSA-110314 | 1.463296e-02 | 1.835 | 0 | 0 |
| Transcription-Coupled Nucleotide Excision Repair (TC-NER) | R-HSA-6781827 | 1.549625e-02 | 1.810 | 0 | 0 |
| SRP-dependent cotranslational protein targeting to membrane | R-HSA-1799339 | 1.540062e-02 | 1.812 | 0 | 0 |
| DNA Replication | R-HSA-69306 | 1.463671e-02 | 1.835 | 0 | 0 |
| Formation of WDR5-containing histone-modifying complexes | R-HSA-9772755 | 1.412493e-02 | 1.850 | 0 | 0 |
| p75NTR signals via NF-kB | R-HSA-193639 | 1.566270e-02 | 1.805 | 0 | 0 |
| Sensory processing of sound by inner hair cells of the cochlea | R-HSA-9662360 | 1.548518e-02 | 1.810 | 0 | 0 |
| Selenocysteine synthesis | R-HSA-2408557 | 1.585164e-02 | 1.800 | 0 | 0 |
| InlA-mediated entry of Listeria monocytogenes into host cells | R-HSA-8876493 | 1.654290e-02 | 1.781 | 0 | 0 |
| Developmental Cell Lineages of the Integumentary System | R-HSA-9734779 | 1.670481e-02 | 1.777 | 0 | 0 |
| Mitotic Anaphase | R-HSA-68882 | 1.704121e-02 | 1.768 | 0 | 0 |
| Formation of the dystrophin-glycoprotein complex (DGC) | R-HSA-9913351 | 1.706896e-02 | 1.768 | 0 | 0 |
| DNA Damage/Telomere Stress Induced Senescence | R-HSA-2559586 | 1.708574e-02 | 1.767 | 0 | 0 |
| Diseases of Telomere Maintenance | R-HSA-9673013 | 1.885163e-02 | 1.725 | 0 | 0 |
| Alternative Lengthening of Telomeres (ALT) | R-HSA-9006821 | 1.885163e-02 | 1.725 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere | R-HSA-9670621 | 1.885163e-02 | 1.725 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to DAXX Mutations | R-HSA-9670613 | 1.885163e-02 | 1.725 | 0 | 0 |
| Loss of MECP2 binding ability to 5hmC-DNA | R-HSA-9022534 | 1.885163e-02 | 1.725 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to ATRX Mutations | R-HSA-9670615 | 1.885163e-02 | 1.725 | 0 | 0 |
| Vpr-mediated nuclear import of PICs | R-HSA-180910 | 1.878984e-02 | 1.726 | 0 | 0 |
| Loss of proteins required for interphase microtubule organization from the centrosome | R-HSA-380284 | 1.900438e-02 | 1.721 | 0 | 0 |
| Loss of Nlp from mitotic centrosomes | R-HSA-380259 | 1.900438e-02 | 1.721 | 0 | 0 |
| Global Genome Nucleotide Excision Repair (GG-NER) | R-HSA-5696399 | 1.854754e-02 | 1.732 | 0 | 0 |
| Regulation of endogenous retroelements | R-HSA-9842860 | 1.723361e-02 | 1.764 | 0 | 0 |
| Anchoring of the basal body to the plasma membrane | R-HSA-5620912 | 1.817147e-02 | 1.741 | 0 | 0 |
| HDMs demethylate histones | R-HSA-3214842 | 1.741827e-02 | 1.759 | 0 | 0 |
| Ca-dependent events | R-HSA-111996 | 1.755482e-02 | 1.756 | 0 | 0 |
| Epigenetic regulation of gene expression | R-HSA-212165 | 1.856592e-02 | 1.731 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of HSCs | R-HSA-8939236 | 1.854754e-02 | 1.732 | 0 | 0 |
| Mitotic Metaphase and Anaphase | R-HSA-2555396 | 1.801757e-02 | 1.744 | 0 | 0 |
| Eukaryotic Translation Termination | R-HSA-72764 | 1.772736e-02 | 1.751 | 0 | 0 |
| HIV Life Cycle | R-HSA-162587 | 1.907517e-02 | 1.720 | 0 | 0 |
| Negative regulation of FLT3 | R-HSA-9706369 | 1.956798e-02 | 1.708 | 0 | 0 |
| Metalloprotease DUBs | R-HSA-5689901 | 2.056514e-02 | 1.687 | 0 | 0 |
| Positive epigenetic regulation of rRNA expression | R-HSA-5250913 | 2.096542e-02 | 1.678 | 0 | 0 |
| NFE2L2 regulates pentose phosphate pathway genes | R-HSA-9818028 | 2.149773e-02 | 1.668 | 0 | 0 |
| NF-kB is activated and signals survival | R-HSA-209560 | 2.149773e-02 | 1.668 | 0 | 0 |
| Regulation of gene expression by Hypoxia-inducible Factor | R-HSA-1234158 | 2.149773e-02 | 1.668 | 0 | 0 |
| Role of ABL in ROBO-SLIT signaling | R-HSA-428890 | 2.151093e-02 | 1.667 | 0 | 0 |
| Regulation of PTEN localization | R-HSA-8948747 | 2.151093e-02 | 1.667 | 0 | 0 |
| Programmed Cell Death | R-HSA-5357801 | 2.241727e-02 | 1.649 | 0 | 0 |
| Regulation of MECP2 expression and activity | R-HSA-9022692 | 2.294931e-02 | 1.639 | 0 | 0 |
| RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | R-HSA-8939243 | 2.294931e-02 | 1.639 | 0 | 0 |
| Signaling by BRAF and RAF1 fusions | R-HSA-6802952 | 2.332524e-02 | 1.632 | 0 | 0 |
| Formation of the beta-catenin:TCF transactivating complex | R-HSA-201722 | 2.336431e-02 | 1.631 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in GG-NER | R-HSA-5696397 | 2.464758e-02 | 1.608 | 0 | 0 |
| Ras activation upon Ca2+ influx through NMDA receptor | R-HSA-442982 | 2.464758e-02 | 1.608 | 0 | 0 |
| AURKA Activation by TPX2 | R-HSA-8854518 | 2.574214e-02 | 1.589 | 0 | 0 |
| Post NMDA receptor activation events | R-HSA-438064 | 2.634748e-02 | 1.579 | 0 | 0 |
| Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE) | R-HSA-936964 | 2.408797e-02 | 1.618 | 0 | 0 |
| Mitotic Spindle Checkpoint | R-HSA-69618 | 2.663486e-02 | 1.575 | 0 | 0 |
| Antiviral mechanism by IFN-stimulated genes | R-HSA-1169410 | 2.581857e-02 | 1.588 | 0 | 0 |
| Downregulation of ERBB2:ERBB3 signaling | R-HSA-1358803 | 2.732870e-02 | 1.563 | 0 | 0 |
| Orc1 removal from chromatin | R-HSA-68949 | 2.584674e-02 | 1.588 | 0 | 0 |
| EPH-Ephrin signaling | R-HSA-2682334 | 2.349408e-02 | 1.629 | 0 | 0 |
| High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells | R-HSA-9856530 | 2.483252e-02 | 1.605 | 0 | 0 |
| Switching of origins to a post-replicative state | R-HSA-69052 | 2.535977e-02 | 1.596 | 0 | 0 |
| MAPK family signaling cascades | R-HSA-5683057 | 2.565008e-02 | 1.591 | 0 | 0 |
| Mitotic G1 phase and G1/S transition | R-HSA-453279 | 2.552535e-02 | 1.593 | 0 | 0 |
| Initiation of Nuclear Envelope (NE) Reformation | R-HSA-2995383 | 2.464758e-02 | 1.608 | 0 | 0 |
| Signaling by NOTCH1 HD Domain Mutants in Cancer | R-HSA-2691230 | 2.732870e-02 | 1.563 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD Domain Mutants | R-HSA-2691232 | 2.732870e-02 | 1.563 | 0 | 0 |
| p75NTR recruits signalling complexes | R-HSA-209543 | 2.732870e-02 | 1.563 | 0 | 0 |
| Formation of Incision Complex in GG-NER | R-HSA-5696395 | 2.777504e-02 | 1.556 | 0 | 0 |
| Glycogen metabolism | R-HSA-8982491 | 2.777504e-02 | 1.556 | 0 | 0 |
| ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | R-HSA-427389 | 2.777504e-02 | 1.556 | 0 | 0 |
| Interactions of Vpr with host cellular proteins | R-HSA-176033 | 2.777504e-02 | 1.556 | 0 | 0 |
| Condensation of Prophase Chromosomes | R-HSA-2299718 | 2.851984e-02 | 1.545 | 0 | 0 |
| Signaling by RAS mutants | R-HSA-6802949 | 2.851984e-02 | 1.545 | 0 | 0 |
| Paradoxical activation of RAF signaling by kinase inactive BRAF | R-HSA-6802955 | 2.851984e-02 | 1.545 | 0 | 0 |
| Signaling by moderate kinase activity BRAF mutants | R-HSA-6802946 | 2.851984e-02 | 1.545 | 0 | 0 |
| Formation of TC-NER Pre-Incision Complex | R-HSA-6781823 | 2.851984e-02 | 1.545 | 0 | 0 |
| Signaling downstream of RAS mutants | R-HSA-9649948 | 2.851984e-02 | 1.545 | 0 | 0 |
| Type I hemidesmosome assembly | R-HSA-446107 | 2.908004e-02 | 1.536 | 0 | 0 |
| Modulation by Mtb of host immune system | R-HSA-9637628 | 2.908004e-02 | 1.536 | 0 | 0 |
| Signaling by Hippo | R-HSA-2028269 | 2.925752e-02 | 1.534 | 0 | 0 |
| Regulation of FZD by ubiquitination | R-HSA-4641263 | 2.925752e-02 | 1.534 | 0 | 0 |
| Glycogen storage diseases | R-HSA-3229121 | 2.925752e-02 | 1.534 | 0 | 0 |
| Cell-cell junction organization | R-HSA-421270 | 2.969630e-02 | 1.527 | 0 | 0 |
| Nuclear import of Rev protein | R-HSA-180746 | 3.015072e-02 | 1.521 | 0 | 0 |
| DNA Repair | R-HSA-73894 | 3.094232e-02 | 1.509 | 0 | 0 |
| SARS-CoV-2-host interactions | R-HSA-9705683 | 3.197870e-02 | 1.495 | 0 | 0 |
| LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production | R-HSA-3134973 | 3.761706e-02 | 1.425 | 0 | 0 |
| IRS activation | R-HSA-74713 | 3.761706e-02 | 1.425 | 0 | 0 |
| NFE2L2 regulating MDR associated enzymes | R-HSA-9818032 | 3.804201e-02 | 1.420 | 0 | 0 |
| Gap junction degradation | R-HSA-190873 | 3.804201e-02 | 1.420 | 0 | 0 |
| PKA activation | R-HSA-163615 | 3.510636e-02 | 1.455 | 0 | 0 |
| Termination of translesion DNA synthesis | R-HSA-5656169 | 3.238736e-02 | 1.490 | 0 | 0 |
| Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) | R-HSA-5619107 | 3.718498e-02 | 1.430 | 0 | 0 |
| Nuclear Pore Complex (NPC) Disassembly | R-HSA-3301854 | 3.428572e-02 | 1.465 | 0 | 0 |
| PRC2 methylates histones and DNA | R-HSA-212300 | 3.879536e-02 | 1.411 | 0 | 0 |
| Degradation of GLI1 by the proteasome | R-HSA-5610780 | 3.524656e-02 | 1.453 | 0 | 0 |
| Viral mRNA Translation | R-HSA-192823 | 3.339971e-02 | 1.476 | 0 | 0 |
| Oncogenic MAPK signaling | R-HSA-6802957 | 3.786355e-02 | 1.422 | 0 | 0 |
| Signaling by ERBB2 in Cancer | R-HSA-1227990 | 3.718498e-02 | 1.430 | 0 | 0 |
| Signaling by ERBB2 KD Mutants | R-HSA-9664565 | 3.238736e-02 | 1.490 | 0 | 0 |
| Signaling by RAF1 mutants | R-HSA-9656223 | 3.524656e-02 | 1.453 | 0 | 0 |
| RET signaling | R-HSA-8853659 | 3.879536e-02 | 1.411 | 0 | 0 |
| VEGFA-VEGFR2 Pathway | R-HSA-4420097 | 3.268885e-02 | 1.486 | 0 | 0 |
| TCF dependent signaling in response to WNT | R-HSA-201681 | 3.668505e-02 | 1.436 | 0 | 0 |
| ESR-mediated signaling | R-HSA-8939211 | 3.327638e-02 | 1.478 | 0 | 0 |
| Response of endothelial cells to shear stress | R-HSA-9860931 | 3.591549e-02 | 1.445 | 0 | 0 |
| Estrogen-dependent gene expression | R-HSA-9018519 | 3.418288e-02 | 1.466 | 0 | 0 |
| Semaphorin interactions | R-HSA-373755 | 3.826555e-02 | 1.417 | 0 | 0 |
| Depolymerization of the Nuclear Lamina | R-HSA-4419969 | 3.510636e-02 | 1.455 | 0 | 0 |
| Nuclear events stimulated by ALK signaling in cancer | R-HSA-9725371 | 3.554238e-02 | 1.449 | 0 | 0 |
| DNA Double-Strand Break Repair | R-HSA-5693532 | 3.894441e-02 | 1.410 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in TC-NER | R-HSA-6782210 | 3.902889e-02 | 1.409 | 0 | 0 |
| Signaling by EGFR | R-HSA-177929 | 3.902889e-02 | 1.409 | 0 | 0 |
| G alpha (12/13) signalling events | R-HSA-416482 | 3.930491e-02 | 1.406 | 0 | 0 |
| DNA Damage Bypass | R-HSA-73893 | 3.947434e-02 | 1.404 | 0 | 0 |
| Manipulation of host energy metabolism | R-HSA-9636667 | 3.963785e-02 | 1.402 | 0 | 0 |
| Signaling by TCF7L2 mutants | R-HSA-5339700 | 3.963785e-02 | 1.402 | 0 | 0 |
| TWIK-releated acid-sensitive K+ channel (TASK) | R-HSA-1299316 | 3.963785e-02 | 1.402 | 0 | 0 |
| Breakdown of the nuclear lamina | R-HSA-352238 | 3.963785e-02 | 1.402 | 0 | 0 |
| CD209 (DC-SIGN) signaling | R-HSA-5621575 | 3.980368e-02 | 1.400 | 0 | 0 |
| G1/S Transition | R-HSA-69206 | 4.045885e-02 | 1.393 | 0 | 0 |
| Amplification of signal from the kinetochores | R-HSA-141424 | 4.097218e-02 | 1.388 | 0 | 0 |
| Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | R-HSA-141444 | 4.097218e-02 | 1.388 | 0 | 0 |
| Translesion Synthesis by POLH | R-HSA-110320 | 4.165869e-02 | 1.380 | 0 | 0 |
| 2-LTR circle formation | R-HSA-164843 | 4.841471e-02 | 1.315 | 0 | 0 |
| Sema3A PAK dependent Axon repulsion | R-HSA-399954 | 5.043834e-02 | 1.297 | 0 | 0 |
| TICAM1, RIP1-mediated IKK complex recruitment | R-HSA-168927 | 5.043834e-02 | 1.297 | 0 | 0 |
| EGFR downregulation | R-HSA-182971 | 4.243795e-02 | 1.372 | 0 | 0 |
| Trafficking of AMPA receptors | R-HSA-399719 | 4.243795e-02 | 1.372 | 0 | 0 |
| IP3 and IP4 transport between cytosol and nucleus | R-HSA-1855196 | 4.243795e-02 | 1.372 | 0 | 0 |
| IP6 and IP7 transport between cytosol and nucleus | R-HSA-1855229 | 4.243795e-02 | 1.372 | 0 | 0 |
| Dual incision in TC-NER | R-HSA-6782135 | 4.713829e-02 | 1.327 | 0 | 0 |
| Recruitment of mitotic centrosome proteins and complexes | R-HSA-380270 | 4.808651e-02 | 1.318 | 0 | 0 |
| Signaling by ERBB4 | R-HSA-1236394 | 5.212699e-02 | 1.283 | 0 | 0 |
| CaMK IV-mediated phosphorylation of CREB | R-HSA-111932 | 4.841471e-02 | 1.315 | 0 | 0 |
| MAP3K8 (TPL2)-dependent MAPK1/3 activation | R-HSA-5684264 | 4.177417e-02 | 1.379 | 0 | 0 |
| DNA strand elongation | R-HSA-69190 | 4.815933e-02 | 1.317 | 0 | 0 |
| Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | R-HSA-5693565 | 5.159793e-02 | 1.287 | 0 | 0 |
| Translesion synthesis by REV1 | R-HSA-110312 | 5.043834e-02 | 1.297 | 0 | 0 |
| Regulation of KIT signaling | R-HSA-1433559 | 4.177417e-02 | 1.379 | 0 | 0 |
| Separation of Sister Chromatids | R-HSA-2467813 | 4.593100e-02 | 1.338 | 0 | 0 |
| Late Phase of HIV Life Cycle | R-HSA-162599 | 5.169675e-02 | 1.287 | 0 | 0 |
| Defective pyroptosis | R-HSA-9710421 | 4.401293e-02 | 1.356 | 0 | 0 |
| InlB-mediated entry of Listeria monocytogenes into host cell | R-HSA-8875360 | 5.043834e-02 | 1.297 | 0 | 0 |
| Negative regulation of MET activity | R-HSA-6807004 | 4.893292e-02 | 1.310 | 0 | 0 |
| Evasion by RSV of host interferon responses | R-HSA-9833109 | 4.243795e-02 | 1.372 | 0 | 0 |
| Vesicle-mediated transport | R-HSA-5653656 | 4.840880e-02 | 1.315 | 0 | 0 |
| Josephin domain DUBs | R-HSA-5689877 | 4.841471e-02 | 1.315 | 0 | 0 |
| Muscle contraction | R-HSA-397014 | 4.829675e-02 | 1.316 | 0 | 0 |
| Sema4D induced cell migration and growth-cone collapse | R-HSA-416572 | 4.893292e-02 | 1.310 | 0 | 0 |
| Apoptosis induced DNA fragmentation | R-HSA-140342 | 4.841471e-02 | 1.315 | 0 | 0 |
| SARS-CoV-2 activates/modulates innate and adaptive immune responses | R-HSA-9705671 | 5.169675e-02 | 1.287 | 0 | 0 |
| Transcriptional regulation by small RNAs | R-HSA-5578749 | 4.426921e-02 | 1.354 | 0 | 0 |
| Positive Regulation of CDH1 Gene Transcription | R-HSA-9764790 | 4.841471e-02 | 1.315 | 0 | 0 |
| Cell death signalling via NRAGE, NRIF and NADE | R-HSA-204998 | 4.808651e-02 | 1.318 | 0 | 0 |
| Sensory processing of sound | R-HSA-9659379 | 4.264787e-02 | 1.370 | 0 | 0 |
| Pexophagy | R-HSA-9664873 | 4.841471e-02 | 1.315 | 0 | 0 |
| RAF/MAP kinase cascade | R-HSA-5673001 | 5.227712e-02 | 1.282 | 0 | 0 |
| Activated NOTCH1 Transmits Signal to the Nucleus | R-HSA-2122948 | 5.269819e-02 | 1.278 | 0 | 0 |
| Formation of RNA Pol II elongation complex | R-HSA-112382 | 5.305580e-02 | 1.275 | 0 | 0 |
| SARS-CoV-1 activates/modulates innate immune responses | R-HSA-9692916 | 5.305580e-02 | 1.275 | 0 | 0 |
| Activation of NMDA receptors and postsynaptic events | R-HSA-442755 | 5.338122e-02 | 1.273 | 0 | 0 |
| Senescence-Associated Secretory Phenotype (SASP) | R-HSA-2559582 | 5.387758e-02 | 1.269 | 0 | 0 |
| DNA Double Strand Break Response | R-HSA-5693606 | 5.428191e-02 | 1.265 | 0 | 0 |
| CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | R-HSA-442742 | 5.435992e-02 | 1.265 | 0 | 0 |
| IPs transport between nucleus and cytosol | R-HSA-1855170 | 5.435992e-02 | 1.265 | 0 | 0 |
| Glutamate binding, activation of AMPA receptors and synaptic plasticity | R-HSA-399721 | 5.435992e-02 | 1.265 | 0 | 0 |
| Cyclin A/B1/B2 associated events during G2/M transition | R-HSA-69273 | 5.435992e-02 | 1.265 | 0 | 0 |
| Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 | R-HSA-1362300 | 6.007805e-02 | 1.221 | 0 | 0 |
| Translesion synthesis by POLI | R-HSA-5656121 | 6.007805e-02 | 1.221 | 0 | 0 |
| Disorders of Developmental Biology | R-HSA-9675151 | 7.069082e-02 | 1.151 | 0 | 0 |
| Processing of Intronless Pre-mRNAs | R-HSA-77595 | 7.069082e-02 | 1.151 | 0 | 0 |
| GRB2 events in ERBB2 signaling | R-HSA-1963640 | 7.069082e-02 | 1.151 | 0 | 0 |
| Translesion synthesis by POLK | R-HSA-5655862 | 7.069082e-02 | 1.151 | 0 | 0 |
| mRNA decay by 5' to 3' exoribonuclease | R-HSA-430039 | 7.069082e-02 | 1.151 | 0 | 0 |
| Unblocking of NMDA receptors, glutamate binding and activation | R-HSA-438066 | 6.569116e-02 | 1.182 | 0 | 0 |
| Negative regulation of NMDA receptor-mediated neuronal transmission | R-HSA-9617324 | 6.569116e-02 | 1.182 | 0 | 0 |
| RAF activation | R-HSA-5673000 | 6.823004e-02 | 1.166 | 0 | 0 |
| Dual Incision in GG-NER | R-HSA-5696400 | 6.823004e-02 | 1.166 | 0 | 0 |
| Aggrephagy | R-HSA-9646399 | 6.080163e-02 | 1.216 | 0 | 0 |
| RNA Polymerase II Transcription Elongation | R-HSA-75955 | 5.820206e-02 | 1.235 | 0 | 0 |
| B-WICH complex positively regulates rRNA expression | R-HSA-5250924 | 5.820206e-02 | 1.235 | 0 | 0 |
| HDACs deacetylate histones | R-HSA-3214815 | 6.945701e-02 | 1.158 | 0 | 0 |
| Centrosome maturation | R-HSA-380287 | 5.639530e-02 | 1.249 | 0 | 0 |
| Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide | R-HSA-9954709 | 5.627112e-02 | 1.250 | 0 | 0 |
| Negative regulation of FGFR3 signaling | R-HSA-5654732 | 6.794147e-02 | 1.168 | 0 | 0 |
| Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template | R-HSA-110313 | 6.733676e-02 | 1.172 | 0 | 0 |
| NOTCH2 Activation and Transmission of Signal to the Nucleus | R-HSA-2979096 | 5.694156e-02 | 1.245 | 0 | 0 |
| UCH proteinases | R-HSA-5689603 | 6.089566e-02 | 1.215 | 0 | 0 |
| Regulation of endogenous retroelements by the Human Silencing Hub (HUSH) complex | R-HSA-9843970 | 6.823004e-02 | 1.166 | 0 | 0 |
| PKA-mediated phosphorylation of CREB | R-HSA-111931 | 5.694156e-02 | 1.245 | 0 | 0 |
| Glucagon signaling in metabolic regulation | R-HSA-163359 | 6.104815e-02 | 1.214 | 0 | 0 |
| PLC beta mediated events | R-HSA-112043 | 6.135633e-02 | 1.212 | 0 | 0 |
| Homology Directed Repair | R-HSA-5693538 | 6.521493e-02 | 1.186 | 0 | 0 |
| Signaling by CSF1 (M-CSF) in myeloid cells | R-HSA-9680350 | 6.823004e-02 | 1.166 | 0 | 0 |
| Listeria monocytogenes entry into host cells | R-HSA-8876384 | 6.569116e-02 | 1.182 | 0 | 0 |
| Transport of Ribonucleoproteins into the Host Nucleus | R-HSA-168271 | 6.733676e-02 | 1.172 | 0 | 0 |
| tRNA processing in the nucleus | R-HSA-6784531 | 6.666469e-02 | 1.176 | 0 | 0 |
| MAPK1/MAPK3 signaling | R-HSA-5684996 | 6.830729e-02 | 1.166 | 0 | 0 |
| Autophagy | R-HSA-9612973 | 7.048404e-02 | 1.152 | 0 | 0 |
| Retrograde transport at the Trans-Golgi-Network | R-HSA-6811440 | 6.572144e-02 | 1.182 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest | R-HSA-6804116 | 6.007805e-02 | 1.221 | 0 | 0 |
| Macroautophagy | R-HSA-1632852 | 7.184315e-02 | 1.144 | 0 | 0 |
| Regulation of NFE2L2 gene expression | R-HSA-9818749 | 6.889041e-02 | 1.162 | 0 | 0 |
| Signaling by VEGF | R-HSA-194138 | 6.514827e-02 | 1.186 | 0 | 0 |
| HIV Infection | R-HSA-162906 | 6.500424e-02 | 1.187 | 0 | 0 |
| Intra-Golgi and retrograde Golgi-to-ER traffic | R-HSA-6811442 | 5.689957e-02 | 1.245 | 0 | 0 |
| Localization of the PINCH-ILK-PARVIN complex to focal adhesions | R-HSA-446343 | 6.589246e-02 | 1.181 | 0 | 0 |
| NOD1/2 Signaling Pathway | R-HSA-168638 | 6.823004e-02 | 1.166 | 0 | 0 |
| Interactions of Rev with host cellular proteins | R-HSA-177243 | 6.080163e-02 | 1.216 | 0 | 0 |
| rRNA modification in the nucleus and cytosol | R-HSA-6790901 | 7.226431e-02 | 1.141 | 0 | 0 |
| Regulation of PTEN gene transcription | R-HSA-8943724 | 5.633556e-02 | 1.249 | 0 | 0 |
| Regulation of innate immune responses to cytosolic DNA | R-HSA-3134975 | 7.069082e-02 | 1.151 | 0 | 0 |
| MAPK6/MAPK4 signaling | R-HSA-5687128 | 6.699730e-02 | 1.174 | 0 | 0 |
| Regulation of Glucokinase by Glucokinase Regulatory Protein | R-HSA-170822 | 6.104815e-02 | 1.214 | 0 | 0 |
| Regulation of BACH1 activity | R-HSA-9708530 | 6.007805e-02 | 1.221 | 0 | 0 |
| Cytosolic sensors of pathogen-associated DNA | R-HSA-1834949 | 6.893017e-02 | 1.162 | 0 | 0 |
| JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | R-HSA-450321 | 5.694156e-02 | 1.245 | 0 | 0 |
| SARS-CoV-2 modulates host translation machinery | R-HSA-9754678 | 6.366765e-02 | 1.196 | 0 | 0 |
| Assembly Of The HIV Virion | R-HSA-175474 | 6.569116e-02 | 1.182 | 0 | 0 |
| Transcriptional regulation by RUNX1 | R-HSA-8878171 | 6.229592e-02 | 1.206 | 0 | 0 |
| p75 NTR receptor-mediated signalling | R-HSA-193704 | 7.310820e-02 | 1.136 | 0 | 0 |
| Regulation of NF-kappa B signaling | R-HSA-9758274 | 6.007805e-02 | 1.221 | 0 | 0 |
| activated TAK1 mediates p38 MAPK activation | R-HSA-450302 | 6.569116e-02 | 1.182 | 0 | 0 |
| Integration of provirus | R-HSA-162592 | 7.334386e-02 | 1.135 | 0 | 0 |
| Mitotic Telophase/Cytokinesis | R-HSA-68884 | 7.334386e-02 | 1.135 | 0 | 0 |
| HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | R-HSA-5693567 | 7.334446e-02 | 1.135 | 0 | 0 |
| Cellular responses to mechanical stimuli | R-HSA-9855142 | 7.334446e-02 | 1.135 | 0 | 0 |
| Negative regulation of MAPK pathway | R-HSA-5675221 | 7.429609e-02 | 1.129 | 0 | 0 |
| FGFR2 alternative splicing | R-HSA-6803529 | 7.518240e-02 | 1.124 | 0 | 0 |
| Downregulation of TGF-beta receptor signaling | R-HSA-2173788 | 7.518240e-02 | 1.124 | 0 | 0 |
| NOTCH3 Activation and Transmission of Signal to the Nucleus | R-HSA-9013507 | 7.518240e-02 | 1.124 | 0 | 0 |
| Sensory processing of sound by outer hair cells of the cochlea | R-HSA-9662361 | 7.557361e-02 | 1.122 | 0 | 0 |
| Negative regulation of FGFR4 signaling | R-HSA-5654733 | 7.645708e-02 | 1.117 | 0 | 0 |
| Cellular response to starvation | R-HSA-9711097 | 7.773917e-02 | 1.109 | 0 | 0 |
| Synthesis of DNA | R-HSA-69239 | 7.785476e-02 | 1.109 | 0 | 0 |
| Degradation of CDH1 | R-HSA-9766229 | 7.876303e-02 | 1.104 | 0 | 0 |
| Cyclin A:Cdk2-associated events at S phase entry | R-HSA-69656 | 8.001126e-02 | 1.097 | 0 | 0 |
| Signaling by FGFR2 | R-HSA-5654738 | 8.128506e-02 | 1.090 | 0 | 0 |
| Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | R-HSA-381676 | 8.168196e-02 | 1.088 | 0 | 0 |
| TP53 Regulates Transcription of Cell Cycle Genes | R-HSA-6791312 | 8.201990e-02 | 1.086 | 0 | 0 |
| Signaling by EGFRvIII in Cancer | R-HSA-5637812 | 8.226409e-02 | 1.085 | 0 | 0 |
| Constitutive Signaling by EGFRvIII | R-HSA-5637810 | 8.226409e-02 | 1.085 | 0 | 0 |
| AUF1 (hnRNP D0) binds and destabilizes mRNA | R-HSA-450408 | 8.408652e-02 | 1.075 | 0 | 0 |
| Cellular response to hypoxia | R-HSA-1234174 | 8.434803e-02 | 1.074 | 0 | 0 |
| SHC1 events in ERBB2 signaling | R-HSA-1250196 | 8.556838e-02 | 1.068 | 0 | 0 |
| Regulation of RAS by GAPs | R-HSA-5658442 | 8.584246e-02 | 1.066 | 0 | 0 |
| Processing of DNA double-strand break ends | R-HSA-5693607 | 8.699179e-02 | 1.061 | 0 | 0 |
| EML4 and NUDC in mitotic spindle formation | R-HSA-9648025 | 8.743647e-02 | 1.058 | 0 | 0 |
| Recruitment of NuMA to mitotic centrosomes | R-HSA-380320 | 8.757843e-02 | 1.058 | 0 | 0 |
| Diseases of programmed cell death | R-HSA-9645723 | 8.757843e-02 | 1.058 | 0 | 0 |
| Oxidative Stress Induced Senescence | R-HSA-2559580 | 8.773805e-02 | 1.057 | 0 | 0 |
| SOS-mediated signalling | R-HSA-112412 | 8.778134e-02 | 1.057 | 0 | 0 |
| Cohesin Loading onto Chromatin | R-HSA-2470946 | 8.778134e-02 | 1.057 | 0 | 0 |
| Loss of function of MECP2 in Rett syndrome | R-HSA-9005891 | 8.782395e-02 | 1.056 | 0 | 0 |
| Pervasive developmental disorders | R-HSA-9005895 | 8.782395e-02 | 1.056 | 0 | 0 |
| Disorders of Nervous System Development | R-HSA-9697154 | 8.782395e-02 | 1.056 | 0 | 0 |
| Constitutive Signaling by Overexpressed ERBB2 | R-HSA-9634285 | 8.782395e-02 | 1.056 | 0 | 0 |
| IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation | R-HSA-975144 | 8.782395e-02 | 1.056 | 0 | 0 |
| IRAK1 recruits IKK complex | R-HSA-937039 | 8.782395e-02 | 1.056 | 0 | 0 |
| Host Interactions of HIV factors | R-HSA-162909 | 9.098944e-02 | 1.041 | 0 | 0 |
| Signaling by high-kinase activity BRAF mutants | R-HSA-6802948 | 9.276079e-02 | 1.033 | 0 | 0 |
| Ovarian tumor domain proteases | R-HSA-5689896 | 9.276079e-02 | 1.033 | 0 | 0 |
| Signaling by ERBB2 ECD mutants | R-HSA-9665348 | 9.477593e-02 | 1.023 | 0 | 0 |
| PKA activation in glucagon signalling | R-HSA-164378 | 9.477593e-02 | 1.023 | 0 | 0 |
| Ephrin signaling | R-HSA-3928664 | 9.477593e-02 | 1.023 | 0 | 0 |
| Polo-like kinase mediated events | R-HSA-156711 | 9.477593e-02 | 1.023 | 0 | 0 |
| Signaling by cytosolic FGFR1 fusion mutants | R-HSA-1839117 | 9.477593e-02 | 1.023 | 0 | 0 |
| Regulation of TP53 Activity through Methylation | R-HSA-6804760 | 9.477593e-02 | 1.023 | 0 | 0 |
| snRNP Assembly | R-HSA-191859 | 9.590619e-02 | 1.018 | 0 | 0 |
| Metabolism of non-coding RNA | R-HSA-194441 | 9.590619e-02 | 1.018 | 0 | 0 |
| Loss of MECP2 binding ability to 5mC-DNA | R-HSA-9022538 | 9.633337e-02 | 1.016 | 0 | 0 |
| G-protein mediated events | R-HSA-112040 | 9.762082e-02 | 1.010 | 0 | 0 |
| HDR through Homologous Recombination (HRR) | R-HSA-5685942 | 9.762082e-02 | 1.010 | 0 | 0 |
| EPHB-mediated forward signaling | R-HSA-3928662 | 9.773372e-02 | 1.010 | 0 | 0 |
| Netrin-1 signaling | R-HSA-373752 | 9.773372e-02 | 1.010 | 0 | 0 |
| Opioid Signalling | R-HSA-111885 | 9.846831e-02 | 1.007 | 0 | 0 |
| APC truncation mutants are not K63 polyubiquitinated | R-HSA-5467333 | 9.879373e-02 | 1.005 | 0 | 0 |
| Neurotransmitter receptors and postsynaptic signal transmission | R-HSA-112314 | 9.912704e-02 | 1.004 | 0 | 0 |
| Deubiquitination | R-HSA-5688426 | 9.976379e-02 | 1.001 | 0 | 0 |
| Intracellular signaling by second messengers | R-HSA-9006925 | 1.005990e-01 | 0.997 | 0 | 0 |
| Cdc20:Phospho-APC/C mediated degradation of Cyclin A | R-HSA-174184 | 1.011205e-01 | 0.995 | 0 | 0 |
| Rev-mediated nuclear export of HIV RNA | R-HSA-165054 | 1.019281e-01 | 0.992 | 0 | 0 |
| CREB1 phosphorylation through the activation of Adenylate Cyclase | R-HSA-442720 | 1.035677e-01 | 0.985 | 0 | 0 |
| Response to elevated platelet cytosolic Ca2+ | R-HSA-76005 | 1.045461e-01 | 0.981 | 0 | 0 |
| G0 and Early G1 | R-HSA-1538133 | 1.055559e-01 | 0.977 | 0 | 0 |
| Downregulation of SMAD2/3:SMAD4 transcriptional activity | R-HSA-2173795 | 1.055559e-01 | 0.977 | 0 | 0 |
| Deposition of new CENPA-containing nucleosomes at the centromere | R-HSA-606279 | 1.063954e-01 | 0.973 | 0 | 0 |
| Nucleosome assembly | R-HSA-774815 | 1.063954e-01 | 0.973 | 0 | 0 |
| Fanconi Anemia Pathway | R-HSA-6783310 | 1.063954e-01 | 0.973 | 0 | 0 |
| Vasopressin regulates renal water homeostasis via Aquaporins | R-HSA-432040 | 1.063954e-01 | 0.973 | 0 | 0 |
| MECP2 regulates transcription of genes involved in GABA signaling | R-HSA-9022927 | 1.298782e-01 | 0.886 | 0 | 0 |
| NFE2L2 regulating ER-stress associated genes | R-HSA-9818035 | 1.298782e-01 | 0.886 | 0 | 0 |
| Inhibition of TSC complex formation by PKB | R-HSA-165181 | 1.298782e-01 | 0.886 | 0 | 0 |
| Formation of annular gap junctions | R-HSA-196025 | 1.085815e-01 | 0.964 | 0 | 0 |
| HuR (ELAVL1) binds and stabilizes mRNA | R-HSA-450520 | 1.310702e-01 | 0.882 | 0 | 0 |
| ALK mutants bind TKIs | R-HSA-9700645 | 1.310702e-01 | 0.882 | 0 | 0 |
| Establishment of Sister Chromatid Cohesion | R-HSA-2468052 | 1.550185e-01 | 0.810 | 0 | 0 |
| ERBB2 Activates PTK6 Signaling | R-HSA-8847993 | 1.204974e-01 | 0.919 | 0 | 0 |
| ERBB2 Regulates Cell Motility | R-HSA-6785631 | 1.385248e-01 | 0.858 | 0 | 0 |
| IKK complex recruitment mediated by RIP1 | R-HSA-937041 | 1.081959e-01 | 0.966 | 0 | 0 |
| Transcription of E2F targets under negative control by DREAM complex | R-HSA-1362277 | 1.224859e-01 | 0.912 | 0 | 0 |
| Synthesis of active ubiquitin: roles of E1 and E2 enzymes | R-HSA-8866652 | 1.334008e-01 | 0.875 | 0 | 0 |
| Tat-mediated HIV elongation arrest and recovery | R-HSA-167243 | 1.334008e-01 | 0.875 | 0 | 0 |
| Pausing and recovery of Tat-mediated HIV elongation | R-HSA-167238 | 1.334008e-01 | 0.875 | 0 | 0 |
| HIV elongation arrest and recovery | R-HSA-167287 | 1.470549e-01 | 0.833 | 0 | 0 |
| Pausing and recovery of HIV elongation | R-HSA-167290 | 1.470549e-01 | 0.833 | 0 | 0 |
| DNA methylation | R-HSA-5334118 | 1.613117e-01 | 0.792 | 0 | 0 |
| Endosomal Sorting Complex Required For Transport (ESCRT) | R-HSA-917729 | 1.613117e-01 | 0.792 | 0 | 0 |
| Inhibition of DNA recombination at telomere | R-HSA-9670095 | 1.217147e-01 | 0.915 | 0 | 0 |
| Autodegradation of Cdh1 by Cdh1:APC/C | R-HSA-174084 | 1.154751e-01 | 0.938 | 0 | 0 |
| APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | R-HSA-179419 | 1.093158e-01 | 0.961 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Securin | R-HSA-174154 | 1.249665e-01 | 0.903 | 0 | 0 |
| Nonhomologous End-Joining (NHEJ) | R-HSA-5693571 | 1.348614e-01 | 0.870 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176409 | 1.268011e-01 | 0.897 | 0 | 0 |
| Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176814 | 1.360799e-01 | 0.866 | 0 | 0 |
| RNA polymerase II transcribes snRNA genes | R-HSA-6807505 | 1.264154e-01 | 0.898 | 0 | 0 |
| Chromosome Maintenance | R-HSA-73886 | 1.187877e-01 | 0.925 | 0 | 0 |
| Negative regulation of FGFR2 signaling | R-HSA-5654727 | 1.397783e-01 | 0.855 | 0 | 0 |
| Ub-specific processing proteases | R-HSA-5689880 | 1.095808e-01 | 0.960 | 0 | 0 |
| Assembly of the ORC complex at the origin of replication | R-HSA-68616 | 1.164124e-01 | 0.934 | 0 | 0 |
| Negative regulation of FGFR1 signaling | R-HSA-5654726 | 1.164124e-01 | 0.934 | 0 | 0 |
| EGFR Transactivation by Gastrin | R-HSA-2179392 | 1.550185e-01 | 0.810 | 0 | 0 |
| Meiotic synapsis | R-HSA-1221632 | 1.093158e-01 | 0.961 | 0 | 0 |
| MAP2K and MAPK activation | R-HSA-5674135 | 1.433693e-01 | 0.844 | 0 | 0 |
| PI3K/AKT activation | R-HSA-198203 | 1.550185e-01 | 0.810 | 0 | 0 |
| VEGFR2 mediated vascular permeability | R-HSA-5218920 | 1.323146e-01 | 0.878 | 0 | 0 |
| RNA Polymerase II Pre-transcription Events | R-HSA-674695 | 1.533192e-01 | 0.814 | 0 | 0 |
| PINK1-PRKN Mediated Mitophagy | R-HSA-5205685 | 1.470549e-01 | 0.833 | 0 | 0 |
| DARPP-32 events | R-HSA-180024 | 1.613117e-01 | 0.792 | 0 | 0 |
| L1CAM interactions | R-HSA-373760 | 1.396409e-01 | 0.855 | 0 | 0 |
| Cilium Assembly | R-HSA-5617833 | 1.520578e-01 | 0.818 | 0 | 0 |
| Adrenoceptors | R-HSA-390696 | 1.085815e-01 | 0.964 | 0 | 0 |
| Receptor-type tyrosine-protein phosphatases | R-HSA-388844 | 1.575531e-01 | 0.803 | 0 | 0 |
| COPI-mediated anterograde transport | R-HSA-6807878 | 1.548527e-01 | 0.810 | 0 | 0 |
| MTOR signalling | R-HSA-165159 | 1.548639e-01 | 0.810 | 0 | 0 |
| Selective autophagy | R-HSA-9663891 | 1.415070e-01 | 0.849 | 0 | 0 |
| Platelet degranulation | R-HSA-114608 | 1.114019e-01 | 0.953 | 0 | 0 |
| Signaling by FLT3 fusion proteins | R-HSA-9703465 | 1.203823e-01 | 0.919 | 0 | 0 |
| Mitophagy | R-HSA-5205647 | 1.397783e-01 | 0.855 | 0 | 0 |
| GLI3 is processed to GLI3R by the proteasome | R-HSA-5610785 | 1.433693e-01 | 0.844 | 0 | 0 |
| Degradation of GLI2 by the proteasome | R-HSA-5610783 | 1.433693e-01 | 0.844 | 0 | 0 |
| Cyclin E associated events during G1/S transition | R-HSA-69202 | 1.197559e-01 | 0.922 | 0 | 0 |
| Signaling by WNT | R-HSA-195721 | 1.309218e-01 | 0.883 | 0 | 0 |
| Signal attenuation | R-HSA-74749 | 1.550185e-01 | 0.810 | 0 | 0 |
| RNA Polymerase I Transcription | R-HSA-73864 | 1.197152e-01 | 0.922 | 0 | 0 |
| Hedgehog 'off' state | R-HSA-5610787 | 1.238602e-01 | 0.907 | 0 | 0 |
| Interleukin-7 signaling | R-HSA-1266695 | 1.080284e-01 | 0.966 | 0 | 0 |
| RNA Polymerase I Promoter Opening | R-HSA-73728 | 1.334008e-01 | 0.875 | 0 | 0 |
| Signaling by Receptor Tyrosine Kinases | R-HSA-9006934 | 1.417930e-01 | 0.848 | 0 | 0 |
| Regulation of mRNA stability by proteins that bind AU-rich elements | R-HSA-450531 | 1.359721e-01 | 0.867 | 0 | 0 |
| NRIF signals cell death from the nucleus | R-HSA-205043 | 1.204974e-01 | 0.919 | 0 | 0 |
| Regulation of necroptotic cell death | R-HSA-5675482 | 1.164124e-01 | 0.934 | 0 | 0 |
| Signaling by PDGFR in disease | R-HSA-9671555 | 1.534911e-01 | 0.814 | 0 | 0 |
| Cellular responses to stimuli | R-HSA-8953897 | 1.454574e-01 | 0.837 | 0 | 0 |
| TNFR1-induced NF-kappa-B signaling pathway | R-HSA-5357956 | 1.334008e-01 | 0.875 | 0 | 0 |
| TNF signaling | R-HSA-75893 | 1.360799e-01 | 0.866 | 0 | 0 |
| Glycolysis | R-HSA-70171 | 1.238602e-01 | 0.907 | 0 | 0 |
| Cellular response to mitochondrial stress | R-HSA-9840373 | 1.310702e-01 | 0.882 | 0 | 0 |
| TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | R-HSA-2173791 | 1.385248e-01 | 0.858 | 0 | 0 |
| Plasma lipoprotein clearance | R-HSA-8964043 | 1.115822e-01 | 0.952 | 0 | 0 |
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | R-HSA-168643 | 1.363628e-01 | 0.865 | 0 | 0 |
| Death Receptor Signaling | R-HSA-73887 | 1.376821e-01 | 0.861 | 0 | 0 |
| Signaling by NOTCH3 | R-HSA-9012852 | 1.268011e-01 | 0.897 | 0 | 0 |
| Sema4D in semaphorin signaling | R-HSA-400685 | 1.080284e-01 | 0.966 | 0 | 0 |
| IRF3-mediated induction of type I IFN | R-HSA-3270619 | 1.385248e-01 | 0.858 | 0 | 0 |
| Signaling by NOTCH4 | R-HSA-9013694 | 1.533192e-01 | 0.814 | 0 | 0 |
| Gene Silencing by RNA | R-HSA-211000 | 1.222908e-01 | 0.913 | 0 | 0 |
| NRAGE signals death through JNK | R-HSA-193648 | 1.360799e-01 | 0.866 | 0 | 0 |
| NOTCH4 Intracellular Domain Regulates Transcription | R-HSA-9013695 | 1.376011e-01 | 0.861 | 0 | 0 |
| SARS-CoV-1 Infection | R-HSA-9678108 | 1.190052e-01 | 0.924 | 0 | 0 |
| Non-integrin membrane-ECM interactions | R-HSA-3000171 | 1.624031e-01 | 0.789 | 0 | 0 |
| NrCAM interactions | R-HSA-447038 | 1.656173e-01 | 0.781 | 0 | 0 |
| Reelin signalling pathway | R-HSA-8866376 | 1.656173e-01 | 0.781 | 0 | 0 |
| Co-inhibition by BTLA | R-HSA-9927353 | 1.656173e-01 | 0.781 | 0 | 0 |
| NFE2L2 regulating inflammation associated genes | R-HSA-9818026 | 1.656173e-01 | 0.781 | 0 | 0 |
| Signaling by membrane-tethered fusions of PDGFRA or PDGFRB | R-HSA-9673768 | 1.656173e-01 | 0.781 | 0 | 0 |
| NOSIP mediated eNOS trafficking | R-HSA-203754 | 1.656173e-01 | 0.781 | 0 | 0 |
| Signaling by SCF-KIT | R-HSA-1433557 | 1.667817e-01 | 0.778 | 0 | 0 |
| Signaling by FGFR4 | R-HSA-5654743 | 1.667817e-01 | 0.778 | 0 | 0 |
| Signal Transduction | R-HSA-162582 | 1.690628e-01 | 0.772 | 0 | 0 |
| Notch-HLH transcription pathway | R-HSA-350054 | 1.701005e-01 | 0.769 | 0 | 0 |
| Developmental Lineage of Mammary Stem Cells | R-HSA-9938206 | 1.701005e-01 | 0.769 | 0 | 0 |
| mTORC1-mediated signalling | R-HSA-166208 | 1.701005e-01 | 0.769 | 0 | 0 |
| RNA Polymerase I Promoter Clearance | R-HSA-73854 | 1.717516e-01 | 0.765 | 0 | 0 |
| RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | R-HSA-8936459 | 1.743520e-01 | 0.759 | 0 | 0 |
| Resolution of Sister Chromatid Cohesion | R-HSA-2500257 | 1.749397e-01 | 0.757 | 0 | 0 |
| Interleukin-37 signaling | R-HSA-9008059 | 1.761355e-01 | 0.754 | 0 | 0 |
| Kinesins | R-HSA-983189 | 1.765831e-01 | 0.753 | 0 | 0 |
| G beta:gamma signalling through CDC42 | R-HSA-8964616 | 1.774799e-01 | 0.751 | 0 | 0 |
| SHC1 events in ERBB4 signaling | R-HSA-1250347 | 1.774799e-01 | 0.751 | 0 | 0 |
| Inactivation of APC/C via direct inhibition of the APC/C complex | R-HSA-141430 | 1.774799e-01 | 0.751 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of growth factors and their receptors | R-HSA-8866910 | 1.774799e-01 | 0.751 | 0 | 0 |
| The CRY:PER:kinase complex represses transactivation by the BMAL:CLOCK (ARNTL:CLOCK) complex | R-HSA-9931521 | 1.774799e-01 | 0.751 | 0 | 0 |
| Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components | R-HSA-141405 | 1.774799e-01 | 0.751 | 0 | 0 |
| TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling | R-HSA-975110 | 1.774799e-01 | 0.751 | 0 | 0 |
| Meiosis | R-HSA-1500620 | 1.779696e-01 | 0.750 | 0 | 0 |
| E3 ubiquitin ligases ubiquitinate target proteins | R-HSA-8866654 | 1.782615e-01 | 0.749 | 0 | 0 |
| SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | R-HSA-2173796 | 1.786555e-01 | 0.748 | 0 | 0 |
| Viral Messenger RNA Synthesis | R-HSA-168325 | 1.875048e-01 | 0.727 | 0 | 0 |
| Defective Mismatch Repair Associated With MSH6 | R-HSA-5632968 | 1.878325e-01 | 0.726 | 0 | 0 |
| TICAM1 deficiency - HSE | R-HSA-5602566 | 1.878325e-01 | 0.726 | 0 | 0 |
| Inhibition of PKR | R-HSA-169131 | 1.878325e-01 | 0.726 | 0 | 0 |
| Respiratory Syncytial Virus Infection Pathway | R-HSA-9820952 | 1.880581e-01 | 0.726 | 0 | 0 |
| APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | R-HSA-174178 | 1.900006e-01 | 0.721 | 0 | 0 |
| TP53 Regulates Transcription of DNA Repair Genes | R-HSA-6796648 | 1.912121e-01 | 0.718 | 0 | 0 |
| Regulation of activated PAK-2p34 by proteasome mediated degradation | R-HSA-211733 | 1.914875e-01 | 0.718 | 0 | 0 |
| Budding and maturation of HIV virion | R-HSA-162588 | 1.914875e-01 | 0.718 | 0 | 0 |
| Negative regulators of DDX58/IFIH1 signaling | R-HSA-936440 | 1.914875e-01 | 0.718 | 0 | 0 |
| ADORA2B mediated anti-inflammatory cytokines production | R-HSA-9660821 | 1.918120e-01 | 0.717 | 0 | 0 |
| NEP/NS2 Interacts with the Cellular Export Machinery | R-HSA-168333 | 1.918120e-01 | 0.717 | 0 | 0 |
| Signaling by FGFR3 | R-HSA-5654741 | 1.918120e-01 | 0.717 | 0 | 0 |
| RIPK1-mediated regulated necrosis | R-HSA-5213460 | 1.925379e-01 | 0.715 | 0 | 0 |
| Degradation of beta-catenin by the destruction complex | R-HSA-195253 | 1.950593e-01 | 0.710 | 0 | 0 |
| Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase | R-HSA-176407 | 1.981988e-01 | 0.703 | 0 | 0 |
| Regulation of APC/C activators between G1/S and early anaphase | R-HSA-176408 | 1.987208e-01 | 0.702 | 0 | 0 |
| Cellular responses to stress | R-HSA-2262752 | 1.997911e-01 | 0.699 | 0 | 0 |
| CDK-mediated phosphorylation and removal of Cdc6 | R-HSA-69017 | 2.020646e-01 | 0.695 | 0 | 0 |
| Defective SLC6A2 causes orthostatic intolerance (OI) | R-HSA-5619109 | 2.680790e-01 | 0.572 | 0 | 0 |
| Defective APRT disrupts adenine salvage | R-HSA-9734195 | 2.680790e-01 | 0.572 | 0 | 0 |
| Defective SLC4A1 causes hereditary spherocytosis type 4 (HSP4), distal renal tubular acidosis (dRTA) and dRTA with hemolytic anemia (dRTA-HA) | R-HSA-5619050 | 2.680790e-01 | 0.572 | 0 | 0 |
| TALDO1 deficiency: failed conversion of Fru(6)P, E4P to SH7P, GA3P | R-HSA-6791462 | 2.680790e-01 | 0.572 | 0 | 0 |
| TRAF3 deficiency - HSE | R-HSA-5602571 | 2.680790e-01 | 0.572 | 0 | 0 |
| TALDO1 deficiency: failed conversion of SH7P, GA3P to Fru(6)P, E4P | R-HSA-6791055 | 2.680790e-01 | 0.572 | 0 | 0 |
| Defective SLC12A6 causes agenesis of the corpus callosum, with peripheral neuropathy (ACCPN) | R-HSA-5619039 | 2.680790e-01 | 0.572 | 0 | 0 |
| Defective PGM1 causes PGM1-CDG | R-HSA-5609974 | 2.680790e-01 | 0.572 | 0 | 0 |
| CDH11 homotypic and heterotypic interactions | R-HSA-9833576 | 2.027905e-01 | 0.693 | 0 | 0 |
| Cam-PDE 1 activation | R-HSA-111957 | 2.027905e-01 | 0.693 | 0 | 0 |
| CDC6 association with the ORC:origin complex | R-HSA-68689 | 2.027905e-01 | 0.693 | 0 | 0 |
| Loss of MECP2 binding ability to the NCoR/SMRT complex | R-HSA-9022537 | 2.027905e-01 | 0.693 | 0 | 0 |
| Regulation of cortical dendrite branching | R-HSA-8985801 | 3.404010e-01 | 0.468 | 0 | 0 |
| Glycogen storage disease type XV (GYG1) | R-HSA-3814836 | 3.404010e-01 | 0.468 | 0 | 0 |
| Glycogen storage disease type 0 (liver GYS2) | R-HSA-3858516 | 3.404010e-01 | 0.468 | 0 | 0 |
| Defective AHCY causes HMAHCHD | R-HSA-5578997 | 3.404010e-01 | 0.468 | 0 | 0 |
| Defective SLC6A5 causes hyperekplexia 3 (HKPX3) | R-HSA-5619089 | 3.404010e-01 | 0.468 | 0 | 0 |
| Glycogen storage disease type 0 (muscle GYS1) | R-HSA-3828062 | 3.404010e-01 | 0.468 | 0 | 0 |
| Glycogen storage disease type IV (GBE1) | R-HSA-3878781 | 3.404010e-01 | 0.468 | 0 | 0 |
| Signaling by RAS GAP mutants | R-HSA-9753510 | 3.404010e-01 | 0.468 | 0 | 0 |
| PTK6 promotes HIF1A stabilization | R-HSA-8857538 | 2.407660e-01 | 0.618 | 0 | 0 |
| Signaling by LTK in cancer | R-HSA-9842640 | 2.407660e-01 | 0.618 | 0 | 0 |
| Autointegration results in viral DNA circles | R-HSA-177539 | 2.407660e-01 | 0.618 | 0 | 0 |
| H139Hfs13* PPM1K causes a mild variant of MSUD | R-HSA-9912529 | 2.407660e-01 | 0.618 | 0 | 0 |
| E2F-enabled inhibition of pre-replication complex formation | R-HSA-113507 | 2.407660e-01 | 0.618 | 0 | 0 |
| RAS signaling downstream of NF1 loss-of-function variants | R-HSA-6802953 | 2.407660e-01 | 0.618 | 0 | 0 |
| Condensation of Prometaphase Chromosomes | R-HSA-2514853 | 2.063743e-01 | 0.685 | 0 | 0 |
| Signaling by GSK3beta mutants | R-HSA-5339716 | 2.063743e-01 | 0.685 | 0 | 0 |
| MECP2 regulates transcription factors | R-HSA-9022707 | 2.790228e-01 | 0.554 | 0 | 0 |
| NOSTRIN mediated eNOS trafficking | R-HSA-203641 | 2.790228e-01 | 0.554 | 0 | 0 |
| Recycling of eIF2:GDP | R-HSA-72731 | 2.790228e-01 | 0.554 | 0 | 0 |
| Signaling by cytosolic PDGFRA and PDGFRB fusion proteins | R-HSA-9673766 | 4.055806e-01 | 0.392 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of other transcription factors | R-HSA-8866906 | 4.055806e-01 | 0.392 | 0 | 0 |
| Axonal growth stimulation | R-HSA-209563 | 4.055806e-01 | 0.392 | 0 | 0 |
| Loss of Function of KMT2D in Kabuki Syndrome | R-HSA-9944971 | 4.055806e-01 | 0.392 | 0 | 0 |
| Loss of Function of KMT2D in MLL4 Complex Formation in Kabuki Syndrome | R-HSA-9944997 | 4.055806e-01 | 0.392 | 0 | 0 |
| Defective DPM2 causes DPM2-CDG | R-HSA-4719377 | 4.055806e-01 | 0.392 | 0 | 0 |
| Defective DPM3 causes DPM3-CDG | R-HSA-4719360 | 4.055806e-01 | 0.392 | 0 | 0 |
| Defective DPM1 causes DPM1-CDG | R-HSA-4717374 | 4.055806e-01 | 0.392 | 0 | 0 |
| Leading Strand Synthesis | R-HSA-69109 | 2.333364e-01 | 0.632 | 0 | 0 |
| Polymerase switching | R-HSA-69091 | 2.333364e-01 | 0.632 | 0 | 0 |
| Signaling by CTNNB1 phospho-site mutants | R-HSA-4839743 | 2.333364e-01 | 0.632 | 0 | 0 |
| CTNNB1 S45 mutants aren't phosphorylated | R-HSA-5358751 | 2.333364e-01 | 0.632 | 0 | 0 |
| CTNNB1 S33 mutants aren't phosphorylated | R-HSA-5358747 | 2.333364e-01 | 0.632 | 0 | 0 |
| CTNNB1 T41 mutants aren't phosphorylated | R-HSA-5358752 | 2.333364e-01 | 0.632 | 0 | 0 |
| CTNNB1 S37 mutants aren't phosphorylated | R-HSA-5358749 | 2.333364e-01 | 0.632 | 0 | 0 |
| CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde | R-HSA-442729 | 3.171349e-01 | 0.499 | 0 | 0 |
| NFE2L2 regulating tumorigenic genes | R-HSA-9818030 | 2.608744e-01 | 0.584 | 0 | 0 |
| Trafficking of GluR2-containing AMPA receptors | R-HSA-416993 | 2.196018e-01 | 0.658 | 0 | 0 |
| Activation of RAC1 downstream of NMDARs | R-HSA-9619229 | 3.547578e-01 | 0.450 | 0 | 0 |
| Lipophagy | R-HSA-9613354 | 3.547578e-01 | 0.450 | 0 | 0 |
| Inactivation of CDC42 and RAC1 | R-HSA-428543 | 3.547578e-01 | 0.450 | 0 | 0 |
| Polymerase switching on the C-strand of the telomere | R-HSA-174411 | 2.236397e-01 | 0.650 | 0 | 0 |
| Erythropoietin activates RAS | R-HSA-9027284 | 3.169160e-01 | 0.499 | 0 | 0 |
| Beta-catenin phosphorylation cascade | R-HSA-196299 | 3.169160e-01 | 0.499 | 0 | 0 |
| G beta:gamma signalling through BTK | R-HSA-8964315 | 3.169160e-01 | 0.499 | 0 | 0 |
| MECP2 regulates transcription of neuronal ligands | R-HSA-9022702 | 3.916162e-01 | 0.407 | 0 | 0 |
| Folding of actin by CCT/TriC | R-HSA-390450 | 3.916162e-01 | 0.407 | 0 | 0 |
| Activation of Ca-permeable Kainate Receptor | R-HSA-451308 | 3.916162e-01 | 0.407 | 0 | 0 |
| EPHA-mediated growth cone collapse | R-HSA-3928663 | 2.617826e-01 | 0.582 | 0 | 0 |
| Packaging Of Telomere Ends | R-HSA-171306 | 2.617826e-01 | 0.582 | 0 | 0 |
| Phosphorylation of the APC/C | R-HSA-176412 | 3.450760e-01 | 0.462 | 0 | 0 |
| Aberrant regulation of mitotic exit in cancer due to RB1 defects | R-HSA-9687136 | 3.450760e-01 | 0.462 | 0 | 0 |
| Formation of HIV elongation complex in the absence of HIV Tat | R-HSA-167152 | 2.215177e-01 | 0.655 | 0 | 0 |
| Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | R-HSA-5625886 | 2.365533e-01 | 0.626 | 0 | 0 |
| Recycling pathway of L1 | R-HSA-437239 | 2.182956e-01 | 0.661 | 0 | 0 |
| Interleukin receptor SHC signaling | R-HSA-912526 | 3.564722e-01 | 0.448 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | R-HSA-167160 | 3.564722e-01 | 0.448 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE | R-HSA-77075 | 3.564722e-01 | 0.448 | 0 | 0 |
| mRNA Splicing - Minor Pathway | R-HSA-72165 | 3.323289e-01 | 0.478 | 0 | 0 |
| Nuclear Receptor transcription pathway | R-HSA-383280 | 2.872401e-01 | 0.542 | 0 | 0 |
| Nuclear signaling by ERBB4 | R-HSA-1251985 | 3.645140e-01 | 0.438 | 0 | 0 |
| Protein ubiquitination | R-HSA-8852135 | 3.642993e-01 | 0.439 | 0 | 0 |
| Post-translational protein phosphorylation | R-HSA-8957275 | 3.485356e-01 | 0.458 | 0 | 0 |
| HCMV Early Events | R-HSA-9609690 | 3.919255e-01 | 0.407 | 0 | 0 |
| Neutrophil degranulation | R-HSA-6798695 | 3.908086e-01 | 0.408 | 0 | 0 |
| Transcription of the HIV genome | R-HSA-167172 | 3.942130e-01 | 0.404 | 0 | 0 |
| Telomere Maintenance | R-HSA-157579 | 2.402416e-01 | 0.619 | 0 | 0 |
| Signaling by NOTCH2 | R-HSA-1980145 | 2.573374e-01 | 0.589 | 0 | 0 |
| Transcriptional Regulation by MECP2 | R-HSA-8986944 | 3.494966e-01 | 0.457 | 0 | 0 |
| HIV Transcription Elongation | R-HSA-167169 | 2.215177e-01 | 0.655 | 0 | 0 |
| GPER1 signaling | R-HSA-9634597 | 2.320255e-01 | 0.634 | 0 | 0 |
| Interferon alpha/beta signaling | R-HSA-909733 | 3.679169e-01 | 0.434 | 0 | 0 |
| Tat-mediated elongation of the HIV-1 transcript | R-HSA-167246 | 2.215177e-01 | 0.655 | 0 | 0 |
| HSF1-dependent transactivation | R-HSA-3371571 | 2.748721e-01 | 0.561 | 0 | 0 |
| Energy dependent regulation of mTOR by LKB1-AMPK | R-HSA-380972 | 3.213592e-01 | 0.493 | 0 | 0 |
| SCF(Skp2)-mediated degradation of p27/p21 | R-HSA-187577 | 2.995693e-01 | 0.524 | 0 | 0 |
| Resolution of D-Loop Structures | R-HSA-5693537 | 4.025673e-01 | 0.395 | 0 | 0 |
| Metabolism of nitric oxide: NOS3 activation and regulation | R-HSA-202131 | 3.281492e-01 | 0.484 | 0 | 0 |
| Resolution of D-loop Structures through Holliday Junction Intermediates | R-HSA-5693568 | 3.822517e-01 | 0.418 | 0 | 0 |
| Regulation of mitotic cell cycle | R-HSA-453276 | 2.058066e-01 | 0.687 | 0 | 0 |
| APC/C-mediated degradation of cell cycle proteins | R-HSA-174143 | 2.058066e-01 | 0.687 | 0 | 0 |
| TRAF3-dependent IRF activation pathway | R-HSA-918233 | 3.731260e-01 | 0.428 | 0 | 0 |
| Epigenetic regulation by WDR5-containing histone modifying complexes | R-HSA-9917777 | 3.389289e-01 | 0.470 | 0 | 0 |
| Diseases of mitotic cell cycle | R-HSA-9675126 | 2.073270e-01 | 0.683 | 0 | 0 |
| Regulation of CDH11 function | R-HSA-9762292 | 3.916162e-01 | 0.407 | 0 | 0 |
| MET activates RAP1 and RAC1 | R-HSA-8875555 | 3.916162e-01 | 0.407 | 0 | 0 |
| Formation of HIV-1 elongation complex containing HIV-1 Tat | R-HSA-167200 | 2.068354e-01 | 0.684 | 0 | 0 |
| Deadenylation-dependent mRNA decay | R-HSA-429914 | 2.666224e-01 | 0.574 | 0 | 0 |
| Phosphorylation and nuclear translocation of the CRY:PER:kinase complex | R-HSA-9931530 | 2.333364e-01 | 0.632 | 0 | 0 |
| NOTCH1 Intracellular Domain Regulates Transcription | R-HSA-2122947 | 2.460484e-01 | 0.609 | 0 | 0 |
| Activation of anterior HOX genes in hindbrain development during early embryogenesis | R-HSA-5617472 | 2.333463e-01 | 0.632 | 0 | 0 |
| Activation of HOX genes during differentiation | R-HSA-5619507 | 2.333463e-01 | 0.632 | 0 | 0 |
| NoRC negatively regulates rRNA expression | R-HSA-427413 | 2.058066e-01 | 0.687 | 0 | 0 |
| PI3K events in ERBB2 signaling | R-HSA-1963642 | 4.009333e-01 | 0.397 | 0 | 0 |
| Nuclear events mediated by NFE2L2 | R-HSA-9759194 | 3.344408e-01 | 0.476 | 0 | 0 |
| Activation of NF-kappaB in B cells | R-HSA-1169091 | 2.748721e-01 | 0.561 | 0 | 0 |
| Signaling by WNT in cancer | R-HSA-4791275 | 2.073270e-01 | 0.683 | 0 | 0 |
| Nef mediated downregulation of CD28 cell surface expression | R-HSA-164939 | 2.680790e-01 | 0.572 | 0 | 0 |
| VLDL clearance | R-HSA-8964046 | 2.790228e-01 | 0.554 | 0 | 0 |
| Gastrin-CREB signalling pathway via PKC and MAPK | R-HSA-881907 | 2.415805e-01 | 0.617 | 0 | 0 |
| FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | R-HSA-8854050 | 2.746887e-01 | 0.561 | 0 | 0 |
| SCF-beta-TrCP mediated degradation of Emi1 | R-HSA-174113 | 2.746887e-01 | 0.561 | 0 | 0 |
| Signaling by NOTCH1 PEST Domain Mutants in Cancer | R-HSA-2644602 | 2.802445e-01 | 0.552 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | R-HSA-2894862 | 2.802445e-01 | 0.552 | 0 | 0 |
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | R-HSA-2644606 | 2.802445e-01 | 0.552 | 0 | 0 |
| Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | R-HSA-2894858 | 2.802445e-01 | 0.552 | 0 | 0 |
| Downstream signaling events of B Cell Receptor (BCR) | R-HSA-1168372 | 2.972702e-01 | 0.527 | 0 | 0 |
| Negative epigenetic regulation of rRNA expression | R-HSA-5250941 | 3.120898e-01 | 0.506 | 0 | 0 |
| Degradation of CRY and PER proteins | R-HSA-9932298 | 4.010585e-01 | 0.397 | 0 | 0 |
| Cyclin D associated events in G1 | R-HSA-69231 | 2.995693e-01 | 0.524 | 0 | 0 |
| G1 Phase | R-HSA-69236 | 2.995693e-01 | 0.524 | 0 | 0 |
| Signal transduction by L1 | R-HSA-445144 | 2.640280e-01 | 0.578 | 0 | 0 |
| RAS processing | R-HSA-9648002 | 3.462883e-01 | 0.461 | 0 | 0 |
| PKA-mediated phosphorylation of key metabolic factors | R-HSA-163358 | 2.027905e-01 | 0.693 | 0 | 0 |
| Inhibition of nitric oxide production | R-HSA-9636249 | 4.055806e-01 | 0.392 | 0 | 0 |
| Formation of intermediate mesoderm | R-HSA-9761174 | 3.916162e-01 | 0.407 | 0 | 0 |
| Intra-Golgi traffic | R-HSA-6811438 | 4.010585e-01 | 0.397 | 0 | 0 |
| Extra-nuclear estrogen signaling | R-HSA-9009391 | 2.816347e-01 | 0.550 | 0 | 0 |
| Protein-protein interactions at synapses | R-HSA-6794362 | 3.760877e-01 | 0.425 | 0 | 0 |
| Degradation of DVL | R-HSA-4641258 | 3.101399e-01 | 0.508 | 0 | 0 |
| ADP signalling through P2Y purinoceptor 1 | R-HSA-418592 | 3.797771e-01 | 0.420 | 0 | 0 |
| Asymmetric localization of PCP proteins | R-HSA-4608870 | 3.158730e-01 | 0.500 | 0 | 0 |
| M-decay: degradation of maternal mRNAs by maternally stored factors | R-HSA-9820841 | 3.827842e-01 | 0.417 | 0 | 0 |
| Cellular response to heat stress | R-HSA-3371556 | 2.470453e-01 | 0.607 | 0 | 0 |
| Translocation of SLC2A4 (GLUT4) to the plasma membrane | R-HSA-1445148 | 3.371790e-01 | 0.472 | 0 | 0 |
| Regulation of T cell activation by CD28 family | R-HSA-388841 | 3.579599e-01 | 0.446 | 0 | 0 |
| Synthesis of PIPs at the plasma membrane | R-HSA-1660499 | 3.080331e-01 | 0.511 | 0 | 0 |
| Signaling by NOTCH1 | R-HSA-1980143 | 2.629987e-01 | 0.580 | 0 | 0 |
| Organelle biogenesis and maintenance | R-HSA-1852241 | 3.496994e-01 | 0.456 | 0 | 0 |
| Inhibition of Host mRNA Processing and RNA Silencing | R-HSA-168315 | 2.680790e-01 | 0.572 | 0 | 0 |
| Defective Mismatch Repair Associated With MSH2 | R-HSA-5632928 | 2.680790e-01 | 0.572 | 0 | 0 |
| Interleukin-33 signaling | R-HSA-9014843 | 3.404010e-01 | 0.468 | 0 | 0 |
| MET interacts with TNS proteins | R-HSA-8875513 | 4.055806e-01 | 0.392 | 0 | 0 |
| Negative regulation of TCF-dependent signaling by DVL-interacting proteins | R-HSA-5368598 | 4.055806e-01 | 0.392 | 0 | 0 |
| Negative regulation of activity of TFAP2 (AP-2) family transcription factors | R-HSA-8866904 | 3.171349e-01 | 0.499 | 0 | 0 |
| Processing of Capped Intronless Pre-mRNA | R-HSA-75067 | 2.052380e-01 | 0.688 | 0 | 0 |
| Activation of the TFAP2 (AP-2) family of transcription factors | R-HSA-8866907 | 3.547578e-01 | 0.450 | 0 | 0 |
| Activation of kainate receptors upon glutamate binding | R-HSA-451326 | 2.813916e-01 | 0.551 | 0 | 0 |
| Vif-mediated degradation of APOBEC3G | R-HSA-180585 | 2.923047e-01 | 0.534 | 0 | 0 |
| Degradation of AXIN | R-HSA-4641257 | 3.101399e-01 | 0.508 | 0 | 0 |
| GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2 | R-HSA-9762114 | 3.101399e-01 | 0.508 | 0 | 0 |
| Glycogen breakdown (glycogenolysis) | R-HSA-70221 | 4.029902e-01 | 0.395 | 0 | 0 |
| PCP/CE pathway | R-HSA-4086400 | 2.872401e-01 | 0.542 | 0 | 0 |
| Signaling by NOTCH1 in Cancer | R-HSA-2644603 | 2.802445e-01 | 0.552 | 0 | 0 |
| Hedgehog 'on' state | R-HSA-5632684 | 2.058066e-01 | 0.687 | 0 | 0 |
| FGFR1 mutant receptor activation | R-HSA-1839124 | 3.822517e-01 | 0.418 | 0 | 0 |
| Signaling by Hedgehog | R-HSA-5358351 | 3.517624e-01 | 0.454 | 0 | 0 |
| TAK1-dependent IKK and NF-kappa-B activation | R-HSA-445989 | 2.182956e-01 | 0.661 | 0 | 0 |
| Interleukin-17 signaling | R-HSA-448424 | 2.972702e-01 | 0.527 | 0 | 0 |
| Signaling by FGFR1 in disease | R-HSA-5655302 | 4.010585e-01 | 0.397 | 0 | 0 |
| Golgi-to-ER retrograde transport | R-HSA-8856688 | 2.847500e-01 | 0.546 | 0 | 0 |
| Aquaporin-mediated transport | R-HSA-445717 | 2.940551e-01 | 0.532 | 0 | 0 |
| Regulation of TNFR1 signaling | R-HSA-5357905 | 3.323289e-01 | 0.478 | 0 | 0 |
| GSK3B-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929356 | 3.462883e-01 | 0.461 | 0 | 0 |
| Gene expression (Transcription) | R-HSA-74160 | 2.166473e-01 | 0.664 | 0 | 0 |
| Estrogen-dependent nuclear events downstream of ESR-membrane signaling | R-HSA-9634638 | 3.564722e-01 | 0.448 | 0 | 0 |
| PTEN Regulation | R-HSA-6807070 | 2.759956e-01 | 0.559 | 0 | 0 |
| ER to Golgi Anterograde Transport | R-HSA-199977 | 3.595295e-01 | 0.444 | 0 | 0 |
| RSV-host interactions | R-HSA-9833110 | 3.250993e-01 | 0.488 | 0 | 0 |
| MAP kinase activation | R-HSA-450294 | 2.940551e-01 | 0.532 | 0 | 0 |
| Nef and signal transduction | R-HSA-164944 | 2.407660e-01 | 0.618 | 0 | 0 |
| Basigin interactions | R-HSA-210991 | 2.868397e-01 | 0.542 | 0 | 0 |
| Vpu mediated degradation of CD4 | R-HSA-180534 | 2.402964e-01 | 0.619 | 0 | 0 |
| Mitochondrial calcium ion transport | R-HSA-8949215 | 3.099146e-01 | 0.509 | 0 | 0 |
| Autodegradation of the E3 ubiquitin ligase COP1 | R-HSA-349425 | 2.573374e-01 | 0.589 | 0 | 0 |
| Ubiquitin-dependent degradation of Cyclin D | R-HSA-75815 | 2.573374e-01 | 0.589 | 0 | 0 |
| Regulation of Apoptosis | R-HSA-169911 | 2.746887e-01 | 0.561 | 0 | 0 |
| Co-inhibition by PD-1 | R-HSA-389948 | 3.473676e-01 | 0.459 | 0 | 0 |
| Regulation of PD-L1(CD274) expression | R-HSA-9909648 | 3.445536e-01 | 0.463 | 0 | 0 |
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | R-HSA-2173793 | 2.270969e-01 | 0.644 | 0 | 0 |
| Signaling by MET | R-HSA-6806834 | 3.120898e-01 | 0.506 | 0 | 0 |
| Signaling by Nuclear Receptors | R-HSA-9006931 | 3.859320e-01 | 0.413 | 0 | 0 |
| Iron uptake and transport | R-HSA-917937 | 3.642993e-01 | 0.439 | 0 | 0 |
| RUNX1 regulates expression of components of tight junctions | R-HSA-8935964 | 2.027905e-01 | 0.693 | 0 | 0 |
| Integration of viral DNA into host genomic DNA | R-HSA-175567 | 2.407660e-01 | 0.618 | 0 | 0 |
| Diseases of Mismatch Repair (MMR) | R-HSA-5423599 | 4.055806e-01 | 0.392 | 0 | 0 |
| Synthesis of IP3 and IP4 in the cytosol | R-HSA-1855204 | 2.236113e-01 | 0.651 | 0 | 0 |
| Regulation of RUNX3 expression and activity | R-HSA-8941858 | 3.645140e-01 | 0.438 | 0 | 0 |
| Negative regulation of NOTCH4 signaling | R-HSA-9604323 | 3.645140e-01 | 0.438 | 0 | 0 |
| Signaling by FGFR1 | R-HSA-5654736 | 3.502448e-01 | 0.456 | 0 | 0 |
| Hh mutants are degraded by ERAD | R-HSA-5362768 | 3.827842e-01 | 0.417 | 0 | 0 |
| SPOP-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929491 | 3.827842e-01 | 0.417 | 0 | 0 |
| Glucose metabolism | R-HSA-70326 | 2.936919e-01 | 0.532 | 0 | 0 |
| Pre-NOTCH Transcription and Translation | R-HSA-1912408 | 3.494966e-01 | 0.457 | 0 | 0 |
| TGF-beta receptor signaling activates SMADs | R-HSA-2173789 | 2.834515e-01 | 0.548 | 0 | 0 |
| Early Phase of HIV Life Cycle | R-HSA-162594 | 2.868397e-01 | 0.542 | 0 | 0 |
| Regulation of TP53 Activity through Phosphorylation | R-HSA-6804756 | 4.021189e-01 | 0.396 | 0 | 0 |
| Assembly and cell surface presentation of NMDA receptors | R-HSA-9609736 | 4.010585e-01 | 0.397 | 0 | 0 |
| Regulation of TP53 Degradation | R-HSA-6804757 | 2.923047e-01 | 0.534 | 0 | 0 |
| Suppression of phagosomal maturation | R-HSA-9637687 | 2.425100e-01 | 0.615 | 0 | 0 |
| Regulation of TP53 Activity through Acetylation | R-HSA-6804758 | 2.236113e-01 | 0.651 | 0 | 0 |
| TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | R-HSA-6804115 | 3.331560e-01 | 0.477 | 0 | 0 |
| Neurodegenerative Diseases | R-HSA-8863678 | 2.052380e-01 | 0.688 | 0 | 0 |
| Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models | R-HSA-8862803 | 2.052380e-01 | 0.688 | 0 | 0 |
| Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A | R-HSA-69601 | 3.158730e-01 | 0.500 | 0 | 0 |
| p53-Independent G1/S DNA Damage Checkpoint | R-HSA-69613 | 3.158730e-01 | 0.500 | 0 | 0 |
| p53-Dependent G1 DNA Damage Response | R-HSA-69563 | 3.822773e-01 | 0.418 | 0 | 0 |
| p53-Dependent G1/S DNA damage checkpoint | R-HSA-69580 | 3.822773e-01 | 0.418 | 0 | 0 |
| Stabilization of p53 | R-HSA-69541 | 3.462883e-01 | 0.461 | 0 | 0 |
| Regulation of TP53 Activity | R-HSA-5633007 | 3.107834e-01 | 0.508 | 0 | 0 |
| Regulation of TP53 Expression and Degradation | R-HSA-6806003 | 3.462883e-01 | 0.461 | 0 | 0 |
| tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis | R-HSA-9708296 | 3.404010e-01 | 0.468 | 0 | 0 |
| Defective Intrinsic Pathway for Apoptosis | R-HSA-9734009 | 2.617826e-01 | 0.582 | 0 | 0 |
| Signaling by FGFR | R-HSA-190236 | 2.503630e-01 | 0.601 | 0 | 0 |
| Transcriptional Regulation by TP53 | R-HSA-3700989 | 3.302404e-01 | 0.481 | 0 | 0 |
| Response of Mtb to phagocytosis | R-HSA-9637690 | 2.834515e-01 | 0.548 | 0 | 0 |
| Inositol phosphate metabolism | R-HSA-1483249 | 3.140874e-01 | 0.503 | 0 | 0 |
| ER Quality Control Compartment (ERQC) | R-HSA-901032 | 2.617826e-01 | 0.582 | 0 | 0 |
| NIK-->noncanonical NF-kB signaling | R-HSA-5676590 | 3.827842e-01 | 0.417 | 0 | 0 |
| Miscellaneous transport and binding events | R-HSA-5223345 | 4.025673e-01 | 0.395 | 0 | 0 |
| Regulation of CDH11 gene transcription | R-HSA-9762293 | 3.547578e-01 | 0.450 | 0 | 0 |
| STING mediated induction of host immune responses | R-HSA-1834941 | 2.415805e-01 | 0.617 | 0 | 0 |
| Regulation of CDH19 Expression and Function | R-HSA-9764302 | 2.027905e-01 | 0.693 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescence | R-HSA-9825895 | 3.171349e-01 | 0.499 | 0 | 0 |
| Export of Viral Ribonucleoproteins from Nucleus | R-HSA-168274 | 2.048832e-01 | 0.688 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected purine | R-HSA-110330 | 3.619081e-01 | 0.441 | 0 | 0 |
| MITF-M-dependent gene expression | R-HSA-9856651 | 3.026430e-01 | 0.519 | 0 | 0 |
| Prevention of phagosomal-lysosomal fusion | R-HSA-9636383 | 2.868397e-01 | 0.542 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | R-HSA-6804114 | 3.731260e-01 | 0.428 | 0 | 0 |
| Tandem pore domain potassium channels | R-HSA-1296346 | 3.916162e-01 | 0.407 | 0 | 0 |
| BMAL1:CLOCK,NPAS2 activates circadian expression | R-HSA-1368108 | 2.573374e-01 | 0.589 | 0 | 0 |
| Selenoamino acid metabolism | R-HSA-2408522 | 2.682214e-01 | 0.572 | 0 | 0 |
| PD-L1(CD274) glycosylation and translocation to plasma membrane | R-HSA-9931295 | 2.868397e-01 | 0.542 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected pyrimidine | R-HSA-110328 | 2.573374e-01 | 0.589 | 0 | 0 |
| Signaling by CSF3 (G-CSF) | R-HSA-9674555 | 3.012718e-01 | 0.521 | 0 | 0 |
| SARS-CoV-2 Infection | R-HSA-9694516 | 3.562425e-01 | 0.448 | 0 | 0 |
| FOXO-mediated transcription of cell cycle genes | R-HSA-9617828 | 3.099146e-01 | 0.509 | 0 | 0 |
| Butyrophilin (BTN) family interactions | R-HSA-8851680 | 3.547578e-01 | 0.450 | 0 | 0 |
| Inactivation of CSF3 (G-CSF) signaling | R-HSA-9705462 | 3.099146e-01 | 0.509 | 0 | 0 |
| Signaling by Leptin | R-HSA-2586552 | 3.916162e-01 | 0.407 | 0 | 0 |
| SARS-CoV Infections | R-HSA-9679506 | 4.098032e-01 | 0.387 | 0 | 0 |
| Meiotic recombination | R-HSA-912446 | 4.157403e-01 | 0.381 | 0 | 0 |
| Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | R-HSA-1234176 | 4.157403e-01 | 0.381 | 0 | 0 |
| Hedgehog ligand biogenesis | R-HSA-5358346 | 4.157403e-01 | 0.381 | 0 | 0 |
| Cleavage of the damaged pyrimidine | R-HSA-110329 | 4.192978e-01 | 0.377 | 0 | 0 |
| Depyrimidination | R-HSA-73928 | 4.192978e-01 | 0.377 | 0 | 0 |
| Calnexin/calreticulin cycle | R-HSA-901042 | 4.228026e-01 | 0.374 | 0 | 0 |
| Regulation of endogenous retroelements by KRAB-ZFP proteins | R-HSA-9843940 | 4.233150e-01 | 0.373 | 0 | 0 |
| Beta-catenin independent WNT signaling | R-HSA-3858494 | 4.255373e-01 | 0.371 | 0 | 0 |
| Myogenesis | R-HSA-525793 | 4.260373e-01 | 0.371 | 0 | 0 |
| Adrenaline,noradrenaline inhibits insulin secretion | R-HSA-400042 | 4.260373e-01 | 0.371 | 0 | 0 |
| Signaling by APC mutants | R-HSA-4839744 | 4.274940e-01 | 0.369 | 0 | 0 |
| Truncations of AMER1 destabilize the destruction complex | R-HSA-5467348 | 4.274940e-01 | 0.369 | 0 | 0 |
| AXIN missense mutants destabilize the destruction complex | R-HSA-5467340 | 4.274940e-01 | 0.369 | 0 | 0 |
| APC truncation mutants have impaired AXIN binding | R-HSA-5467337 | 4.274940e-01 | 0.369 | 0 | 0 |
| Synthesis of PIPs at the ER membrane | R-HSA-1483248 | 4.274940e-01 | 0.369 | 0 | 0 |
| Formation of the posterior neural plate | R-HSA-9832991 | 4.274940e-01 | 0.369 | 0 | 0 |
| Ionotropic activity of kainate receptors | R-HSA-451306 | 4.274940e-01 | 0.369 | 0 | 0 |
| PECAM1 interactions | R-HSA-210990 | 4.274940e-01 | 0.369 | 0 | 0 |
| Bicarbonate transporters | R-HSA-425381 | 4.274940e-01 | 0.369 | 0 | 0 |
| ChREBP activates metabolic gene expression | R-HSA-163765 | 4.274940e-01 | 0.369 | 0 | 0 |
| Regulation of RUNX2 expression and activity | R-HSA-8939902 | 4.277315e-01 | 0.369 | 0 | 0 |
| G beta:gamma signalling through PLC beta | R-HSA-418217 | 4.283807e-01 | 0.368 | 0 | 0 |
| Platelet sensitization by LDL | R-HSA-432142 | 4.283807e-01 | 0.368 | 0 | 0 |
| Presynaptic function of Kainate receptors | R-HSA-500657 | 4.283807e-01 | 0.368 | 0 | 0 |
| RNA Polymerase I Promoter Escape | R-HSA-73772 | 4.324298e-01 | 0.364 | 0 | 0 |
| AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274) | R-HSA-9931269 | 4.324298e-01 | 0.364 | 0 | 0 |
| Neurexins and neuroligins | R-HSA-6794361 | 4.324298e-01 | 0.364 | 0 | 0 |
| Nuclear Envelope (NE) Reassembly | R-HSA-2995410 | 4.328723e-01 | 0.364 | 0 | 0 |
| COPI-dependent Golgi-to-ER retrograde traffic | R-HSA-6811434 | 4.362894e-01 | 0.360 | 0 | 0 |
| TBC/RABGAPs | R-HSA-8854214 | 4.374650e-01 | 0.359 | 0 | 0 |
| Hh mutants abrogate ligand secretion | R-HSA-5387390 | 4.374650e-01 | 0.359 | 0 | 0 |
| PIP3 activates AKT signaling | R-HSA-1257604 | 4.374871e-01 | 0.359 | 0 | 0 |
| Oncogene Induced Senescence | R-HSA-2559585 | 4.429089e-01 | 0.354 | 0 | 0 |
| Amyloid fiber formation | R-HSA-977225 | 4.465834e-01 | 0.350 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex | R-HSA-170834 | 4.487301e-01 | 0.348 | 0 | 0 |
| Golgi Associated Vesicle Biogenesis | R-HSA-432722 | 4.490532e-01 | 0.348 | 0 | 0 |
| Signaling by NOTCH | R-HSA-157118 | 4.525008e-01 | 0.344 | 0 | 0 |
| Downstream TCR signaling | R-HSA-202424 | 4.542743e-01 | 0.343 | 0 | 0 |
| Abortive elongation of HIV-1 transcript in the absence of Tat | R-HSA-167242 | 4.553656e-01 | 0.342 | 0 | 0 |
| Impaired BRCA2 binding to PALB2 | R-HSA-9709603 | 4.553656e-01 | 0.342 | 0 | 0 |
| Specification of the neural plate border | R-HSA-9834899 | 4.553656e-01 | 0.342 | 0 | 0 |
| Prostacyclin signalling through prostacyclin receptor | R-HSA-392851 | 4.553656e-01 | 0.342 | 0 | 0 |
| E2F mediated regulation of DNA replication | R-HSA-113510 | 4.553656e-01 | 0.342 | 0 | 0 |
| Rap1 signalling | R-HSA-392517 | 4.553656e-01 | 0.342 | 0 | 0 |
| The NLRP3 inflammasome | R-HSA-844456 | 4.553656e-01 | 0.342 | 0 | 0 |
| MHC class II antigen presentation | R-HSA-2132295 | 4.562014e-01 | 0.341 | 0 | 0 |
| G1/S DNA Damage Checkpoints | R-HSA-69615 | 4.586210e-01 | 0.339 | 0 | 0 |
| Interferon Signaling | R-HSA-913531 | 4.605277e-01 | 0.337 | 0 | 0 |
| Activation of RAC1 | R-HSA-428540 | 4.622252e-01 | 0.335 | 0 | 0 |
| Phosphorylation of CLOCK, acetylation of BMAL1 (ARNTL) at target gene promoters | R-HSA-9931512 | 4.622252e-01 | 0.335 | 0 | 0 |
| PI3K events in ERBB4 signaling | R-HSA-1250342 | 4.622252e-01 | 0.335 | 0 | 0 |
| Sensing of DNA Double Strand Breaks | R-HSA-5693548 | 4.622252e-01 | 0.335 | 0 | 0 |
| Signaling by AXIN mutants | R-HSA-4839735 | 4.622252e-01 | 0.335 | 0 | 0 |
| Signaling by AMER1 mutants | R-HSA-4839748 | 4.622252e-01 | 0.335 | 0 | 0 |
| APOBEC3G mediated resistance to HIV-1 infection | R-HSA-180689 | 4.622252e-01 | 0.335 | 0 | 0 |
| ATF6 (ATF6-alpha) activates chaperone genes | R-HSA-381183 | 4.622252e-01 | 0.335 | 0 | 0 |
| Triglyceride catabolism | R-HSA-163560 | 4.628404e-01 | 0.335 | 0 | 0 |
| TLR3-mediated TICAM1-dependent programmed cell death | R-HSA-9013957 | 4.643228e-01 | 0.333 | 0 | 0 |
| PLCG1 events in ERBB2 signaling | R-HSA-1251932 | 4.643228e-01 | 0.333 | 0 | 0 |
| Defective LFNG causes SCDO3 | R-HSA-5083630 | 4.643228e-01 | 0.333 | 0 | 0 |
| Regulation of gap junction activity | R-HSA-191650 | 4.643228e-01 | 0.333 | 0 | 0 |
| SARS-CoV-2 targets PDZ proteins in cell-cell junction | R-HSA-9705677 | 4.643228e-01 | 0.333 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of cell cycle factors | R-HSA-8866911 | 4.643228e-01 | 0.333 | 0 | 0 |
| TNFR1-mediated ceramide production | R-HSA-5626978 | 4.643228e-01 | 0.333 | 0 | 0 |
| Electric Transmission Across Gap Junctions | R-HSA-112303 | 4.643228e-01 | 0.333 | 0 | 0 |
| Regulation of HMOX1 expression and activity | R-HSA-9707587 | 4.643228e-01 | 0.333 | 0 | 0 |
| Transmission across Electrical Synapses | R-HSA-112307 | 4.643228e-01 | 0.333 | 0 | 0 |
| FLT3 signaling through SRC family kinases | R-HSA-9706374 | 4.643228e-01 | 0.333 | 0 | 0 |
| Formation of the HIV-1 Early Elongation Complex | R-HSA-167158 | 4.713675e-01 | 0.327 | 0 | 0 |
| Formation of the Early Elongation Complex | R-HSA-113418 | 4.713675e-01 | 0.327 | 0 | 0 |
| Circadian clock | R-HSA-9909396 | 4.724529e-01 | 0.326 | 0 | 0 |
| Defective CFTR causes cystic fibrosis | R-HSA-5678895 | 4.734440e-01 | 0.325 | 0 | 0 |
| Dectin-1 mediated noncanonical NF-kB signaling | R-HSA-5607761 | 4.734440e-01 | 0.325 | 0 | 0 |
| Signaling by Interleukins | R-HSA-449147 | 4.772778e-01 | 0.321 | 0 | 0 |
| Stimuli-sensing channels | R-HSA-2672351 | 4.792069e-01 | 0.319 | 0 | 0 |
| G2/M DNA damage checkpoint | R-HSA-69473 | 4.811287e-01 | 0.318 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to PALB2 loss of function | R-HSA-9701193 | 4.817998e-01 | 0.317 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function | R-HSA-9704646 | 4.817998e-01 | 0.317 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function | R-HSA-9704331 | 4.817998e-01 | 0.317 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA1 loss of function | R-HSA-9701192 | 4.817998e-01 | 0.317 | 0 | 0 |
| VxPx cargo-targeting to cilium | R-HSA-5620916 | 4.817998e-01 | 0.317 | 0 | 0 |
| BBSome-mediated cargo-targeting to cilium | R-HSA-5620922 | 4.817998e-01 | 0.317 | 0 | 0 |
| G alpha (z) signalling events | R-HSA-418597 | 4.819953e-01 | 0.317 | 0 | 0 |
| SIRT1 negatively regulates rRNA expression | R-HSA-427359 | 4.825548e-01 | 0.316 | 0 | 0 |
| Cleavage of the damaged purine | R-HSA-110331 | 4.825548e-01 | 0.316 | 0 | 0 |
| Regulation of pyruvate metabolism | R-HSA-9861718 | 4.911912e-01 | 0.309 | 0 | 0 |
| KEAP1-NFE2L2 pathway | R-HSA-9755511 | 4.918396e-01 | 0.308 | 0 | 0 |
| RNA Polymerase II Transcription | R-HSA-73857 | 4.923989e-01 | 0.308 | 0 | 0 |
| Plasma lipoprotein assembly, remodeling, and clearance | R-HSA-174824 | 4.930369e-01 | 0.307 | 0 | 0 |
| Signaling by Erythropoietin | R-HSA-9006335 | 4.935330e-01 | 0.307 | 0 | 0 |
| Impaired BRCA2 binding to RAD51 | R-HSA-9709570 | 4.935330e-01 | 0.307 | 0 | 0 |
| mRNA Capping | R-HSA-72086 | 4.935330e-01 | 0.307 | 0 | 0 |
| Regulation of CDH11 Expression and Function | R-HSA-9759475 | 4.935330e-01 | 0.307 | 0 | 0 |
| Platelet activation, signaling and aggregation | R-HSA-76002 | 4.941761e-01 | 0.306 | 0 | 0 |
| Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | R-HSA-9027276 | 4.956860e-01 | 0.305 | 0 | 0 |
| Z-decay: degradation of maternal mRNAs by zygotically expressed factors | R-HSA-9820865 | 4.956860e-01 | 0.305 | 0 | 0 |
| Maple Syrup Urine Disease | R-HSA-9865114 | 4.956860e-01 | 0.305 | 0 | 0 |
| Interleukin-15 signaling | R-HSA-8983432 | 4.956860e-01 | 0.305 | 0 | 0 |
| SHC-related events triggered by IGF1R | R-HSA-2428933 | 4.956860e-01 | 0.305 | 0 | 0 |
| Serotonin clearance from the synaptic cleft | R-HSA-380615 | 4.956860e-01 | 0.305 | 0 | 0 |
| RUNX3 regulates NOTCH signaling | R-HSA-8941856 | 4.956860e-01 | 0.305 | 0 | 0 |
| GRB2 events in EGFR signaling | R-HSA-179812 | 4.956860e-01 | 0.305 | 0 | 0 |
| Regulation of FOXO transcriptional activity by acetylation | R-HSA-9617629 | 4.956860e-01 | 0.305 | 0 | 0 |
| Regulation of IFNG signaling | R-HSA-877312 | 4.956860e-01 | 0.305 | 0 | 0 |
| Signaling by LTK | R-HSA-9842663 | 4.956860e-01 | 0.305 | 0 | 0 |
| Erythrocytes take up oxygen and release carbon dioxide | R-HSA-1247673 | 4.956860e-01 | 0.305 | 0 | 0 |
| Repression of WNT target genes | R-HSA-4641265 | 4.956860e-01 | 0.305 | 0 | 0 |
| OAS antiviral response | R-HSA-8983711 | 4.956860e-01 | 0.305 | 0 | 0 |
| Advanced glycosylation endproduct receptor signaling | R-HSA-879415 | 4.956860e-01 | 0.305 | 0 | 0 |
| AKT phosphorylates targets in the cytosol | R-HSA-198323 | 4.956860e-01 | 0.305 | 0 | 0 |
| Rab regulation of trafficking | R-HSA-9007101 | 4.957558e-01 | 0.305 | 0 | 0 |
| Interleukin-1 signaling | R-HSA-9020702 | 4.981153e-01 | 0.303 | 0 | 0 |
| Interleukin-1 family signaling | R-HSA-446652 | 5.017940e-01 | 0.299 | 0 | 0 |
| Depurination | R-HSA-73927 | 5.020132e-01 | 0.299 | 0 | 0 |
| TCR signaling | R-HSA-202403 | 5.027591e-01 | 0.299 | 0 | 0 |
| Lagging Strand Synthesis | R-HSA-69186 | 5.076079e-01 | 0.294 | 0 | 0 |
| G-protein activation | R-HSA-202040 | 5.076079e-01 | 0.294 | 0 | 0 |
| ADP signalling through P2Y purinoceptor 12 | R-HSA-392170 | 5.076079e-01 | 0.294 | 0 | 0 |
| RNA Polymerase III Transcription Initiation | R-HSA-76046 | 5.152973e-01 | 0.288 | 0 | 0 |
| Aberrant regulation of mitotic cell cycle due to RB1 defects | R-HSA-9687139 | 5.152973e-01 | 0.288 | 0 | 0 |
| NOTCH3 Intracellular Domain Regulates Transcription | R-HSA-9013508 | 5.152973e-01 | 0.288 | 0 | 0 |
| RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression | R-HSA-9933387 | 5.152973e-01 | 0.288 | 0 | 0 |
| NTRK2 activates RAC1 | R-HSA-9032759 | 5.172631e-01 | 0.286 | 0 | 0 |
| Trafficking of myristoylated proteins to the cilium | R-HSA-5624138 | 5.172631e-01 | 0.286 | 0 | 0 |
| Resolution of AP sites via the single-nucleotide replacement pathway | R-HSA-110381 | 5.172631e-01 | 0.286 | 0 | 0 |
| Activation of C3 and C5 | R-HSA-174577 | 5.172631e-01 | 0.286 | 0 | 0 |
| Muscarinic acetylcholine receptors | R-HSA-390648 | 5.172631e-01 | 0.286 | 0 | 0 |
| Interleukin-36 pathway | R-HSA-9014826 | 5.172631e-01 | 0.286 | 0 | 0 |
| Nectin/Necl trans heterodimerization | R-HSA-420597 | 5.172631e-01 | 0.286 | 0 | 0 |
| DEx/H-box helicases activate type I IFN and inflammatory cytokines production | R-HSA-3134963 | 5.172631e-01 | 0.286 | 0 | 0 |
| Zinc efflux and compartmentalization by the SLC30 family | R-HSA-435368 | 5.172631e-01 | 0.286 | 0 | 0 |
| Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin | R-HSA-9725554 | 5.211799e-01 | 0.283 | 0 | 0 |
| Signaling by ALK | R-HSA-201556 | 5.211799e-01 | 0.283 | 0 | 0 |
| Integration of energy metabolism | R-HSA-163685 | 5.252092e-01 | 0.280 | 0 | 0 |
| Gluconeogenesis | R-HSA-70263 | 5.260554e-01 | 0.279 | 0 | 0 |
| NGF-stimulated transcription | R-HSA-9031628 | 5.260554e-01 | 0.279 | 0 | 0 |
| XBP1(S) activates chaperone genes | R-HSA-381038 | 5.275150e-01 | 0.278 | 0 | 0 |
| HDR through MMEJ (alt-NHEJ) | R-HSA-5685939 | 5.277885e-01 | 0.278 | 0 | 0 |
| CD28 dependent Vav1 pathway | R-HSA-389359 | 5.277885e-01 | 0.278 | 0 | 0 |
| Adenylate cyclase activating pathway | R-HSA-170660 | 5.277885e-01 | 0.278 | 0 | 0 |
| Frs2-mediated activation | R-HSA-170968 | 5.277885e-01 | 0.278 | 0 | 0 |
| ATF6 (ATF6-alpha) activates chaperones | R-HSA-381033 | 5.277885e-01 | 0.278 | 0 | 0 |
| DDX58/IFIH1-mediated induction of interferon-alpha/beta | R-HSA-168928 | 5.311154e-01 | 0.275 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 2 Promoter | R-HSA-76066 | 5.327273e-01 | 0.273 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in cell cycle and proliferation | R-HSA-9825892 | 5.327273e-01 | 0.273 | 0 | 0 |
| HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand | R-HSA-3371497 | 5.340548e-01 | 0.272 | 0 | 0 |
| Regulated Necrosis | R-HSA-5218859 | 5.340548e-01 | 0.272 | 0 | 0 |
| Attenuation phase | R-HSA-3371568 | 5.400229e-01 | 0.268 | 0 | 0 |
| Extension of Telomeres | R-HSA-180786 | 5.459918e-01 | 0.263 | 0 | 0 |
| Reproduction | R-HSA-1474165 | 5.538833e-01 | 0.257 | 0 | 0 |
| Transcriptional regulation of white adipocyte differentiation | R-HSA-381340 | 5.559697e-01 | 0.255 | 0 | 0 |
| CLEC7A (Dectin-1) signaling | R-HSA-5607764 | 5.559697e-01 | 0.255 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 1 Promoter | R-HSA-76061 | 5.571065e-01 | 0.254 | 0 | 0 |
| Dopamine Neurotransmitter Release Cycle | R-HSA-212676 | 5.571065e-01 | 0.254 | 0 | 0 |
| Ethanol oxidation | R-HSA-71384 | 5.571065e-01 | 0.254 | 0 | 0 |
| TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain | R-HSA-6803205 | 5.571065e-01 | 0.254 | 0 | 0 |
| Toll Like Receptor 3 (TLR3) Cascade | R-HSA-168164 | 5.581924e-01 | 0.253 | 0 | 0 |
| CRMPs in Sema3A signaling | R-HSA-399956 | 5.584744e-01 | 0.253 | 0 | 0 |
| Removal of the Flap Intermediate | R-HSA-69166 | 5.584744e-01 | 0.253 | 0 | 0 |
| Signal regulatory protein family interactions | R-HSA-391160 | 5.584744e-01 | 0.253 | 0 | 0 |
| HDL assembly | R-HSA-8963896 | 5.584744e-01 | 0.253 | 0 | 0 |
| Chromatin modifications during the maternal to zygotic transition (MZT) | R-HSA-9821002 | 5.585132e-01 | 0.253 | 0 | 0 |
| Transcriptional Regulation by VENTX | R-HSA-8853884 | 5.585132e-01 | 0.253 | 0 | 0 |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | R-HSA-381426 | 5.603325e-01 | 0.252 | 0 | 0 |
| Adipogenesis | R-HSA-9843745 | 5.643987e-01 | 0.248 | 0 | 0 |
| Nef Mediated CD8 Down-regulation | R-HSA-182218 | 5.649742e-01 | 0.248 | 0 | 0 |
| SLIT2:ROBO1 increases RHOA activity | R-HSA-8985586 | 5.649742e-01 | 0.248 | 0 | 0 |
| IkBA variant leads to EDA-ID | R-HSA-5603029 | 5.649742e-01 | 0.248 | 0 | 0 |
| PTK6 Regulates Cell Cycle | R-HSA-8849470 | 5.649742e-01 | 0.248 | 0 | 0 |
| Inhibition of Signaling by Overexpressed EGFR | R-HSA-5638303 | 5.649742e-01 | 0.248 | 0 | 0 |
| Signaling by Overexpressed Wild-Type EGFR in Cancer | R-HSA-5638302 | 5.649742e-01 | 0.248 | 0 | 0 |
| Signaling by RNF43 mutants | R-HSA-5340588 | 5.649742e-01 | 0.248 | 0 | 0 |
| Loss-of-function mutations in DBT cause MSUD2 | R-HSA-9865113 | 5.649742e-01 | 0.248 | 0 | 0 |
| Loss-of-function mutations in DLD cause MSUD3/DLDD | R-HSA-9907570 | 5.649742e-01 | 0.248 | 0 | 0 |
| Aryl hydrocarbon receptor signalling | R-HSA-8937144 | 5.649742e-01 | 0.248 | 0 | 0 |
| Pentose phosphate pathway disease | R-HSA-6791465 | 5.649742e-01 | 0.248 | 0 | 0 |
| Synthesis of dolichyl-phosphate mannose | R-HSA-162699 | 5.649742e-01 | 0.248 | 0 | 0 |
| Signalling to p38 via RIT and RIN | R-HSA-187706 | 5.649742e-01 | 0.248 | 0 | 0 |
| Negative feedback regulation of MAPK pathway | R-HSA-5674499 | 5.649742e-01 | 0.248 | 0 | 0 |
| Orexin and neuropeptides FF and QRFP bind to their respective receptors | R-HSA-389397 | 5.649742e-01 | 0.248 | 0 | 0 |
| Release of apoptotic factors from the mitochondria | R-HSA-111457 | 5.649742e-01 | 0.248 | 0 | 0 |
| CLEC7A/inflammasome pathway | R-HSA-5660668 | 5.649742e-01 | 0.248 | 0 | 0 |
| Constitutive Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant | R-HSA-2660826 | 5.649742e-01 | 0.248 | 0 | 0 |
| Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant | R-HSA-2660825 | 5.649742e-01 | 0.248 | 0 | 0 |
| SMAC, XIAP-regulated apoptotic response | R-HSA-111469 | 5.649742e-01 | 0.248 | 0 | 0 |
| Translation | R-HSA-72766 | 5.680058e-01 | 0.246 | 0 | 0 |
| Transmission across Chemical Synapses | R-HSA-112315 | 5.687557e-01 | 0.245 | 0 | 0 |
| Telomere C-strand (Lagging Strand) Synthesis | R-HSA-174417 | 5.766251e-01 | 0.239 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9683701 | 5.766251e-01 | 0.239 | 0 | 0 |
| IRS-related events triggered by IGF1R | R-HSA-2428928 | 5.767160e-01 | 0.239 | 0 | 0 |
| Formation of paraxial mesoderm | R-HSA-9793380 | 5.767160e-01 | 0.239 | 0 | 0 |
| G-protein beta:gamma signalling | R-HSA-397795 | 5.777742e-01 | 0.238 | 0 | 0 |
| HDR through Single Strand Annealing (SSA) | R-HSA-5685938 | 5.777742e-01 | 0.238 | 0 | 0 |
| Regulation of Expression and Function of Type II Classical Cadherins | R-HSA-9764260 | 5.777742e-01 | 0.238 | 0 | 0 |
| Potential therapeutics for SARS | R-HSA-9679191 | 5.779931e-01 | 0.238 | 0 | 0 |
| Transcriptional activation of mitochondrial biogenesis | R-HSA-2151201 | 5.782147e-01 | 0.238 | 0 | 0 |
| Regulation of insulin secretion | R-HSA-422356 | 5.803045e-01 | 0.236 | 0 | 0 |
| Prefoldin mediated transfer of substrate to CCT/TriC | R-HSA-389957 | 5.807047e-01 | 0.236 | 0 | 0 |
| The role of Nef in HIV-1 replication and disease pathogenesis | R-HSA-164952 | 5.807047e-01 | 0.236 | 0 | 0 |
| G beta:gamma signalling through PI3Kgamma | R-HSA-392451 | 5.807047e-01 | 0.236 | 0 | 0 |
| Response of EIF2AK1 (HRI) to heme deficiency | R-HSA-9648895 | 5.807047e-01 | 0.236 | 0 | 0 |
| Syndecan interactions | R-HSA-3000170 | 5.807047e-01 | 0.236 | 0 | 0 |
| Constitutive Signaling by AKT1 E17K in Cancer | R-HSA-5674400 | 5.807047e-01 | 0.236 | 0 | 0 |
| Growth hormone receptor signaling | R-HSA-982772 | 5.807047e-01 | 0.236 | 0 | 0 |
| Adenylate cyclase inhibitory pathway | R-HSA-170670 | 5.877100e-01 | 0.231 | 0 | 0 |
| SHC1 events in EGFR signaling | R-HSA-180336 | 5.877100e-01 | 0.231 | 0 | 0 |
| Processive synthesis on the lagging strand | R-HSA-69183 | 5.877100e-01 | 0.231 | 0 | 0 |
| Telomere C-strand synthesis initiation | R-HSA-174430 | 5.877100e-01 | 0.231 | 0 | 0 |
| RIP-mediated NFkB activation via ZBP1 | R-HSA-1810476 | 5.877100e-01 | 0.231 | 0 | 0 |
| Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | R-HSA-9673767 | 5.877100e-01 | 0.231 | 0 | 0 |
| Signaling by PDGFRA extracellular domain mutants | R-HSA-9673770 | 5.877100e-01 | 0.231 | 0 | 0 |
| Protein methylation | R-HSA-8876725 | 5.877100e-01 | 0.231 | 0 | 0 |
| Formation of the anterior neural plate | R-HSA-9823739 | 5.877100e-01 | 0.231 | 0 | 0 |
| NCAM signaling for neurite out-growth | R-HSA-375165 | 5.916990e-01 | 0.228 | 0 | 0 |
| The role of GTSE1 in G2/M progression after G2 checkpoint | R-HSA-8852276 | 5.916990e-01 | 0.228 | 0 | 0 |
| Transcriptional regulation of granulopoiesis | R-HSA-9616222 | 5.916990e-01 | 0.228 | 0 | 0 |
| Activation of GABAB receptors | R-HSA-991365 | 5.943361e-01 | 0.226 | 0 | 0 |
| Developmental Lineage of Mammary Gland Luminal Epithelial Cells | R-HSA-9927418 | 5.943361e-01 | 0.226 | 0 | 0 |
| GABA B receptor activation | R-HSA-977444 | 5.943361e-01 | 0.226 | 0 | 0 |
| RNA Polymerase I Transcription Initiation | R-HSA-73762 | 5.943361e-01 | 0.226 | 0 | 0 |
| Association of TriC/CCT with target proteins during biosynthesis | R-HSA-390471 | 5.975521e-01 | 0.224 | 0 | 0 |
| Deadenylation of mRNA | R-HSA-429947 | 6.034905e-01 | 0.219 | 0 | 0 |
| Thromboxane signalling through TP receptor | R-HSA-428930 | 6.034905e-01 | 0.219 | 0 | 0 |
| Plasma lipoprotein assembly | R-HSA-8963898 | 6.034905e-01 | 0.219 | 0 | 0 |
| ABC-family proteins mediated transport | R-HSA-382556 | 6.040486e-01 | 0.219 | 0 | 0 |
| IRE1alpha activates chaperones | R-HSA-381070 | 6.041081e-01 | 0.219 | 0 | 0 |
| Cytoprotection by HMOX1 | R-HSA-9707564 | 6.044462e-01 | 0.219 | 0 | 0 |
| Ca2+ pathway | R-HSA-4086398 | 6.051630e-01 | 0.218 | 0 | 0 |
| Activation of NIMA Kinases NEK9, NEK6, NEK7 | R-HSA-2980767 | 6.079723e-01 | 0.216 | 0 | 0 |
| STAT5 Activation | R-HSA-9645135 | 6.079723e-01 | 0.216 | 0 | 0 |
| Erythropoietin activates STAT5 | R-HSA-9027283 | 6.079723e-01 | 0.216 | 0 | 0 |
| Branched-chain ketoacid dehydrogenase kinase deficiency | R-HSA-9912481 | 6.079723e-01 | 0.216 | 0 | 0 |
| Defective SLC16A1 causes symptomatic deficiency in lactate transport (SDLT) | R-HSA-5619070 | 6.079723e-01 | 0.216 | 0 | 0 |
| Loss-of-function mutations in BCKDHA or BCKDHB cause MSUD | R-HSA-9865125 | 6.079723e-01 | 0.216 | 0 | 0 |
| Hydrolysis of LPE | R-HSA-1483152 | 6.079723e-01 | 0.216 | 0 | 0 |
| HDL clearance | R-HSA-8964011 | 6.079723e-01 | 0.216 | 0 | 0 |
| VLDL assembly | R-HSA-8866423 | 6.079723e-01 | 0.216 | 0 | 0 |
| Neurofascin interactions | R-HSA-447043 | 6.079723e-01 | 0.216 | 0 | 0 |
| Regulation of PTEN stability and activity | R-HSA-8948751 | 6.084282e-01 | 0.216 | 0 | 0 |
| MyD88-independent TLR4 cascade | R-HSA-166166 | 6.153492e-01 | 0.211 | 0 | 0 |
| TRIF (TICAM1)-mediated TLR4 signaling | R-HSA-937061 | 6.153492e-01 | 0.211 | 0 | 0 |
| Activation of SMO | R-HSA-5635838 | 6.154823e-01 | 0.211 | 0 | 0 |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | R-HSA-354194 | 6.154823e-01 | 0.211 | 0 | 0 |
| SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | R-HSA-399955 | 6.154823e-01 | 0.211 | 0 | 0 |
| WNT5A-dependent internalization of FZD4 | R-HSA-5099900 | 6.154823e-01 | 0.211 | 0 | 0 |
| Prolonged ERK activation events | R-HSA-169893 | 6.154823e-01 | 0.211 | 0 | 0 |
| Phase 4 - resting membrane potential | R-HSA-5576886 | 6.154823e-01 | 0.211 | 0 | 0 |
| Regulation of glycolysis by fructose 2,6-bisphosphate metabolism | R-HSA-9634600 | 6.154823e-01 | 0.211 | 0 | 0 |
| Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells | R-HSA-210744 | 6.154823e-01 | 0.211 | 0 | 0 |
| Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding | R-HSA-6814122 | 6.167644e-01 | 0.210 | 0 | 0 |
| eNOS activation | R-HSA-203615 | 6.167644e-01 | 0.210 | 0 | 0 |
| Signal amplification | R-HSA-392518 | 6.167644e-01 | 0.210 | 0 | 0 |
| Diseases of DNA Double-Strand Break Repair | R-HSA-9675136 | 6.167644e-01 | 0.210 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA2 loss of function | R-HSA-9701190 | 6.167644e-01 | 0.210 | 0 | 0 |
| Signaling by FGFR in disease | R-HSA-1226099 | 6.187093e-01 | 0.209 | 0 | 0 |
| IGF1R signaling cascade | R-HSA-2428924 | 6.208365e-01 | 0.207 | 0 | 0 |
| Ion transport by P-type ATPases | R-HSA-936837 | 6.208365e-01 | 0.207 | 0 | 0 |
| Base-Excision Repair, AP Site Formation | R-HSA-73929 | 6.239292e-01 | 0.205 | 0 | 0 |
| G protein gated Potassium channels | R-HSA-1296059 | 6.254412e-01 | 0.204 | 0 | 0 |
| Activation of G protein gated Potassium channels | R-HSA-1296041 | 6.254412e-01 | 0.204 | 0 | 0 |
| Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits | R-HSA-997272 | 6.254412e-01 | 0.204 | 0 | 0 |
| Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) | R-HSA-5693554 | 6.254412e-01 | 0.204 | 0 | 0 |
| VEGFR2 mediated cell proliferation | R-HSA-5218921 | 6.254412e-01 | 0.204 | 0 | 0 |
| Formation of the nephric duct | R-HSA-9830364 | 6.254412e-01 | 0.204 | 0 | 0 |
| Regulation of HSF1-mediated heat shock response | R-HSA-3371453 | 6.271393e-01 | 0.203 | 0 | 0 |
| MITF-M-regulated melanocyte development | R-HSA-9730414 | 6.277262e-01 | 0.202 | 0 | 0 |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | R-HSA-2404192 | 6.349673e-01 | 0.197 | 0 | 0 |
| Presynaptic phase of homologous DNA pairing and strand exchange | R-HSA-5693616 | 6.353930e-01 | 0.197 | 0 | 0 |
| COPI-independent Golgi-to-ER retrograde traffic | R-HSA-6811436 | 6.390719e-01 | 0.194 | 0 | 0 |
| Galactose catabolism | R-HSA-70370 | 6.417949e-01 | 0.193 | 0 | 0 |
| Acetylcholine regulates insulin secretion | R-HSA-399997 | 6.417949e-01 | 0.193 | 0 | 0 |
| Synthesis of PG | R-HSA-1483148 | 6.417949e-01 | 0.193 | 0 | 0 |
| RAB GEFs exchange GTP for GDP on RABs | R-HSA-8876198 | 6.422114e-01 | 0.192 | 0 | 0 |
| Somitogenesis | R-HSA-9824272 | 6.448832e-01 | 0.191 | 0 | 0 |
| Postmitotic nuclear pore complex (NPC) reformation | R-HSA-9615933 | 6.465418e-01 | 0.189 | 0 | 0 |
| TRP channels | R-HSA-3295583 | 6.465418e-01 | 0.189 | 0 | 0 |
| RUNX3 regulates WNT signaling | R-HSA-8951430 | 6.467227e-01 | 0.189 | 0 | 0 |
| Binding of TCF/LEF:CTNNB1 to target gene promoters | R-HSA-4411364 | 6.467227e-01 | 0.189 | 0 | 0 |
| TRIF-mediated programmed cell death | R-HSA-2562578 | 6.467227e-01 | 0.189 | 0 | 0 |
| Progressive trimming of alpha-1,2-linked mannose residues from Man9/8/7GlcNAc2 to produce Man5GlcNAc2 | R-HSA-964827 | 6.467227e-01 | 0.189 | 0 | 0 |
| Disinhibition of SNARE formation | R-HSA-114516 | 6.467227e-01 | 0.189 | 0 | 0 |
| Pre-NOTCH Processing in the Endoplasmic Reticulum | R-HSA-1912399 | 6.467227e-01 | 0.189 | 0 | 0 |
| SHOC2 M1731 mutant abolishes MRAS complex function | R-HSA-9726840 | 6.467227e-01 | 0.189 | 0 | 0 |
| PTK6 Expression | R-HSA-8849473 | 6.467227e-01 | 0.189 | 0 | 0 |
| Nef Mediated CD4 Down-regulation | R-HSA-167590 | 6.467227e-01 | 0.189 | 0 | 0 |
| Activated NTRK3 signals through PI3K | R-HSA-9603381 | 6.467227e-01 | 0.189 | 0 | 0 |
| LDL remodeling | R-HSA-8964041 | 6.467227e-01 | 0.189 | 0 | 0 |
| Insulin effects increased synthesis of Xylulose-5-Phosphate | R-HSA-163754 | 6.467227e-01 | 0.189 | 0 | 0 |
| Cation-coupled Chloride cotransporters | R-HSA-426117 | 6.467227e-01 | 0.189 | 0 | 0 |
| Uptake and function of diphtheria toxin | R-HSA-5336415 | 6.467227e-01 | 0.189 | 0 | 0 |
| POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation | R-HSA-2892245 | 6.467227e-01 | 0.189 | 0 | 0 |
| Displacement of DNA glycosylase by APEX1 | R-HSA-110357 | 6.467227e-01 | 0.189 | 0 | 0 |
| Pre-NOTCH Expression and Processing | R-HSA-1912422 | 6.478539e-01 | 0.189 | 0 | 0 |
| RNA Polymerase III Transcription | R-HSA-74158 | 6.534241e-01 | 0.185 | 0 | 0 |
| RNA Polymerase III Abortive And Retractive Initiation | R-HSA-749476 | 6.534241e-01 | 0.185 | 0 | 0 |
| HSF1 activation | R-HSA-3371511 | 6.534241e-01 | 0.185 | 0 | 0 |
| Inactivation, recovery and regulation of the phototransduction cascade | R-HSA-2514859 | 6.608241e-01 | 0.180 | 0 | 0 |
| Diseases of DNA repair | R-HSA-9675135 | 6.608241e-01 | 0.180 | 0 | 0 |
| Cytokine Signaling in Immune system | R-HSA-1280215 | 6.611145e-01 | 0.180 | 0 | 0 |
| Cellular response to chemical stress | R-HSA-9711123 | 6.660767e-01 | 0.176 | 0 | 0 |
| Chaperonin-mediated protein folding | R-HSA-390466 | 6.662404e-01 | 0.176 | 0 | 0 |
| Removal of the Flap Intermediate from the C-strand | R-HSA-174437 | 6.666650e-01 | 0.176 | 0 | 0 |
| p130Cas linkage to MAPK signaling for integrins | R-HSA-372708 | 6.666650e-01 | 0.176 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) | R-HSA-5358565 | 6.666650e-01 | 0.176 | 0 | 0 |
| Synthesis of PIPs at the late endosome membrane | R-HSA-1660517 | 6.666650e-01 | 0.176 | 0 | 0 |
| Modulation of host responses by IFN-stimulated genes | R-HSA-9909505 | 6.666650e-01 | 0.176 | 0 | 0 |
| Specification of primordial germ cells | R-HSA-9827857 | 6.666650e-01 | 0.176 | 0 | 0 |
| CD28 dependent PI3K/Akt signaling | R-HSA-389357 | 6.667841e-01 | 0.176 | 0 | 0 |
| Disassembly of the destruction complex and recruitment of AXIN to the membrane | R-HSA-4641262 | 6.667841e-01 | 0.176 | 0 | 0 |
| Insulin processing | R-HSA-264876 | 6.667841e-01 | 0.176 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in Cytochrome C Release | R-HSA-6803204 | 6.667841e-01 | 0.176 | 0 | 0 |
| Ion channel transport | R-HSA-983712 | 6.678581e-01 | 0.175 | 0 | 0 |
| TRAF6 mediated IRF7 activation | R-HSA-933541 | 6.708478e-01 | 0.173 | 0 | 0 |
| EPH-ephrin mediated repulsion of cells | R-HSA-3928665 | 6.762942e-01 | 0.170 | 0 | 0 |
| HCMV Infection | R-HSA-9609646 | 6.802149e-01 | 0.167 | 0 | 0 |
| Activated NTRK2 signals through FYN | R-HSA-9032500 | 6.816449e-01 | 0.166 | 0 | 0 |
| RSK activation | R-HSA-444257 | 6.816449e-01 | 0.166 | 0 | 0 |
| EGFR interacts with phospholipase C-gamma | R-HSA-212718 | 6.816449e-01 | 0.166 | 0 | 0 |
| Signaling by MRAS-complex mutants | R-HSA-9660537 | 6.816449e-01 | 0.166 | 0 | 0 |
| Gain-of-function MRAS complexes activate RAF signaling | R-HSA-9726842 | 6.816449e-01 | 0.166 | 0 | 0 |
| Formyl peptide receptors bind formyl peptides and many other ligands | R-HSA-444473 | 6.816449e-01 | 0.166 | 0 | 0 |
| Interleukin-9 signaling | R-HSA-8985947 | 6.816449e-01 | 0.166 | 0 | 0 |
| Co-stimulation by ICOS | R-HSA-9927354 | 6.816449e-01 | 0.166 | 0 | 0 |
| Activation of RAS in B cells | R-HSA-1169092 | 6.816449e-01 | 0.166 | 0 | 0 |
| Fructose biosynthesis | R-HSA-5652227 | 6.816449e-01 | 0.166 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of myeloid cells | R-HSA-8939246 | 6.816449e-01 | 0.166 | 0 | 0 |
| Axonal growth inhibition (RHOA activation) | R-HSA-193634 | 6.816449e-01 | 0.166 | 0 | 0 |
| Nucleotide salvage defects | R-HSA-9734207 | 6.816449e-01 | 0.166 | 0 | 0 |
| Interleukin-23 signaling | R-HSA-9020933 | 6.816449e-01 | 0.166 | 0 | 0 |
| Telomere Extension By Telomerase | R-HSA-171319 | 6.861664e-01 | 0.164 | 0 | 0 |
| Phase 0 - rapid depolarisation | R-HSA-5576892 | 6.861664e-01 | 0.164 | 0 | 0 |
| Inflammasomes | R-HSA-622312 | 6.861664e-01 | 0.164 | 0 | 0 |
| MET promotes cell motility | R-HSA-8875878 | 6.876577e-01 | 0.163 | 0 | 0 |
| Homologous DNA Pairing and Strand Exchange | R-HSA-5693579 | 6.876577e-01 | 0.163 | 0 | 0 |
| PCNA-Dependent Long Patch Base Excision Repair | R-HSA-5651801 | 6.901207e-01 | 0.161 | 0 | 0 |
| GAB1 signalosome | R-HSA-180292 | 6.901207e-01 | 0.161 | 0 | 0 |
| Serotonin Neurotransmitter Release Cycle | R-HSA-181429 | 6.901207e-01 | 0.161 | 0 | 0 |
| Mismatch Repair | R-HSA-5358508 | 6.901207e-01 | 0.161 | 0 | 0 |
| ZBP1(DAI) mediated induction of type I IFNs | R-HSA-1606322 | 6.901207e-01 | 0.161 | 0 | 0 |
| Nephron development | R-HSA-9831926 | 6.901207e-01 | 0.161 | 0 | 0 |
| Tie2 Signaling | R-HSA-210993 | 6.901207e-01 | 0.161 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition | R-HSA-9926550 | 6.901207e-01 | 0.161 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9679504 | 6.901207e-01 | 0.161 | 0 | 0 |
| Co-stimulation by CD28 | R-HSA-389356 | 6.912872e-01 | 0.160 | 0 | 0 |
| Epigenetic regulation of gene expression by MLL3 and MLL4 complexes | R-HSA-9818564 | 6.955790e-01 | 0.158 | 0 | 0 |
| Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes | R-HSA-9851695 | 6.955790e-01 | 0.158 | 0 | 0 |
| MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis | R-HSA-9841922 | 6.955790e-01 | 0.158 | 0 | 0 |
| MyD88 cascade initiated on plasma membrane | R-HSA-975871 | 6.958199e-01 | 0.158 | 0 | 0 |
| Toll Like Receptor 10 (TLR10) Cascade | R-HSA-168142 | 6.958199e-01 | 0.158 | 0 | 0 |
| Toll Like Receptor 5 (TLR5) Cascade | R-HSA-168176 | 6.958199e-01 | 0.158 | 0 | 0 |
| Developmental Cell Lineages | R-HSA-9734767 | 7.001695e-01 | 0.155 | 0 | 0 |
| Base Excision Repair | R-HSA-73884 | 7.004421e-01 | 0.155 | 0 | 0 |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | R-HSA-975138 | 7.021060e-01 | 0.154 | 0 | 0 |
| Expression of BMAL (ARNTL), CLOCK, and NPAS2 | R-HSA-9931509 | 7.038507e-01 | 0.153 | 0 | 0 |
| Glucagon-type ligand receptors | R-HSA-420092 | 7.046918e-01 | 0.152 | 0 | 0 |
| Gap junction trafficking and regulation | R-HSA-157858 | 7.057988e-01 | 0.151 | 0 | 0 |
| N-glycan trimming in the ER and Calnexin/Calreticulin cycle | R-HSA-532668 | 7.057988e-01 | 0.151 | 0 | 0 |
| GABA receptor activation | R-HSA-977443 | 7.090932e-01 | 0.149 | 0 | 0 |
| Viral Infection Pathways | R-HSA-9824446 | 7.095594e-01 | 0.149 | 0 | 0 |
| MyD88 dependent cascade initiated on endosome | R-HSA-975155 | 7.120121e-01 | 0.148 | 0 | 0 |
| Germ layer formation at gastrulation | R-HSA-9754189 | 7.121984e-01 | 0.147 | 0 | 0 |
| Signaling by FGFR2 IIIa TM | R-HSA-8851708 | 7.121984e-01 | 0.147 | 0 | 0 |
| Erythrocytes take up carbon dioxide and release oxygen | R-HSA-1237044 | 7.121984e-01 | 0.147 | 0 | 0 |
| O2/CO2 exchange in erythrocytes | R-HSA-1480926 | 7.121984e-01 | 0.147 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9694631 | 7.121984e-01 | 0.147 | 0 | 0 |
| Cargo trafficking to the periciliary membrane | R-HSA-5620920 | 7.130823e-01 | 0.147 | 0 | 0 |
| Interleukin-21 signaling | R-HSA-9020958 | 7.131167e-01 | 0.147 | 0 | 0 |
| AMPK inhibits chREBP transcriptional activation activity | R-HSA-163680 | 7.131167e-01 | 0.147 | 0 | 0 |
| MASTL Facilitates Mitotic Progression | R-HSA-2465910 | 7.131167e-01 | 0.147 | 0 | 0 |
| Calcineurin activates NFAT | R-HSA-2025928 | 7.131167e-01 | 0.147 | 0 | 0 |
| Activation of the AP-1 family of transcription factors | R-HSA-450341 | 7.131167e-01 | 0.147 | 0 | 0 |
| APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway | R-HSA-5649702 | 7.131167e-01 | 0.147 | 0 | 0 |
| p75NTR regulates axonogenesis | R-HSA-193697 | 7.131167e-01 | 0.147 | 0 | 0 |
| Estrogen-stimulated signaling through PRKCZ | R-HSA-9634635 | 7.131167e-01 | 0.147 | 0 | 0 |
| Regulation of commissural axon pathfinding by SLIT and ROBO | R-HSA-428542 | 7.131167e-01 | 0.147 | 0 | 0 |
| ARMS-mediated activation | R-HSA-170984 | 7.131167e-01 | 0.147 | 0 | 0 |
| Regulation of signaling by NODAL | R-HSA-1433617 | 7.131167e-01 | 0.147 | 0 | 0 |
| WNT mediated activation of DVL | R-HSA-201688 | 7.131167e-01 | 0.147 | 0 | 0 |
| Regulation of NPAS4 gene transcription | R-HSA-9768777 | 7.131167e-01 | 0.147 | 0 | 0 |
| Regulated proteolysis of p75NTR | R-HSA-193692 | 7.131167e-01 | 0.147 | 0 | 0 |
| NOTCH4 Activation and Transmission of Signal to the Nucleus | R-HSA-9013700 | 7.131167e-01 | 0.147 | 0 | 0 |
| Interleukin-1 processing | R-HSA-448706 | 7.131167e-01 | 0.147 | 0 | 0 |
| Lysosomal oligosaccharide catabolism | R-HSA-8853383 | 7.131167e-01 | 0.147 | 0 | 0 |
| Respiratory syncytial virus genome replication | R-HSA-9834752 | 7.131167e-01 | 0.147 | 0 | 0 |
| Caspase activation via Dependence Receptors in the absence of ligand | R-HSA-418889 | 7.131167e-01 | 0.147 | 0 | 0 |
| GP1b-IX-V activation signalling | R-HSA-430116 | 7.131167e-01 | 0.147 | 0 | 0 |
| PI3K/AKT Signaling in Cancer | R-HSA-2219528 | 7.175626e-01 | 0.144 | 0 | 0 |
| Hemostasis | R-HSA-109582 | 7.176205e-01 | 0.144 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation by EBF2 | R-HSA-9844594 | 7.194269e-01 | 0.143 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation | R-HSA-9843743 | 7.194269e-01 | 0.143 | 0 | 0 |
| RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | R-HSA-73779 | 7.194269e-01 | 0.143 | 0 | 0 |
| Interleukin-2 family signaling | R-HSA-451927 | 7.194269e-01 | 0.143 | 0 | 0 |
| Generation of second messenger molecules | R-HSA-202433 | 7.194269e-01 | 0.143 | 0 | 0 |
| Azathioprine ADME | R-HSA-9748787 | 7.198268e-01 | 0.143 | 0 | 0 |
| DAP12 signaling | R-HSA-2424491 | 7.223684e-01 | 0.141 | 0 | 0 |
| Thrombin signalling through proteinase activated receptors (PARs) | R-HSA-456926 | 7.223684e-01 | 0.141 | 0 | 0 |
| Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | R-HSA-1474151 | 7.223684e-01 | 0.141 | 0 | 0 |
| Signaling by NTRK1 (TRKA) | R-HSA-187037 | 7.229542e-01 | 0.141 | 0 | 0 |
| trans-Golgi Network Vesicle Budding | R-HSA-199992 | 7.249388e-01 | 0.140 | 0 | 0 |
| Neuronal System | R-HSA-112316 | 7.283203e-01 | 0.138 | 0 | 0 |
| Protein folding | R-HSA-391251 | 7.323381e-01 | 0.135 | 0 | 0 |
| Co-inhibition by CTLA4 | R-HSA-389513 | 7.329415e-01 | 0.135 | 0 | 0 |
| Protein hydroxylation | R-HSA-9629569 | 7.329415e-01 | 0.135 | 0 | 0 |
| The phototransduction cascade | R-HSA-2514856 | 7.333709e-01 | 0.135 | 0 | 0 |
| Heme signaling | R-HSA-9707616 | 7.343457e-01 | 0.134 | 0 | 0 |
| Resolution of Abasic Sites (AP sites) | R-HSA-73933 | 7.343889e-01 | 0.134 | 0 | 0 |
| PI Metabolism | R-HSA-1483255 | 7.363572e-01 | 0.133 | 0 | 0 |
| Diseases of carbohydrate metabolism | R-HSA-5663084 | 7.364554e-01 | 0.133 | 0 | 0 |
| Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | R-HSA-389958 | 7.392082e-01 | 0.131 | 0 | 0 |
| Respiratory syncytial virus (RSV) attachment and entry | R-HSA-9820960 | 7.392082e-01 | 0.131 | 0 | 0 |
| Downstream signal transduction | R-HSA-186763 | 7.392082e-01 | 0.131 | 0 | 0 |
| Negative regulation of the PI3K/AKT network | R-HSA-199418 | 7.403123e-01 | 0.131 | 0 | 0 |
| Erythropoietin activates Phospholipase C gamma (PLCG) | R-HSA-9027277 | 7.414791e-01 | 0.130 | 0 | 0 |
| DNA replication initiation | R-HSA-68952 | 7.414791e-01 | 0.130 | 0 | 0 |
| Metabolism of serotonin | R-HSA-380612 | 7.414791e-01 | 0.130 | 0 | 0 |
| WNT5A-dependent internalization of FZD2, FZD5 and ROR2 | R-HSA-5140745 | 7.414791e-01 | 0.130 | 0 | 0 |
| Activation of PPARGC1A (PGC-1alpha) by phosphorylation | R-HSA-2151209 | 7.414791e-01 | 0.130 | 0 | 0 |
| Ion influx/efflux at host-pathogen interface | R-HSA-6803544 | 7.414791e-01 | 0.130 | 0 | 0 |
| PAOs oxidise polyamines to amines | R-HSA-141334 | 7.414791e-01 | 0.130 | 0 | 0 |
| Cross-presentation of particulate exogenous antigens (phagosomes) | R-HSA-1236973 | 7.414791e-01 | 0.130 | 0 | 0 |
| Receptor Mediated Mitophagy | R-HSA-8934903 | 7.414791e-01 | 0.130 | 0 | 0 |
| CASP4 inflammasome assembly | R-HSA-9948001 | 7.414791e-01 | 0.130 | 0 | 0 |
| Assembly and release of respiratory syncytial virus (RSV) virions | R-HSA-9820962 | 7.414791e-01 | 0.130 | 0 | 0 |
| Unfolded Protein Response (UPR) | R-HSA-381119 | 7.447766e-01 | 0.128 | 0 | 0 |
| Activation of gene expression by SREBF (SREBP) | R-HSA-2426168 | 7.463730e-01 | 0.127 | 0 | 0 |
| RNA Polymerase II HIV Promoter Escape | R-HSA-167162 | 7.487416e-01 | 0.126 | 0 | 0 |
| HIV Transcription Initiation | R-HSA-167161 | 7.487416e-01 | 0.126 | 0 | 0 |
| RNA Polymerase II Transcription Initiation | R-HSA-75953 | 7.487416e-01 | 0.126 | 0 | 0 |
| Toll Like Receptor 7/8 (TLR7/8) Cascade | R-HSA-168181 | 7.495140e-01 | 0.125 | 0 | 0 |
| Constitutive Signaling by Aberrant PI3K in Cancer | R-HSA-2219530 | 7.522907e-01 | 0.124 | 0 | 0 |
| Antigen processing: Ubiquitination & Proteasome degradation | R-HSA-983168 | 7.550112e-01 | 0.122 | 0 | 0 |
| Inwardly rectifying K+ channels | R-HSA-1296065 | 7.552267e-01 | 0.122 | 0 | 0 |
| Insulin receptor signalling cascade | R-HSA-74751 | 7.580019e-01 | 0.120 | 0 | 0 |
| Maternal to zygotic transition (MZT) | R-HSA-9816359 | 7.616273e-01 | 0.118 | 0 | 0 |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | R-HSA-6811558 | 7.616273e-01 | 0.118 | 0 | 0 |
| Transport to the Golgi and subsequent modification | R-HSA-948021 | 7.632659e-01 | 0.117 | 0 | 0 |
| C-type lectin receptors (CLRs) | R-HSA-5621481 | 7.647997e-01 | 0.116 | 0 | 0 |
| NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 | R-HSA-933543 | 7.670389e-01 | 0.115 | 0 | 0 |
| Interleukin-2 signaling | R-HSA-9020558 | 7.670389e-01 | 0.115 | 0 | 0 |
| vRNP Assembly | R-HSA-192905 | 7.670389e-01 | 0.115 | 0 | 0 |
| Chylomicron assembly | R-HSA-8963888 | 7.670389e-01 | 0.115 | 0 | 0 |
| RHOBTB3 ATPase cycle | R-HSA-9706019 | 7.670389e-01 | 0.115 | 0 | 0 |
| Synthesis of PI | R-HSA-1483226 | 7.670389e-01 | 0.115 | 0 | 0 |
| Activated NTRK3 signals through RAS | R-HSA-9034864 | 7.670389e-01 | 0.115 | 0 | 0 |
| SARS-CoV-2 modulates autophagy | R-HSA-9754560 | 7.670389e-01 | 0.115 | 0 | 0 |
| CD163 mediating an anti-inflammatory response | R-HSA-9662834 | 7.670389e-01 | 0.115 | 0 | 0 |
| Nuclear RNA decay | R-HSA-9930044 | 7.704421e-01 | 0.113 | 0 | 0 |
| Signaling by NTRK3 (TRKC) | R-HSA-9034015 | 7.706191e-01 | 0.113 | 0 | 0 |
| Ribavirin ADME | R-HSA-9755088 | 7.706191e-01 | 0.113 | 0 | 0 |
| Toll Like Receptor 9 (TLR9) Cascade | R-HSA-168138 | 7.753790e-01 | 0.110 | 0 | 0 |
| RNA Polymerase II Promoter Escape | R-HSA-73776 | 7.756499e-01 | 0.110 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9694635 | 7.791210e-01 | 0.108 | 0 | 0 |
| Pyruvate metabolism | R-HSA-70268 | 7.792973e-01 | 0.108 | 0 | 0 |
| Fcgamma receptor (FCGR) dependent phagocytosis | R-HSA-2029480 | 7.853225e-01 | 0.105 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 3 Promoter | R-HSA-76071 | 7.876593e-01 | 0.104 | 0 | 0 |
| Regulation of IFNA/IFNB signaling | R-HSA-912694 | 7.876593e-01 | 0.104 | 0 | 0 |
| Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants | R-HSA-9670439 | 7.876593e-01 | 0.104 | 0 | 0 |
| Signaling by KIT in disease | R-HSA-9669938 | 7.876593e-01 | 0.104 | 0 | 0 |
| Fructose metabolism | R-HSA-5652084 | 7.876593e-01 | 0.104 | 0 | 0 |
| LDL clearance | R-HSA-8964038 | 7.876593e-01 | 0.104 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in lysosome biogenesis and autophagy | R-HSA-9857377 | 7.876593e-01 | 0.104 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9694676 | 7.876593e-01 | 0.104 | 0 | 0 |
| Proteasome assembly | R-HSA-9907900 | 7.882252e-01 | 0.103 | 0 | 0 |
| Amine ligand-binding receptors | R-HSA-375280 | 7.882252e-01 | 0.103 | 0 | 0 |
| Gap junction trafficking | R-HSA-190828 | 7.882252e-01 | 0.103 | 0 | 0 |
| Transcriptional regulation by RUNX3 | R-HSA-8878159 | 7.890305e-01 | 0.103 | 0 | 0 |
| Endosomal/Vacuolar pathway | R-HSA-1236977 | 7.900730e-01 | 0.102 | 0 | 0 |
| Proton-coupled monocarboxylate transport | R-HSA-433692 | 7.900730e-01 | 0.102 | 0 | 0 |
| Reduction of cytosolic Ca++ levels | R-HSA-418359 | 7.900730e-01 | 0.102 | 0 | 0 |
| Inhibition of replication initiation of damaged DNA by RB1/E2F1 | R-HSA-113501 | 7.900730e-01 | 0.102 | 0 | 0 |
| Activated NTRK2 signals through RAS | R-HSA-9026519 | 7.900730e-01 | 0.102 | 0 | 0 |
| Sodium/Calcium exchangers | R-HSA-425561 | 7.900730e-01 | 0.102 | 0 | 0 |
| Ion homeostasis | R-HSA-5578775 | 7.939296e-01 | 0.100 | 0 | 0 |
| ER-Phagosome pathway | R-HSA-1236974 | 7.975548e-01 | 0.098 | 0 | 0 |
| Regulation of cholesterol biosynthesis by SREBP (SREBF) | R-HSA-1655829 | 7.984358e-01 | 0.098 | 0 | 0 |
| NPAS4 regulates expression of target genes | R-HSA-9768919 | 7.985484e-01 | 0.098 | 0 | 0 |
| Mitochondrial biogenesis | R-HSA-1592230 | 7.993019e-01 | 0.097 | 0 | 0 |
| RNA Polymerase II Transcription Initiation And Promoter Clearance | R-HSA-76042 | 8.002303e-01 | 0.097 | 0 | 0 |
| Interleukin-20 family signaling | R-HSA-8854691 | 8.035738e-01 | 0.095 | 0 | 0 |
| IRS-mediated signalling | R-HSA-112399 | 8.046473e-01 | 0.094 | 0 | 0 |
| Synthesis of PA | R-HSA-1483166 | 8.046473e-01 | 0.094 | 0 | 0 |
| HCMV Late Events | R-HSA-9610379 | 8.063593e-01 | 0.093 | 0 | 0 |
| NOTCH2 intracellular domain regulates transcription | R-HSA-2197563 | 8.108308e-01 | 0.091 | 0 | 0 |
| Scavenging by Class F Receptors | R-HSA-3000484 | 8.108308e-01 | 0.091 | 0 | 0 |
| MET activates RAS signaling | R-HSA-8851805 | 8.108308e-01 | 0.091 | 0 | 0 |
| Trafficking and processing of endosomal TLR | R-HSA-1679131 | 8.108308e-01 | 0.091 | 0 | 0 |
| Synthesis of GDP-mannose | R-HSA-446205 | 8.108308e-01 | 0.091 | 0 | 0 |
| Activated NTRK2 signals through FRS2 and FRS3 | R-HSA-9028731 | 8.108308e-01 | 0.091 | 0 | 0 |
| Reversal of alkylation damage by DNA dioxygenases | R-HSA-73943 | 8.108308e-01 | 0.091 | 0 | 0 |
| Signalling to ERKs | R-HSA-187687 | 8.114859e-01 | 0.091 | 0 | 0 |
| Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells | R-HSA-9860927 | 8.114859e-01 | 0.091 | 0 | 0 |
| NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | R-HSA-9029569 | 8.149182e-01 | 0.089 | 0 | 0 |
| Signaling by NTRKs | R-HSA-166520 | 8.175208e-01 | 0.088 | 0 | 0 |
| TRAF6 mediated NF-kB activation | R-HSA-933542 | 8.184186e-01 | 0.087 | 0 | 0 |
| Translocation of ZAP-70 to Immunological synapse | R-HSA-202430 | 8.184186e-01 | 0.087 | 0 | 0 |
| Signaling by FLT3 ITD and TKD mutants | R-HSA-9703648 | 8.184186e-01 | 0.087 | 0 | 0 |
| Replacement of protamines by nucleosomes in the male pronucleus | R-HSA-9821993 | 8.184186e-01 | 0.087 | 0 | 0 |
| Interferon gamma signaling | R-HSA-877300 | 8.190726e-01 | 0.087 | 0 | 0 |
| GPVI-mediated activation cascade | R-HSA-114604 | 8.237131e-01 | 0.084 | 0 | 0 |
| G1/S-Specific Transcription | R-HSA-69205 | 8.237131e-01 | 0.084 | 0 | 0 |
| Gastrulation | R-HSA-9758941 | 8.238662e-01 | 0.084 | 0 | 0 |
| Peroxisomal protein import | R-HSA-9033241 | 8.247517e-01 | 0.084 | 0 | 0 |
| Triglyceride metabolism | R-HSA-8979227 | 8.247517e-01 | 0.084 | 0 | 0 |
| tRNA processing | R-HSA-72306 | 8.266793e-01 | 0.083 | 0 | 0 |
| Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) | R-HSA-9661069 | 8.295372e-01 | 0.081 | 0 | 0 |
| Microbial factors inhibit CASP4 activity | R-HSA-9956593 | 8.295372e-01 | 0.081 | 0 | 0 |
| Processing of SMDT1 | R-HSA-8949664 | 8.295372e-01 | 0.081 | 0 | 0 |
| Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | R-HSA-75035 | 8.295372e-01 | 0.081 | 0 | 0 |
| Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects | R-HSA-9659787 | 8.295372e-01 | 0.081 | 0 | 0 |
| Platelet Adhesion to exposed collagen | R-HSA-75892 | 8.295372e-01 | 0.081 | 0 | 0 |
| Reversible hydration of carbon dioxide | R-HSA-1475029 | 8.295372e-01 | 0.081 | 0 | 0 |
| Formation of axial mesoderm | R-HSA-9796292 | 8.295372e-01 | 0.081 | 0 | 0 |
| Diseases of nucleotide metabolism | R-HSA-9735804 | 8.295372e-01 | 0.081 | 0 | 0 |
| rRNA modification in the mitochondrion | R-HSA-6793080 | 8.295372e-01 | 0.081 | 0 | 0 |
| Interconversion of polyamines | R-HSA-351200 | 8.295372e-01 | 0.081 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9683610 | 8.295372e-01 | 0.081 | 0 | 0 |
| Regulation of TP53 Activity through Association with Co-factors | R-HSA-6804759 | 8.295372e-01 | 0.081 | 0 | 0 |
| Interleukin-6 signaling | R-HSA-1059683 | 8.295372e-01 | 0.081 | 0 | 0 |
| Replication of the SARS-CoV-1 genome | R-HSA-9682706 | 8.295372e-01 | 0.081 | 0 | 0 |
| TGFBR3 expression | R-HSA-9839394 | 8.322495e-01 | 0.080 | 0 | 0 |
| Acyl chain remodelling of PS | R-HSA-1482801 | 8.322495e-01 | 0.080 | 0 | 0 |
| MicroRNA (miRNA) biogenesis | R-HSA-203927 | 8.322495e-01 | 0.080 | 0 | 0 |
| PIWI-interacting RNA (piRNA) biogenesis | R-HSA-5601884 | 8.322495e-01 | 0.080 | 0 | 0 |
| TNFR2 non-canonical NF-kB pathway | R-HSA-5668541 | 8.331668e-01 | 0.079 | 0 | 0 |
| tRNA Aminoacylation | R-HSA-379724 | 8.341578e-01 | 0.079 | 0 | 0 |
| Nuclear Events (kinase and transcription factor activation) | R-HSA-198725 | 8.371359e-01 | 0.077 | 0 | 0 |
| MECP2 regulates neuronal receptors and channels | R-HSA-9022699 | 8.451218e-01 | 0.073 | 0 | 0 |
| Phosphorylated BMAL1:CLOCK (ARNTL:CLOCK) activates expression of core clock genes | R-HSA-9931510 | 8.451218e-01 | 0.073 | 0 | 0 |
| Diseases of branched-chain amino acid catabolism | R-HSA-9865118 | 8.451218e-01 | 0.073 | 0 | 0 |
| Resolution of AP sites via the multiple-nucleotide patch replacement pathway | R-HSA-110373 | 8.451218e-01 | 0.073 | 0 | 0 |
| Synthesis of IP2, IP, and Ins in the cytosol | R-HSA-1855183 | 8.451218e-01 | 0.073 | 0 | 0 |
| Caspase activation via extrinsic apoptotic signalling pathway | R-HSA-5357769 | 8.451218e-01 | 0.073 | 0 | 0 |
| SLC-mediated transport of inorganic anions | R-HSA-9958790 | 8.461414e-01 | 0.073 | 0 | 0 |
| BCKDH synthesizes BCAA-CoA from KIC, KMVA, KIV | R-HSA-9859138 | 8.463947e-01 | 0.072 | 0 | 0 |
| Retrograde neurotrophin signalling | R-HSA-177504 | 8.463947e-01 | 0.072 | 0 | 0 |
| CLEC7A (Dectin-1) induces NFAT activation | R-HSA-5607763 | 8.463947e-01 | 0.072 | 0 | 0 |
| N-glycan trimming and elongation in the cis-Golgi | R-HSA-964739 | 8.463947e-01 | 0.072 | 0 | 0 |
| Transport of fatty acids | R-HSA-804914 | 8.463947e-01 | 0.072 | 0 | 0 |
| Hydrolysis of LPC | R-HSA-1483115 | 8.463947e-01 | 0.072 | 0 | 0 |
| Formation of the active cofactor, UDP-glucuronate | R-HSA-173599 | 8.463947e-01 | 0.072 | 0 | 0 |
| Physiological factors | R-HSA-5578768 | 8.463947e-01 | 0.072 | 0 | 0 |
| Non-canonical inflammasome activation | R-HSA-9686114 | 8.463947e-01 | 0.072 | 0 | 0 |
| Zinc transporters | R-HSA-435354 | 8.463947e-01 | 0.072 | 0 | 0 |
| P2Y receptors | R-HSA-417957 | 8.463947e-01 | 0.072 | 0 | 0 |
| Signaling by FGFR4 in disease | R-HSA-5655291 | 8.463947e-01 | 0.072 | 0 | 0 |
| SARS-CoV-1 Genome Replication and Transcription | R-HSA-9679514 | 8.463947e-01 | 0.072 | 0 | 0 |
| PI3K Cascade | R-HSA-109704 | 8.521999e-01 | 0.069 | 0 | 0 |
| Regulation of PD-L1(CD274) Post-translational modification | R-HSA-9909615 | 8.559657e-01 | 0.068 | 0 | 0 |
| Respiratory syncytial virus (RSV) genome replication, transcription and translation | R-HSA-9820965 | 8.563962e-01 | 0.067 | 0 | 0 |
| Processive synthesis on the C-strand of the telomere | R-HSA-174414 | 8.570898e-01 | 0.067 | 0 | 0 |
| RNA Polymerase I Transcription Termination | R-HSA-73863 | 8.570898e-01 | 0.067 | 0 | 0 |
| Phosphorylation of CD3 and TCR zeta chains | R-HSA-202427 | 8.570898e-01 | 0.067 | 0 | 0 |
| Signaling by NTRK2 (TRKB) | R-HSA-9006115 | 8.570898e-01 | 0.067 | 0 | 0 |
| Mitochondrial unfolded protein response (UPRmt) | R-HSA-9841251 | 8.570898e-01 | 0.067 | 0 | 0 |
| Maturation of hRSV A proteins | R-HSA-9828806 | 8.570898e-01 | 0.067 | 0 | 0 |
| TP53 Regulates Transcription of Cell Death Genes | R-HSA-5633008 | 8.608397e-01 | 0.065 | 0 | 0 |
| Lysosphingolipid and LPA receptors | R-HSA-419408 | 8.615861e-01 | 0.065 | 0 | 0 |
| p38MAPK events | R-HSA-171007 | 8.615861e-01 | 0.065 | 0 | 0 |
| Competing endogenous RNAs (ceRNAs) regulate PTEN translation | R-HSA-8948700 | 8.615861e-01 | 0.065 | 0 | 0 |
| Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA | R-HSA-450513 | 8.615861e-01 | 0.065 | 0 | 0 |
| FASTK family proteins regulate processing and stability of mitochondrial RNAs | R-HSA-9837092 | 8.615861e-01 | 0.065 | 0 | 0 |
| Transport and metabolism of PAPS | R-HSA-174362 | 8.615861e-01 | 0.065 | 0 | 0 |
| STAT3 nuclear events downstream of ALK signaling | R-HSA-9701898 | 8.615861e-01 | 0.065 | 0 | 0 |
| Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA | R-HSA-450385 | 8.615861e-01 | 0.065 | 0 | 0 |
| SARS-CoV-1 targets host intracellular signalling and regulatory pathways | R-HSA-9735871 | 8.615861e-01 | 0.065 | 0 | 0 |
| DNA Damage Reversal | R-HSA-73942 | 8.615861e-01 | 0.065 | 0 | 0 |
| Activation of AMPK downstream of NMDARs | R-HSA-9619483 | 8.682065e-01 | 0.061 | 0 | 0 |
| Insulin receptor recycling | R-HSA-77387 | 8.682065e-01 | 0.061 | 0 | 0 |
| Transcriptional Regulation by NPAS4 | R-HSA-9634815 | 8.695238e-01 | 0.061 | 0 | 0 |
| Antigen processing-Cross presentation | R-HSA-1236975 | 8.750251e-01 | 0.058 | 0 | 0 |
| Class I peroxisomal membrane protein import | R-HSA-9603798 | 8.752758e-01 | 0.058 | 0 | 0 |
| Atorvastatin ADME | R-HSA-9754706 | 8.752758e-01 | 0.058 | 0 | 0 |
| Activation of the phototransduction cascade | R-HSA-2485179 | 8.752758e-01 | 0.058 | 0 | 0 |
| Fructose catabolism | R-HSA-70350 | 8.752758e-01 | 0.058 | 0 | 0 |
| Killing mechanisms | R-HSA-9664420 | 8.752758e-01 | 0.058 | 0 | 0 |
| WNT5:FZD7-mediated leishmania damping | R-HSA-9673324 | 8.752758e-01 | 0.058 | 0 | 0 |
| Caspase activation via Death Receptors in the presence of ligand | R-HSA-140534 | 8.752758e-01 | 0.058 | 0 | 0 |
| Amino acids regulate mTORC1 | R-HSA-9639288 | 8.775105e-01 | 0.057 | 0 | 0 |
| Generic Transcription Pathway | R-HSA-212436 | 8.782592e-01 | 0.056 | 0 | 0 |
| MAPK targets/ Nuclear events mediated by MAP kinases | R-HSA-450282 | 8.785231e-01 | 0.056 | 0 | 0 |
| ABC transporter disorders | R-HSA-5619084 | 8.816182e-01 | 0.055 | 0 | 0 |
| MyD88:MAL(TIRAP) cascade initiated on plasma membrane | R-HSA-166058 | 8.835291e-01 | 0.054 | 0 | 0 |
| Toll Like Receptor TLR6:TLR2 Cascade | R-HSA-168188 | 8.835291e-01 | 0.054 | 0 | 0 |
| SLC-mediated transport of neurotransmitters | R-HSA-442660 | 8.836483e-01 | 0.054 | 0 | 0 |
| Antigen processing: Ub, ATP-independent proteasomal degradation | R-HSA-9912633 | 8.876123e-01 | 0.052 | 0 | 0 |
| Heme assimilation | R-HSA-9927020 | 8.876123e-01 | 0.052 | 0 | 0 |
| STAT5 activation downstream of FLT3 ITD mutants | R-HSA-9702518 | 8.876123e-01 | 0.052 | 0 | 0 |
| Passive transport by Aquaporins | R-HSA-432047 | 8.876123e-01 | 0.052 | 0 | 0 |
| Biosynthesis of maresin-like SPMs | R-HSA-9027307 | 8.876123e-01 | 0.052 | 0 | 0 |
| Coenzyme A biosynthesis | R-HSA-196783 | 8.876123e-01 | 0.052 | 0 | 0 |
| tRNA modification in the mitochondrion | R-HSA-6787450 | 8.876123e-01 | 0.052 | 0 | 0 |
| Neurotransmitter clearance | R-HSA-112311 | 8.880891e-01 | 0.052 | 0 | 0 |
| Class B/2 (Secretin family receptors) | R-HSA-373080 | 8.882832e-01 | 0.051 | 0 | 0 |
| Cytosolic tRNA aminoacylation | R-HSA-379716 | 8.916507e-01 | 0.050 | 0 | 0 |
| Toll Like Receptor TLR1:TLR2 Cascade | R-HSA-168179 | 8.983320e-01 | 0.047 | 0 | 0 |
| Toll Like Receptor 2 (TLR2) Cascade | R-HSA-181438 | 8.983320e-01 | 0.047 | 0 | 0 |
| Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters | R-HSA-164938 | 8.987293e-01 | 0.046 | 0 | 0 |
| Regulation of NPAS4 gene expression | R-HSA-9768759 | 8.987293e-01 | 0.046 | 0 | 0 |
| Sulfide oxidation to sulfate | R-HSA-1614517 | 8.987293e-01 | 0.046 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) | R-HSA-5358606 | 8.987293e-01 | 0.046 | 0 | 0 |
| Uptake and function of anthrax toxins | R-HSA-5210891 | 8.987293e-01 | 0.046 | 0 | 0 |
| Replication of the SARS-CoV-2 genome | R-HSA-9694686 | 8.987293e-01 | 0.046 | 0 | 0 |
| Signaling by Insulin receptor | R-HSA-74752 | 9.045797e-01 | 0.044 | 0 | 0 |
| Late SARS-CoV-2 Infection Events | R-HSA-9772573 | 9.045797e-01 | 0.044 | 0 | 0 |
| Developmental Lineage of Multipotent Pancreatic Progenitor Cells | R-HSA-9937080 | 9.051573e-01 | 0.043 | 0 | 0 |
| Regulation of ornithine decarboxylase (ODC) | R-HSA-350562 | 9.051573e-01 | 0.043 | 0 | 0 |
| DAP12 interactions | R-HSA-2172127 | 9.061891e-01 | 0.043 | 0 | 0 |
| FOXO-mediated transcription of cell death genes | R-HSA-9614657 | 9.087472e-01 | 0.042 | 0 | 0 |
| Synaptic adhesion-like molecules | R-HSA-8849932 | 9.087472e-01 | 0.042 | 0 | 0 |
| Apoptotic factor-mediated response | R-HSA-111471 | 9.087472e-01 | 0.042 | 0 | 0 |
| Nucleotide-like (purinergic) receptors | R-HSA-418038 | 9.087472e-01 | 0.042 | 0 | 0 |
| Integrin signaling | R-HSA-354192 | 9.127483e-01 | 0.040 | 0 | 0 |
| Diseases associated with glycosylation precursor biosynthesis | R-HSA-5609975 | 9.127483e-01 | 0.040 | 0 | 0 |
| Cardiogenesis | R-HSA-9733709 | 9.127483e-01 | 0.040 | 0 | 0 |
| Assembly of collagen fibrils and other multimeric structures | R-HSA-2022090 | 9.170530e-01 | 0.038 | 0 | 0 |
| Pre-NOTCH Processing in Golgi | R-HSA-1912420 | 9.177746e-01 | 0.037 | 0 | 0 |
| Strand-asynchronous mitochondrial DNA replication | R-HSA-9913635 | 9.177746e-01 | 0.037 | 0 | 0 |
| mRNA decay by 3' to 5' exoribonuclease | R-HSA-429958 | 9.177746e-01 | 0.037 | 0 | 0 |
| Mechanical load activates signaling by PIEZO1 and integrins in osteocytes | R-HSA-9856532 | 9.177746e-01 | 0.037 | 0 | 0 |
| Amine Oxidase reactions | R-HSA-140179 | 9.177746e-01 | 0.037 | 0 | 0 |
| Transport of nucleotide sugars | R-HSA-727802 | 9.177746e-01 | 0.037 | 0 | 0 |
| SARS-CoV-2 Genome Replication and Transcription | R-HSA-9694682 | 9.177746e-01 | 0.037 | 0 | 0 |
| NFE2L2 regulating anti-oxidant/detoxification enzymes | R-HSA-9818027 | 9.197662e-01 | 0.036 | 0 | 0 |
| Acyl chain remodelling of PC | R-HSA-1482788 | 9.197662e-01 | 0.036 | 0 | 0 |
| Effects of PIP2 hydrolysis | R-HSA-114508 | 9.197662e-01 | 0.036 | 0 | 0 |
| EGR2 and SOX10-mediated initiation of Schwann cell myelination | R-HSA-9619665 | 9.197662e-01 | 0.036 | 0 | 0 |
| Glutamate and glutamine metabolism | R-HSA-8964539 | 9.197662e-01 | 0.036 | 0 | 0 |
| Sphingolipid de novo biosynthesis | R-HSA-1660661 | 9.224024e-01 | 0.035 | 0 | 0 |
| Platelet homeostasis | R-HSA-418346 | 9.225565e-01 | 0.035 | 0 | 0 |
| Toll Like Receptor 4 (TLR4) Cascade | R-HSA-166016 | 9.254279e-01 | 0.034 | 0 | 0 |
| Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | R-HSA-9609523 | 9.259095e-01 | 0.033 | 0 | 0 |
| Signaling by NODAL | R-HSA-1181150 | 9.259095e-01 | 0.033 | 0 | 0 |
| Acyl chain remodelling of PI | R-HSA-1482922 | 9.259095e-01 | 0.033 | 0 | 0 |
| Formation of definitive endoderm | R-HSA-9823730 | 9.259095e-01 | 0.033 | 0 | 0 |
| Pregnenolone biosynthesis | R-HSA-196108 | 9.259095e-01 | 0.033 | 0 | 0 |
| Developmental Lineage of Mammary Gland Alveolar Cells | R-HSA-9927426 | 9.262501e-01 | 0.033 | 0 | 0 |
| Signaling by TGFB family members | R-HSA-9006936 | 9.268272e-01 | 0.033 | 0 | 0 |
| Potassium Channels | R-HSA-1296071 | 9.272295e-01 | 0.033 | 0 | 0 |
| Collagen degradation | R-HSA-1442490 | 9.274398e-01 | 0.033 | 0 | 0 |
| Mitochondrial protein import | R-HSA-1268020 | 9.321804e-01 | 0.031 | 0 | 0 |
| Transferrin endocytosis and recycling | R-HSA-917977 | 9.322369e-01 | 0.030 | 0 | 0 |
| Acyl chain remodelling of PE | R-HSA-1482839 | 9.322369e-01 | 0.030 | 0 | 0 |
| PERK regulates gene expression | R-HSA-381042 | 9.322369e-01 | 0.030 | 0 | 0 |
| Acetylcholine Neurotransmitter Release Cycle | R-HSA-264642 | 9.332400e-01 | 0.030 | 0 | 0 |
| Signalling to RAS | R-HSA-167044 | 9.332400e-01 | 0.030 | 0 | 0 |
| SHC-mediated cascade:FGFR3 | R-HSA-5654704 | 9.332400e-01 | 0.030 | 0 | 0 |
| ERK/MAPK targets | R-HSA-198753 | 9.332400e-01 | 0.030 | 0 | 0 |
| Zygotic genome activation (ZGA) | R-HSA-9819196 | 9.332400e-01 | 0.030 | 0 | 0 |
| Transcriptional regulation by RUNX2 | R-HSA-8878166 | 9.335092e-01 | 0.030 | 0 | 0 |
| Developmental Biology | R-HSA-1266738 | 9.357655e-01 | 0.029 | 0 | 0 |
| Regulation of actin dynamics for phagocytic cup formation | R-HSA-2029482 | 9.371807e-01 | 0.028 | 0 | 0 |
| Glycosphingolipid transport | R-HSA-9845576 | 9.377615e-01 | 0.028 | 0 | 0 |
| FGFR2 mutant receptor activation | R-HSA-1839126 | 9.377615e-01 | 0.028 | 0 | 0 |
| FOXO-mediated transcription | R-HSA-9614085 | 9.384373e-01 | 0.028 | 0 | 0 |
| Signaling by FGFR2 in disease | R-HSA-5655253 | 9.398061e-01 | 0.027 | 0 | 0 |
| SHC-mediated cascade:FGFR4 | R-HSA-5654719 | 9.398456e-01 | 0.027 | 0 | 0 |
| FRS-mediated FGFR3 signaling | R-HSA-5654706 | 9.398456e-01 | 0.027 | 0 | 0 |
| Glutathione synthesis and recycling | R-HSA-174403 | 9.398456e-01 | 0.027 | 0 | 0 |
| Metabolism of Angiotensinogen to Angiotensins | R-HSA-2022377 | 9.398456e-01 | 0.027 | 0 | 0 |
| NR1H2 and NR1H3-mediated signaling | R-HSA-9024446 | 9.399190e-01 | 0.027 | 0 | 0 |
| Neddylation | R-HSA-8951664 | 9.424042e-01 | 0.026 | 0 | 0 |
| Voltage gated Potassium channels | R-HSA-1296072 | 9.428567e-01 | 0.026 | 0 | 0 |
| FRS-mediated FGFR4 signaling | R-HSA-5654712 | 9.457979e-01 | 0.024 | 0 | 0 |
| RAF-independent MAPK1/3 activation | R-HSA-112409 | 9.457979e-01 | 0.024 | 0 | 0 |
| Cholesterol biosynthesis via lathosterol | R-HSA-6807062 | 9.457979e-01 | 0.024 | 0 | 0 |
| SLC transporter disorders | R-HSA-5619102 | 9.464457e-01 | 0.024 | 0 | 0 |
| Purine salvage | R-HSA-74217 | 9.475533e-01 | 0.023 | 0 | 0 |
| tRNA modification in the nucleus and cytosol | R-HSA-6782315 | 9.484614e-01 | 0.023 | 0 | 0 |
| PKR-mediated signaling | R-HSA-9833482 | 9.504376e-01 | 0.022 | 0 | 0 |
| Fc epsilon receptor (FCERI) signaling | R-HSA-2454202 | 9.510257e-01 | 0.022 | 0 | 0 |
| Regulation of PTEN mRNA translation | R-HSA-8943723 | 9.511616e-01 | 0.022 | 0 | 0 |
| Mitochondrial mRNA modification | R-HSA-9937008 | 9.511616e-01 | 0.022 | 0 | 0 |
| Organic anion transport by SLCO transporters | R-HSA-879518 | 9.511616e-01 | 0.022 | 0 | 0 |
| Carnitine shuttle | R-HSA-200425 | 9.511616e-01 | 0.022 | 0 | 0 |
| Biosynthesis of maresins | R-HSA-9018682 | 9.511616e-01 | 0.022 | 0 | 0 |
| Cross-presentation of soluble exogenous antigens (endosomes) | R-HSA-1236978 | 9.518804e-01 | 0.021 | 0 | 0 |
| Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) | R-HSA-381771 | 9.518804e-01 | 0.021 | 0 | 0 |
| Pentose phosphate pathway | R-HSA-71336 | 9.518804e-01 | 0.021 | 0 | 0 |
| Signaling by the B Cell Receptor (BCR) | R-HSA-983705 | 9.530754e-01 | 0.021 | 0 | 0 |
| TP53 Regulates Metabolic Genes | R-HSA-5628897 | 9.548087e-01 | 0.020 | 0 | 0 |
| Diseases associated with the TLR signaling cascade | R-HSA-5602358 | 9.558650e-01 | 0.020 | 0 | 0 |
| Diseases of Immune System | R-HSA-5260271 | 9.558650e-01 | 0.020 | 0 | 0 |
| rRNA processing in the mitochondrion | R-HSA-8868766 | 9.558650e-01 | 0.020 | 0 | 0 |
| Mitochondrial tRNA aminoacylation | R-HSA-379726 | 9.558650e-01 | 0.020 | 0 | 0 |
| Formation of tubulin folding intermediates by CCT/TriC | R-HSA-389960 | 9.559948e-01 | 0.020 | 0 | 0 |
| Norepinephrine Neurotransmitter Release Cycle | R-HSA-181430 | 9.559948e-01 | 0.020 | 0 | 0 |
| SHC-mediated cascade:FGFR1 | R-HSA-5654688 | 9.559948e-01 | 0.020 | 0 | 0 |
| Mitochondrial RNA degradation | R-HSA-9836573 | 9.559948e-01 | 0.020 | 0 | 0 |
| TNFs bind their physiological receptors | R-HSA-5669034 | 9.559948e-01 | 0.020 | 0 | 0 |
| Interleukin-6 family signaling | R-HSA-6783589 | 9.559948e-01 | 0.020 | 0 | 0 |
| Paracetamol ADME | R-HSA-9753281 | 9.588932e-01 | 0.018 | 0 | 0 |
| Aflatoxin activation and detoxification | R-HSA-5423646 | 9.595326e-01 | 0.018 | 0 | 0 |
| Purine ribonucleoside monophosphate biosynthesis | R-HSA-73817 | 9.595326e-01 | 0.018 | 0 | 0 |
| Tight junction interactions | R-HSA-420029 | 9.603499e-01 | 0.018 | 0 | 0 |
| Synthesis of PIPs at the early endosome membrane | R-HSA-1660516 | 9.603499e-01 | 0.018 | 0 | 0 |
| FRS-mediated FGFR1 signaling | R-HSA-5654693 | 9.603499e-01 | 0.018 | 0 | 0 |
| Hyaluronan degradation | R-HSA-2160916 | 9.603499e-01 | 0.018 | 0 | 0 |
| Laminin interactions | R-HSA-3000157 | 9.603499e-01 | 0.018 | 0 | 0 |
| COPII-mediated vesicle transport | R-HSA-204005 | 9.610832e-01 | 0.017 | 0 | 0 |
| Detoxification of Reactive Oxygen Species | R-HSA-3299685 | 9.619555e-01 | 0.017 | 0 | 0 |
| Scavenging by Class A Receptors | R-HSA-3000480 | 9.629068e-01 | 0.016 | 0 | 0 |
| Transcriptional and post-translational regulation of MITF-M expression and activity | R-HSA-9856649 | 9.637564e-01 | 0.016 | 0 | 0 |
| Leishmania phagocytosis | R-HSA-9664417 | 9.639180e-01 | 0.016 | 0 | 0 |
| Parasite infection | R-HSA-9664407 | 9.639180e-01 | 0.016 | 0 | 0 |
| FCGR3A-mediated phagocytosis | R-HSA-9664422 | 9.639180e-01 | 0.016 | 0 | 0 |
| MET activates PTK2 signaling | R-HSA-8874081 | 9.642743e-01 | 0.016 | 0 | 0 |
| Glutamate Neurotransmitter Release Cycle | R-HSA-210500 | 9.642743e-01 | 0.016 | 0 | 0 |
| Urea cycle | R-HSA-70635 | 9.642743e-01 | 0.016 | 0 | 0 |
| Synthesis of PIPs at the Golgi membrane | R-HSA-1660514 | 9.642743e-01 | 0.016 | 0 | 0 |
| Incretin synthesis, secretion, and inactivation | R-HSA-400508 | 9.660098e-01 | 0.015 | 0 | 0 |
| Protein localization | R-HSA-9609507 | 9.669672e-01 | 0.015 | 0 | 0 |
| Parasitic Infection Pathways | R-HSA-9824443 | 9.673996e-01 | 0.014 | 0 | 0 |
| Leishmania infection | R-HSA-9658195 | 9.673996e-01 | 0.014 | 0 | 0 |
| Early SARS-CoV-2 Infection Events | R-HSA-9772572 | 9.674474e-01 | 0.014 | 0 | 0 |
| Cristae formation | R-HSA-8949613 | 9.678104e-01 | 0.014 | 0 | 0 |
| SHC-mediated cascade:FGFR2 | R-HSA-5654699 | 9.678104e-01 | 0.014 | 0 | 0 |
| Signaling by FGFR3 in disease | R-HSA-5655332 | 9.678104e-01 | 0.014 | 0 | 0 |
| Disorders of transmembrane transporters | R-HSA-5619115 | 9.682014e-01 | 0.014 | 0 | 0 |
| Cardiac conduction | R-HSA-5576891 | 9.683988e-01 | 0.014 | 0 | 0 |
| Class I MHC mediated antigen processing & presentation | R-HSA-983169 | 9.689223e-01 | 0.014 | 0 | 0 |
| FRS-mediated FGFR2 signaling | R-HSA-5654700 | 9.709967e-01 | 0.013 | 0 | 0 |
| Pyrimidine salvage | R-HSA-73614 | 9.709967e-01 | 0.013 | 0 | 0 |
| Prednisone ADME | R-HSA-9757110 | 9.709967e-01 | 0.013 | 0 | 0 |
| RUNX2 regulates osteoblast differentiation | R-HSA-8940973 | 9.709967e-01 | 0.013 | 0 | 0 |
| Pyroptosis | R-HSA-5620971 | 9.709967e-01 | 0.013 | 0 | 0 |
| Metabolism of polyamines | R-HSA-351202 | 9.721843e-01 | 0.012 | 0 | 0 |
| Interleukin-4 and Interleukin-13 signaling | R-HSA-6785807 | 9.723030e-01 | 0.012 | 0 | 0 |
| Nitric oxide stimulates guanylate cyclase | R-HSA-392154 | 9.738678e-01 | 0.011 | 0 | 0 |
| Downstream signaling of activated FGFR3 | R-HSA-5654708 | 9.738678e-01 | 0.011 | 0 | 0 |
| Platelet calcium homeostasis | R-HSA-418360 | 9.738678e-01 | 0.011 | 0 | 0 |
| Activation of Matrix Metalloproteinases | R-HSA-1592389 | 9.738678e-01 | 0.011 | 0 | 0 |
| Platelet Aggregation (Plug Formation) | R-HSA-76009 | 9.738905e-01 | 0.011 | 0 | 0 |
| Degradation of cysteine and homocysteine | R-HSA-1614558 | 9.738905e-01 | 0.011 | 0 | 0 |
| Purinergic signaling in leishmaniasis infection | R-HSA-9660826 | 9.761009e-01 | 0.011 | 0 | 0 |
| Cell recruitment (pro-inflammatory response) | R-HSA-9664424 | 9.761009e-01 | 0.011 | 0 | 0 |
| Signaling by TGFBR3 | R-HSA-9839373 | 9.761009e-01 | 0.011 | 0 | 0 |
| Signaling by PDGF | R-HSA-186797 | 9.762627e-01 | 0.010 | 0 | 0 |
| Downstream signaling of activated FGFR4 | R-HSA-5654716 | 9.764549e-01 | 0.010 | 0 | 0 |
| G alpha (s) signalling events | R-HSA-418555 | 9.765795e-01 | 0.010 | 0 | 0 |
| FCGR3A-mediated IL10 synthesis | R-HSA-9664323 | 9.786292e-01 | 0.009 | 0 | 0 |
| Cargo concentration in the ER | R-HSA-5694530 | 9.787859e-01 | 0.009 | 0 | 0 |
| Anti-inflammatory response favouring Leishmania parasite infection | R-HSA-9662851 | 9.788799e-01 | 0.009 | 0 | 0 |
| Leishmania parasite growth and survival | R-HSA-9664433 | 9.788799e-01 | 0.009 | 0 | 0 |
| Intraflagellar transport | R-HSA-5620924 | 9.799913e-01 | 0.009 | 0 | 0 |
| Metal ion SLC transporters | R-HSA-425410 | 9.799913e-01 | 0.009 | 0 | 0 |
| Sealing of the nuclear envelope (NE) by ESCRT-III | R-HSA-9668328 | 9.827789e-01 | 0.008 | 0 | 0 |
| Recycling of bile acids and salts | R-HSA-159418 | 9.827789e-01 | 0.008 | 0 | 0 |
| Collagen formation | R-HSA-1474290 | 9.831793e-01 | 0.007 | 0 | 0 |
| Kidney development | R-HSA-9830369 | 9.841148e-01 | 0.007 | 0 | 0 |
| Toll-like Receptor Cascades | R-HSA-168898 | 9.841848e-01 | 0.007 | 0 | 0 |
| Regulation of CDH1 posttranslational processing and trafficking to plasma membrane | R-HSA-9768727 | 9.844841e-01 | 0.007 | 0 | 0 |
| Vitamin B5 (pantothenate) metabolism | R-HSA-199220 | 9.844841e-01 | 0.007 | 0 | 0 |
| Heme degradation | R-HSA-189483 | 9.844841e-01 | 0.007 | 0 | 0 |
| Branched-chain amino acid catabolism | R-HSA-70895 | 9.846995e-01 | 0.007 | 0 | 0 |
| G alpha (q) signalling events | R-HSA-416476 | 9.849027e-01 | 0.007 | 0 | 0 |
| Uptake and actions of bacterial toxins | R-HSA-5339562 | 9.860146e-01 | 0.006 | 0 | 0 |
| Antigen Presentation: Folding, assembly and peptide loading of class I MHC | R-HSA-983170 | 9.860206e-01 | 0.006 | 0 | 0 |
| Hyaluronan metabolism | R-HSA-2142845 | 9.860206e-01 | 0.006 | 0 | 0 |
| RA biosynthesis pathway | R-HSA-5365859 | 9.860206e-01 | 0.006 | 0 | 0 |
| Infection with Mycobacterium tuberculosis | R-HSA-9635486 | 9.864215e-01 | 0.006 | 0 | 0 |
| Developmental Lineage of Pancreatic Ductal Cells | R-HSA-9925563 | 9.864992e-01 | 0.006 | 0 | 0 |
| FCERI mediated NF-kB activation | R-HSA-2871837 | 9.866367e-01 | 0.006 | 0 | 0 |
| Nucleotide biosynthesis | R-HSA-8956320 | 9.872194e-01 | 0.006 | 0 | 0 |
| Downstream signaling of activated FGFR2 | R-HSA-5654696 | 9.874050e-01 | 0.006 | 0 | 0 |
| Downstream signaling of activated FGFR1 | R-HSA-5654687 | 9.874050e-01 | 0.006 | 0 | 0 |
| Metabolism of ingested SeMet, Sec, MeSec into H2Se | R-HSA-2408508 | 9.874050e-01 | 0.006 | 0 | 0 |
| Metabolism of cofactors | R-HSA-8978934 | 9.885377e-01 | 0.005 | 0 | 0 |
| RUNX2 regulates bone development | R-HSA-8941326 | 9.886524e-01 | 0.005 | 0 | 0 |
| Phospholipid metabolism | R-HSA-1483257 | 9.890517e-01 | 0.005 | 0 | 0 |
| Interconversion of nucleotide di- and triphosphates | R-HSA-499943 | 9.894425e-01 | 0.005 | 0 | 0 |
| NCAM1 interactions | R-HSA-419037 | 9.897763e-01 | 0.004 | 0 | 0 |
| Beta-oxidation of very long chain fatty acids | R-HSA-390247 | 9.897763e-01 | 0.004 | 0 | 0 |
| Collagen chain trimerization | R-HSA-8948216 | 9.897763e-01 | 0.004 | 0 | 0 |
| Metabolism of folate and pterines | R-HSA-196757 | 9.897763e-01 | 0.004 | 0 | 0 |
| Aspirin ADME | R-HSA-9749641 | 9.902783e-01 | 0.004 | 0 | 0 |
| tRNA processing in the mitochondrion | R-HSA-6785470 | 9.907890e-01 | 0.004 | 0 | 0 |
| Transcriptional regulation of pluripotent stem cells | R-HSA-452723 | 9.907890e-01 | 0.004 | 0 | 0 |
| ROS and RNS production in phagocytes | R-HSA-1222556 | 9.910500e-01 | 0.004 | 0 | 0 |
| Tryptophan catabolism | R-HSA-71240 | 9.925235e-01 | 0.003 | 0 | 0 |
| Amino acid transport across the plasma membrane | R-HSA-352230 | 9.925869e-01 | 0.003 | 0 | 0 |
| Regulation of beta-cell development | R-HSA-186712 | 9.925869e-01 | 0.003 | 0 | 0 |
| Peptide hormone metabolism | R-HSA-2980736 | 9.930600e-01 | 0.003 | 0 | 0 |
| PPARA activates gene expression | R-HSA-1989781 | 9.931460e-01 | 0.003 | 0 | 0 |
| RAB geranylgeranylation | R-HSA-8873719 | 9.932346e-01 | 0.003 | 0 | 0 |
| Maturation of spike protein | R-HSA-9694548 | 9.932642e-01 | 0.003 | 0 | 0 |
| Cholesterol biosynthesis | R-HSA-191273 | 9.935861e-01 | 0.003 | 0 | 0 |
| Nucleotide salvage | R-HSA-8956321 | 9.938268e-01 | 0.003 | 0 | 0 |
| FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | R-HSA-9615017 | 9.939315e-01 | 0.003 | 0 | 0 |
| Regulation of lipid metabolism by PPARalpha | R-HSA-400206 | 9.939478e-01 | 0.003 | 0 | 0 |
| Mitochondrial protein degradation | R-HSA-9837999 | 9.944689e-01 | 0.002 | 0 | 0 |
| Metabolism of carbohydrates and carbohydrate derivatives | R-HSA-71387 | 9.952107e-01 | 0.002 | 0 | 0 |
| Methylation | R-HSA-156581 | 9.955626e-01 | 0.002 | 0 | 0 |
| Extracellular matrix organization | R-HSA-1474244 | 9.964142e-01 | 0.002 | 0 | 0 |
| Nicotinate metabolism | R-HSA-196807 | 9.964490e-01 | 0.002 | 0 | 0 |
| SLC-mediated transport of amino acids | R-HSA-9958863 | 9.964490e-01 | 0.002 | 0 | 0 |
| Synthesis of PC | R-HSA-1483191 | 9.967554e-01 | 0.001 | 0 | 0 |
| Collagen biosynthesis and modifying enzymes | R-HSA-1650814 | 9.967634e-01 | 0.001 | 0 | 0 |
| Sulfur amino acid metabolism | R-HSA-1614635 | 9.970067e-01 | 0.001 | 0 | 0 |
| Plasma lipoprotein remodeling | R-HSA-8963899 | 9.970770e-01 | 0.001 | 0 | 0 |
| Fatty acyl-CoA biosynthesis | R-HSA-75105 | 9.973122e-01 | 0.001 | 0 | 0 |
| Adaptive Immune System | R-HSA-1280218 | 9.974555e-01 | 0.001 | 0 | 0 |
| Cell surface interactions at the vascular wall | R-HSA-202733 | 9.975621e-01 | 0.001 | 0 | 0 |
| Synthesis of Prostaglandins (PG) and Thromboxanes (TX) | R-HSA-2162123 | 9.976278e-01 | 0.001 | 0 | 0 |
| Complex IV assembly | R-HSA-9864848 | 9.978629e-01 | 0.001 | 0 | 0 |
| Neurotransmitter release cycle | R-HSA-112310 | 9.978772e-01 | 0.001 | 0 | 0 |
| Transport of vitamins, nucleosides, and related molecules | R-HSA-425397 | 9.981495e-01 | 0.001 | 0 | 0 |
| Glycerophospholipid biosynthesis | R-HSA-1483206 | 9.982262e-01 | 0.001 | 0 | 0 |
| Glucuronidation | R-HSA-156588 | 9.984376e-01 | 0.001 | 0 | 0 |
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | R-HSA-983695 | 9.984987e-01 | 0.001 | 0 | 0 |
| Bile acid and bile salt metabolism | R-HSA-194068 | 9.986984e-01 | 0.001 | 0 | 0 |
| SLC-mediated transport of organic anions | R-HSA-9955298 | 9.987285e-01 | 0.001 | 0 | 0 |
| Integrin cell surface interactions | R-HSA-216083 | 9.987285e-01 | 0.001 | 0 | 0 |
| Intrinsic Pathway for Apoptosis | R-HSA-109606 | 9.987321e-01 | 0.001 | 0 | 0 |
| Dectin-2 family | R-HSA-5621480 | 9.988579e-01 | 0.000 | 0 | 0 |
| Role of LAT2/NTAL/LAB on calcium mobilization | R-HSA-2730905 | 9.989410e-01 | 0.000 | 0 | 0 |
| Glutathione conjugation | R-HSA-156590 | 9.991651e-01 | 0.000 | 0 | 0 |
| Signaling by Retinoic Acid | R-HSA-5362517 | 9.991651e-01 | 0.000 | 0 | 0 |
| Asparagine N-linked glycosylation | R-HSA-446203 | 9.991779e-01 | 0.000 | 0 | 0 |
| Synthesis of bile acids and bile salts | R-HSA-192105 | 9.991862e-01 | 0.000 | 0 | 0 |
| Role of phospholipids in phagocytosis | R-HSA-2029485 | 9.992703e-01 | 0.000 | 0 | 0 |
| Peroxisomal lipid metabolism | R-HSA-390918 | 9.992783e-01 | 0.000 | 0 | 0 |
| Degradation of the extracellular matrix | R-HSA-1474228 | 9.993893e-01 | 0.000 | 0 | 0 |
| Infectious disease | R-HSA-5663205 | 9.994025e-01 | 0.000 | 0 | 0 |
| CD22 mediated BCR regulation | R-HSA-5690714 | 9.994503e-01 | 0.000 | 0 | 0 |
| Xenobiotics | R-HSA-211981 | 9.994503e-01 | 0.000 | 0 | 0 |
| Glycosphingolipid biosynthesis | R-HSA-9840309 | 9.994503e-01 | 0.000 | 0 | 0 |
| Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation | R-HSA-163841 | 9.994571e-01 | 0.000 | 0 | 0 |
| Metabolism of steroid hormones | R-HSA-196071 | 9.995982e-01 | 0.000 | 0 | 0 |
| Developmental Cell Lineages of the Exocrine Pancreas | R-HSA-9820448 | 9.996104e-01 | 0.000 | 0 | 0 |
| Formation of the cornified envelope | R-HSA-6809371 | 9.996572e-01 | 0.000 | 0 | 0 |
| Glycosphingolipid catabolism | R-HSA-9840310 | 9.997063e-01 | 0.000 | 0 | 0 |
| Diseases associated with O-glycosylation of proteins | R-HSA-3906995 | 9.997355e-01 | 0.000 | 0 | 0 |
| Metal ion assimilation from the host | R-HSA-9638482 | 9.997355e-01 | 0.000 | 0 | 0 |
| ECM proteoglycans | R-HSA-3000178 | 9.997355e-01 | 0.000 | 0 | 0 |
| Metabolism of porphyrins | R-HSA-189445 | 9.997355e-01 | 0.000 | 0 | 0 |
| FCGR activation | R-HSA-2029481 | 9.997469e-01 | 0.000 | 0 | 0 |
| Purine catabolism | R-HSA-74259 | 9.997617e-01 | 0.000 | 0 | 0 |
| FCERI mediated MAPK activation | R-HSA-2871796 | 9.997657e-01 | 0.000 | 0 | 0 |
| Immune System | R-HSA-168256 | 9.997710e-01 | 0.000 | 0 | 0 |
| Transport of small molecules | R-HSA-382551 | 9.998386e-01 | 0.000 | 0 | 0 |
| Visual phototransduction | R-HSA-2187338 | 9.998458e-01 | 0.000 | 0 | 0 |
| Post-translational protein modification | R-HSA-597592 | 9.998809e-01 | 0.000 | 0 | 0 |
| Innate Immune System | R-HSA-168249 | 9.998836e-01 | 0.000 | 0 | 0 |
| Developmental Lineage of Pancreatic Acinar Cells | R-HSA-9925561 | 9.998854e-01 | 0.000 | 0 | 0 |
| Metabolic disorders of biological oxidation enzymes | R-HSA-5579029 | 9.998854e-01 | 0.000 | 0 | 0 |
| Biosynthesis of DHA-derived SPMs | R-HSA-9018677 | 9.999070e-01 | 0.000 | 0 | 0 |
| Drug ADME | R-HSA-9748784 | 9.999180e-01 | 0.000 | 0 | 0 |
| G alpha (i) signalling events | R-HSA-418594 | 9.999740e-01 | 0.000 | 0 | 0 |
| Binding and Uptake of Ligands by Scavenger Receptors | R-HSA-2173782 | 9.999744e-01 | 0.000 | 0 | 0 |
| Scavenging of heme from plasma | R-HSA-2168880 | 9.999843e-01 | 0.000 | 0 | 0 |
| Metabolism of steroids | R-HSA-8957322 | 9.999905e-01 | 0.000 | 0 | 0 |
| Glycosphingolipid metabolism | R-HSA-1660662 | 9.999906e-01 | 0.000 | 0 | 0 |
| Sphingolipid metabolism | R-HSA-428157 | 9.999931e-01 | 0.000 | 0 | 0 |
| Metabolism of nucleotides | R-HSA-15869 | 9.999939e-01 | 0.000 | 0 | 0 |
| Post-translational modification: synthesis of GPI-anchored proteins | R-HSA-163125 | 9.999945e-01 | 0.000 | 0 | 0 |
| Synthesis of substrates in N-glycan biosythesis | R-HSA-446219 | 9.999965e-01 | 0.000 | 0 | 0 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | R-HSA-198933 | 9.999973e-01 | 0.000 | 0 | 0 |
| Antimicrobial peptides | R-HSA-6803157 | 9.999974e-01 | 0.000 | 0 | 0 |
| Disease | R-HSA-1643685 | 9.999977e-01 | 0.000 | 0 | 0 |
| Initial triggering of complement | R-HSA-166663 | 9.999983e-01 | 0.000 | 0 | 0 |
| FCERI mediated Ca+2 mobilization | R-HSA-2871809 | 9.999986e-01 | 0.000 | 0 | 0 |
| Metabolism of amino acids and derivatives | R-HSA-71291 | 9.999986e-01 | 0.000 | 0 | 0 |
| GPCR downstream signalling | R-HSA-388396 | 9.999986e-01 | 0.000 | 0 | 0 |
| Metabolism of proteins | R-HSA-392499 | 9.999994e-01 | 0.000 | 0 | 0 |
| Sensory perception of sweet, bitter, and umami (glutamate) taste | R-HSA-9717207 | 9.999994e-01 | 0.000 | 0 | 0 |
| Regulation of Complement cascade | R-HSA-977606 | 9.999995e-01 | 0.000 | 0 | 0 |
| Nucleotide catabolism | R-HSA-8956319 | 9.999997e-01 | 0.000 | 0 | 0 |
| Signaling by GPCR | R-HSA-372790 | 9.999997e-01 | 0.000 | 0 | 0 |
| Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein | R-HSA-446193 | 9.999998e-01 | 0.000 | 0 | 0 |
| Sensory perception of taste | R-HSA-9717189 | 9.999998e-01 | 0.000 | 0 | 0 |
| Diseases of glycosylation | R-HSA-3781865 | 9.999999e-01 | 0.000 | 0 | 0 |
| Keratinization | R-HSA-6805567 | 9.999999e-01 | 0.000 | 0 | 0 |
| Peptide ligand-binding receptors | R-HSA-375276 | 9.999999e-01 | 0.000 | 0 | 0 |
| Biosynthesis of specialized proresolving mediators (SPMs) | R-HSA-9018678 | 1.000000e+00 | 0.000 | 0 | 0 |
| SLC-mediated transmembrane transport | R-HSA-425407 | 1.000000e+00 | 0.000 | 0 | 0 |
| Complement cascade | R-HSA-166658 | 1.000000e+00 | 0.000 | 0 | 0 |
| Respiratory electron transport | R-HSA-611105 | 1.000000e+00 | 0.000 | 0 | 0 |
| Aerobic respiration and respiratory electron transport | R-HSA-1428517 | 1.000000e+00 | 0.000 | 0 | 0 |
| Arachidonate metabolism | R-HSA-2142753 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of water-soluble vitamins and cofactors | R-HSA-196849 | 1.000000e+00 | 0.000 | 0 | 0 |
| Phase I - Functionalization of compounds | R-HSA-211945 | 1.000000e+00 | 0.000 | 0 | 0 |
| Bacterial Infection Pathways | R-HSA-9824439 | 1.000000e+00 | 0.000 | 0 | 0 |
| Glycosaminoglycan metabolism | R-HSA-1630316 | 1.000000e+00 | 0.000 | 0 | 0 |
| Diseases of metabolism | R-HSA-5668914 | 1.000000e+00 | 0.000 | 0 | 0 |
| Cytochrome P450 - arranged by substrate type | R-HSA-211897 | 1.000000e+00 | 0.000 | 0 | 0 |
| Infection with Enterobacteria | R-HSA-9640148 | 1.000000e+00 | 0.000 | 0 | 0 |
| Phase II - Conjugation of compounds | R-HSA-156580 | 1.000000e+00 | 0.000 | 0 | 0 |
| Class A/1 (Rhodopsin-like receptors) | R-HSA-373076 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of vitamins and cofactors | R-HSA-196854 | 1.000000e+00 | 0.000 | 0 | 0 |
| GPCR ligand binding | R-HSA-500792 | 1.000000e+00 | 0.000 | 0 | 0 |
| Fatty acid metabolism | R-HSA-8978868 | 1.000000e+00 | 0.000 | 0 | 0 |
| Biological oxidations | R-HSA-211859 | 1.000000e+00 | 0.000 | 0 | 0 |
| Expression and translocation of olfactory receptors | R-HSA-9752946 | 1.000000e+00 | -0.000 | 0 | 0 |
| Olfactory Signaling Pathway | R-HSA-381753 | 1.000000e+00 | -0.000 | 0 | 0 |
| Sensory Perception | R-HSA-9709957 | 1.000000e+00 | -0.000 | 0 | 0 |
| Metabolism of lipids | R-HSA-556833 | 1.000000e+00 | -0.000 | 0 | 0 |
| Metabolism | R-HSA-1430728 | 1.000000e+00 | -0.000 | 0 | 0 |